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The term “nutraceuticals” is derived from “nutrition” and “pharmaceuticals” and is used
for nutrition products that are also used as medicine [1]. “Nutraceuticals” often contain
modified/unmodified whole food, plant extracts alone or in combination, semipurified and purified
phytochemicals, or a combination of different phytochemicals. On the other hand, nutritional
supplements are nutritional compounds that supplement one’s diet by increasing one’s total daily
intake. Nutritional supplements also contain substances alone or in combination with vitamins and
minerals, with or without other herbal products, with or without zoochemicals (creatinine, glucosamine,
melatonin, bee pollens) and with or without probiotics.
Nutraceuticals and nutrition supplements are collectively referred to as “dietary supplements,”
intended to be taken orally [2]. The use of supplements is suggested to (but may not claim to)
diagnose, cure, mitigate, treat, or prevent diseases. Often, background information suggests that
they are intended to affect the structure or function of the body [3]. However, they do not undergo
premarket approval. The common reasons for using dietary supplements are to improve conditions
such as overall health and disease prevention, performance (athletics, sports, sex, etc.) and appearance
(weight loss, sex appeal) [4]. These are often perceived as “safe” and less likely to have side effects.
The scientific research on nutraceuticals and nutrition supplements is frequently misinterpreted or
overstretched for commercial interests because of high consumer demands. The manufacturing and
marketing of supplements are full of challenges.
Several challenges associated with the development of nutraceuticals are often ignored because of
a lack of authoritative control. These challenges include identification of the authentic source of raw
materials, purity of the compound, presence of other active compounds, quality, lack of experimental
evidence, false advertising, contamination with heavy metals, and interactions between supplements
and drugs. For example, a common herb “ginseng” has several varieties [5] such as California ginseng,
wild ginseng, prickly ginseng, Pacific ginseng, Malaysian ginseng, Indian ginseng, Peruvian ginseng,
Southern ginseng, Brazilian ginseng, and wild-red ginseng. All of these are sold as ginseng, but none
of these belongs to the genus Panax, which contains real ginseng including Korean ginseng (P. ginseng),
South China ginseng (P. notoginseng) and American ginseng (P. quinquefolius). Some varieties of star
anise have several hundred-fold anisatin, a neurotoxin, that the authentic star anise (Illicium verum)
has [6]. The supplements that are not prepared under strict GMP conditions may have unintentional
contamination [7], including microbes (pathogens/nonpathogens), pesticides, mycotoxin (aflatoxin),
heavy metals (seaweeds), zinc (cadmium), and calcium (lead). In addition, some supplements such as
those commonly used for weight loss, body building, and sex enhancement are spiked with prohibited
drugs to improve efficacy [8]. Some manufacturers also try to use a closely related herb, which may
Nutrients 2020, 12, 1593; doi:10.3390/nu12061593 www.mdpi.com/journal/nutrients1
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or may not have the active ingredients. For example, goldenseal (Hydrastis canadensis), used for
berberine/hydrastine content, is often substituted with goldthread (Coptis chinensis) or Oregon grape
(Mahonia aquifolium), which may have low or no berberine/hydrastine [9].
Besides, maintaining the quality of nutraceuticals is another challenge, as phytochemistry is
inherently variable due to seasonal and geographical variations [10]. It is challenging to measure
and maintain consistency in finished products and limit undesirable constituents. Interaction of
herbal supplements with medicinal drugs is also a big concern [11]. For example, St. John’s wort
(Hypericum perforaum) is used as an effective antidepressant, but it also activates several cytochrome
P450 isoenzymes, which make a large number of medicinal drugs ineffective [12,13]. Among all the
major concerns for using the nutraceuticals is the lack of scientific evidence [14]. Some are never tested
under properly controlled experimental conditions, and unlike pharmaceuticals, most nutraceuticals
do not undergo “randomized controlled clinical studies.”
The purpose of this Special Issue on “Nutraceuticals, Nutrition Supplements, and Human Health”
is to comprehensively review the data from basic and clinical research to discuss the benefits as well as
potential adverse effects of “functional food-derived” products. We have invited international experts,
researchers and authors to submit original research and review articles that address the progress
and our current understanding of nutraceuticals/supplements from in vitro and in vivo studies,
as well as from clinical trials describing the benefits/adverse effects with underlying mechanisms.
This Special Issue presents a compendium of excellent laboratory and clinical studies using plant
extracts [15–20], purified compounds [21–23], modified formulations [22,24], and probiotics [25–28] to
improve many health conditions, including metabolic disorders [17,20], cardiovascular disease [29],
muscle metabolism [18,25], obesity [16,17,20], neurological disorders [30], infectious diseases [26,27],
aging [23], and cancers [18,21,24,31].
This Special Issue’s overall goal is to present readers with high-quality scientific evidence for the
use of dietary supplements, nutraceuticals, and functional foods that can be appropriately used to
improve health parameters in various stages of one’s lifecycle. We thank all the contributors for their
contributions and for their dedication to making a difference in human health with low-cost remedies.
Author Contributions: R.A.S. and M.H.M. equally contributed in the preparation of this editorial. All authors
have read and agreed to the published version of the manuscript.
Funding: None.
Acknowledgments: The authors greatly acknowledge the contribution of all authors for this Special Issue.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: A previous clinical study on pre-obesity subjects revealed that Bifidobacterium breve B-3
shows anti-obesity effects and possibly increases muscle mass. Here, we investigated the effects of
B-3 on muscle function, such as muscle strength and metabolism, and some signaling pathways in
skeletal muscle. Male rodents were orally administered live B-3 (B-3L) or heat-killed B-3 (B-3HK) for
4 weeks. We found that administration of B-3 to rats tended to increase muscle mass and affect muscle
metabolism, with stronger effects in the B-3HK group than in the B-3L group. B-3HK significantly
increased muscle mass and activated Akt in the rat soleus. With regard to muscle metabolism,
B-3HK significantly increased phosphorylated AMP-activated protein kinase (AMPK), peroxisome
proliferator-activated receptor gamma coactivator (PGC)-1α and cytochrome c oxidase (CCO) gene
expression in the rat soleus, suggesting an effect on the AMPK-PGC1α-mitochondrial biogenesis
pathway. Furthermore, B-3HK promoted oxidative muscle fiber composition in the gastrocnemius.
We also observed a significantly higher level of murine grip strength in the B-3HK group than in the
control group. These findings suggest the potential of heat-killed B-3 in promoting muscle hypertrophy
and modifying metabolic functions, possibly through the Akt and AMPK pathways, respectively.
Keywords: skeletal muscles; probiotics; Bifidobacterium breve B-3; muscle mass; mitochondria
1. Introduction
Bifidobacterium breve B-3 (B-3), a probiotic strain originating from the gut of an infant, has been
demonstrated to exert anti-obesity effects [1,2] through mechanisms speculated to include improvement
of intestinal barrier function; adiponectin and colonic proglucagon production; and the production of
B-3-derived metabolites with anti-obesity activity (e.g., acetic acids and conjugated linoleic acids) [1,3].
In a clinical study on mild obesity subjects, body fat mass was significantly lower in the B-3 group than
in the placebo group. Remarkably, B-3 administration also significantly increased muscle mass [2],
suggesting potential effects of B-3 on muscle.
Accumulating evidence has indicated that gut microbiota are associated with host health conditions
in numerous ways [4], including through energy metabolism and mitochondrial function [5,6].
Moreover, the cross-talk pathway between the gut microbiota and skeletal muscle, i.e., the gut-muscle
axis, has been extensively studied, and microbiota composition and the intestinal environment
have been suggested to influence muscle mass and function, possibly by modification of microbiota
composition, immune function, energy metabolism and oxidative stress [7,8].
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However, studies on the effects of probiotics on muscle mass and function have been scarcely
reported, and the potential effects of probiotics on physical performance and their underlying
mechanisms remain unclear. Few studies have suggested the potential impact of probiotics on the gut
microbiomes of athletes [9], and the possible involvement of metabolites of gut microbiota, such as
acetic acid, in the stimulation of muscular energy metabolism [10], and the enhancement of endurance
performance [11].
Recently, heat-killed microorganisms have attracted attention as postbiotics [12]. Numerous
studies have indicated the effects of the cell components of probiotic bacteria in modulating the immune
functions and enhancing the intestinal barrier [13,14]. Piqué et al. showed that non-viable bacteria
and bacterial fractions could pass through the mucus and stimulate epithelial cells more efficiently
compared with viable bacteria [15]. In addition, although the use of probiotic bacteria has been
demonstrated to meet safety concerns, some uses of probiotic strains have been pointed at regarding
risks such as systemic infections due to translocation, particularly in vulnerable patients and pediatric
populations [15]. Therefore, from a safety point of view, there is an increasing interest in non-viable
beneficial microbes to be used as functional ingredients. Furthermore, heat-killed bacteria are generally
easier and more suitable for industrial applications in different types of foods and dietary supplements.
We investigated whether B-3 influences muscle mass and muscle metabolism using rodents fed a
regular chow diet. To understand the mechanisms, the activations of Akt and AMPK involved in the
signalling pathway related to muscle mass and muscle metabolism in skeletal muscle, respectively,
were evaluated [16,17]. Moreover, animals were treated with heat-killed B-3 to evaluate the potential
effects of heat-killed bacteria and to understand the underlying mechanisms of the effects of B-3 on
skeletal muscle.
2. Materials and Methods
2.1. Preparation of the Samples
B-3 (MCC1274) lyophilized powder was obtained from the Morinaga Milk Industry (Tokyo,
Japan). The live B-3 (B-3L) were suspended in saline just before daily administration. The heat-killed
B-3 (B-3HK) were prepared as previously described with slight modifications [18], by heating B-3
lyophilized powder suspended in saline at 90 ◦C for 30 min. A lack of viable bacteria was confirmed
with anaerobic culture methods using TOS propionate agar (Eiken Chemical, Tokyo, Japan). B-3HK was
stored at −20 ◦C until an administration.
2.2. Animal Experiments
All animal studies were approved by the Animal Research Committee of Morinaga Milk Industry
(approval dates: 22 February 2018 and 21 September 2018) and performed in accordance with the
relevant guidelines and regulations. Male, 8-week-old Crl:CD (SD) rats and C57BL/6J mice (CRJ,
Inc., Kanagawa, Japan) were housed in individual cages under controlled lighting conditions (12 h
light/dark cycle; lights on from 8:00 to 20:00) at a constant temperature (25 ◦C) and were provided
Labo MR Stock food (NOSAN Corporation, Kanagawa, Japan) and water ad libitum.
In Experiment 1 (rearing date: 6 March to 19 April 2018), rats were used for evaluation of the effects
of B-3 on the anabolic and catabolic signaling pathways. Fifty rats were divided into the following four
groups (n = 12 or 13): a control group (given saline), a positive control group for mTOR activation
(given leucine at 1 mmol/kg/day), a B-3L group (given 1 × 109 cfu/rat) and a B-3HK group (given an
amount of B-3HK equivalent to the number of cells given to the B-3L group). Each ingredient was
orally administered six days a week for 28 days with the exception of the dissection date. Body weight
and food intake per day were monitored weekly (Figure 1).
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Figure 1. Protocol for the In Vivo test. Fifty male rats were acclimatized to the environmental conditions
for 7 d after receipt and were then divided into four groups (n = 12 or 13). Each treatment (e.g., B-3L or
B-3HK) was orally administered for 4 weeks. Body weight and food intake were monitored weekly.
After administration for 4 weeks, the tissues were collected in order to evaluate the effects on muscle.
In Experiment 2 (rearing date: 2 October to 22 November 2018), mice were evaluated for fitness
performance. Thirty-six mice were divided into 2 groups (n = 18): a control group (given saline) and a
B-3HK group (given the same dosage as in experiment 1). The treatments were orally administered for
4 weeks, as in Experiment 1, and then a grip test was conducted at 2 and 4 weeks.
2.3. Western Blotting
The left solei of the rats (20 mg) were stored at−80 ◦C after freezing with liquid nitrogen. The frozen
tissues were homogenized for 2 min on ice with RIPA buffer (Cell Signaling Technology [CST], Danvers,
MA, USA), protease inhibitor (Invitrogen, Carlsbad, CA, USA) and 1 mM phenylmethylsulfonyl
fluoride (PMSF, Nacalai Tesque, Inc., Kyoto, Japan) using a BioMasher (Nippi, Inc., Tokyo, Japan).
After centrifugation at 13,000× g for 15 min at 4 ◦C, the protein in the supernatant was measured
with a bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Waltham, MA, USA). After heat
treatment for 5 min at 95 ◦C, the lysate samples were loaded (10 μg of protein per well) with SDS
sample buffer (250 mM Tris-HCl (pH 6.8), 5% glycerol, 5% 2-mercaptoethanol, 2% SDS and 0.01%
bromophenol blue) onto NuPAGE gels with MOPS buffer (Invitrogen) and separated. After SDS-PAGE,
the proteins were transferred to PVDF membranes using an iBlot system (Invitrogen). The membranes
were blocked for 1 h at RT with Blocking One buffer (Nacalai Tesque, Inc., Kyoto, Japan), and then
incubated overnight at 4 ◦C with phosphorylated Akt (pAkt, catalogue number 2965, CST, Boston, MA,
USA), Akt (catalogue number 2966, CST), phosphorylated mammallian target of rapamycin (pmTOR,
catalogue number 5536, CST), mTOR (catalogue number 4517, CST), phosphorylated p70 S6 kinase
(pp70S6K, catalogue number 9206, CST), p70S6K (catalogue number 2708, CST), phosphorylated
AMP-activated protein kinase (pAMPK, catalogue number 2535, CST) and AMPK (catalogue number
2793, CST) or β-actin (catalogue number sc-47778, Santa Cruz Biotechnology, Inc., Dallas, TX, USA)
antibodies at 1:1000 dilutions. The membranes were washed with TBS buffer with 1% Tween 20 and
incubated for 1 h at RT with anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary
antibodies (catalogue number 074-1516 or 074-1806, KPL, Gaithersburg, MD, USA) at a concentration
of 0.1 μg/mL. After washing, the immunoreactive bands were visualized using ECL Prime Western
Blotting Detection Reagent (GE Healthcare, Tokyo, Japan), and the band intensities were measured
with a ChemiDoc™MP Imaging System (Bio-Rad Laboratories, Hercules, CA, USA).
2.4. Quantitative Real-Time PCR (qPCR) Analysis
Total RNA was extracted from 20 mg rat soleus samples stored with RNAlater (Thermo Fisher
Scientific) at −20 ◦C using a TissueLyser and RNeasy Mini Kit with DNase (Qiagen, Valencia, CA,
USA). qPCR was performed using an ABI PRISM 7500 Fast Real-Time PCR system (Thermo Fisher
Scientific K.K., Uppsala, Sweden) with SYBR Premix Ex Taq (TaKaRa Bio, Shiga, Japan) following
reverse transcription of the RNA into cDNA using a PrimeScript™ RT Reagent Kit (TaKaRa Bio).
The primer sets used in this study are shown in Supplementary Table S1. The expression levels of the
target mRNAs were normalized to those of GAPDH mRNA.
2.5. Histological Analysis
After scarification, the right gastrocnemius of rats was fixed in 4% paraformaldehyde (Wako,
Tokyo, Japan) at 4 ◦C for 2 days and then placed in 70% ethanol for storage. The thickest part of the
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fixed tissues was cut out, embedded in paraffin block, and sliced to 3 μm using a microtome. The sliced
tissues were adhered to silane-coated slide glass (Muto Pure Chemicals Co., Ltd., Tokyo, Japan),
which was used for immunohistochemistry (IHC) against SERCA2 ATPase. The deparaffinizing tissues
with xylene and ethanol were incubated in Histo VT One (Nacalai tesque, Inc., Kyoto, Japan), heated
antigen retrieval solution for 30 min at 90 ◦C, and reacted with the first antibody against SERCA2
ATPase (ab2861, Abcam, Cambridge, UK) overnight at 4 ◦C after blocking with 5% normal goat serum
(Nichirei bioscience, Inc., Tokyo, Japan) for 1 h at room temperature (RT). After washing with PBS,
the slides were reacted with Histofine Simple Stain Rat MAX-PO (M) (Nacalai tesque, Inc.) for 30 min
at RT. After washing with Tris-buffered saline (TBS) buffer, ImmPACT™ DAB (Vector Laboratories,
Inc., Burlingame, CA, USA) and hematoxylin were used for staining. The 450 fibers in a medial head
of gastrocnemius were randomly counted and SERCA2 ATPase positively stained fibers were viewed
using a stereoscopic microscope BX53 and Olympus cellSens Dimension software (Olympus, Tokyo,
Japan). This counting was carried out under the blind. The images are provided in Supplementary
Figure S1.
2.6. Grip Test
The fitness performance of the treated mice was determined at 2 and 4 weeks by testing whole-body
grip strength using 4 limbs with a grip strength machine (MELQUEST Co., Ltd., Toyama, Japan),
as described previously with slight modifications [19]. The grip tests were repeated five times, and all
replicates were conducted within 5 min. The median was used as a representative value.
2.7. Statistical Analysis
The data are presented as means and standard errors (SEs). One-way ANOVA was used for
parametric analyses, and followed by a Student’s t-test or Tukey–Kramer test. The Mann–Whitney U
test and Steel–Dwass test were used as the non-parametric analysis methods.
2.8. Data Availability
The datasets generated and analyzed during the current study are available from the corresponding
author, K.T., upon reasonable request.
3. Results
To verify the beneficial effect of B-3 administration on muscle tissue and muscle function, we used
two different animals. Rats were used to examine the muscle mass and some activated signaling
pathways (Experiment 1). On the other hand, mice were used for functional evaluation of B-3HK on
the muscle strength (Experiment 2).
Experiment 1
3.1. The Effects of B-3 Administration on Body and Tissue Weight in Rats
We first evaluated changes in muscle mass in rats after B-3 administration according to the
schedules described (Figure 1). A significant increase in the weight of the soleus (a slow oxidative
(SO) fiber-dominant muscle) per total body weight was observed in the B-3HK group compared with
the control group. In addition, the weights of the plantaris and gastrocnemius (fast glycolytic (FG)
fiber-dominant muscles) per total body weight tended to be higher in the B-3HK group than in the
control group (Table 1), but without statistical significance. Although the masses of these muscles were
also higher in the B-3L group and the leucine (a muscle hypertrophy promoting nutrients) group than
in the control group, the differences were not significant. A significant difference in food intake was
observed at week 1 between the control and B-3HK groups, but there were no significant differences
afterwards. There were no significant differences in body weight at each time point, or in liver weights
at week 4, between each group (Table 1).
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3.2. B-3HK Promoted Phosphorylation of Akt in the Rat Soleus
To clarify the mechanisms by which B-3HK increased muscle mass, we investigated the activation
of Akt, one of the key regulators of protein synthesis in skeletal muscle [20]. The western blot
results indicate that the levels of activated Akt in the soleus were significantly increased by B-3HK
administration (Figure 2). It is well known that activated Akt in skeletal muscle induces the mTOR
signaling pathway, which is a critical pathway regulating protein synthesis, leading to increased muscle
mass. We observed that B-3HK tended to induce phosphorylation of mTOR and its downstream
molecule p70S6K in soleus, similarly to leucine (Figure 3), indicating that the possible involvement of
the Akt-mTOR-p70S6K signaling pathway in increased muscle mass by B-3HK administration.
 
Figure 2. The effects of B-3 on Akt activation in the soleus. Representative bands and the expression
ratio of pAkt to Akt in the soleus are shown (n = 9, 10). Difference was analyzed for statistical
significance using Mann–Whitney U test (* p < 0.05). The data are expressed as the means and SEs.
Figure 3. The effects of B-3 on mTOR signaling in soleus. Western blotting was used for the signaling
pathways related protein synthesis in rat soleus muscle. (A) Representative bands and the expression
ratio of (B) p-mTOR to mTOR and (C) p-p70S6K to p70S6K are shown (n = 6). Leucine was used as a
positive control for induction of mTOR. The data are expressed as the means and SEs. Abbreviations:
Cont, control; Leu, leucine; B-3L, live B-3; B-3HK, heat-killed B-3.
10
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3.3. The Effects of B-3 on the AMPK-PGC-1α-Mitochondrial Biogenesis Pathway in the Rat Soleus
We then examined the effects of B-3 administration on muscle metabolism, which is related to
energy productivity and consumption [21]. B-3HK significantly promoted the activation of AMPK
(Figure 4A,B), which regulates energy balance at both the cellular and physiological levels as a
master regulator of metabolism [22,23]. No change was observed in the group treated with leucine,
a well-known muscle hypertrophy-promoting nutrient. Moreover, B-3HK also significantly increased
the mRNA expression of peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α,
a master regulator of mitochondrial biogenesis [24], and cytochrome c oxidase (CCO), which has been
reported to control enzymes related to the mitochondrial oxidative phosphorylation system (OXPHOS)
at the mitochondrial membrane [25,26], in the soleus (Figure 4C,D). Although the expression of these
genes was also higher in the B-3L group than in the control group, the differences were not significant.
 
Figure 4. B-3 enhanced the AMPK-PGC-1α-mitochondrial biogenesis signaling pathway in the soleus.
(A) Representative bands and (B) the expression ratio of pAMPK to AMPK in the soleus are shown
(n = 6). (C,D) qPCR was used to evaluate the relative mRNA expressions of PGC-1α, CCO1, CCO2,
CCO4 and CCO5B in the soleus (n = 12–13). Statistical differences were analyzed for significance using
the Steel–Dwass test (* p < 0.05, ** p < 0.01, versus control). The data are expressed as means and SEs.
Abbreviations: Cont, control; Leu, leucine; B-3L, live B-3; B-3HK, heat-killed B-3.
3.4. B-3HK Promoted the Distribution of Oxidative Fibers in the Gastrocnemius in Rats
A high expression of PGC-1α is well known to be involved in shifting muscle fiber type
distribution toward oxidative fibers [27]. To examine the enhancing effect of B-3HK on the oxidative
fiber composition in the gastrocnemius, an FG fiber-dominant muscle adjoining soleus was evaluated
by counting the number of sarco-/endoplasmic reticulum Ca2+ (SERCA)2 ATPase-positive fibers
(Figure 5A). The administration of B-3HK significantly increased the relative abundance of type I
muscle fibers (the most oxidative fibers) compared with saline administration (Figure 5B). B-3HK had
a greater effect than B-3L in promoting the distribution of oxidative fibers. This finding indicates that
B-3HK induced PGC-1α expression in the gastrocnemius as well as in the soleus.
11
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Figure 5. B-3 promoted the switching of type 1 fibers through the AMPK signaling pathway in
rats. (A) Representative results of immunohistochemistry against SERCA2 ATPase in the rat medial
gastrocnemius. The scale bar represents 100 μm. (B) The mean percentage of SERCA2 ATPase-positive
fibers was determined among 450 fibers in three sections per rat (n = 7). Statistical differences were
analyzed for significance using the Steel–Dwass test (* p < 0.05, versus control). The data are expressed
as the means and SEs.
Experiment 2
3.5. B-3HK-Enhanced Fitness Performance in Mice
Since increasing muscle mass was expected to enhance muscle strength, we used a murine model
to evaluate the effects of B-3HK on muscle function. We observed a significantly higher level of grip
strength in the B-3HK group compared to the control group at both two and four weeks (Figure 6),
in addition to significantly increased muscle mass in the mice’s solei (Supplementary Table S2).
 
Figure 6. The effect of B-3 on whole-body grip strength in mice. Physical performance was analyzed by
the grip strength test at 2 and 4 weeks (n = 18). Differences with the control group were analyzed for
significance using Student’s t-test (** p < 0.01). The data are expressed as the means and SEs.
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4. Discussion
Skeletal muscle is the largest organ in the body; in most mammals, it makes up ~45%–55% of
the body mass and is a major determinant of the basal metabolic rate [28–30]. Our previous clinical
results in mild obesity subjects indicated that B-3 administration both decreases body fat percentage
and increases muscle mass [2]. Thus, we hypothesized that B-3 exerts beneficial effects on muscle mass
and function related to basal muscle metabolism that might contribute to its anti-obesity effects.
Indeed, in the present study, we found that daily administration of B-3 to rats for a prolonged
period tended to increase muscle mass and activate AMPK, a well-known master metabolic regulator,
in the soleus [22,23]. Furthermore, the gene expression of PGC-1α and CCO was higher in the B-3
administration group than in the control group. The increase in PGC-1α and CCO gene expression
indicates a possibility of the enhancement of basal metabolism through mitochondrial biogenesis and
OXPHOS [24–26]. Thus, these results suggest that B-3 induces mitochondrial biogenesis in skeletal
muscle through the AMPK-PGC-1α signaling pathway, which might be a mechanism by which B-3
exerts its anti-obesity effects.
Intriguingly, B-3HK had a greater effect than B-3L in eliciting some muscle improvements.
For example, B-3HK activated Akt-mTOR-protein synthesis signaling, and consequently increased
muscle mass. Through its beneficial effects, B-3HK was observed for the possible enhancement of grip
strength in a murine model. In addition, B-3HK was suggested to enhance mitochondrial biogenesis
(e.g., increase CCO gene expression) through AMPK-PGC-1α signaling pathways, probably leading
to increased mitochondrial energy productivity, and induced an oxidative fiber type composition in
the gastrocnemius.
In general, AMPK is well known to inhibit protein synthesis through the suppression of the mTOR,
a critical regulator of anabolic pathways [22,23], which indicates that the co-activation of both anabolic
and catabolic pathways does not occur in the skeletal muscle at the same time. However, we observed
the co-activation of Akt and AMPK in response to B-3HK by western blotting analysis. These results
suggest that several independent pathways from B-3HK might activate both Akt and AMPK. Since the
bacterial cells of B-3HK might contain various components, such as lipoteichoic acid, peptide glycans
and nucleotides, each component might separately activate the Akt and/or AMPK signaling pathway
with various strengths in the skeletal muscle. As a result, the mTOR-protein synthesis pathway might
be positively influenced in response to B-3HK for muscle hypertrophy, in spite of AMPK activation.
To unravel the reasons for this, further studies are required for the identification of bioactive factors.
Similarly to our observation, it has been reported that Lactobacillus plantarum TWK10 increases
muscle mass and promotes type I fibers (slow muscle) in murine gastrocnemius muscle [31]. Moreover,
TWK10 has shown potential as an ergogenic aid to improve aerobic endurance performance via
physiological adaptation effects in amateur runners and healthy humans [32,33].
Furthermore, the way in which heat-killing treatment enhances the effects of B-3 remains to be
elucidated. Plovier et al. reported that heat-killed Akkermansia muciniphila exerted stronger anti-obesity
effects than live A. muciniphila in high-fat diet-fed mice [34,35]. In addition, another study reported
that although the administration of heat-killed A. muciniphila improved several metabolic parameters,
such as insulin sensitivity and plasma total cholesterol, in obese insulin-resistant volunteers, it did not
change the gut microbiome structure [36]. Therefore, it has been suggested that the mechanism by
which heat-killed A. muciniphila exerts its effects involves the modulation of host immune responses and
the intestinal barrier function by an outer membrane protein (Amuc_1100 protein) through activation of
TLR2 and TLR4 [34,35]. It is also well known that Bifidobacterium has cell components that can regulate
TLR signaling pathways [37,38]. Thus, we speculate that certain cell component(s) of B-3HK might
exhibit enhanced ligand binding with targeted receptors to activate signaling pathways in intestinal
cells (e.g., intestinal epithelial cells or intestinal immune cells), and then induce the production of some
bioactive factors. Notably, the administration of serum from B-3HK-treated rats activated AMPK in a
differentiated L6 rat myoblast cell line (Supplementary Figure S2), indicating that bioactive factors
such as cytokines and hormones could have been present in the serum. In addition, some reports
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suggested that live and heat-killed probiotics strains had different immune responses, such as cytokine
secretion profiles [39,40], which may be one of the possible mechanisms by which heat-killed B-3 is
more effective on muscle functions. To clarify the differences in activity between B-3L and B-3HK,
further studies are needed to elucidate the specific B-3HK-affected signaling pathway and to identify
the bioactive factors in B-3HK-treated rat serum.
Recent studies have suggested that Bifidobacterium is recognized as a key taxon for physical
frailty and sarcopenia in elderly individuals [8]; however, it remains unclear whether the decreases
in bifidobacterial abundance that occur with age influence muscle health [7,41]. The present study
explored the positive relationships between Bifidobacterium and muscle health. Although further
studies using ageing models [42] are required, B-3HK was expected to be useful for improving muscle
atrophy, such as that occurring in sarcopenia according to the increase in muscle mass by B-3HK.
There are some limitations in this study. Firstly, we used leucine as a positive control for
activation of mTOR signaling pathway. Leucine tended to promote phosphorylation mTOR and
p70S6K (Figure 3b,c), but the effect appeared to be weaker than expected. Moreover, owing to the
limits of administrated volume and the solubility of leucine in saline, leucine was administrated at
0.131 g/kg/day, which was lower compared to previous study (>0.675 g/kg/day) by Fumiaki et al. [43].
The low dosage of leucine used in the present study might have influenced the degree of mTOR
phosphorylation induction. Secondly, the mechanisms of the effects of B-3, and the reason why
heat-killed B-3 was more effective, were not clarified. Moreover, since the results were observed
in animal models, translation of the effects to humans remains unknown. These issues need to be
addressed in future studies.
5. Conclusions
Daily administration of B-3, a probiotic strain for anti-obesity, promoted mitochondrial biogenesis
through the AMPK-PGC-1α signaling pathway in skeletal muscle, and the distribution of oxidative
muscle fibers through increasing in PGC-1α gene expression; and induced muscle hypertrophy through
the Akt signaling pathway in rats. Remarkably, it was observed that heat-killing treatment enhanced
the activities of B-3. In addition, B-3HK also showed potential in increasing grip strength in a mouse
model. These findings may contribute to the understanding of the mechanism of the anti-obesity
effects of B-3 and suggest its potential benefits for improving physical fitness and ameliorating physical
fatigue and muscle atrophy; in particular, after heat-killing treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/1/219/s1.
Figure S1. Histopathological images. Figure S2. The effects of the rat serum on AMPK activation in vitro. Table S1.
List of primer sets. Table S2. The effects of B-3 on body and tissue weight in the treated mice at 4 weeks.
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Abstract: Vitamin K health benefits have been recently widely shown to extend beyond blood
homeostasis and implicated in chronic low-grade inflammatory diseases such as cardiovascular
disease, osteoarthritis, dementia, cognitive impairment, mobility disability, and frailty. Novel and
more efficient nutritional and therapeutic options are urgently needed to lower the burden and the
associated health care costs of these age-related diseases. Naturally occurring vitamin K comprise the
phylloquinone (vitamin K1), and a series of menaquinones broadly designated as vitamin K2 that
differ in source, absorption rates, tissue distribution, bioavailability, and target activity. Although
vitamin K1 and K2 sources are mainly dietary, consumer preference for diet supplements is growing,
especially when derived from marine resources. The aim of this review is to update the reader
regarding the specific contribution and effect of each K1 and K2 vitamers in human health, identify
potential methods for its sustainable and cost-efficient production, and novel natural sources of
vitamin K and formulations to improve absorption and bioavailability. This new information will
contribute to foster the use of vitamin K as a health-promoting supplement, which meets the increasing
consumer demand. Simultaneously, relevant information on the clinical context and direct health
consequences of vitamin K deficiency focusing in aging and age-related diseases will be discussed.
Keywords: vitamin K; diet supplement; age-related diseases; vitamin K-dependent proteins;
pathological calcification; inflammation
1. Introduction
Historically recognized as a key factor for the synthesis of blood clotting factors in the liver, vitamin
K is currently known to be involved in a wide range of biological processes and is associated with
many pathological conditions. Since its discovery in 1936 [1], the most well-known function of vitamin
K is as a cofactor for the γ-glutamyl carboxylase (GGCX) enzyme responsible for the post-translational
modification of vitamin K-dependent proteins (VKDPs) through the conversion of specific glutamic acid
(Glu) into calcium binding γ-carboxyglutamic acid (Gla) residues [2,3]. In humans, at least 17 different
VKDPs, which are also known as Gla proteins, have been identified to date, and are generally referred
to as hepatic and extra-hepatic VKDPs, according to the synthesis location (Table 1). The hepatic group
of VKDPs synthetized in the liver are essential for regulating blood coagulation and comprise the
coagulation factors II, VII, IX, and X, and the anti-coagulation proteins C, S, and Z. Extra-hepatic VKDPs
include matrix Gla protein (MGP), osteocalcin (OC), Gla-rich protein (GRP), growth arrest-specific
protein 6 (Gas6), proline-rich Gla proteins (PRGP1 and 2), transmembrane Gla proteins (TMG3 and
4), periostin, and the GGCX enzyme. These extra-hepatic VKDPs, which are mostly known for their
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protective role in the bone and cardiovascular system, exhibit a broad tissue distribution and are
involved in a wide range of biological functions such as bone homeostasis, ectopic calcification, cell
differentiation and proliferation, inflammation, and signal transduction. γ-carboxylation has been
shown essential for the correct function of VKDPs. In addition, vitamin K deficiency has been linked
to several pathological conditions such as cardiovascular diseases (CVD), chronic kidney disease
(CKD) [4], osteoarthritis (OA) [5], rheumatoid arthritis (RA), osteoporosis, cancer, dementia, certain
skin pathologies, functional decline, and disability [6]. Most of these chronic health conditions are
associated with pathological calcification and inflammation, where the role of VKDPs and vitamin K is
being highlighted. Since both inflammation and pathological mineralization are associated with the
aging process and these diseases are highly prevalent in the elderly, a new concept on the involvement
of vitamin K in inflammation is growing. In addition, novel roles have been disclosed for vitamin
K independent of its activity as a cofactor for GGCX, such as an antioxidant, anti-inflammatory,
promoter of cognition, inhibition of tumor progression, and transcriptional regulator of osteoblastic
genes. However, in clinical practice, vitamin K is mainly used in blood clotting-associated prophylaxis.
The number of in vitro, in vivo, and clinical data showing the beneficial effects of vitamin K without
adverse effects or documented toxicity raised increasing interest on the use of vitamin K as a health
promoting supplement. In fact, aging societies represent a major economic challenge for health care
systems, and diet supplements promoting healthy aging and improving the prognosis of age-related
diseases, are required to be implemented in clinical practice.
In this context, it is crucial to highlight that naturally occurring vitamin K comprise the vitamin
K1 (also known as phylloquinone or phytonadione), and a series of menaquinones (MKs), designated
as vitamin K2 [3,6]. A growing amount of scientific evidence has demonstrated differences between
vitamin K1 and K2 in terms of source, function, and target activity. While vitamin K1 and K2 from
different sources are currently commercially available and are becoming popular as health supplements,
novel tactics for more efficient and affordable attainment of both vitamers are currently being explored.
However, it is important to clearly establish a specific cause-effect for each of the vitamin K vitamers to
increase efficacy and disease-target specificity.
This work thoroughly reviews available data regarding differences between vitamin K1 and
K2, contextualized with clinical aspects of vitamin K deficiency, including their sources, functions,
target activity, and involvement in age-related diseases. Processes for the chemical and biological
production of vitamin K1 and K2 will be briefly addressed. Additionally, novel sources with potential
biotechnological application, and new formulations to improve vitamin K absorption and bioavailability
are presented.
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2. Clinical Context of Vitamin K
2.1. Vitamin K Deficiency
Vitamin K deficiency is clinically characterised by a bleeding tendency due to the loss of function
of vitamin K-dependent hepatic clotting factors. Vitamin K deficiency is not very common in adults
and is usually associated with specific conditions, such as malabsorption disorders, antibiotics, and
drug interactions, especially with coumarin-based anticoagulants, or an extremely poor vitamin
K-content diet. Anticoagulant treatment with coumarin derivatives is widely prescribed to prevent
thromboembolic events or stroke in patients with atrial fibrillation or cardiac disease. Clinical evaluation
of the vitamin K status is assessed only in specific conditions, such as individuals with bleeding disorders
or under anticoagulants. 4-hydroxycoumarin anticoagulant drugs such as warfarin, acenocoumarol,
and phenprocoumon are widely used oral anticoagulants acting as vitamin K antagonists (VKAs). In
these cases, prothrombin time, which is indicative of the time necessary for blood clotting and known as
the International Normalized Ratio (INR), is usually the parameter used for a drug dosage. Treatment
with VKAs inhibits the recycling of vitamin K and the synthesis of the vitamin K-dependent biologically
active clotting factors II, VII, IX, and X. Patients’ warfarin dose is adapted based on INR scores so that
it remains in the therapeutic range to prevent thrombosis or haemorrhagic complications [34].
Gastrointestinal disorders can compromise the pancreatic/biliary functions and trigger fat
absorptive mechanisms, such as in the case of celiac disease, cystic fibrosis, ulcerative colitis, cholestasis,
short bowel syndrome, or in a situation of bariatric surgical intervention. These conditions might lead
to a situation of inadequate absorption of vitamin K and, ultimately, to a status of vitamin K deficiency.
Antibiotics also interfere with vitamin K levels since they generally contribute to a decrease of
vitamin K-producing bacteria in the gut [35]. Vitamin K deficiency is currently observed in patients
with prolonged oral broad-spectrum antibiotic therapy. Antibiotics such as cephalosporins, which
include the N-methylthiotetrazole side chain, are suggested as inhibitors of hepatic vitamin K epoxide
reductase [36–38]. A nested case-control study performed in a cohort of 6191 patients concluded that
patients receiving cephalosporins and other antibiotics for more than 48 h had an increased risk of
haemorrhagic events [39].
Some medications are also reported to interfere with vitamin K absorption. These are drugs
prescribed to reduce cholesterol in a dyslipidemia scenario, or drugs that interfere with lipases
activity used for obesity treatment such as orlistat, or bile acid sequestrants, such as colesevelam and
cholestyramine. Overall, these medications can affect the absorption of fat-soluble vitamins and lead to
a decrease in the vitamin K status [40,41]. In these situations, monitoring and supplementation might
be recommended.
Newborns might experiment with vitamin K deficiency during the first few weeks of life as a
consequence of a combination of factors that contribute to low levels of vitamin K [42]. Poor vitamin K
carriage through placenta, low content of vitamin K1 in breast milk, and liver immaturity that leads
to an inefficient use of vitamin K and recycling represent part of the conditions that could lead to a
situation known as vitamin K deficiency bleeding (VKDB) [43,44]. To reduce the incidence of VKDB,
oral vitamin K prophylaxis with phytomenadione, or administration of a single intramuscular (IM)
dose of 0.5–1 mg at birth is recommended by the World Health Organization (WHO) [45].
In the last decade, the bulk of research on vitamin K has shifted beyond coagulation, which further
explores its physiological role in skeletal, CVD, and brain health [46,47]. Vitamin K deficiency has
been associated with a higher risk of age-related chronic diseases such as osteoporosis, CVD, RA,
and OA, which contributes to its onset and progression [5,48–50]. Several extra-hepatic VKDPs such
as MGP, GRP, and OC are well described to be of vital importance in the pathophysiology of these
age-related diseases. More recently, several in vitro and in vivo studies, as well as clinical data, have
highlighted the role of vitamin K in cognitive performance, particularly associated with Alzheimer’s
disease. The action of vitamin K in brain cells’ development and survival has been linked with its
role in the synthesis of sphingolipids, and through the function of the VKDPs, Gas6, and protein
22
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S [51]. Although the association between vitamin K deficiency and cognitive impairment is still not
definitively established, several works have shown a direct correlation between low levels of vitamin
K and deterioration of cognitive and behavioural performances (recently reviewed in Reference [47]).
In fact, the current use of oral anticoagulants acting as VKAs, has also been associated with adverse
clinical outcomes in extra-hepatic tissues such as bone, cartilage, the vascular tree, and brain [52–55].
2.2. Vitamin K Antagonists (VKAs)
The role of vitamin K in arterial calcification has been associated with its function as a co-factor
for carboxylation of MGP and GRP. The role of MGP as an inhibitor of vascular calcification (VC) is
strictly dependent on its γ-carboxylation status [56]. In addition, only the carboxylated form of GRP
was shown to have calcification inhibitory properties [26]. Preclinical studies clearly demonstrate
that the use of VKAs induces a vitamin K deficiency status, which enhances medial and intimal
calcification in the vascular tree. Vitamin K treatment was shown not only to be able to inhibit
mineralization in warfarin-treated rats, but even to promote the regression of the pre-formed medial
elastocalcinosis [57]. This is in line with several studies demonstrating negative effects of warfarin
treatment in cardiovascular health [58]. In humans, the detrimental effect of VKAs on extra-coronary
calcification has been shown on a small cross-sectional study in patients on long-term oral coumarin
treatment [59]. In another cohort study assessing 430 patients, the presence of calcification in peripheral
arteries was compared between warfarin patient users and non-users. In this study, the prevalence of
arterial calcification was 44% greater in patients on warfarin therapy versus without warfarin use [60].
Several [61–63] clinical studies, but not all [64] clinical studies, give indications that warfarin
promotes atherosclerotic calcification, since an increase in coronary calcification, which is predominantly
atherosclerotic, was observed in patients using VKAs. An observational study reported that the use of
VKAs is related with increased aortic stiffness in end-stage CKD patients undergoing haemodialysis
(HD) [65]. In a retrospective clinical study including patients on haemodialysis who developed
calciphylaxis, 6/8 patients were on VKAs therapy. This suggests VKAs therapy as one of the factors
involved in the development of calciphylaxis [66], which is a rare but fatal complication in CKD patients,
characterized by ischemic skin ulceration due to mineralization affecting subcutaneous small arterioles.
Recently, a large population-based cohort study including individuals from the Gutenberg health
study comprising 287 VKAs users and 14,564 VKAs non-users demonstrated that patients on VKAs
therapy had a higher cardiovascular burden. In this cross-sectional study, although no cause-effect
interpretation could be made, the authors suggest a relation between VKAs use and several parameters
of clinical and subclinical CVD, such as with increased arterial stiffness, decreased cardiac systolic
function, and higher left ventricular mass. This study also shows an association and dose-response
effect of VKAs intake with low grade systemic inflammation. This was shown by the high levels of
high-sensitivity C-reactive protein (hsCRP) found in long-term VKAs users when compared with
short-term VKAs intake users [67]. A post hoc analysis used serial coronary intravascular ultrasound
examinations and involved eight prospective randomized trials. Changes in coronary atheroma burden
were compared between patients with coronary artery disease patients treated with (n = 171) and
without (n = 4129) warfarin for 18 to 24 months. In this study, the authors concluded that warfarin
use was independently associated with serial coronary calcification with no association with renal
function, statin therapy, or changes in atheroma volume [68].
Overall, the available studies and the information on the detrimental side effects of VKAs reinforces
the notion that special care should be given on their clinical use. This is even more relevant for patients
requiring long-time anticoagulant therapy and for those considered to be at higher atherosclerotic risk.
Furthermore, new direct oral anticoagulants (DOACs) drugs that do not inhibit vitamin K recycling
and target different factors in the coagulation cascade, specifically factor Xa and thrombin, such as
dabigatran, rivaroxaban, apixaban, and edoxaban, are now available as medications. More recently,
a cross-sectional observational study including 236 atrial fibrillation patients were divided in three
groups, according to the type of anticoagulation therapy (no oral anticoagulation, VKAs or DOACs).
23
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The main findings of this study pointed toward an increased prevalence of calcification of the thoracic
aorta in patients treated with VKAs when compared to patients with DOACs treatment, with no effect
on calcification observed in DOACs-treated patients compared with no oral anticoagulation group [69].
DOACs are recognized as an attractive alternative option to VKAs for short-term and long-term
coagulation due to their single-dose oral administration without the need for repeated blood monitoring,
their proven safety, and short half-life [70]. This will allow the safe use of vitamin K as a supplement to
prevent soft tissue pathological mineralization in aging diseases such as osteoporosis, OA, CKD, and
CVD. Nevertheless, randomized controlled trials addressing causality of VKAs and DOACs on VC are
still warranted.
3. Vitamin K1 and K2: Similar Function but Different Absorption, Storage, Bioavailability,
and Targets
3.1. Vitamin K Chemical Structure
Vitamin K are fat-soluble vitamins that occur and function in the membranes of living organisms
and comprise vitamin K1 and vitamin K2. Both forms share a 2-methyl-1,4-naphtoquinone double ring
structure in their chemical backbone (menadione, vitamin K3) but differ in their lipophilic side chain
(Figure 1). While vitamin K1 has a phytyl substituted chain, vitamin K2 contains unsaturated isoprenyl
side chains, designated as MK-4 through to MK-13, depending on its length [71,72]. Vitamin K1 is
present in vegetables, mainly in green leafy vegetables, vegetable oils, and some fruits and it is the main
source of vitamin K in diet. Vitamin K2 is found in animal-based and fermented foods or produced by
bacteria in the human gut. MK-4 is an exception since is not a common product of bacterial synthesis
but considered to be of animal origin based on its tissue-specific conversion from vitamin K1 [73,74].
On the other hand, although often referred to as vitamin K3, menadione is not a natural component of
foods but is considered a product of catabolism of vitamin K1 and a circulating precursor of tissue
MK-4 [72,74]. For this reason, it should, more adequately, be known as a pro-vitamin.
Figure 1. Chemical Structure of Vitamin K vitamers. Phylloquinone or vitamin K1 (A), menaquinone-n
(MKn), or vitamin K2 (B) and menadione or vitamin K3 (C).
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3.2. Vitamin K Functions
Both vitamin K1 and K2 can act as cofactors in the carboxylation process of VKDPs. The
reduced form of vitamin K (vitamin K hydroquinone, KH2) is the active cofactor for the γ-glutamyl
carboxylase (GGCX) enzyme, which modifies Glu residues to Gla residues in VKDPs. The reaction
also requires carbon dioxide and oxygen. During the carboxylation reaction, vitamin K 2,3-epoxide
(KO) is continuously recycled by vitamin K epoxide reductase (VKOR) and vitamin K reductase
(VKR), to its quinone (K) and KH2 forms in a process known as the vitamin K cycle [75–77]. Due to
this efficient cell recycling process, the organism can preserve limited nutritional stores of vitamin
K depending on minimal vitamin K amounts to cover its daily diet requirements [78]. Of note, a
higher bioactivity of MK-7 relative to K1 as a cofactor of GGCX-mediated protein carboxylation in
both hepatic and extra-hepatic tissues is supported by several in vitro and in vivo studies. An in vitro
study demonstrated that cofactor activity of vitamin K increased with the length of the aliphatic side
chain [79].
In addition to the proposed involvement of some VKDPs in inflammation processes, vitamin K
has been proposed to act as an anti-inflammatory and antioxidant agent independent of its GGCX
cofactor activity. Several in vitro and animal studies have shown that vitamin K reduced the activation
of nuclear factor kappa B (NFκB) and inhibited IkappaB kinase (IKB) α/β phosphorylation, with
a consequent decrease in the production of pro-inflammatory cytokines [80–82]. This action was
proposed to be mediated through the naphthoquinone ring of vitamin K, and it is not surprising
that both vitamin K1 and K2 (MK-3, MK-4, and MK-7) were found to suppress a liposaccharide
(LPS)-induced inflammatory state in vitro and in vivo in the mouse model. In addition, a role for
vitamin K as an antioxidant agent has been proposed. The reduced form of vitamin K (KH2) was
shown to protect phospholipid membranes from peroxidation by direct reactive oxygen species (ROS)
uptake [83,84]. An important player in this antioxidant activity is the paralogous enzyme of the vitamin
K epoxide reductase complex subunit 1 (VKORC1), which is the vitamin K epoxide reductase complex
subunit 1 (VKORC1)-like 1 (VKORC1L1), responsible for increasing KH2 intracellularly and limiting
the amount of intracellular ROS [85]. In cultured neurons and oligodendrocytes, vitamin K was shown
to prevent cell death caused by oxidative stress by inhibiting the activation of 12-lipoxygenase (12-LOX).
Both vitamin K1 and K2 have been shown to have antioxidant properties [86,87]. Recently, a study
aiming to evaluate the effect of vitamin K on the redox metabolism of human osteoblasts cultured in the
presence of hydroxyapatite-based biomaterials showed that vitamin K prevented a redox imbalance by
decreasing ROS levels. The highest effect was obtained with MK-7 [88].
The involvement of vitamin K with sphingolipids metabolism, although known for some decades,
has recently gained renewed attention due to suggested implications of alterations in sphingolipid
metabolism with the aging process [89] and neurodegenerative disorders such as Alzheimer’s and
Parkinson’s diseases [90,91]. It has been shown that vitamin K activates 3-ketodihydrosphingosine
(3-KDS) synthase (also known as serine palmitoyltransferase), which is the enzyme involved in the initial
step of sphingolipid biosynthesis [92], and the sulfotransferase responsible for sulfatide synthesis [93]. In
rats, warfarin treatments were associated with decreased activity of 3-KDS synthase and sulfotransferase,
and significant reductions in brain sulfatides, sphingomyelin, and cerebrosides [93,94]. Data on the
association of specific vitamin K vitamers with sphingolipid metabolism in humans is still scarce
and warrants further investigation. The predominant form of vitamin K in the brain of rats and
humans is MK-4 [95,96]. In rats, the stimulatory effect of vitamin K on the activity of sphingolipids
metabolism enzymes was observed with either K1 or MK-4 as a source of vitamin K [97]. In addition,
the concentration of MK-4 in the rat brain was shown to positively correlate with the concentration of
sphingolipids, particularly with sulfatides and sphingomyelin, and both K1 and MK-4 increased with
K1 intake [96]. This is in line with our knowledge that MK-4 is a result of K1 conversion, and that
cerebral MK-4 originates from K1 intake [98]. In humans, a few studies have shown a relationship
between low levels of K1 and Alzheimer’s disease and impaired memory performance in older
adults [99,100]. However, specific relationships between higher K1 or MK-4 levels and sphingolipid
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synthesis requires further elucidation. A currently active field of research around vitamin K relates
to its potential anti-cancer effect. Although this topic will not be explored in this review, vitamin K
has been implicated with the inhibition of several neoplastic cell lines mainly by inducing apoptosis
and cell cycle arrest of cancer cells through various mechanisms [101]. Among the different forms of
vitamin K tested, vitamin K2 was shown to inhibit several cancer cell lines without side effects and
has been selected as a promising agent for cancer prevention and clinical therapy. Clinical trials have
demonstrated the potential of vitamin K2 to improve the prognosis of cancer patients [102,103].
3.3. Vitamin K1 and K2 Absorption, Storage, and Bioavailability
Although both vitamin K1 and K2 are involved in γ-carboxylation of VKDPs, these molecular
forms act differently in processes such as absorption, transport, cellular uptake, tissue distribution,
and turnover [78]. Despite sharing a similar structure (Figure 1) and physicochemical characteristics,
natural vitamin K forms have different lipophilicity. The longer-chain menaquinones, including MK7,
are much more hydrophobic and have longer half-times. Although there are many studies reporting
different results, it seems clear that the length and degree of saturation of the isoprene side chain
influences their clearance from circulation and bioavailability [72]. In healthy adults, absorption of
MKs (MK-4, MK-7, and MK-9) has been compared with K1. The results indicate that MK-7 is the most
efficiently absorbed form of vitamin K [104–106]. Although K1 is the major type (>90%) of dietary
vitamin K, it is poorly retained in the organism. Its concentrations in animal tissues are remarkably
low when compared with those of MKs, especially MK-4, which is the major form (>90%) of vitamin K
found in animal tissues [74,107].
Both vitamin K1 and K2 forms follow a similar and well-established intestinal absorption
pathway. Following their packing into chylomicrons, they are further transported in circulation to
their target tissues by lipoproteins [78,106]. While vitamin K1 in circulation is mostly associated with
triacylglycerol-rich lipoproteins (TLR), vitamin K2 is mainly transported by low-density lipoproteins
(LDL). This difference could also justify the higher half-life time, bioavailability, and higher bioactivity
of MK-7 when compared with vitamin K1. A study comparing vitamin K1 and MK-7 shows that MK-7
had a half-life time of 68 h compared with only 1–2 h for K1 [105]. This results in more stable blood
levels and a higher bioavailability of MK-7, while vitamin K1 is rapidly removed from circulation,
accumulated in the liver, and excreted in urine and bile. In the Japanese population, known for its
higher K2 diet intake, mainly due to natto consumption, MK-7 was found to be the predominant
circulation form of vitamin K [108]. The concept that long-chain MKs are available longer in circulation
than K1 for cell uptake supports the suggestion that vitamin K2 represent a more adequate form of
vitamin K delivery to extra-hepatic tissues such as bone and the vasculature. In fact, using equimolar
amounts of both vitamin K forms as supplements, a cross-over study showed that circulating levels of
carboxylated OC were higher in subjects taking MK-7 when compared to the vitamin K1 supplemented
group [105]. In the same study population, another cross-over study shows that MK-7 was almost three
times more potent than K1 in counteracting the effect of coumarin anticoagulants [105]. This rationale
might explain the reported prevalent association of vitamin K2 and not K1 intake, with a reduced
risk of CVD [109]. In fact, although several studies have demonstrated a relation between vitamin K1
and cardiovascular health, studies aiming to compare the effects of K1 and K2 clearly highlight the
prevalence of K2 as a cardiovascular protective agent. In the prospective, population-based Rotterdam
Study, comprising 4807 subjects free from myocardial infarction at baseline, followed up for 7 years,
low levels of vitamin K2 but not K1 were associated with a significant risk in coronary heart disease
(CHD), all-cause mortality, and severe aortic calcification [109]. In the Prospect-EPIC cohort study,
enrolling 16,057 women free from CVD at baseline, with a mean follow-up of 8.1 years, an inverse
association between vitamin K2 (particularly MK-7, MK-8, and MK-9) and risk of CHD was found
with an 85%–100% reduction in coronary events for every 10 μg increase in vitamin K2 intake [110].
Again, vitamin K1 intake was not significantly associated with cardiovascular outcomes [110,111].
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In relation to bone health, although vitamin K2 has been suggested as the vitamer with the highest
bone-protecting effects, available clinical data is still conflicting in this subject. In fact, the effect of
vitamin K supplementation has been evaluated in several clinical trials using either K1 or K2, with
results pointing for a protective effect of both vitamers through the improvement of bone quality with
increased strength and reduced turnover, and a reduction in fractures (reviewed in Reference [6]).
Several inconsistent results are found in the literature concerning the specific effects of each vitamin
K vitamer. This might be explained by the small sample number in interventional studies and the
heterogeneity associated with these studies specifically related to different evaluation methods for
vitamin K status, supplementation doses, and specific types of vitamin K. Importantly, simultaneous
comparisons between the effects of K1 and different MKs such as MK-4 and MK-7 on bone outcomes
should help the clarification of the most suitable vitamer for improving bone health.
4. Dietary Sources of Vitamin K1 and K2
Vertebrates, including humans, do not synthesise vitamin K and depend on dietary sources to
obtain the required daily allowance. Moreover, vitamin K body storage is rapidly depleted in the
absence of a regular dietary intake [112]. Comprehensive reviews addressing both vitamers content in
a variety of foods have recently become available [104,113–115]. However, only a few national food
composition databases including vitamin K content are available, and most of them do not include
specific information on K1 and K2 content in each food item.
Vitamin K1 is a final product of the shikimate pathway in the photosynthesis process, and, therefore,
can be found in all photosynthetic organisms, including plants, algae, and cyanobacteria [116,117]. The
main sources of dietary vitamin K are green leafy vegetables such as kale, romaine lettuce, broccoli,
cabbage, and spinach [115]. Vegetable oils such as soybean, sunflower, olive, and canola are the next
best dietary source of K1 [118,119]. Lower amounts of K1 can also be found in fruits, cereals, meat, and
dairy products [120]. High levels of vitamin K1 can be found in common Japanese food items such as in
vegetables, with the highest value found in perilla (raw, 1007 μg/100 g), in edible seaweed such as hijiki
(Sargassum fusiform, dried, 175 μg/100 g) and wakame (Undaria pinnatifida dried, 1293 μg/100 g) [121].
Different vitamin K contents have been reported for the edible red algae Porphyra sp., commonly
known as laver or nori, describing levels of around 2600 μg/100 g on a dry basis in the dried nori, with
a significant reduction found in toasted dry nori (approximately 390 μg/100 g on a dry basis) [122] and
in roasted and seasoned laver (dried 413 μg/100 g) [121]. Additionally, different types of vegetable fats
and oils such as soybean oil (234 μg/100 g) and green powdered tea (3049 μg/100 g), which are widely
consumed in Japan, are reported to contain high amounts of K1 [108].
Vitamin K2 is mainly produced by bacteria, except for MK-4, which can be produced by
tissue-specific conversion from vitamin K1 in animals. This reaction is catalysed by the UbiA
prenyltransferase domain-containing 1 enzyme [74], which involves the menadione form as an
intermediate. In fact, MK-4 formed from vitamin K1 can be found in higher amounts in animal
organs not commonly consumed in the diet (liver, brain, pancreas, or kidney) [95]. Vitamin K2, such
as MK-7, MK-8, and MK-9, which is the most recognized forms in terms of nutrition value [123],
are biosynthesized by several obligate and facultative anaerobic bacteria [113,124]. In addition, the
bacterial flora in the human gut is described to produce several long-chain MKs. In the human large
intestine, the major forms of K2 found to be present, including MK-6, MK7, MK-8, MK-10, and MK11,
are produced by several types of enterobacteria such as Bacteroides, Enterobacteria, Eubacterium lentum,
and Veillonella [125,126]. Although intestinal bacteria synthesis is described to contribute to vitamin K
requirements [127], it is not yet clear its true contribution to human vitamin K2 nutrition, and there is a
need for further progress in this area [123].
The use of bacteria in food production processes has greatly increased in the last decade [128]
along with the interest in the production of food products enriched with vitamin K2. Several lactic
acid bacteria commonly used for making fermented food products, and generally recognized as
safe (GRAS), have been used for the biosynthetic production of MKs for the last few decades, with
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significant production amounts of MKs (MK-7 to MK-10) [129]. Nevertheless, some genera of bacteria
widely used in the food industry, including Lactobacillus and Streptococcus, have lost the functional
ability to produce vitamin K2. Due to this, the K2 content of food products using these bacteria is
almost undetectable [130]. A study examining the capacity of several bacterial strains to produce K
compounds selected three strains of Lactococcus lactis ssp. cremoris, two strains of Lactococcus lactis
ssp. lactis, and Leuconostoc lactis as high producers able to deliver more than 230 nmol/g dried cells of
MK-7 to MK-10 [129]. In fact, several other bacterial species including Brevibacterium linens, Brochontrix
thermosphacta, Hafnia alvei, Staphylococcus xylosus, Staphylococcus equorum, and Arthrobacter nicotinae,
which are commonly used in industrial food fermentations, are well-known to produce several forms
of K2, from MK-5 to MK-9, in different amounts [113].
Other major sources of vitamin K2 are meat, especially chicken, bacon, and ham [120]. In addition,
egg yolks and high-fat dairy products, such as hard cheeses, provide appreciated amounts of this
vitamer [73]. Of note, cheese was found to be the most important source of dietary long-chain MKs
(MK-8 and MK-9) [131]. In particular, propionibacteria-fermented cheese, such as Norwegian Jarlsberg
cheese and Swiss Emmental cheese, were shown to have the highest concentration of vitamin K2 in the
form of tetrahydromenaquinone-9 [132]. Another important dietary source of vitamin K2, with interest
for the industry, are fermented plant foods, such as natto. Natto is a traditional Japanese soybean food
produced by fermenting cooked soybean with Bacillus subtilis natto and considered one of the most
relevant dietary sources of MK-7 (around 1000 μg/100 g natto) [104,121,133].
5. Vitamin K1 and K2 Chemical and Biotechnological Production Methods
The health benefits of vitamin K [46,134], together with the growing trend for sustainable and
natural health products, has led to a high interest on the search for sustainable and cost-effective
processes to produce natural vitamin K. Both chemical and biochemical synthetic strategies for vitamin
K are currently being explored. Chemical synthesis processes for both vitamin K forms, either vitamin
K1 or vitamin K2, have been developed in the past few years [135–137], while biosynthetic production
methods have been mostly explored for MKs (MK-4/MK-7). In addition, the continuous discovery
of vitamin K vitamers in aquatic organisms, widely recognized as a valuable source of bioactive
compounds and with biotechnological potentialities, might open new perspectives for novel vitamin K
sources and production methods.
5.1. Vitamin K1
Currently, a chemical synthesis process for vitamin K1 is well established [138,139] and used in a
wide range of commercial applications, from human nutrition to pharmaceutical products [140–142],
but not in cosmetics where vitamin K1 formulations were banned from use in 2009 [143]. Improvements
on the chemical synthesis methods of vitamin K1 have been mainly focused on the reduction of the
inactive Z-isomer formation [141], and in decreasing the use of toxic chemicals that are hazardous to
both the environment and humans [142,144]. One of the major chemical synthesis challenges resides
in eliminating menadione traces [138,144]. In fact, menadione and its derivates such as menadione
sodium bisulfite and menadione sodium diphosphate were banned from human products since 1963
due to evidence of toxicity, even though they are still used for animal feed as pro-vitamins [145].
Research on the biotechnological production of vitamin K1 is still quite incipient but constitute a
promising route to increase the quality of the final product (active trans(E)-isomer), and to reduce the
costs associated with the inclusion of this vitamin in diet supplements [146].
5.2. Vitamin K2
Chemical synthesis of vitamin K2, although described almost 40 years ago [147], remains
challenging due to the need of stereoselective synthesis of the bioactive all-trans configuration. Despite
traditional high cost and low yield, chemically synthetized vitamin K2 has gained renewed interest
with new and optimized methods for an efficient and stereoselective production of high pure (99.9%)
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all-trans vitamin MK-7 with a moderate yield (11% starting from menadione) [148]. Additionally,
chemical approaches have been used to synthetize novel vitamin K2 analogues, reported to have higher
bioactivities when compared with their natural counterparts [136,149–151]. These new compounds,
with vitamin K activity but different pharmacological properties compared with the natural homologues,
might reveal novel and interesting biological activities for commercialization as active diet supplements.
Compared to chemical synthesis, biosynthetic production methods for natural vitamin K2
using bacterial fermentation have been the most studied and reported production systems for this
vitamer [152–154]. This is mainly due to the advantage of selective production of the all-trans isomer
by microorganisms, and the easy manipulation and culture conditions optimization of many bacterial
strains. Over recent years, research on vitamin K2 biotechnological production has moved from the
identification of bacterial types producing K2, to screening of K2 high-producing bacterial strains,
often combined with genetic mutations and resistant mutants leading to improved K2 yields. More
recently, bioengineered K2 metabolic pathways using high-producing bacterial strains and improved
culture conditions have been described.
Biotechnological strategies using either liquid and solid state fermentation processes (LSF and SSF),
and modifications in culture conditions such as media composition and carbon source, temperature,
shaking speed, and time in culture, have been developed for vitamin K2 production in several bacterial
types such as Flavobacterium sp., Lactic acid bacteria, Bacillus subtilis, Bacillus subtilis natto, Bacillus
amyloliquefaciens, and Bacillus licheniformis (reviewed in [155]). In general, the highest levels of vitamin
K2 are produced by Bacillus species. Since Bacillus subtilis has been granted the status of GRAS [156],
and several methods to improve vitamin K2 bacterial productivity have resulted in high yield, these are
positioned among the most important industrial vitamin K producers for its use as diet supplements
providing human health benefits. Particularly, Bacillus subtilis natto has been shown to produce a
range of vitamin K2 homologues (MK-4, MK-5, MK-6, MK-7, and MK-8) with the major component
being MK7 and accounting for more than 90% of total vitamin K2 production [157]. Depending on the
strategy employed, Bacillus subtilis natto has been reported to produce MK-7 with yields of 3.6 mg/L in
a mutant strain resistant to 1-hydroxy-2-naphthoic acid (HNA) [158], 32.2 mg/L in an isolated strain
from the traditional Japanese food natto fermented for 72 h [159], 35.0 mg/L in a menadione-resistant
mutant strain isolated from natto cultivated for four days [160], and 1719 μg/100 g natto [161] in a
multiple resistant mutant strain. More recently, approaches of metabolic engineering to enhance MK-7
production in Bacillus subtilis have been reported [162]. This strategy is based on the overexpression
of different combinations of rate-limiting enzymes involved in MK-7 biosynthetic pathways. Using
these approaches in the B. subtilis 168 strain, yields of 50 mg/L [163] and 69.5 mg/L [164] of MK-7
were reported. This represents a considerable improvement on vitamin K2 production, and further
optimization may open the perspective for new and affordable manufacturing processes allowing a
considerable reduction of costs that will benefit the final consumer.
5.3. Aquatic Organisms as Sources of Vitamin K with a Potential Biotechnological Application
In recent years, an increasing interest is given to aquatic organisms, as a source of useful
and sustainable bioproducts meeting the increasing market and consumer demands for nutritional
supplements, with benefits in human health promotion and disease prevention [165]. Freshwater
and marine organisms, especially macroalgae, microalgae, and several species of cyanobacteria, have
been widely recognised as a valuable source of diet supplements and functional ingredients with
great health benefits [166,167]. In this area, a considerable amount of research efforts has been focused
on improving the biomass supply and bioactive extraction by developing safe, sustainable, and
environmentally-friendly processes [168].
The ability to synthesise vitamin K has been already described for several marine organisms
such as macroalgae, microalgae, and cyanobacteria. In particular, the synthesis of vitamin K1 is
reported in different species of macroalgae and microalgae such as Porphyra sp. (Rhodophyta),
Sargassum muticum, Sargassum fusiforme, Undaria pinnatifida, Nannochloropsis oculata (Ochrophyta),
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Tetraselmis suecica, Dunaliella salina, Desmodesmus asymmetricus, Chlorella vulgaris, Chlamydomonas
reinhardtii (Chlorophyta), Isochrysis galbana, Pavlova lutheri (Haptophyta), and Skeletonema costatum
(Bacillariophyta) [121,122,169,170]. Additionally, several species of cyanobacteria are described to be
able to biosynthesise and produce vitamin K1 such as Anabaena cylindrica, Anabena variabilis, Spirulina
sp., and Nostoc muscorum, Synechocytis sp. PCC 6803 [124,171]. Biosynthesis of phylloquinone has been
mainly associated with oxygenic photosynthetic organisms such as plants, algae, and cyanobacteria.
MKs are described to be synthetized by a limited number of obligate and facultative anaerobic bacteria.
Nevertheless, several species of cyanobacteria and microalgae, such as the cyanobacteria Gloeobacter
violaceus [172] and Synechococcus sp. PCC 7002 [173], the diatom Chaetoceros gracilis [174], and the red
algae Cyanidium caldarium [175] have been shown to synthetize MK-4. Moreover, evidence from the
literature describes several aquatic species with different content in vitamin K1 [169]. This suggests that
algae should be an attractive and potential source of biomass for biosynthesis of vitamin K production
with potential for biotechnological applications [146]. In fact, vitamin K1 has been found in variable
amounts in several species of macroalgae, microalgae, and cyanobacteria, as summarized in Table 2.
In a recent study analysing seven different microalgae species, the cyanobacteria Anabaena cylindrica
was identified as the richest source of the active E-isomer of vitamin K1 (200 μg/g dry weight) [170]
(Table 2). This concentration was around six times higher when compared with parsley (Petroselinum
crispum) [170], which is a known rich dietary source of K1, and higher than any other previously
reported phylloquinone dietary source [115,175–177]. Additionally, the method proposed in this study
uses low temperatures, low pressures, and sustainable feedstocks, precluding great prospects for
biotechnological and industrial application. Furthermore, the cyanobacteria Spirulina sp. was found to
have a content of 0.255 μg/g dry weight [170], and, in the marine green microalgae Tetraselmis suecica,
the concentration of vitamin K1 on a dry weight basis was 28 μg/g [169].
Table 2. Vitamin K1 content in algae.
Phylum Species Designation Content (μg/g)
Macroalgae
Ochrophyta
Undaria pinnatifida *1 12.9 [121]
Sargassum fusiforme *2 1.75 [121]
Sargassum muticum 750 [169]
Rhodophyta Porphyra sp. *3 26 [122,169]
Microalgae
Bacillariophyta Skeletonema costatum 5.5 [169]
Chlorophyta
Tetraselmis suecica 28 [169]
Dunaliella salina 0.1 [170]
Desmodesmus asymmetricus 0.46 [170]
Chlorella vulgaris 0.73 [170]
Cyanobacteria Anabaena cylindrica 200.25 [170]
Spirulina sp. 12.70 [170]
Haptophyta Isochrysis galbana 8 [169]
Pavlova lutheri 6.5 [169]
Ochrophyta Nannochloropsis oculata 0.17 [171]
*1 Also known as Wakame. *2 Also known as Hijiki. *3 Also known as Nori.
Within macroalgae, two species of edible seaweeds native to Japan, Sargassum muticum and
Undaria pinnatifida are considered highly invasive species with negative economic and ecological
impacts for the region [178,179]. Both macroalgae species were tested as biomass for the extraction and
quantification of vitamin K1 and shown to have different contents with 12.9 μg/g dry mass in Undaria
pinnatifida [121] as well as a remarkably high content in Sargassum muticum (750 μg/g dry matter) [169].
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The exploitation of this biomass as a vitamin K1 source should encourage its harvesting and control,
bringing a potential economic and environmental interest.
Macroalgae species have been described as a potential alternative for the biosynthetic production
of vitamin K1 due to its higher vitamin K1 content when compared to terrestrial plants. On the
other hand, microalgae and cyanobacteria represent an interesting alternative for the biotechnological
industrial production of vitamin K1 due to their easy cell manipulation when compared with plant cell
cultures. Another advantage of using microalgae for industrial production of products intended for
human consumption is the fact that many species are considered as GRAS.
6. Vitamin K Formulations and Impact on Absorption and Bioavailability
Recently, a few studies have addressed the production of novel and more stable vitamin K
formulations to improve vitamin K absorption and bioavailability. This is of crucial importance
for patients with cholestasis due to extremely low level of bile salts in the intestine. Konakion®
(phytomenadione) mixed micelles (MM) is a formulation composed of phytomenadione in clear bile
acid/lecithin MM solution, for oral or parenteral administration, used for the prophylaxis and treatment
of VKDB [180]. Nevertheless, some reports describe that these formulations do not increase vitamin
K bioavailability because they are unstable and tend to aggregate in gastric pH conditions [181].
Strategies to increase its stability, absorption, and bioavailability include mixed formulations with
poly (ethylene glycol) [182] and saponins [183], which are preferred components due to its natural
plant origin (such as quillaja bark and soybean) and consist of a hydrophobic polycyclic aglycone tail,
attached to one or more saccharide moieties. Saponin-containing Konakion® MM were shown to be a
promising oral formulation for vitamin K due to its increased stability at low pH, cytocompatibility,
and cell uptake capacity [183].
Intramuscular administration of vitamin K1, although effective, has raised concerns related with
the administration, such as injection pain, skin bruising, and toxic ingredients, which compromise
therapy compliance [183,184]. Recently, an innovative drug delivery mechanism was developed as an
alternative to the hypodermic conventional needles drug administration, consisting of drug-loaded
microneedles (MNs). MNs matrix or baseplate are impregnated with the required molecule/drug. After
dermic application, the interstitial fluid is able to dissolve the MNs and allow the content release, which
represents a micro-dimensional and less invasive method. Several substances were already successfully
delivered using this system by enabling the transdermal delivery of drugs that can be absorbed directly
into the systemic circulation [185–188]. A recent study was developed to investigate the production
of microneedles for the delivery of vitamin K [189]. The in vitro results showed that vitamin K in a
microneedle array was successfully delivered in neonatal porcine skin over 24 h. This methodology,
even though it still needs to be clinically validated, anticipates great potential for improvement of
patient compliance in vitamin K prophylaxis in developed countries and might contribute to reduce
VKDB cases in undeveloped countries [189].
7. Conclusions
Overall, the concept of multifunctional vitamins associated with vitamin K has been growing
in recent decades with evidence showing its involvement in a wide range of biological functions
with a pivotal role in several highly prevalent low-grade inflammatory diseases. Several age-related
diseases such as skeletal and CVD, Alzheimer’s disease, and dementia are becoming a major social and
economic burden in our aging society. Compelling clinical evidence combined with a strong scientific
biological rational clearly support a beneficial health effect of vitamin K and has led to an increased
procurement of vitamin K as a health promoting supplement. Interestingly, some scientific evidence
from in vitro and in vivo models, as well as from clinical studies, suggests a synergistic effect of vitamin
K combined with vitamin D, with beneficial effects of joint supplementation at optimal concentrations
of both vitamins, particularly for bone health [190,191]. However, although the benefits of vitamin
D in bone health are well established, high levels of vitamin D might promote hypercalcemia and
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soft tissue calcification with consequent detrimental effects on the cardiovascular system [192]. While
additional studies are required to establish the optimal concentration of a combined supplementation
with vitamins K and D, high levels of K1, MK4, or MK7 have no documented toxicity or adverse
health effect. No hypercoagulable state was observed in individuals consuming doses above the
recommended daily allowance of 75 micrograms vitamin K (Commission Directive 2008/100/EC) [193].
Additional specific cases of extremely high levels of vitamin K intake have also been reported without
adverse effects [194,195]. However, the current and increasing knowledge on the different types of
vitamin K vitamers and their specific biological activity imply a clearer differentiation between the
potential health effect and target specificity for each vitamer. It is well accepted that both K1 and
K2 can play an important role in the pathogenesis and progression of many diseases. Nevertheless,
the K2 vitamer (MK-7) has been shown to have advantages given its superior bioavailability and
higher half-life in circulation when compared with other K vitamers. In addition, the vast majority
of available clinical studies are still related to the effects of vitamin K1 in health, while K2 has been
shown to have a prevalent function in extra-hepatic tissues with a protective role in the vascular system
reducing the risk of CVD, mitigating cognitive diseases, and suppressing inflammation. Although
both vitamin K1 and K2 are commercially available, optimized production methods and more efficient
formulations for each vitamer are needed to meet the increasing customer requirements at affordable
prices. Additionally, marine diet supplements and functional products are already well represented in
the global market and the exploitation of new aquatic-derived sources for vitamin K should represent
a benefit for human health with a potential economic and environmental interest.
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CHD Coronary heart disease
CKD Chronic kidney disease
CRP C-reactive protein
CVD Cardiovascular disease
DOACs Direct oral anticoagulants
GGCX γ-glutamyl carboxylase
Gas6 Growth arrest-specific protein 6
Gla γ-carboxyglutamic acid
Glu Glutamic acid




INR International normalized ratio
KH2 Vitamin K hydroquinone
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NF-κB Nuclear factor kappa B
OA Osteoarthritis
OC Osteocalcin
PRGP1 Proline-rich Gla proteins
RA Rheumatoid arthritis
ROS Reactive oxygen species
SSF Solid-state fermentation process
TLR Triacylglycerol-rich lipoproteins
TMG Transmembrane Gla proteins
VC Vascular calcification
VKAs Vitamin K antagonists
VKDB Vitamin K deficiency bleeding
VKDPs Vitamin K-dependent proteins
VKORC1 Vitamin K epoxide reductase complex subunit 1
VKORC1L1 Vitamin K epoxide reductase complex subunit 1-like 1
WHO World Health Organization
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Abstract: Quelites are Mexican wild plants, reported as excellent sources of nutritional compounds
such as amino acids (serine, glycine, and cysteine), minerals (Mg, Fe, and Zn), and phytochemicals,
as phenolic acids (chlorogenic acid) and flavonoids (phloridzin and naringenin); on the other hand,
high biological activity has been shown in these compounds. This work aimed to evaluate the effect
of a supplementation with two endemic quelites of Mexico (Chenopodium berlandieri L. and Portulaca
Oleracea L.); in addition to supplementation, a nutritional intervention was performed; the biomarkers
of hemoglobin (Hb), urinary malondialdehyde (UMDA), and urinary arsenic (UAs) were measured in
adolescents exposed to arsenic. A clinical intervention study was conducted in 27 adolescents ages 11
to 12 years for 4 weeks. Weekly anthropometric and dietary evaluations were carried out, as well as the
concentration of Hb; the UMDA and UAs were performed by plate-based colorimetric measurement
and atomic absorption spectrophotometry with the hydrides generation system, respectively. The
results showed that UMDA concentrations had a significant improvement in the supplemented group
(SG) vs. control group (CG) (SG = 1.59 ± 0.89 μM/g creatinine vs. CG = 2.90 ± 0.56 μM/g creatinine)
in the second week of intervention; on the other hand, the supplemented group showed an increase
in Hb levels (15.12 ± 0.99 g/dL) in the same week; finally after the second week, an increase in UAs
levels was observed significantly compared to the baseline value (Baseline: 56.85; Week 2: 2.02 μg/g
creatinine). Therefore, the results show that the mixture of quelites (a rich source of phytochemicals
and nutrients) improved hemoglobin and UMDA levels, and urinary arsenic excretion from the
second week in the exposed population.
Keywords: quelites; supplementation; arsenic
1. Introduction
Arsenic (As) is an element that is naturally distributed on the surface of the earth’s crust, it can be
filtered to groundwater reserves, due to soil drilling, water movements, and when there is mining
activity. In other cases, depending on the composition of the rock, water can dissolve and drag
these elements, producing natural pollution and increasing the concentration in ground and surface
waters [1,2], which become the main source of drinking water in rural areas. There are many other
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types of pollution of As, including chemical pollution into bodies of water and soil through improper
disposal practices and agricultural activities, due for use of pesticides and fertilizers, among other
factors that compromise human health.
In countries such as Thailand, India, China, Argentina, and Mexico, concentrations of As have
been found in ranges from 0.5 to 5000 μg/L [3,4]. As for Mexico, the highest concentrations of As
are found in the northeast and central parts of the country [5], generally in arid and semi-arid areas,
including Coahuila, Zacatecas, Hidalgo, San Luis Potosí, and Guanajuato [6]. Particularly in the state
of Guanajuato, in the northeast region, given its location in the vicinity of three geological provinces,
combined with volcanic activity alternated with periods of intense erosion and sedimentation, give rise
to different dissolved elements [1,7]. But in the central area of the state of Guanajuato, since 2004,
they have been identified in several communities with high levels of As in water [8].
According to the World Health Organization (WHO) [9], As, due to its ubiquity characteristic,
is classified as one of the chemicals of greatest concern worldwide, which, if not handled properly, can be
very dangerous for the environment and health. Chronic exposure to As can cause hyperkeratosis,
dermatitis, respiratory diseases, cancer, adverse thyroid effects, and neurotoxicity [8–11].
Few studies have shown that a high intake of antioxidants and fructooligosaccharides (FOS)
identified in the Mexican diet foods such as beans, lentils, bananas, and onions can prevent or reverse
some of the effects involved in the development of cancer and cardiovascular diseases and chronic,
caused by this pollutant, by avoiding bioaccumulate in the organism and thus an improvement in the
excretion in the urine [12,13]; therefore, the consumption of foods rich in phytochemicals with adequate
nutritional contributions and with high antioxidant capacity, has been considered a strategy to reduce
the effects of this element when people have acute or chronic exposure, by providing the requirements
of various nutrients such as cysteine, methionine, vitamin C [14,15], and phenolic compounds [16–18],
essential for arsenic detoxification [19], to increase antiradical effects (ROS), and reduce the production
of malondialdehyde (MDA) in the body [17,18].
Mexico has a wide variety of wild edible plants found in rural areas referred to as quelites [20];
between them, we can differentiate two important species, Chenopodium berlandieri L. and Portulaca
oleraceae L., which naturally grow in abundance in mountains, flat fields, or near corn or bean crops
of Mexican territory [21]. The leaves and stems of these species have a high nutritional contribution
(dietary fiber, proteins, minerals) and bioactive compounds (carotenoids, chlorophyll, phenolic acids,
and flavonoids) [22], as well as a high antioxidant capacity and provide biological effects of interest in
human health [21,22]. Recent studies have found excellent results when using plants that belong to
the genera of Chenopodium spp., reporting a reduction in MDA and increased activity of antioxidant
enzymes in rats induced with toxic agents [23] or decreasing levels of lipid peroxidation in lines
of cancer cells [24]. Finally, when using Portulaca spp. in animal models, the potential effect of its
bioactive compounds on the integrity of the CNS (Central Nervous System) [25], hepatoprotective
capacity [26], and the reduction of damage by stress mechanisms against external factors such as
pollutants (rotenone) [27] have been observed.
In Mexico, there is evidence that shows that the administration of supplements that incorporate
vegetables such as broccoli and fruits such as grapes, as well as minerals and vitamins essential for the
detoxification process [14–19], promote better arsenic excretion and improve the nutritional status,
in this case, by inducing an increase in hemoglobin (Hb) levels of participants [28]. However, given
these bases and the nutritional contribution of these quelites, the aim of this research was to evaluate
the effect of a supplement made with two novelty ingredients (Portulaca oleraceae L. and Chenopodium
berlandieri L.), economical, accessible, and with sufficient evidence of its antioxidant and nutritional
potential, on hemoglobin (Hb), urinary arsenic excretion (UAs), and urinary malondialdehyde (UMDA)
concentration, which will be biomarkers of interest to know the positive effect of this supplement
provided in adolescents from a rural area in Guanajuato, Mexico, exposed to arsenic.
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2. Materials and Methods
2.1. Reagents and Equipments
Nitric acid, perchloric acid, sodium borohydride, potassium iodide, sodium hydroxide,
hydrochloric acid, and ascorbic acid were purchased from J.T Baker (Avantor Performance Materials,
Ecatepec, Estado de Mexico, Mexico) and Fermont (Rye S.A de C.V, Tlalnepantla, Estado de Mexico,
Mexico). The microcuvettes for hemoglobin determination (Hb-201) were purchased from HemoCue
(HemoCue, Ciudad de Mexico, Mexico). The TBARS assay kit (MDA) was purchased from Cayman
Chemical (Cayman Chemical, Ann Arbor, MI, USA). The arsenic standard was purchased from Agilent
(Agilent, Santa Clara, CA, USA). The quality control for As (ClinChek®-urine control lyophilised for
trace elements, level II) was purchased from Iris Tech (IRIS Technologies International GmbH, Olathe,
KS, USA). The concentration of arsenic (As) in drinking water with Arsenator®-Digital Arsenic Test
Kit from Wagtech WTD, Palintest, CO, USA). All solutions were prepared using deionized water.
2.2. Intervention Design, Study Groups, and Acquisition of Data
A clinical intervention study was conducted in 27 participants (13 men and 14 women) ages 11 to
12 years belonging to the rural area of Valencianita, Irapuato, in the state of Guanajuato, Mexico. It was
a randomized study to assess the effect of supplementation on UAs excretion. The random assignment
code was generated using a randomized block design with SAS® (Cary, NC, USA). All participants
were randomly assigned in into two groups referred to as control and supplemented (4 g of supplement).
The details of the study are mentioned by section and in Figure 1.
Figure 1. Flow diagram of patient progress through the phases of the randomized trial.
2.2.1. Eligibility Criteria
Inclusion criteria: High school students #117 of the community of Valencianita, Irapuato in the
state of Guanajuato, men and women with a minimum residence of three years in the community,
arsenic concentrations in drinking water above 25 μg/L (hydroarsenism) [29].
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Exclusion criteria: Participants who are taking a supplement (trademarks of natural products),
or drug (treatment or over-the-counter), participants with some type of kidney or liver damage
confirmed by the clinical history, participants who did not want to join the study, and participants who
provided a single urine sample or were evaluated only once.
2.2.2. Pre-Selection Phase and Ethical Statement
Parents and adolescents received verbal and written information about the study, informed
parental consent, and consent from the adolescents were obtained before they participated in the study.
The study was free, anonymous, and voluntary, was conducted in accordance with the Declaration
of Helsinki, and approved by the institutional research bioethics committee of the University of
Guanajuato (Code-CIBIUG-P34-2018).
2.2.3. Selection Phase and Clinical Intervention
Participants who met the inclusion criteria were incorporated into the study. It was confirmed
that the adolescents included in the research did not have acute or chronic diseases, their liver function
was normal, and they were not taking drugs or supplements before and during the intervention.
The adolescents were divided into two groups: the supplemented group with 15 participants
(9 men and 6 women) and the control group with 12 participants (4 men and 8 women).
Before beginning treatment and during the intervention, parents and adolescents were informed
of the importance of consuming treated and purified water to observe a better recovery process.
In addition, a questionnaire was applied to the mothers of the participants for the acquisition of
information concerning drinking water, and later these data were confirmed with the analysis of water
samples consumed at the participants’ homes and provided by the mothers during the intervention.
The clinical intervention was carried out according to Monroy-Torres et al. [28]. A detailed
nutritional history was obtained for each child and a physical examination was performed,
which included anthropometric parameters.
2.3. Supplement of Quelites
In this research a powder supplement made with two endemic vegetable ingredients from Mexico
was used; these plants contained, in dietary supplement, belong to the species of Chenopodium berlandieri
L. and Portulaca Oleraceae L. In addition, each species was characterized [22], and also the nutritional and
functional evaluation of the supplement was performed [30]; the research considered the nutritional
profile [macronutrients and micronutrients (minerals and amino acids)] and antioxidant properties
(antioxidant compounds and antioxidant activity) [30].
2.4. Dietary Supplementation
Parents and adolescents belonged to the supplemented group were informed about storage and
intake of the supplement before the beginning of the study; two units of 60 g each of supplement were
delivered to the parents for the total period of the intervention. The dose of the treatment was 4 g per
day for 4 consecutive weeks (November 2018) and with a single dose 1 h before the intake of any food
during morning hours, considering taking it at the same time every day; on the other hand, no placebo
was administered to the control group because of the social and cultural factors previously identified in
the rural community. The adolescents included in this work were not provided an orientation about an
adequate diet, allowing them to maintain their diet as usual during the study. The supplement intake
monitoring was evaluated by adherence questionnaires once a week at the school and by telephone
two days per week. At the end of the study, the participants were asked to return any pouches not
consumed. The dose of the supplement was selected by extrapolated calculations on the basis of a
previous animal studies [23,27] and a previous clinical intervention [28].
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2.5. Urine Sample
The urine samples were collected in polyethylene containers previously washed with HNO3
(10%) and being the first urine in the morning. These samples were requested from the participant
minutes before the corresponding evaluation and stored in refrigeration at 4 ◦C until the end of the
day indicators measurement. Later, samples were transported inside thermal containers. Before
submitting the samples to the freezing process, a 1 mL aliquot of urine was extracted from each
container and stored in previously labeled microtubes, which were taken to ultra-freezing (−76 ◦C)
(Thermo-Scientific, 703, Outside, USA) for the subsequent MDA assay; the samples collected in the
polyethylene containers were stored in freezing at −20 ◦C until the moment of analysis. The creatinine
content of the samples was determined within the week of collection of each batch and according to the
Jaffe reaction method [31]. The results of the urinary biomarkers were adjusted per grams of creatinine.
2.6. Anthropometric Assessment
Weight (Kg), fat mass (%), and lean body mass (%) were obtained with the impedance technique
(bioimpedance analyzer, InBody® R20); waist (cm) and abdominal (cm) circumferences (metal tape
measure, Lufkin) were measured; also height (cm) (stadiometer, Seca®) of each participant was
measured. The anthropometric measurements were obtained according to Lohman et al. [32]. With
the weight and height, the body mass index (BMI) was calculated and they were classified in obesity,
overweight, or normal weight; in addition, height-for-age (H/A) was obtained; WHO reference
tables [33] and WHO Anthro Plus® software were used for data interpretation. A BMI with thinness
(malnutrition) with <−2 standard deviation (SD), normal between −2 to +1 (SD), overweight with
>+1 (SD), and obesity with >+2 (SD) was considered. On the other hand, low height-for-age [<−2
(SD)] and normal height [−2 to +3 (SD)] were estimated. The measurements were being made weekly
by nutritionists.
2.7. Dietary Assessment
A food frequency questionnaire (FFQ) was carried out, as well as a 24-h dietary recall (24 DR) [34].
The quantification of the average energy consumption (kcal), proteins (g), carbohydrates (g), fats (g),
sugars (g), fiber (g), vitamin A (μg), B1 (mg), B2 (mg), B6 (mg), B12 (μg), C (mg), folic acid (μg), niacin
(mg), vitamin E (mg), Ca (mg), Fe (mg), K (mg), Mg (mg), Na (mg), P (mg), Se (μg), and Zn (mg)
were determined with NutriKcal® (nutritional software based on food composition tables in Mexico
and derived from 24-h dietary recall); on the other hand, adherence questionnaires and treatment
monitoring were applied. The register was made and monitored weekly by nutritionists.
2.8. Hemoglobin Concentration
The concentration of hemoglobin (Hb) in capillary blood was carried out by photometry; participant
was stung on a finger with a sterile lancet and Hb was measured from a drop of blood (preferably the
third drop) using a microcuvette and deposited in the portable Hb analyzer (HemoCue®, 201, Brea,
CA, USA), with a detection range of 0 to 24.6 g/dL. Hb was used to evaluate the absorption of nutrients
from the diet during the intervention. The results were expressed as grams of hemoglobin per deciliter
(g Hb/dL).
2.9. Urine Malondialdehyde Concentration
According to the most recent study carried out in the rural community of Valencianita where
the first effects of a supplement were reported in the first month [28], it was decided to include
3 measurements, taking into account a Baseline measurement (week 0), at week 2 and at the end of the
study (week 4).
The concentration of malondialdehyde in urine (UMDA) was carried out with a TBARS assay kit
purchased from Cayman Chemical (Cayman Chemical, Ann Arbor, MI, USA) and according to the
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recommendations described by the manufacturer. Briefly, an aliquot of the urine sample (100 μL) was
mixed with SDS solution (100 μL) and color reagent (4 mL) in a screw cap tube glass, and allowed to
stand in a water bath at constant temperature (90 ◦C) for 1 h; later, tubes were removed and taken to an
ice bath for 10 min to stop the reaction. After, samples were poured into 15 mL tubes to centrifuge for
10 min at 1600× g at 4 ◦C. Finally, 150 μL aliquots of the supernatant (duplicate) were taken and placed
on clear plates (96-well solid plate) and read at an absorbance of 530–540 nm in a plate reader (Biotek
instruments, ELx800, VT, USA). The concentration of the lipid peroxidation product was calculated
from a standard MDA curve. The results were expressed as micromole of malondialdehyde per gram
of creatinine (μM MDA/g creatinine).
2.10. Concentrations of Arsenic in Drinking Water and Urine
2.10.1. Water
The concentration of arsenic (As) in drinking water was carried out using the hydrides generation
technique using an As analysis kit (Arsenator®-Digital Arsenic Test Kit from Wagtech WTD, Palintest,
CO, USA) for rural communities. The detection range of the Arsenator® was 0 to 100 μg/L.
Concentrations were expressed as micrograms of arsenic per liter (μg As/L). The evaluations were
conducted weekly, one month prior to the study and during the intervention. School and household
water sources used for consumption were analyzed. The procedure is described as follows: a 50 mL
sample of water was obtained which was taken with a 250 mL flask, then a powder sachet (sulfamic
acid) was added to the sample and a catalyst tablet, both provided by the kit. Then, two filter slides
were used to remove (red) the excess of arsine gas and collect the arsenic gas (black) both inserted in a
bung device. Immediately the bung device was pushed down firmly into the flask. Later, after 20 min,
the black filter slide was removed from the bung device. The black arsenic filter slide was read into the
DigiPAsS. The validation process was carried out according to the reference coloration parameters
(Palintest).
2.10.2. Urine
Quantification of As in urine (UAs) was performed according to the Cox method [35]. A 5 mL
of urine sample was digested with a mixture of HNO3 and HClO4 (1:6); the mixture was stirred
and covered with a watch glass and placed on a low-temperature hot plate for 15 min and later the
temperature was increased to 80 ◦C until the sample was dried; briefly, the content was resuspended in
10 mL of HCl (3%). All procedures were performed in duplicate. For the reduction of As+5 to As+3,
5 mL of the digested sample was reduced with 1 mL of KI (3%) and 4 mL of HCl (1.5%) for 5 min
at 80 ◦C in darkness. Before the process of reduction of the samples, the reagents for the hydrides
generation were prepared; NaOH (1%) was prepared using deionized water, and later, NaBH4 (3%)
was prepared with the NaOH solution previously made. Reagents were made separately and then
mixed. The final NaBH4 solution was filtered using a #5 filter paper and a vacuum pump. The filtered
solution was covered with aluminum foil and refrigerated for use on the same day. Finally, 10 mL of
reduced sample was poured into a reaction flask; an average of 40 mL of NaBH4 reagent for every
6 samples analyzed was used. The sample was analyzed by atomic absorption spectrophotometry
(AAS) with hydrides generation system (PerkinElmer, PinAAcle900H, Wellesley, MA, USA) using
the software Syngistix 2.0 and under the following conditions: the wavelength of 197.20 nm, slit 0.7,
EDL lamp (energy >50), argon as the carrier gas, and as signal mode the peak height. The results were
expressed as micrograms of arsenic per gram of creatinine (μg As/g creatinine).
The concentration of As was calculated from a standard curve. The curve was calculated from a
standard stock solution of 1000 ppb of As, dilutions were made for 0.5, 1.0, 5.0, 10.0, and 20.0 ppb of
As, as well as a blank. The slope of the resulting curve was m = 0.0135 with a correlation coefficient of
R2 = 0.9844.
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For quality control, the ClinChek® brand was used as a reference standard, with an average As
concentration of 83.3 μg/L (66.6–99.9). For the preparation, 10 mL of deionized water was added to the
control urine, and then 3 mL was taken and the digestion and reduction process were the same as the
urine samples. A total of eight quality controls were performed with an average recovery percentage
of 102.33% ± 2.43%.
The analysis considered 2 blanks (acids) and a quality control (ClinChek®) in duplicate for each
batch (intervention week) evaluated.
2.11. Statistical Analysis
For the statistical analysis, the data were grouped according to age ranges, sex, and by group of
participants (supplemented and controls). They were analyzed and compared using the statistical
software SPSS® 25.0. For selection of statistical tests, the Shapiro–Wilk normality test and Levene
test for equality of variances were used. Comparative analysis between sex and study group was
determined with the independent samples t Student and the Mann–Whitney U test for data with
normality and without it respectively. The comparison of baseline and final variables was performed
with paired sample t-Test and Wilcoxon signed-rank test; besides, to compare the intervention weeks,
repeated measures ANOVA test was used as well as Friedman test, according to the characteristics of




The groups formed were two, the first referred to as supplemented and the second one referred to
as control, which were previously described. The indexes (height-for-age and body mass index for
age) were calculated using the Z-Score for individuals ages 5–19 years. The baseline characteristics
of both groups (supplemented and control group) were homogeneous (Table 1), without statistically
significant differences between them (NS); only the percentage of fat mass and muscle mass showed
differences, being higher in women and men respectively (Table 2).





n = 12 p-Value
Age (years) 11.80 ± 0.41 12 ± 0.36 3 NS
Weight (kg) 47.31 ± 10.54 48.95 ± 11.33 NS
Height (cm) 150.31 ± 6.74 153.30 ± 7.21 NS
1 H/A interpretation (Z-Score) NS
Normal height 15 ± 82.19 12 ± 91.42
2 BMI interpretation (Z-Score) NS
Obesity 2 ± 10.14 2 ± 16.05
Overweight 5 ± 33.67 3 ± 19.36
Normal weight 8 ± 31.94 7 ± 35.02
Fat mass (%) 21.92 ± 14.71 23.02 ± 14.07 NS
Muscular mass (%) 33.46 ± 11.08 32.12 ± 8.95 NS
Waist circumference (cm) 71.19 ± 12.05 71.48 ± 9.44 NS
Abdominal circumference (cm) 76.28 ± 11.58 79.33 ± 10.27 NS
The table shows the mean ± standard deviation (SD) for each baseline variable and the p-value according to the
independent samples t-Test (p < 0.05). 1 H/A: height-for-age [ages 5–19 years (Z-Score)]; 2 BMI: body mass index for
age [ages 5–19 years (Z-Score)]; 3 NS: not significant.
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n = 14 p-Value
Age (years) 11.88 ± 0.32 11.84 ± 0.37 11.92 ± 0.26 3 NS
Weight (kg) 48.13 ± 10.72 48.07 ± 10.89 48.19 ± 10.98 NS
Height (cm) 151.78 ± 7.01 152.56 ± 7.28 151.00 ± 6.64 NS
1 H/A interpretation (Z-Score) NS
Normal height 27 ± 98.42 13 ± 86.24 14 ± 93.37
2 BMI interpretation (Z-Score) NS
Obesity 4 ± 31.26 1 ± 9.32 3 ± 17.21
Overweight 8 ± 35.74 5 ± 35.11 3 ± 21.17
Normal weight 15 ± 42.31 8 ± 32.29 7 ± 35.18
Fat mass (%) 22.46 ± 14.16 13.98 ± 12.64 30.32 ± 10.74 <0.001
Muscular mass (%) 32.80 ± 10.03 40.47 ± 9.25 25.67 ± 2.93 <0.001
Waist circumference (cm) 71.34 ± 10.77 71.20 ± 11.77 71.47 ± 10.20 NS
Abdominal circumference (cm) 77.81 ± 10.96 75.62 ± 10.90 79.84 ± 11.01 NS
The table shows the mean ± standard deviation (SD) for each baseline variable and the p-value according to the
independent samples t-Test (p < 0.05). 1 H/A: height-for-age in men and women ages 5–19 years (Z-Score); 2 BMI:
body mass index for age in men and women ages 5–19 years (Z-Score); 3 NS: not significant.
3.2. Diet
Baseline analysis of the ingested nutrients is shown in Tables 3 and 4. Evaluations showed scarce
differences between supplemented and control group pre and post-intervention, showing that the
dietary patterns remained homogeneous throughout the study. There was a significant difference by
group (Table 3) only in energy (p < 0.002) and K (p < 0.05) intake; however the intake by sex (Table 4),
showed that the macro and micronutrients were higher in men than in women (p < 0.002), with the
exception of vitamin C, E, and magnesium where no significant difference was found; on the other
hand, the intake of fiber and sugar did not show significant differences by sex.
Regarding the dietary reference intakes by age (9–13 years) for each macro and micronutrient [36],
it was observed that the values for protein were according to the DRI (Dietary Reference Intakes) for
men and women (>34 g/day); however, the intake of total fats and carbohydrates were high in both
sexes. On the other hand, the men’s diet complied with the DRI for B vitamins, vitamin A, C, and
niacin, but not for folic acid (78%) and vitamin E (24%). Regarding minerals, men showed adequate
DRI for Fe, Mg, and Se, but the minimum recommended for Ca (85%), K (45%), P (60%), and Zn (75%)
was not met.
High consumption of Na was reported for men (>2 g/day). On the other hand, women did not
meet the minimum requirements for vitamins (16%–66%) and minerals (25%–77%) and regarding
the sodium intake, did not exceed the recommended DRI (DRI: <2 g/day). Finally, according to the
recommended dietary allowance of fiber, the intake was low in both sexes (DRI: 26–31 g/day).
On the other hand, according to the FFQ, the results showed a high intake (4–5 days per week) of
ultra-processed food products (chips and pastries), sweets, popsicles, chocolates, cola drinks (Coke and
Pepsi), and other carbonated beverages with flavorings, sweeteners, and high sugar content. Regarding
meals provided at home, a preference for fried or oil foods was shown, mostly using this method
and rarely roasted and steamed. Moreover, the consumption of fruits and vegetables was low, and
the foods of greater preference by the participants were the banana, apple, and orange for fruits, and
potatoes, onions, and tomatoes for vegetables (cooked), these with weekly consumption frequency (2–3
fruits per week; 2–4 vegetables per week); it is important to comment that the participants showed no
interest in consuming raw (salad) or steamed vegetables (preference for fried and sugary foods), or as
a snack due the bitter and weird flavors of these foods. Regarding animal products such as poultry
and meat (beef and pork), the limitation of their frequency (1–2 times every 15 days) was observed due
50
Nutrients 2020, 12, 98
to costs, the egg and bean being the main source of protein (2–3 times per week), complemented with
other foods, such as corn tortilla (daily) and pork rinds (1–2 times per week) to increase satiety.





n = 12 p-Value
Energy (kcal) 2006.04 ± 5.07 2000.12 ± 3.49 <0.002
Protein (g) 70.05 ± 27.52 69.96 ± 27.96 1 NS
Fat (g) 70.02 ± 33.71 66.15 ± 29.66 NS
Cholesterol (mg) 284.21 ± 169.46 282.59 ± 180.64 NS
Carbohydrates (g) 290.38 ± 96.12 273.41 ± 51.34 NS
Sugar (g) 32.36 ± 31.67 30.02 ± 36.32 NS
Fiber (g) 21.09 ± 12.20 20.17 ± 8.91 NS
Vitamin A-Retinol (μg) 767.04 ± 182.09 753.62 ± 173.48 NS
Vitamin B1(mg) 1.15 ± 0.50 1.09 ± 0.38 NS
Vitamin B2 (mg) 1.23 ± 0.57 1.21 ± 0.45 NS
Vitamin B6 (mg) 0.94 ± 0.55 0.81 ± 0.46 NS
Vitamin B12 (μg) 1.93 ± 1.12 1.91 ± 1.27 NS
Vitamin C (mg) 52.47 ± 45.74 34.03 ± 29.79 NS
Folic acid (μg) 186.39 ± 174.18 136.25 ± 88.08 NS
Niacin (mg) 12.28 ± 6.60 9.08 ± 5.67 NS
Vitamin E (mg) 2.67 ± 2.01 1.97 ± 3.73 NS
Ca (mg) 947.59 ± 361.72 937.66 ± 363.81 NS
Fe (mg) 14.82 ± 7.30 13.29 ± 4.43 NS
K (mg) 1605.14 ± 654.99 1094.35 ± 566.09 <0.05
Mg (mg) 303.39 ± 220.35 240.26 ± 184.69 NS
Na (mg) 2501.90 ± 811.04 1949.78 ± 721.42 NS
P (mg) 631.40 ± 304.63 595.08 ± 264.43 NS
Se (μg) 51.95 ± 30.00 50.06 ± 23.06 NS
Zn (mg) 4.68 ± 2.60 4.26 ± 2.00 NS
The values show the mean ± SD for each nutrient and the p-value according to the independent samples t-Test (p <
0.05). 1 NS: not significant.
These results show high consumption of ultra-processed foods, rich in sugars and saturated fats
and low consumption of fruits and vegetables which reflects in the increase of carbohydrates, total fats,
and sodium (Na) in the participants’ diet.
Table 4. Daily intake of energy and nutrients of all adolescents and by group (men and women)







n = 14 p-Value
Energy (kcal) 2003.07 ± 1.24 2345.11 ± 1.35 1490 ± 1.11 <0.001
Protein (g) 70.24 ± 32.01 87.84 ± 27.96 43.85 ± 19.88 <0.001
Fat (g) 68.19 ± 29.36 81.03 ± 26.83 48.93 ± 8.62 <0.001
Cholesterol (mg) 283.63 ± 127.38 398.28 ± 142.17 111.67 ± 101.48 <0.001
Carbohydrates (g) 281.85 ± 82.19 321.01 ± 72.98 223.13 ± 27.13 <0.001
Sugar (g) 31.07 ± 29.70 38.01 ± 36.21 20.65 ± 14.98 1 NS
Fiber (g) 20.64 ± 8.56 22.81 ± 10.68 17.39 ± 3.81 NS
Vitamin A-Retinol (μg) 759.60 ± 128.11 877.67 ± 143.62 582.50 ± 105.69 <0.001
Vitamin B1(mg) 1.13 ± 0.54 1.41 ± 0.52 0.69 ± 0.11 <0.001
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n = 14 p-Value
Vitamin B2 (mg) 1.22 ± 0.65 1.60 ± 0.55 0.64 ± 0.30 <0.001
Vitamin B6 (mg) 0.87 ± 0.56 1.11 ± 0.50 0.50 ± 0.34 <0.001
Vitamin B12 (μg) 1.92 ± 1.10 2.46 ± 1.01 1.11 ± 0.88 <0.001
Vitamin C (mg) 43.30 ± 44.13 52.41 ± 50.86 29.65 ± 11.81 NS
Folic acid (μg) 161.33 ± 198.05 235.89 ± 219.80 49.49 ± 21.16 <0.002
Niacin (mg) 10.69 ± 6.75 13.97 ± 6.61 5.76 ± 1.50 <0.001
Vitamin E (mg) 2.33 ± 1.80 2.67 ± 1.80 1.82 ± 1.87 NS
Ca (mg) 942.63 ± 270.27 1133.50 ± 332.51 656.33 ± 255.79 <0.001
Fe (mg) 14.10 ± 9.59 18.31 ± 9.57 7.79 ± 2.49 <0.001
K (mg) 1349.47 ± 436.12 1597.94 ± 445.58 976.75 ± 407.24 <0.001
Mg (mg) 271.83 ± 222.07 328.83 ± 238.09 186.33 ± 164.75 NS
Na (mg) 2226.77 ± 658.33 2993.61 ± 776.12 1076.50 ± 501.16 <0.001
P (mg) 613.67 ± 307.02 754 ± 220.09 403.17 ± 225.73 <0.001
Se (μg) 51.33 ± 29.33 67.56 ± 19.44 27 ± 14.33 <0.001
Zn (mg) 4.46 ± 2.94 5.99 ± 2.49 2.15 ± 1.37 <0.001
The values show the mean ± SD for each nutrient and the p-value according to the independent samples t-Test
(p < 0.05). 1 NS: not significant.
3.3. Hb Concentration
The Hb levels were compared, finding differences between both study groups (supplemented
and control) (Figure 2a). The initial Hb averages were 13.47 ± 1.50 and 13.22 ± 1.01 g/dL for
supplemented and control respectively; there were no differences in the baseline measurement and
week 1, however, week 2, 3, and 4 showed statistically significant differences between supplemented
group (W2: 15.12 ± 0.99; W3: 14.89 ± 0.56; W4: 14.83 ± 0.96 g/dL) and control (W2: 12.78 ± 1.08; W3:
13.02 ± 0.80; W4: 13.13 ± 0.85 g/dL) according to the independent samples t-Test (p < 0.001) (Figure 2a);
reflecting an increase in this nutritional biomarker in the supplemented group from the second week
of supplementation and later showing stable values in weeks 3 and 4.
Figure 2. Concentrations of (a) Hb (Hemoglobin) (mean ± SD) and (b) UMDA (Urinary
malondialdehyde) (mean ± SD) before, during, and after 4 weeks of supplementation in the
supplemented and control group (W0: baseline; W1: week 1; W2: week 2; W3: week 3; W4:
week 4). * Statistically significant difference between groups according to the independent samples
t-Test (p < 0.001).
Furthermore, a comparative analysis was performed between the baseline values and values
obtained at the fourth week by the group of study (supplemented and control), which show statistically
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significant differences in the supplemented group (W0 vs. W4) according to the paired sample t-Test
(p < 0.05); no differences were found for the control group.
3.4. MDA Concentration
According to the results of this research, no differences were found by intragroup (supplemented)
sex; however, it was presented for the control group according to the independent samples t-Test
(p < 0.05) (Table 5). On the other hand, significant differences were found between men of the
supplemented and control group and women of the supplemented and control group after two weeks
of intervention (Table 6). Comparative analysis between the supplemented and control group was
performed, finding statistically significant differences (Figure 2b); in addition, a significant difference
was found in the means of the concentration of MDA before (week 0) and after (week 4) of the
supplementation (supplemented group) according to the paired sample t-Test (p < 0.001); on the
other hand, according to the repeated measures ANOVA test, it was observed that the levels of
MDA were different throughout the treatment, rejecting the equality of the means between weeks,
and showing a decrease of this compound from week 2 (p < 0.001); the control group did not show
significant differences between weeks. The Bonferroni correction was used, confirming the results
previously mentioned.
Table 5. Urinary MDA concentrations in men, women, and total participants before, during, and after















Weeks Urinary MDA concentrations (μM/g creatinine)
p-value p-value
Baseline 3.01 ± 0.85 3.26± 0.97 2.63± 0.48 NS 2.88 ± 0.61 3.44± 0.35 2.59± 0.51 <0.014
2 1.59 ± 0.89 1.84± 1.06 1.21± 0.36 NS 2.90 ± 0.56 3.47± 0.39 2.61± 0.38 <0.004
4 0.98 ± 0.80 1.13± 1.01 0.75± 0.28 NS 2.94 ± 0.57 3.51± 0.26 2.66± 0.44 <0.006
The values show the mean ± SD of UMDA (Urinary malondialdehyde) concentrations (μM/g creatinine) in
supplemented and the control group before, during and after 4 weeks of supplementation. The week zero represents
baseline. NS: no statistically significant difference between men and women of the same group per week according
to the independent samples t-Test.
Table 6. Urinary MDA concentrations in men of the supplemented and control group and women of











Weeks Urinary MDA concentrations (μM/g creatinine)
p-value p-value
Baseline 3.26 ± 0.97 3.44 ± 0.35 NS 2.63 ± 0.48 2.59 ± 0.51 NS
2 1.84 ± 1.06 3.47 ± 0.39 <0.014 1.21 ± 0.36 2.61 ± 0.38 <0.001
4 1.13 ± 1.01 3.51 ± 0.26 <0.001 0.75 ± 0.28 2.66 ± 0.44 <0.001
The values show the mean ± SD of UMDA (Urinary malondialdehyde) concentrations (μM/g creatinine) in men of
supplemented and control group and women of supplemented and control group, before, during and after 4 weeks
of supplementation. The week zero represents baseline. NS: no statistically significant difference between men
of supplemented and control group and women of supplemented and control group per week according to the
independent samples t-Test.
3.5. As Concentrations in Water and Urine
A month prior to the study, a questionnaire was applied to know the main source of water for
daily intake and food preparation; later, water was monitored in the school and participants’ homes
(2 months), where the concentrations of As were identified. It was observed that 16% of the participants
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exclusively used purified water (bottle) to drink and prepare food, 15% reported consuming only
drinking water to drink and prepare food, including water from the school tap during recess hours;
the percentage of households that mixed water (purified water for drinking and household drinking
water for food preparation) was 69%. The source and concentrations obtained of As in water samples
were as follows: >100 ± 1.51 μg/L (drinking water from the school tap), 84.79 ± 17.00 μg/L (drinking
water from the participants’ homes) and 1.94 ± 1.73 μg/L (purified water). The values were stable the
prior month and during the study.
Regarding the concentrations of urinary As, Table 7 shows the values obtained by the group, sex,
and week of intervention. The results showing a lack of significant differences in the supplemented
group; however, in the control group, only a difference was shown by sex at week 3, according to the
Mann–Whitney U test (p < 0.05).
















Weeks Urinary As concentrations (μg/g creatinine)
p-value p-value
0 56.85 57.42 52.09 NS 51.34 53.98 50.81 NS
1 53.60 53.90 53.48 NS 52.57 53.13 52.19 NS
2 2.02 3.95 0.45 NS 56.49 58.62 54.02 NS
3 0.29 0.27 0.30 NS 50.97 54.53 49.76 <0.05
4 0.29 0.27 0.30 NS 54.60 54.78 54.45 NS
The values show the median of UAs (Urinary arsenic) concentrations (μg/g creatinine) in the supplemented and
control group. The week zero represents baseline. NS: no statistically significant difference between men and
women of the same group per week according to the Mann–Whitney U test.
In addition, Figure 3 shows the maximum and minimum UAs values obtained by sex in the
supplemented (Figure 3a) and control (Figure 3b) group during 4 weeks of supplementation. On the
other hand, the comparative analysis between the supplemented and control group was carried out,
showing statistically significant differences at week 2, 3, and 4 (p < 0.001) (Figure 4a); also, according to
the Wilcoxon signed-rank test, significant differences were found between weeks of supplementation
(supplemented group) (Figure 4b). Differences were observed between most of the weeks (W0 vs. W1:
p < 0.05; W1 vs. W2: p < 0.001; W2 vs. W3: p < 0.001; W0 vs. W4: p < 0.001), but without differences
between W3 vs. W4 (NS) in the supplemented group; the control group did not show significant
differences. Finally, the values of the two study groups before and after the intervention (W0-W4)
were compared according to the Friedman test [p-value < 0.001; x2 (2) = 58.13]. The analysis reflected
differences between the weeks of supplementation (supplemented group). In addition, the UAs
medians obtained before (baseline: 56.85 μg/g creatinine) and after (W4: 0.29 μg/g creatinine) indicate
treatment effectiveness by decreasing the concentrations of UAs through the time. The control group
did not show significant differences [x2 (2) = 4.44, NS] (Figure 4b).
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                      (a)    (b) 
Figure 3. UAs (Urinary arsenic) (median) concentration by sex in the supplemented group (a) and
control group (b) (W0: baseline; W1: week 1; W2: week 2; W3: week 3; W4: week 4). * Statistically
significant difference by sex according to the Mann–Whitney U test (p < 0.05).
Figure 4. (a) Comparison of UAs (Urinary arsenic) concentrations (median) in the supplemented
group and control group (W0: baseline; W1: week 1; W2: week 2; W3: week 3; W4: week 4).
** Statistically significant difference between groups according to the Mann–Whitney U test (p < 0.001);
(b) Comparison of UAs concentration (median) between supplemented and control group per week of
treatment. The Friedman and Wilcoxon tests were carried out to determine differences between weeks
of supplementation.
3.6. NNT
The number needed to treat for second week was NNT = 2 (CI = 2 to 4), RR = 4.47 (CI = 1.47 to
16.0), which indicates that to increase the urinary arsenic excretion, treating at least two is required.
4. Discussion
4.1. As in Drinking Water
Previous studies have reported high values of As in drinking water of this population [28],
which when compared with the results found in the present study, have remained unchanged through
the time; the present concentrations of this element remain of concern, as they exceed the established
limits [29]. This element has been recognized as one of the most serious pollutants found in drinking
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water, which, in addition to being ubiquitous in the environment, has a wide list of adverse health
effects [9].
Although tap water samples from school and homes contain concentrations up to 3 times higher
than allowed (As: >100 μg/L) of this pollutant, which has been reported through communication
programs in the same community [28], the changes observed in this study have been minimal since
the percentage that continues to drink drinking water is higher (84%) compared to the participants
who use exclusively purified water (16%). These findings can be attributed to the fact that there
is a greater proportion of families that cannot afford to supply purified water, so that drinking
water is used for all needs, including water for food consumption and preparation; according to
Meza-Lozano et al. [37], families having no access to an economical source of purified water, prefer
not to consume it because of the high cost involved. Therefore, it is necessary to propose strategies
that, in addition to understanding direct communication, and water treatment, incorporate accessible
food sources (quelites) rich in phytochemicals, which can be incorporated into the diet in the form of
mixtures or formulations, since, at the moment, there are no changes and the exposure remains.
4.2. Hb, UMDA, and UAs
4.2.1. Hb Concentration
The levels of Hb found in baseline were normal for men and women [38], however, this study
showed that by incorporating a supplement with quelites into the diet, this nutritional biomarker
can increase to 1.65 g/dL, concentrations that were higher compared to other studies. According
to Egbi et al. [39] in a supplementation study with children ages 6–9 years, it was found that the
consumption of green leafy vegetables, among them, plants of the genera Amaranthus spp., increases
Hb concentrations in supplemented children (12.1 g/dL) compared to the control group (11.3 g/dL) at
the end of the study, minimizing the prevalence of anemia (supplemented: 33.3%; control: 57.5%) in
participants treated with the powder preparation. On the other hand, Monroy-Torres et al. [28] show
that after supplementation in adolescents ages 12–15 years using a trademark based on grape, broccoli,
and cranberry, Hb values increased 1 g/dL.
In this research, although both groups did not show low Hb levels, there was a significant
difference from week 2 until the end of supplementation (Figure 2a). According to Egbi et al. [39],
micronutrients such as Zn, Fe, and β-carotene from wild plant sources (green leafy vegetable powder),
lead to an improvement in nutritional status, increasing Hb values and decreasing the proportions of
anemia. Concentrations of this indicator are attributable to the quality of the diet, mainly the less varied
diets with low consumption of fruits and vegetables, and mostly made up of cereals and legumes,
have high concentrations of anti-nutrients such as tannins and phytates, known as inhibitors of the
absorption and bioavailability of iron and zinc [39]. Another factor involved is inflammation processes,
which affects red blood cells and retinol serum levels [39]. In addition, You et al. [40] report that fat
consumption improves the bioavailability of carotene.
All these dietary patterns were observed in both study groups (Tables 3 and 4). Therefore, the
results obtained in the supplemented group show that supplementation with quelites provides essential
micronutrients and possibly improves their bioavailability for the increase in Hb.
4.2.2. MDA Concentration
MDA is a product of lipid peroxidation (LPO), the elevation of this in urine reflects the degree
of oxidative stress, so this biomarker is usually used to evaluate LPO and DNA damage caused by
exogenous free radicals or endogenous reactive oxygen species (ROS) [41]. It has been reported that
the increase in MDA has a high correlation with exposure to pollutants, including As [41]. The results
of MDA in both study groups (supplemented: 3.01 μM/g creatinine; control: 2.88 μM/g creatinine)
(baseline), confirm the ability of this element to induce significant increases in MDA (Figure 2b; Tables 5
and 6), indicating that participants have a high level of oxidative stress due to prolonged exposure.
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These values are similar to those reported by Wang et al. [41] which shows concentrations of 3.52 and
2.48 μM/g creatinine in men and women respectively (<20 years) exposed to As. Flora et al. [42] explain
that the toxicity of As can be manifested directly with the attack on sulfhydryl groups or indirectly
through the generation of ROS such as hydrogen peroxide, hydroxyl radical species, or superoxide
anion, and where hydroxyl radicals play a role as initiators of LPO. On the other hand, according to
Khuda-Bukhsh et al. [43], free radicals are electrophilic species that can react with cellular components.
LPO process is initiated by the attack of a free radical, which could be emanated by As over unsaturated
fats and the resulting chain reaction is terminated by the production of fat decomposition products
such as alcohols and aldehydes (malondialdehyde).
On the other hand, in this study, after 4-week supplementation, the results showed a significant
decrease in MDA concentrations (>50%) (Figure 2b; Tables 5 and 6). Similar results have been reported
in rats induced with toxic agents [23,27]; in these trials, it was revealed that when administered varying
doses of Chenopodium spp. and Portulaca spp. plants, the production of hydrogen peroxide (40%) and
concentration of MDA (50%) can be reduced; in addition, an increase in the activity of antioxidant
enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX)
was reported.
Some studies show that these antioxidant enzymes can reduce the toxic effects of ROS by
eliminating them since they are the first line of defense against oxidative stress, however, these can
be affected if ROS production is excessive, so phytonutrients become alternatives to minimize the
toxic effect of As [42,44]. It has been reported that the presence of non-enzymatic antioxidants from
food (plants, vegetables, leaves, flowers) helps to neutralize or remove free radicals [42,44]. These act
by reducing peroxide concentrations and even inhibiting lipid peroxidation and repairing oxidized
membranes or promoting the strengthening or restoration of the antioxidant defenses of the cells; on
the other hand, supplementation with non-enzymatic antioxidant molecules (phytonutrients) reduce
the possibility of the metalloid interacting with biomolecules and inducing oxidative damage [42,44].
Among these compounds are some phytochemicals of the phenolic type such as phenolic acids (caffeic
acid), flavonoids (quercetin, naringenin, phloretin), and non-phenolic such as carotenoids (β-carotene),
chlorophylls, vitamin A, vitamin E, vitamin C, some minerals like zinc, manganese, magnesium, and
selenium and amino acids like cysteine [42,44,45], nutritional compounds that were presented in high
concentrations in the supplement administered [30].
In addition, according to Pace et al. [44], the ability of phenolic antioxidants to neutralize oxidants
is due to the donation of a hydrogen atom from polyphenolic antioxidants, leading to the formation of
phenoxy-radical, which can be stabilized through intermolecular bonds between two polyphenols or
by reaction with other radicals. Therefore, the results obtained in both groups are consistent with the
reported evidence.
4.2.3. UAs Concentration
Regarding UAs concentrations, the results showed that both groups had high baseline values with
51.34 μg/g creatinine and 56.85 μg/g creatinine for control and supplemented group respectively. The
CDC [46] establishes diagnostic criteria for As, with concentrations greater than 50 μg/L, however, the
health effects may vary depending on the acute or chronic exposure of this pollutant [9]. Subclinical
complications were not evaluated in this research so their presence is not ruled out.
According to Monroy-Torres et al. [28], after supplementation in a group of adolescents ages
12–15, an increase in the excretion of UAs in the second week (53.9 μg/g creatinine) and third week
(51.1 μg/g creatinine) was shown. However, our study did not register an increase in the excretion of
this pollutant between weeks. The baseline values obtained were high, and later at the end of each week
during the supplementation, a decrease of these concentrations was observed in the supplemented
group (Table 7; Figure 4b). On the other hand, the results observed in the control group showed no
significant difference between weeks, showing concentrations greater than 50 μg/g creatinine during
the study (Table 7; Figure 4b). The variations found in this research regarding the literature may be due
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to the fact that the highest percentage of excretion of UAs may have occurred in the first days of the
first and second week after supplementation, but with higher intensity in this latter week. Therefore,
we infer that because the sample collection was carried out at the end of each week and not daily,
the results obtained reflect the levels of this pollutant after its maximum excretion; thus, promoting an
efficient balance and recovery process in the supplemented group. Nowadays, there are no clinical
trials that report the biological effect of herbal remedies or the use of quelites as alternative recovery
therapies in cases of arsenic exposure. Therefore, this research has reported interesting results. Our
results showed an increase of UAs content during the first 2 weeks (high excretion and then a recovery
process), and after 30 days of treatment, showing that a supplementation with quelites could enhance
the mobilization of As during the first 15 days, observing a significant decrease (90%) of this pollutant
(recovery process) (Table 7). In our study, UAs concentrations showed a fluctuation after the first week
of treatment in the treated group and a notable difference being observed at week 2, resulting in an
evident and periodic removal of arsenic from the body in the supplemented group. On the other hand,
a decrease in the MDA level (50%) was observed (Figure 2b; Tables 5 and 6). Other investigations
have been reported similar behaviors to what was observed in our study about arsenic excretion.
An intervention study [47] showed that in participants aged 18, urine arsenic concentrations were
stable during the day, however, variations may exist throughout the days. Hence, the evidence of our
study proposes a mechanism for the excretion of As in the urine and could establish a new balance
process for this pollutant.
Regarding results obtained by sex, in our research, similar values of UAs among men and women
without a statistical difference (Table 7) were observed. The literature reports an absence of differences
in UAs concentrations by gender [47,48]. On the other hand, the significant decrease observed in
this study is attributed to the fact that growing children have a more efficient process of methylation
than adults because in this latter group, the number of factors that affect methylation increases with
age, such as smoking, or decreased hepatic functions [48–50]. In addition, it has been reported that
children retain lower amounts of As in the body, because the second step of the methylation process
is more active and allows an increase in the value of concentrations [51]; so that the results obtained
in this investigation are consistent and supported by the previously reported evidence, since the
supplemented group showed a surprising reduction of this pollutant after supplementation (98%).
On the other hand, As can also have different excretion patterns in participants of the same group
(intra-individual variability; inter-individual variability) [52] or between groups [28,51]. However, the
literature reports that many factors influence arsenic metabolism and condition its efficiency, including
genetic factors (example: polymorphisms of the arsenite methyltransferase), metabolic capacity, sex,
hormonal mechanisms, nutritional status, and diet [28,48,52,53].
During this clinical intervention study, it was observed that the diet of the participants in both
study groups remained unchanged throughout the research. Despite the fact that the DRI of some
macro and micronutrients were mainly met by men, most of these were from ultra-processed products,
so the diet was considered of low quality in both groups due to the high consumption of these
foods, such as drinks of cola and flavored drinks, foods high in saturated fats, and with high energy
content, and on the other hand, a low consumption of plant-based foods was observed. According to
Monroy-Torres et al. [54], it was observed that nutrient consumption considered as antioxidants in a
population exposed to As was low, while the consumption of foods that promote greater oxidation
and inflammation in the body was high (sugary drinks and ultra-processed foods), showing a high
baseline concentration of As. This evidence is similar to that observed in our study for both groups,
regarding the diet quality and the situation of the baseline concentrations of the biomarkers evaluated,
and on the other hand, the behavior of biomarkers in the control group during the research (Tables 3
and 4; Figures 2b and 4a). According to Monroy-Torres et al. [54], this dietary situation promotes
the onset of obesity and pathologies directly associated with arsenic (hepatopathy and nephropathy),
directly contributing to the disorders and effects caused by exposure to the metalloid.
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On the other hand, according to Hervert-Hernández et al. [55], the inclusion of fruits, vegetables,
even roots, stems, and leaves contributes to high consumption of antioxidants, and therefore improves
to the diet quality. However, nowadays the importance of consuming these potential sources of
phytochemicals such as quelites has been forgotten, which could be used as alternative therapies to
reduce the effects of various pathophysiological conditions, including As toxicity [21]. Some studies
on populations exposed to As have reported that the consumption of natural supplements or foods
rich in bioactive compounds improve the processes of methylation and increase the levels of excretion
of As, promoting an efficient recovery process [28,42,53,56]. On the other hand, nutritional deficiencies
due to low consumption of micronutrients contribute to increasing the risk of arsenic-induced skin
lesions [57]. In our study, the quelites included in the supplement were evaluated (each plant and
mixtures) showing an excellent nutritional profile when an optimized mixture was made [22,30]. The
supplement was rich in antioxidant compounds [carotenoids, chlorophyll, phenolic acids (chlorogenic
acid), flavonoids (quercetin, naringenin, phloretin, and phloridzin), amino acids (methionine, cysteine,
serine, and glycine), minerals (Zn, Se, Mg, and P between others), and dietary fiber [22,30].
It has been reported that the administration of vitamin C leads to the formation of complexes with
heavy metals and in addition with vitamin E, promotes an efficient recovery process by decreasing
As concentrations [41]. On the other hand, supplementation with essential elements such as Zn and
Se, reduces the toxicity effects of As, promoting their elimination, by chelation mechanisms, with the
formation of reversible compounds [42,58]. Regarding Se, an antagonistic relationship with arsenic
has been demonstrated where one reduces the toxicity of the other [59]; other studies report that
possibly As and Se form a complex in the lysosome (As2Se) which is excreted in the urine [60]; in
addition, As and Se compete for the union with functional proteins, thus reducing the availability of
toxic metals [42]. Other studies have reported that the presence of selenium and folates increases the
methylation of As in children, improving the efficiency of the 1-carbon metabolism, essential for the
methylation and excretion of As. It is likely that this result in metabolism and the availability of methyl
groups are particularly important in growing children to meet the production demands of creatine,
proteins, phospholipids, and DNA [48].
On the other hand, other nutrients and compounds have been reported as beneficial, such as dietary
fiber, carotenoids, and organic acids present in parts of plants and vegetables which reduce the toxic
effects of heavy metals, including As [21,28,42]. Moreover, another study showed that low diets in green
leafy vegetables and micronutrients such as calcium, folates, and vitamin C increase the probability of
presenting toxic effects characteristic of As [57]. According to López-Carrillo et al. [56], the consumption
of methionine, vitamin C, B6, B12, Fe, and Zn plays an important role in the metabolism of As. Each
component improves the elimination of this toxic, participating in the metabolism of 1-carbon as
catalyst components or donors of methyl groups. On the other hand, other studies report that vitamin
C, methionine, and cysteine participate in the processes of As detoxification, promoting chelation
and facilitating its removal from the body [14,42]. Finally, according to Kurzius-Spencer et al. [53],
some amino acids are associated with the 1-carbon pathway such as methionine, cysteine, serine, and
glycine, promoting the As methylation process. Other mechanisms have been reported to explain
the beneficial effects of these nutrients and the exposure of As. Clemente et al. [61] describe that
the treatments based on Fe, cysteine, flavonoids (quercetin, catechin, epigallocatechin), Mg, P, fruit,
and vegetable extracts of green leaves (rich in polyphenols), reduce the transport of As through the
intestinal monolayer, decreasing its absorption. Polyphenols have been reported to modulate tight
junctions affecting toxic transport (paracellular permeability). On the other hand, there is possibly
a relationship between the content of dietary fiber in food, the presence of As, and the interaction
with the intestinal microbial ecosystem, favoring the DF-As ligand and lowering the percentage of
bioaccessibility; however, this bioaccessibility will be influenced by intestinal motility, nutritional
status, and genotype [62].
This evidence reinforces our results obtained in the supplemented group. As previously mentioned,
during supplementation, a decrease in UAs concentrations was observed in the supplemented group
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and without differences in the control group, despite the content consumed of some components
important for arsenic detoxification (Se, vitamin A, vitamin C, B vitamins) being similar in both
study groups. On the other hand, the foods included in the diet were mostly ultra-processed.
In addition, it was observed that during the entire study, other essential nutrients such as dietary fiber,
vitamin E, folates, and Zn did not meet the dietary reference intakes in the supplemented and control
group. Therefore, this indicates that the supplement administered provided a high-quality source of
micronutrients and antioxidant compounds in the treated group that possibly allowed the reduction
of the bioavailability of As, promoted the chelation and methylation process, reduced toxic effects,
and finally, promoted a balancing mechanism and a recovery process.
Regarding the result of NNT being necessary to treat the observed from the second week on, it is
important to compare this result with that of Monroy-Torres et al. [28], where the NNT was 7 but non
confidence interval, which may lead us to demonstrate that we would be facing an advancement not
only of the effects of the key nutrients that participate in arsenic excretion, but in what should be the
best methodology and its intervention time.
This study approached the effect of a supplementation with two endemic quelites on urinary
excretion of arsenic in adolescents exposed to water contaminated with the metalloid in a community in
the state of Guanajuato for four weeks, which seems to increase the excretion of arsenic from the second
week compared to the control group, in addition to improving other nutritional variables. Mexico is
rich in plant biodiversity, where the quelites, in addition to being rich in nutrients, showed that they
can have a beneficial effect on the urinary excretion of the metalloid.
5. Conclusions
This study showed that during supplementation based on two quelites, there was a significant
reduction in MDA (1.59 μM/g creatinine) and UAs (2.02 μg/g creatinine) from week two; in addition
to an improvement in Hb levels (15.12 g/dL). The decrease in arsenic was kept until the end of the
treatment. Therefore, the incorporation in the diet of these plants high in phytochemicals could be a
viable alternative therapy, by increasing the intake of macronutrients, micronutrients, and antioxidant
compounds essential for detoxification, thus providing a more efficient recovery process against
this pollutant. Prevention and orientation campaigns regarding consumption of tap water and the
importance of a healthy diet have been carried out in this community; however, the current results show
the null action to this problem, even though previous studies have reported this situation. Another
reason that has also been considered, is the lack of technological solutions available to society, so it
is necessary for sustainable strategies that can improve the nutritional and health status of members
of rural communities exposed to arsenic, such as incorporating food with beneficial effects on the
excretion of this pollutant.
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Abstract: The sector of food supplements is certainly varied and growing: an ever wider offer of
new products is launched on the market every year. This is reflected in new reorganization of drug
companies and new marketing strategies, in the adoption of new production technologies with
resulting changes in dietary supplements regulation. In this context, information on composition
reported in labels of selected dietary supplements was collected and updated for the development
of a Dietary Supplement Label Database according to products’ availability on the Italian market
and also including items consumed in the last Italian Dietary Survey. For each item, a code was
assigned following the food classification and description system FoodEx2, revision 2. A total of
558 products have been entered into the database at present, trying to give a uniform image and
representation of the major classes of food supplements, and 82 descriptors have been compiled.
Various suggestions on how the number of FoodEx2 system descriptors could be expanded were noted
during the compilation of the database and the coding procedure, which are presented in this article.
Limits encountered in compiling the database are represented by the changes in the formulation of
products on the market and therefore by the need for a constant database update. The database here
presented can be a useful tool in clinical trials, dietary plans, and pharmacological programs.
Keywords: Dietary Supplement Label Database; dietary supplements; food description; food
classification; FoodEx2
1. Introduction
The sector of food supplements is certainly varied and growing: a wider and wider selection of
new products is launched on the market every year. This is reflected in new reorganization of drug
companies, in new marketing strategies, and in the adoption of new production technologies with
resulting changes in the dietary supplements regulation. The growth of this sector is encouraged by
growing interest of consumers in improving their health and physical and mental wellbeing, often to
compensate for an incorrect lifestyle [1].
Dietary supplements are considered in epidemiological studies and in the analysis of food
consumption patterns [2]. There are several implications in dietary adequacy assessment especially
with regard to the issue of upper limits in daily intake of certain nutrients. Moreover, several
factors may influence the use of dietary supplements, such as gender, age, socio-economic status,
educational level, dietary habits, etc. A first attempt to harmonize information on food supplements
between European countries was performed by EFSA [3] with the purpose of producing a food
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composition database including both foods and food supplements to estimate nutrient intakes in
European Countries. In this regard, it is worth mentioning some ongoing initiatives such as Global
Dietary Database (GDD) (https://globaldietarydatabase.org/) and FAO/WHO Global Individual Food
consumption data Tool (FAO/WHO GIFT) (http://www.fao.org/gift-individual-food-consumption/en/)
aimed at the harmonization of dietary datasets worldwide for global diet monitoring using a common
food classification and description system [4,5]. Considering the importance of dietary supplements
in the evaluation of dietary intake, it is worth mentioning in particular the Dietary Supplement
Label Database (DSLD) (https://dsld.nlm.nih.gov/dsld/) by the National Institutes of Health [6,7]; at
present, it contains label information (brand name, ingredients, amount per serving, and manufacturer
contact information) of more than 71,000 dietary supplements present and consumed in the U.S.
marketplace [8,9]. The DSLD can be used to track changes in product composition and capture new
products entering the market. Browsing options were developed and organized to search by product,
ingredient, or contact of manufacturer, representing a unique resource that policymakers, researchers,
clinicians, and consumers may find valuable for multiple applications [8,9].
In this context, information on composition reported on the product labels of selected dietary
supplements has been collected and updated for the development of a Dietary Supplement Label
Database for Italy, according to products’ availability on the Italian market and also including items
from both the third Italian National Food Consumption Survey, INRAN-SCAI 2005-06 database [2] and
the ongoing Italian national dietary survey IV SCAI. The design and construction of a food database
requires above all identifying foods through an adequate food nomenclature and a precise description.
The FoodEx2 system has been used for the classification and description of dietary supplements in
the aforementioned database. FoodEx2 is a standardized food classification and description system
developed by EFSA to better describe characteristics of foods and dietary supplements in exposure
assessment studies; this system, nowadays at revised version 2, consists of flexible combinations
of classifications and descriptions based on a hierarchical system for different food safety-related
domains (i.e., food consumption, chemical contaminants, pesticide residues, zoonoses and food
composition) [10–14]. This system is characterized by a compromise between comprehensiveness
(sufficiently detailed description) and feasibility in different areas of food data collection. In fact, it
consists of a fixed and sufficiently large set of food categories or groups (food classification—organization
of terms identifying/assigning different food items into groups) defined at high level of detail that
constitute the “core list” and represent the minimum recommended level for coding during data
collection [15]. More detailed terms can be found on the “extended list”; terms present in the core
and extended lists may be aggregated in a hierarchical parent–child relationship in several ways
according to different food safety domains. Descriptors, defined “facets”, are aimed at registering all
relevant food items characteristics and can be used to add details to create new categories responding
to particular study requirements.
This work has been undertaken to study the application of FoodEx2 system starting from FoodEx2
categories (or terms) belonging to the FoodEx2 group “Products for non-standard diets, food imitates
and food supplements” (A03RQ) for classifying the items that make up the Italian Dietary Supplement
Label Database here presented.
2. Materials and Methods
The starting set of supplements has been drawn from the nationwide dietary surveys including the
third Italian National Food Consumption Survey, INRAN-SCAI 2005-06 database [2] and items from
preliminary results of the ongoing Italian national dietary survey IV SCAI. National food consumption
surveys were designed with the aim of representativeness of the total population at national level and
in the four main geographical areas, taking energy intake as the referring parameter.
Subsequently, products’ labels had been searched on the internet using the following keywords
in Italian: dietary supplements, botanical, herbal formulations, vitamin-based supplements,
mineral-based supplements, protein-based supplement, carnitine-based supplements, prebiotic
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formulations, probiotic formulations, algae-based formulations, enzyme-based formulations,
yeast-based formulations, common supplements.
Afterwards, label surveys visiting retail points to directly observe products on shelves were
carried out.
The official register of supplements authorized by the Italian Ministry of Health (http://www.
salute.gov.it/imgs/C_17_pagineAree_3668_listaFile_itemName_1_file.pdf) was consulted.
The coding procedure was carried out by a qualified compiler who constantly follows the FoodEx2
system updates, taking part in training courses organized by system developers [14]. Another qualified
compiler double-checked the codes.
Procedurally, information on composition of dietary supplements was taken from labels, and a
code was assigned to each item following the food classification and description system FoodEx2,
revision 2; the exposure hierarchy was used for coding [10–14]. The FoodEx2 categories (terms)
belonging to the FoodEx2 group “Products for non-standard diets, food imitates and food supplements”
(A03RQ) were considered for classification of the items.
FoodEx2 system consists of 21 clearly defined food groups. Detailed food groups represent the
basis of the systems; a food only fits in one group and a parent–child structure is present within the
food groups. Facets descriptors, of which there are 28 in total, can be viewed as characteristics of
foods from different points of view; the facets give additional information for a peculiar aspect of food,
i.e., part nature, ingredient, packaging material, production method, qualitative information, process,
target consumer. Peculiarity of FoodEx2 is that each food group lists term with included implicit facet
descriptors, to which further descriptors of different characteristics can be added; during compilation
procedure, in FoodEx2 for each food item, the terms may be aggregated in different ways according to
the needs [16]. “Implicit facets” means facets proper of the base term chosen for classification, and
therefore, implicitly assigned to it, whereas “added facets” means the facet descriptors that are added
by the coder to the chosen base term while coding a food item. The procedure consists of organizing
them to reduce the coding time and prevent general imprecision.
For each food item, the terms may be aggregated in different ways according to the needs, without
following a general scheme; a typical case is given by a base term, followed (optionally) by a hashtag
“#” and a sequence of facet descriptors separated by dollar character “$”.
During this practical experience of compiling the Dietary Supplement Label Database, feedbacks
and suggestions for possible enhancement of FoodEx2 were formulated and forwarded to system
developers. These suggestions can be grouped as “Additional items”, “Clarifications”, and “Typing
suggestions”.
3. Results and Discussion
A total of 558 products have been entered into the database at present, as an attempt to provide
an adequate representation of the major categories of food supplements, and 82 descriptors have been
compiled. Particular attention has been given to supplements/formulations based on medical herbs
and plant extracts, one of the classes currently emerging [17,18].
3.1. Database Description
Items in the Dietary Supplements Label Database are organized in groups defined by base terms
and additional facets.
Table S1 (Supplementary Material) reports ingredients and nutritional composition of the 558
products and Table S2 (Supplementary Material) reports the FoodEx2 codes of the 558 products.
3.1.1. Base Terms
The base terms reported for describing the 558 products are distributed in the subgroups as
follows: 73 Mixed supplements/formulations [A03TC], 28 Vitamin only supplements [A03SL], 27
Mineral only supplements [A03SM], 49 Combination of Vitamin and mineral only supplements [A03SN],
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6 Bee-produced formulations [A03SQ], 7 Fiber supplements [A03SR], 283 Herbal formulations and
plant extracts [A03SS], 14 Algae-based formulations (e.g., spirulina, chlorella) [A03ST], 8 Probiotic
or prebiotic formulations [A0F3Y], 15 Formulations containing special fatty acids (e.g., Omega-3,
essential fatty acids) [A03SX], 10 Protein and amino acids supplements [A03SY], 2 Coenzyme Q10
formulations [A03SZ], 1 Enzyme-based formulations [A03TA], 4 Yeast-based formulations [A03TB], 10
Other common supplements [A03SV], 3 Protein and protein components for sports people [A03SA],
6 Micronutrients supplement for sports people [A03SB], 7 Carnitine or creatine-based supplement
for sports people [A03SC], 2 Nutritionally complete formulae [A03SE], 3 Imitation yoghurt, non-soy
[A03TZ].
3.1.2. Facets
Additional facets used for describing the dietary supplements are: FACET F03 “PHYSICAL
STATE”, FACET F04 “INGREDIENT”, FACET F23 “TARGET CONSUMER”, FACET F33 “LEGISLATIVE
CLASSES”. FACET F03 defines the physical state of a product such as: Tablets [A06JH], Powder
[A06JD], Liquid [A06JL].
FACET F04 defines the characterizing ingredients. Common terms used are aggregation term
Chemical elements [A0EVF], including core terms Calcium [A0EXH], Magnesium [A0EXF], Iron
[A0EXD], Potassium [A0EXJ], Zinc [A0EXE], Fluorine [A0F3A]; aggregation term Vitamins [A0EVG],
including core terms Vitamin C (Ascorbic acid) [A0EXN], Vitamin D (Cholecalciferol) [A0EXM], Vitamin
E (Tocopherols, tocotrienols) [A0EXL, Vitamin A (retinol, carotenoids) [A0EXZ], Vitamin B9 (Folic
acid, folinic acid) [A0EXQ], etc.; aggregation term Special fatty acids [A0EVS], including core terms
Omega-3 fatty acids [A0EVV] and Omega-6 fatty acids [A0EVT]; aggregation term Phytochemicals
[A0EVM], including core terms Phytosterols [A0EVQ], Polyphenols [A0EVP], Carotenoids [A0EVN];
the core term Dietary fiber [(A0EVR]; the extended terms Carnitine [A0F4N] and Creatine-creatinine
[A0F4P]; the aggregation term Bee-produced fortifying agents [A0EVH], including the core term Royal
jelly [A0CVG]; the aggregation term Live microorganisms for food production [A048X] including core
terms Yeast cultures [A048Z]; the core term Caffeine [A0EVK]; the core term Algae-based fortifying
agents (e.g., spirulina, chlorella) [A0EVL].
It is worth mentioning that the most used terms to indicate the ingredients present in the food
supplements from the category Herbal formulations and plant extracts [A03SS] are Powdered extract
of plant origin [A0ETZ], Liquid extract of plant origin [A0EVA], Extracts of plant origin [A0ETY],
Dried herbs [A016T], Dried vegetables [A00ZQ], Dried fruit [A01MA], Dehydrated/powdered fruit
juice [A03CG], Dehydrated/powdered vegetable juice [A03DA].
Examples of descriptors for FACET 23, used to indicate the target consumers for whom the
product is intended are Children’s food [A07TL], including the Children’s food 4–8 years [A07TM] and
Children’s food 9–15 years [A07TN]; Infant or toddler’s food [A07TF].
Within FACET F33, defining the legislative class, descriptors from the classification defined in the
food additives legislation (Regulation (EC) No. 1333/2008) are used for dietary supplements as follows:
FA-17.1 Food supplements supplied in a solid form including capsules and tablets and similar forms
excluding chewable forms [A0C16], FA-17.2 Food supplements supplied in a liquid form [A0C15],
FA-17.3 Food supplements supplied in a syrup-type or chewable form [A0C14].
3.1.3. Groups’ Description
Examples of group Vitamin only supplements [A03SL] are dietary supplements containing
vitamin D such as the product coded by [A03SL#F03.A06JH$F04.A0EXM$F33.A0C16] (Re-coded:
Vitamin only supplements, STATE = Tablets, INGRED = Vitamin D (cholecalciferol), LEGIS =
FA-17.1 Food supplements supplied in a solid form including capsules and tablets and similar forms,
excluding chewable forms) or the one by [A03SL#F03.A06JL$F04.A0EXM$F33.A0C15] (Re-coded:
Vitamin only supplements, STATE = Liquid, INGRED = Vitamin D (cholecalciferol), LEGIS = FA-17.2
Food supplements supplied in a liquid form); dietary supplements containing vitamin C such
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as the product coded by [A03SL#F04.A0EXN$F33.A0C14] (Re-coded: Vitamin only supplements,
INGRED = Vitamin C (ascorbic acid), LEGIS = FA-17.3 Food supplements supplied in a syrup-type
or chewable form); dietary supplements containing vitamin B9 such as the product coded by
[A03SL#F03.A06JH$F04.A0EXQ$F33.A0C16], (Re-coded: Vitamin only supplements, STATE = Tablets,
INGRED = Vitamin B9 (folic acid, folinic acid), LEGIS = FA-17.1 Food supplements supplied in a solid
form including capsules and tablets and similar forms, excluding chewable forms); etc.
For group Mineral only supplements [A03SM], including all supplements based only
on minerals, examples are dietary supplements containing, i.e., iron, potassium, magnesium,
zinc, or combination such as potassium and magnesium widespread used. An example of
FoodEx2 code of a product containing potassium and magnesium is as follows: FoodEx2 code
[A03SM#F03.A06JH$F04.A0EXJ$F04.A0EXF$F33.A0C16], Re-coded: Mineral only supplements, STATE
= Tablets, INGRED = Potassium, INGRED =Magnesium, LEGIS = FA-17.1 Food supplements supplied
in a solid form including capsules and tablets and similar forms, excluding chewable forms.
Examples for group Combination of vitamin and mineral only supplements [A03SN] that
comprises all supplements based only on formulations including both minerals and vitamins are dietary
supplements containing vitamin D and Calcium, i.e., FoodEx2 Code: [A03SN#F04.A0EXM$F04.A0EXH],
Re-coded: Combination of vitamin and mineral only supplements, INGRED = Vitamin D
(cholecalciferol), INGRED = Calcium; dietary supplements containing vitamin C and iron, i.e.,
FoodEx2 Code: [A03SN#F03.A06JH$F04.A0EXN$F04.A0EXD$F33.A0C16], Re-coded: Combination
of vitamin and mineral only supplements, STATE = Tablets, INGRED = Vitamin C (ascorbic acid),
INGRED = Iron, LEGIS = FA-17.1 Food supplements supplied in a solid form including capsules and
tablets and similar forms, excluding chewable forms.
The Herbal formulations and plant extracts [A03SS] include any type of supplement based on
herbal formulations and/or plant extracts. Typical ingredients are ginkgo biloba, dog rose, star anise,
tamarind, aloe, rhubarb, acacia, dandelion, astragalus, psyllium, holy basil, sage and others; these
occur as dried products or liquid or powdered extracts. In addition to the classic medical herbs just
mentioned, there are also foods with functional components such as artichoke, garlic, pineapple,
black currant, whose use has become frequent. An example of coding of artichoke- based product
is FoodEx2 Code: [A03SS#F03.A06JL$F04.A0EVA$F33.A0C15], (Re-coded: Herbal formulations and
plant extracts, STATE = Liquid, INGRED = Liquid extract of plant origin, LEGIS = FA-17.2 Food
supplements supplied in a liquid form), and in the Remark is noted: “The ingredient indicated as
Liquid extract of plant origin is hydroalcoholic extract of artichoke leaves”. For a garlic-based product,
FoodEx2 Code is [A03SS#F04.A0ETZ$F33.A0C16] (Re-coded: Herbal formulations and plant extracts,
INGRED = Powdered extract of plant origin, LEGIS = FA-17.1 Food supplements supplied in a solid
form including capsules and tablets and similar forms, excluding chewable forms) and in the Remark
is noted: “The ingredient indicated as Powdered extract of plant origin is garlic bulb dry extract”.
The group Other Common Supplements [A03SV], referring to any type of other common
supplements, includes formulations containing, as the main ingredient, compounds such as alpha lipoic
acid, beta glucans, lactoferrin, melatonin, etc. An example of product containing lipoic acid is given
by the code [A03SV#F03.A06JH$F04.A0F4M$F33.A0C16], (Re-coded: Other common supplements,
STATE = Tablets, INGRED = Co-factors to metabolism, LEGIS = FA-17.1 Food supplements supplied
in a solid form including capsules and tablets and similar forms, excluding chewable forms) and in the
Remark is noted “The ingredient indicated as Co-factors of metabolism is α-lipoic acid”.
Another example is given by a product containing melatonin coded as
[A03SV#F03.A06JH$F04.A0EVM$F33.A0C16] (Re-coded: Other common supplements, STATE =
Tablets, INGRED = Phytochemicals, LEGIS = FA-17.1 Food supplements supplied in a solid form
including capsules and tablets and similar forms, excluding chewable forms) and in the Remark is
noted “The ingredient indicated as phytochemicals is melatonin”.
The group Mixed supplements/formulations [A03TC] includes any type of supplements
combining different principles without a strong prevalence of one. Moreover, various products
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belonging to this group present bioactive molecules among the ingredients, such as rutin,
quercetin, coenzyme Q10. An example is given by product containing powdered extract of plant
origin and fish oil, quercetin, vitamin C, vitamin B5, and Methylsulfonylmethane; it is coded
as [A03TC#F03.A06JH$F04.A0ETZ$F04.A0EVP$F04.A0EXN$F04.A0EXT$F04.A038M$F04.A0EVV$F33.
A0C16] (Re-coded by Mixed supplements/formulations, STATE = Tablets, INGRED = Powdered extract
of plant origin, INGRED = Polyphenols, INGRED = Vitamin C (ascorbic acid), INGRED = Vitamin
B5 (pantothenic acid), INGRED = Fish oil, INGRED = Omega-3 fatty acids, LEGIS = FA-17.1 Food
supplements supplied in a solid form including capsules and tablets and similar forms, excluding
chewable forms) and in the Remark is noted “The ingredients indicated as licorice root dry extract,
plantain leaves dry extract, chamomile flowers dry extracts, nettle aerial parts. The ingredient indicated
as Polyphenols is quercetin. Methylsulfonylmethane is also contained”.
3.2. Feedback and Suggestions for FoodEx2 Revision 2 Implementation: Focus on Dietary Supplements
Here we report the feedback and suggestions for implementation of FoodEx2 formulated during
the development and updating of Dietary Supplement Label Database in Italy. Concerning additional
items, supplementary aggregation terms for proteins and amino acids should be added, including core
terms for main amino acids used in dietary supplements as well as within “Special fatty acids”, extended
terms for “Omega-3 fatty acids” and “Omega-6 fatty acids”. Considering the widespread growth
in the consumption of herbal remedies, additional items, such as powdered dried fruit, powdered
dried vegetables and powdered dried herbs would be very useful. At the same time, attention should
be given to additional terms linked to description of bioactive compounds; in this order, within the
aggregation term “Phytochemicals”, several core terms, i.e., alkaloids, nitrogen-containing compounds,
organosulfur compounds, should be added, including their corresponding extended terms. Moreover,
extended terms should be associated to the core terms just present in FoodEx2 System, “Carotenoids”
and “Polyphenols”.
In line with technological progress, facet descriptors, i.e., capsules, softgels, opercula, chewable
tablets, and gastro-resistant tablets should be considered.
Details on additional items proposed were reported in Table 1.
“Clarification” about “scope notes”(textual information helping describing the selected term)
of “protein and amino acids supplements” and “protein and protein components for sports people”
should be underlined; differences in “protein and amino acids supplements [A03SY]” and “protein and
protein components for sports people [A03SA]” should be clarified as well as if dietary supplements
containing fiber with a marked prebiotic activity should be included in “Fiber supplements [A03SR]”
or “Probiotic or prebiotic formulations [A0F3Y]”. Moreover, several typing suggestions were indicated,
i.e., “Chemical elements” should be replaced by “Minerals” and “Fiber” by “Fibre”.
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Table 1. Proposed descriptors for implementation of FoodEx2 distinguished by type of term in FoodEx2
hierarchical structure *.



























Special fatty acids [A0EVS]
Omega-3 fatty acids [A0EVV]
DOCOSAHEXAENOIC ACID (DHA)
EICOSAPENTAENOIC ACID (EPA)
ALPHA LINOLENIC ACID (ALA)
Omega-6 fatty acids [A0EVT]
LINOLEIC ACID
ARACHIDONIC ACID





















Brown algae [A00VK] FUCUS
ASCOPHYLLUM NODOSUM
Green algae [A00VB] CHLORELLA
Dried fruit [A01MA] POWDERED DRIED FRUIT
Dried vegetables [A00ZQ] POWDERED DRIED VEGETABLES
Dried herbs [A016T] POWDERED DRIED HERBS
* Proposed FoodEx2 descriptors are in upper case and bold.
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4. Conclusions
A total of 558 products have been entered into the database at present, with the aim of providing
an adequate representation of the major classes of food supplements, and 82 descriptors have
been compiled.
This paper represents one of first works describing the procedure of coding dietary supplements
through the FoodEx2 classification system and could be a useful tool/guide for other compilers
and users.
The Dietary Supplement Label Database here presented is intended to be a first example of
building a database of information on marketed dietary supplements and provides several suggestions
for improving the adopted classification coding system. This database is intended as a basis for a
dynamic database that can be expanded as new products are offered on the market. The main feature
of a database dedicated to food supplements is its intrinsic dynamism linked to the frequent changes
in the formulation of food supplements, with the consequent need to monitor the market and update
the database regularly, both by inserting new formulations and expanding the number of descriptors.
A precise and available description of the dietary supplements through coding is essential to recognize
the type, the main ingredients, and the target consumers by users from different countries.
This database will help consumers to make healthy choices and will represent a valid tool for
dietary intake calculations. This database can be useful in different contexts, such as, for example, in
clinical trials, dietary plans and pharmacological programs, but also to expand the food composition
databases for the purpose of daily nutrient intake estimations.
Considering the integrity of the labels of dietary supplements and whether they reflect the actual
amount of each ingredient contained in the product or not, as properly pointed by Betz et al. [19], a new
challenge is given by the development of analytically validated laboratory-derived dietary supplement
databases. A valid, rapid, and environmental friendly tool in this direction could be represented by
the use of infrared spectroscopy joined with chemometrics in the perspective of integrated research
approach; as for instance, the development of a “fingerprint spectra database” of dietary supplements
could be useful for further researches and applications in the assessment of quality and safety, i.e.,
monitoring production and/or shelf life of a product, identifying contaminants, and confirming an
incoming product.
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Abstract: Curcumin has been used as a traditional medicine and/or functional food in several cultures
because of its health benefits including anticancer properties. However, poor oral bioavailability of
curcumin has limited its oral usage as a food supplement and medical food. Here we formulated
curcumin pellets using a solid dispersion technique. The pellets had the advantages of reduced
particle size, improved water solubility, and particle porosity. This pellet form led to an improvement
in curcumin’s oral bioavailability. Additionally, we used the C-Map and Library of Integrated
Network-Based Cellular Signatures (LINCS) Unified Environment (CLUE) gene expression database
to determine the potential biological functions of formulated curcumin. The results indicated that,
similar to conventional curcumin, the formulated curcumin acted as an NF-κB pathway inhibitor.
Moreover, ConsensusPathDB database analysis was used to predict possible targets and it revealed
that both forms of curcumin exhibit similar biological functions, including apoptosis. Biochemical
characterization revealed that both the forms indeed induced apoptosis of hepatocellular carcinoma
(HCC) cell lines. We concluded that the formulated curcumin increases the oral bioavailability in
animals, and, as expected, retains characteristics similar to conventional curcumin at the cellular level.
Our screening platform using big data not only confirms that both the forms of curcumin have similar
mechanisms but also predicts the novel mechanism of the formulated curcumin.
Keywords: curcumin; formulated curcumin; pharmacokinetics; aurora kinase A; hepatocellular
carcinoma
1. Introduction
The use of nutraceutical or functional and medical foods as alternative medicine, in addition to
supplementary foods, has been on the rise in recent years [1,2]. The delivery of active ingredients is
important in order to obtain beneficial effects for the human body.
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Curcumin has been used for many years as a naturally occurring alternative medicine and
functional food for the treatment of many diseases. Curcumin is a polyphenol extracted from the
rhizome of Curcuma longa L., which has phenolic groups and conjugated double bonds [3]. It has strong
anti-oxidant, anti-inflammatory, anti-septic, anti-proliferative, and wound-healing properties [4–8].
In addition, curcumin can reverse multidrug resistance of cancer cells, suggesting that it can also serve
as a supplement to traditional chemotherapy [9,10]. Several lines of evidence show that curcumin
exerts potent anticancer effects against a broad range of human cancer cells, including prostate, colon,
breast, ovarian, lung, and liver cancers, and can induce cancer cell apoptosis, for example, in liver
cancer cell lines, including but not limited to HepG2, SK-Hep-1, Hep3B, SUN449, and Huh7 cells,
with low cytotoxic effects on normal cells [11–16].
Despite curcumin’s beneficial effects, its low oral bioavailability (due to its low absorption
in the gut because of low solubility in water, fast metabolism by the liver, and rapid systemic
elimination) has limited its applications [17–19]. Various methods have been developed to improve
the oral bioavailability of curcumin, such as the use of a natural enhancer, a curcumin-phospholipid
complex, cyclodextrin and microemulsions, and the development of curcumin analogs [20–22]. In this
study, we selected the pellet form, a multiple-unit dosage form, as a vehicle for compound delivery.
Pellets disperse freely in the gastrointestinal tract, so they invariably maximize drug absorption [23].
In addition, to improve the solubility of curcumin, we used a solid dispersion technique to formulate
pellets. In solid dispersions, the particle size of poorly soluble drugs is reduced and their wettability
and dispersibility enhanced, thereby improving their dissolution and absorption rate [24].
The Connectivity Map (C-Map) is a systematic database that establishes the relationship between
diseases, genes, and compounds [25]. Recently, the database has been expanded and renamed C-Map
and Library of Integrated Network-Based Cellular Signatures (LINCS) Unified Environment (CLUE)
(https://clue.io/) [26]. Briefly, C-Map and CLUE use gene expression profiles to describe the biological
states of cultured human cancer or normal cells to determine their chemical or genetic constructs
(short hairpin RNA [shRNA] constructs). The new, low-cost, high-throughput generic solution for
gene expression profiles is termed “L1000.” CLUE not only expands the 1309 compounds listed in
C-Map to 19,811 small molecules but also includes 5075 shRNA and overexpression genes. In addition,
users find CLUE relatively convenient to quickly search for a drug class with a similar mechanism
of action (MOA) as a target drug or the same gene family of genetic perturbagens, they codify the
class-level annotation required considerable effort, perturbagen classes (PCLs). For example, users can
compare their target, such as a disease gene signature or a novel compound, with C-Map and CLUE
through pattern-matching algorithms and predict dissimilarities (search for a drug to reverse a disease)
or similarities (search for a similar MOA via known compounds). They could upload gene expression
profiles to C-Map and CLUE to calculate the connectivity score of each profile. A positive connectivity
score would indicate a degree of similar mechanism, while a negative connectivity score would denote
the reverse.
HCC is the fifth-most common malignancy worldwide. More than 75% of HCC cases occur in
the Asia-Pacific region. The high mortality rate because of HCC is due to the difficulty in diagnosis
and poor prognosis. Chemotherapy is a traditional choice for inoperable HCC, but drug resistance
limits the therapeutic effect [27,28]. Sorafenib is a multi-kinase inhibitor that targets Raf kinases as
well as vascular endothelial growth factor receptor (VEGFR)-2/VEGFR-3, platelet-derived growth
factor receptor beta (PDGFR-β), Flt-3, and c-Kit. Because of its potential in providing a survival
advantage of two to three months, as per results of two-phase III clinical studies, sorafenib is a Food
and Drug Administration (FDA)-approved, first-line targeted therapy agent for treating advanced
HCC patients [29,30]. However, the low tumor response rate and side effects of sorafenib indicate the
need for investigating other new potential drugs or supplementary foods for HCC [31,32]. In this
study, we investigated the anticancer activity of conventional and formulated curcumin and their
combination with sorafenib in order to determine whether this combination can induce HCC cell
apoptosis and autophagy and inhibit HCC cell proliferation. Formulated curcumin can be used as
76
Nutrients 2019, 11, 2982
a functional food and alternative medicine in cancer therapy as it not only causes mitotic defects and
cell cycle arrest in cancer cells but also alters chemosensitivity toward anticancer drugs by inducing
Aurora-A suppression.
2. Materials and Methods
2.1. Materials and Methods Used in Manufacturing Formulated Curcumin
2.1.1. Preparation of Curcumin Solid Dispersion Loaded Pellet
A curcumin standard with a purity > 95.6% was purchased from Sigma-Aldrich.
We used a solid dispersion technique to enhance the solubility and dissolution rate of curcumin [24].
Briefly, the process of making formulated curcumin included dispersing curcumin powder into a solid
dispersion solution and spraying it onto sugar spheres. Tumeric extract powder contained 95%
curcumin in 80 g (as the active drug). The excipients used in the preparation process of solid dispersion
curcumin were Polyvinylpyrrolidone #k30 800 g (PVP K30, as the non-volatile polymer solvent for
curcumin) and alcohol 3200 g (as the volatile solvent for curcumin). The turmeric extract powder was
mixed with the excipients. The drug-polymer interaction evenly dispersed curcumin in the solvent.
Next, the solvent containing solid dispersion curcumin was loaded onto sugar spheres by spray-drying
to make solid dispersion pellets; the solvent evaporated during fluid-bed granulation (Figure 1).
Figure 1. Preparation of solid dispersion curcumin. Turmeric extract powder, containing 80 g of
95% curcumin (as the active drug), was mixed with excipients (800 g PVP as the nonvolatile polymer
solvent in the presence of alcohol as the volatile solvent for curcumin). The drug-polymer interaction
evenly dispersed curcumin in the solvent. Then, the solvent containing solid dispersion curcumin
was loaded onto sugar spheres by fluid-bed granulation to make solid dispersion curcumin pellets.
PVP, polyvinylpyrrolidone.
2.1.2. Measurements of Particle Size and Zeta Potential
Particle size (Z-average, nm), polydispersity index (PDI), and ζ-potential (ZP, mV) of curcumin
particles after re-dispersion in water were determined at 25 ◦C by dynamic light scattering (DLS) using
a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK). Measurements were performed with
a detector at a fixed angle of 90◦, in triplicate, and results were shown as mean ± SD. About 60 mg
of pellets were dispersed into 2 mL water and centrifuged at 2000 × g for 1 minute to remove starch
particles originated from sugar spheres. Supernatant was aspirated to measure size and ZP.
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2.1.3. Dissolution Test
A dissolution test was conducted by the US Pharmacopeia 41 basket method (apparatus 1) using
a dissolution tester (708-DS Dissolution apparatus, Agilent, USA). The samples of 89 mg conventional
curcumin (equivalent to 72 mg curcumin) and 2180 mg formulated curcumin (equivalent to 72 mg
curcumin) were placed into 900 mL of dissolution medium containing 1% sodium dodecyl sulfate
(SDS) at 37 ◦C ± 0.5 ◦C, under a stirring speed of 100 ± 2 rpm. A 5 mL sample was withdrawn at each
time interval (5, 10, 15, 20, 30, 45, and 60 minutes) and was mixed and filtered through a 0.45-μm pore
membrane. Then, 2 mL of filtrate was diluted with mobile phase so that the total volume became
10 mL and subjected to HPLC analysis (Agilent 1260, USA). The HPLC program consisted of a mobile
phase of tetrahydrofuran: 0.1% citric acid solution (4:6). The column used was 4.6 mm × 20 cm with
5-μm packing L1. The flow rate was 1 mL/minute, and the injection volume was 20 μL using a 420 nm
wavelength detector. The percentages of curcumin dissolved from the conventional curcumin and
pellets (formulated curcumin) into the medium were calculated and compared.
2.2. Pharmacokinetic Study
2.2.1. Animal Model
All animal treatment procedures followed the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health (NIH) publication, 85–23, revised 1996) as well as the Animal research:
Reporting in vivo experiments (ARRIVE) guidelines, and were approved by the Animal Research
Committee at National Yang-Ming University, Taipei, Taiwan, under Institutional Animal Care and
Use Committees (IACUC) approval no: 990103. All surgeries and experimental procedure were carried
out under anesthesia with all efforts to minimize animal suffering.
Twelve male Sprague Dawley (SD) rats (270 ± 15 g body weight) were obtained from Bio-Lasco,
Taipei, Taiwan. Water was provided ad libitum, regardless of administration route. All animals were
acclimatized and quarantined in quarantine room of the Rosetta animal facility for about 1 week,
and then transferred to feeding room. The humidity and temperature were well controlled as 30%–70%
and 19–25 ◦C. The light and dark cycle was set as 12 h: 12 h. Food and drinking water were allowed ad
libitum during housing.
Rats were randomly divided into two groups treated with curcumin and formulated curcumin.
Curcumin (conventional; 500 mg/kg, n = 6) and 500 mg/kg formulated curcumin (equal to curcumin
60 mg/kg, n = 6) were administrated by gavage to the freely moving rats, respectively. A 300 μL blood
sample was collected from the tail vein into a tube rinsed with heparin at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6 h
after oral administration.
2.2.2. Sample Pretreatment
Plasma was obtained by centrifuging the blood sample at 4000 rpm for 10 minutes at 4 ◦C.
The 10 μL plasma was mixed with 50 μL of the internal standard solution containing 0.1 ng/μL of
agomelatine. The samples were vortexed and centrifuged at 13,000 rpm for 5 minutes. The 50 μL of
supernatant was transferred to the 1.5 mL tube contained 50 μL solution of 25% acetonitrile and 0.1%
acetic acid. After that, 50 μL of the solution was injected onto LC-MS system.
2.2.3. LC/MS/MS Conditions and Data Analysis
Curcumin concentrations in the samples were determined by positive ion electrospray tandem
mass spectrometry using multiple reaction monitoring (MRM). Separation of curcumin was conducted
on a Cosmosil column (5C18-MS-IIPacked column, 120 Å, 5 μm, 4.6 mm I.D. x 150 mm; NACALAI
TESQUE, Inc., Japan) with a mobile phase of acetonitrile-water-formic acid. MS/MS conditions
consisted of a declustering potential of 50 V, desolvation temperature of 550 ◦C, spray needle of 5500 V,
and collision energy of 30 V.
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Pharmacokinetic analysis was calculated using a non-compartmental model with the Phoenix
WinNonlin®(Version 8.0) software. The area under the drug concentration-time curve (AUC) was
used to measure the total amount of curcumin reaching the systemic circulation. The relative oral
bioavailability (BA) of curcumin was calculated according to the following equation: BA (%) = 100
× [(AUCformulated curcumin/doseformulated curcumin]/[(AUCcurcumin/dosecurcumin)]. The pharmacokinetic
results were represented as the mean ± SD. Statistical analysis was performed by t test (SPSS version
10.0) to compare the differences between groups. The level of significance was set at p < 0.05.
2.3. Cell Lines and Cell Culture
The Huh7 and PLC5 cell lines were obtained from National Taiwan University Hospital, Taiwan.
The Mahlavu cell lines were provided by Dr. Muh-Hwa Yang (Institute of Clinical Medicine, National
Yang-Ming University, Taiwan). Hep3B cells were obtained from American Type Culture Collection
(ATCC), Rockville, MD, USA.
HCC cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO)
supplemented with 10% (v/v) fetal bovine serum (FBS, GIBCO), non-essential amino acids (NEAA,
GIBCO), L-glutamine (GlutaMAX™-I Supplement, GIBCO) and 10% penicillin-streptomycin (GIBCO).
These cells were maintained in a humidified incubator with 5% CO2 at 37 ◦C and were regularly
subcultured every 2–3 days.
2.4. Drug Preparation and Cell Exposure
The conventional curcumin was prepared as a 30 mM stock solution in dimethyl sulfoxide (DMSO;
Sigma) and stored at -20 ◦C. Final curcumin concentrations of 1–90 μM were obtained by dilution in
culture medium so that the final concentration of DMSO was less than 1%. Controls contained 0.1%
DMSO in all experiments.
The formulated curcumin was prepared as a 30 mM stock solution (based on the weight of
curcumin) in double distilled water and stored at -20 ◦C. The formulated curcumin was diluted with
cell culture medium to obtain the concentration indicated.
2.5. Proliferation and Viability Assays
Cells were seeded into a 96-well plate (1500–2000 cells/well) overnight and then treated with
curcumin and the formulated curcumin respectively for 0, 24, 48, 72, 96 and 120 h. After treatment,
0.5 μg/mL 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was added to each well
and cultured for 2 h at 37 ◦C. After incubation, the media were removed from the wells. The formazan
crystals formed were then solubilized in DMSO at room temperature for 10 minutes, and then the
absorbance was measured in a multimode microplate reader at 570 nm.
2.6. Mitochondrial Membrane Potential Assay
We employed 5, 5’, 6, 6’-tetrachloro-l, 1’, 3, 3’-tetraethylbenzimidazolcarbocyanine iodide (JC-1),
which was obtained from Cayman Chemical Co., to analyze the mitochondrial membrane potential.
The cells were seeded in 96-well black plates at a density of 7000 cells/well and cultured overnight.
After treatment, JC-1 staining solution was added to each well and incubated at 37 ◦C for 15–30 minutes
in the dark. The plates were obtained by centrifuged at 400 × g at room temperature for 5 minutes,
and the supernatant was discarded. Then, JC-1 assay buffer was added to each well, followed by
centrifugation at 400 × g at room temperature for 5 minutes, after which the supernatant was discarded.
Finally, JC-1 assay buffer was added again to each well for fluorescent analysis using a fluorescent
plate reader.
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2.7. Annexin V and Propidium Iodide (PI) Double Staining by Flow Cytometry
The Huh7 were incubated with various concentrations of conventional and formulated curcumin
for 24 h. Annexin V/PI staining was performed to quantify cell apoptosis using an Annexin V-fluorescein
isothiocyanate (FITC) Apoptosis Detection Kit (BioVision, Inc., Milpitas, CA, USA) according to the
manufacturer’s protocol. Annexin V-FITC was then added followed by incubation for 15 minutes in
the dark in a 100 μL cell suspension. PI was then spiked into 400 μL Annexin V binding buffer and
added immediately to the cell suspension, and subsequently analyzed on a FACScan flow cytometer
(BD Biosciences, USA).
2.8. Western Blot
The cells were incubated with various treatment (conventional and formulated curcumin
or combination of sorafenib and conventional and formulated curcumin), and then collected
for western blot. Aliquots of cell lysates containing 20–50 μg of protein were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a polyvinylidene difluoride
(PVDF) membrane and detected using specific primary and secondary antibodies. The protein bands
were visualized by an enhanced chemiluminescence (ECL) detection kit (ImmobilonTM western,
Millipore). The membranes were reprobed for β-actin as a loading control. All western blots were
carried out at least three times for each experiment. The data were normalized to β-actin. The following
primary antibodies were used: anti-extracellular regulated protein kinases (ERK), anti-caspase-3,
anti-poly (ADP-ribose) polymerase (PARP) (all from Cell Signaling Technology) and anti-aurora kinase
A (AURKA) (BD Biosciences). All antibodies were used at a 1:1000 dilution.
2.9. Cell Cycle Analysis
After treatment, the cells were collected by trypsinization and fixed in precooled 70% ethanol
overnight. The cells were then incubated with PI in the presence of RNase A. The DNA content was
analyzed by a FACSCalibur, and the data were analyzed by Flowjo software. The percentage of cells in
the sub-G1 was used to indicate the apoptosis rate.
2.10. Analysis the Similar Mechanism of Gene Expression Profiles of Conventional and Formulated Curcumin
Using the L1000 Microarray
Human HCC (HepG2) and human colorectal cancer (HT29) cell lines (ATCC) were treated in
triplicate with 20μM of conventional curcumin or 2μM of formulated curcumin. Briefly, for experiments
using formulated curcumin, 2 μM of curcumin formulation and curcumin excipient were dissolved in
DMSO and incubated with HepG2 and HT29 cell lines. The samples were submitted to Genometry,
Inc. (Cambridge, MA, USA) for L1000 microarray analysis and to obtain the gene expression profiles
of formulated curcumin in HepG2 and HT29. Each set of gene expression profiles consisted of up-
and down-regulated gene signatures. Subsequently, CLUE was used to decipher the gene signatures
in order to uncover potential mechanisms via mapping to compounds with known MOAs. To filter
output data, we used a score > 90 for compounds and a score > 70 for PCLs.
2.11. Statistical Analysis
All values were expressed as the mean ± SD. The data were analyzed using a two-tailed student’s
t test. A p < 0.05 was considered as statistically significant.
3. Result
3.1. Preparation and Evaluation Formulated Curcumin
First, we prepared the formulated curcumin from powder to pellets with a solid dispersion
technique as described in detail in the Materials and Methods section. The pellet size of formulated
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curcumin estimated by sieving was distributed in the range of 830–1000 μm. Curcumin content
quantified by HPLC was 3.3%. Z-average (nm), PDI, and ZP (mV) of curcumin particles after
re-dispersion in water were 141.9 ± 5.1, 0.308 ± 0.029 and −2.49 ± 0.39, respectively (Table 1).
The dissolution rates of conventional curcumin were 0.00%, 9.80%, 13.60%, 14.05%, 17.28%, 19.41%,
24.06%, and 26.28%, while those of the formulated curcumin were 0.00%, 59.03%, 87.50%, 98.78%,
100.22%, 101.20%, 102.29%, and 103.65% at 0, 5, 10, 15, 20, 30, 45, and 60 minutes, respectively
(Supplementary Figure S1). In the 1% SDS medium, more than 85% of curcumin was almost immediately
released from the pellets after 10 minutes. Additionally, when compared to the US Pharmacopeia
specifications for dissolution of curcuminoid capsules or curcuminoid tablets, the dissolution of the
formulated curcumin was not lower than 75% after 60 minutes, suggesting that the formulation greatly
increased curcumin’s solubility.
Table 1. Properties of formulated curcumin.
Properties of Formulated Curcumin Value
Pellet size (μm) 830–1000
Curcumin level (%) 3.3
Z-average (nm) 141.9 ± 5.1
Polydispersity index (PDI) 0.308 ± 0.029
Zeta potential (mV) –2.49 ± 0.39
3.2. Oral Administration of Formulated Curcumin Shows an Increase in Bioavailability over Conventional
Curcumin via Pharmacokinetic Analysis
To determine the actual amount of curcumin that was released and existed in the formulated
curcumin, a high-performance liquid chromatography assay and LC-MS method was adopted for
the quantification of curcumin. To investigate whether the bioavailability of curcumin was increased
after formulation, 60 mg/kg of formulated curcumin was orally administered in a rat model and
the plasma samples were subjected to chromatography. To confirm the reliability of the method for
analyzing curcumin in plasma samples, a method validation was performed. The retention times of
curcumin were about 5.14 minutes, with no visible interference peak in the blank plasma chromatogram
(data not shown). To perform a pharmacokinetic analysis, the curcumin concentrations in rat plasma
at different time points following oral administration of 500 mg/kg of curcumin and 60 mg/kg of
formulated curcumin were compared (Figure 2). However, administration of 500 mg/kg of curcumin
had very low amount of curcumin in rat plasma and resulted to a huge increase of bioavailability.
Therefore, the pharmacokinetic parameters of curcumin represented an estimated number and will be
compared with others from literatures (see later in discussion). AUC represents the total drug exposure
over time. Based on the pharmacokinetic parameters (Table 2), the AUC represents the total drug
exposure over time. The AUC normalized by dose of curcumin was increased from 0.0021 to 1.864,
which is an 887.6-fold increase after formulation. Overall, this result showed that oral administration
of formulated curcumin significantly increased the oral bioavailability of curcumin compared with
conventional curcumin.
3.3. Gene Expression Analysis of Formulated Curcumin and Prediction of Highly Correlated Pathways
We queried CLUE with regard to the analyzed group of genes in order to identify potential
biological functions of formulated curcumin. The top 30 compounds (Figure 3C) and PCLs (Figure 3A)
with the highest scores were obtained from CLUE. Intersection of results from both cell lines revealed that
seven compounds (e.g., menadione and angiogenesis inhibitor; Figure 3D) and two PCLs (e.g., NF-κB
pathway inhibitors; Figure 3B) shared common functions with conventional curcumin. In summary,
formulated curcumin was similar to conventional curcumin, and both functioned as, for example, NF-κB
pathway inhibitors, which is consistent with previous studies [33]. We intersected two sample groups
to identify common PCL/compound classes between formulated curcumin treatment of HT29 cells and
81
Nutrients 2019, 11, 2982
formulated curcumin treatment of HepG2 cells. Consequently, we identified two PCLs (including NF-κB
pathway inhibitors and vesicular transport loss of function (LOF; Figure 3B), and seven compounds
belonging to the NF-κB pathway inhibitor PCL class were common among all groups.
In fact, CLUE revealed that only the MOA of compounds or shRNAs was similar to that of
formulated curcumin; CLUE did not indicate the target of formulated curcumin. Therefore, to obtain
more information about formulated curcumin, we used another database for assistance pathway
analysis, ConsensusPathDB (CPDB). CPDB comprises interactions among different types of various
intracellular information, such as genes, RNA, proteins, and metabolites, to predict a relatively
comprehensive and unbiased cellular biology signal result. We used the Venny website to intersect our
two sets of PCL results (Figure 3B) and selected their targets and members genes to predict potential
pathways of formulated curcumin (Figure 4). According to q < 0.001, we listed the top 20 pathways at
the bottom of Figure 4, and the details are in Supplementary Figure S2. In addition, we showed similar
effects in L1000 microarray profiles between conventional and formulated curcumin in heatmaps
(Figure 5). These data suggested that formulated curcumin exhibits similar biological functions as
conventional curcumin.
Table 2. Pharmacokinetic parameters of curcumin in rat plasma following oral administration.
Parameters
Oral
Conventional Curcumin* (n = 5) Formulated Curcumin (n = 6)
500 mg/kg 60 mg/kg
Cmax (ng/mL) 0.704 ± 0.272 109.200 ± 41.651
AUC0-t (h × ng/mL) 1.1 ± 1.2 111.8 ± 16.4
AUC0-t/Dose 0.0022 ± 0.0024 1.863 ± 0.273
Tmax(h) 1.25 ± 0.83 0.38 ± 0.14
The data are expressed as the mean ± SD. Cmax: the maximum plasma concentration; Tmax: the time at which
Cmax is observed; AUC0-t: area under the concentration-time curve from the time of drug administration to the last
quantifiable concentration. *: Conventional curcumin in some rat plasma samples was very low and was assigned to
0 for calculations. We were unable to detect curcumin from the plasma of one rat during the experimental periods,
and thus data from five rats were used for calculations.
Figure 2. Mean plasma concentration-time profiles of curcumin in male SD rats following 500 mg/kg
conventional curcumin (A) and 60 mg/ kg formulated curcumin (B) after single dose oral gavage
(P.O.) linear ordinate. The data are expressed as mean ± SD, n = 5 for curcumin and n = 6 for
formulated curcumin.
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Figure 3. Gene analysis data of formulated curcumin. (A) The L1000 gene expression profiles of HT29
and HepG2 cells treated with formulated curcumin were analyzed by CLUE. The output data of PCLs
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in both HT29 and HepG2 are shown at the bottom (score > 70). (B) PCLs list a score > 70 and are
intersected by Venny website. Two common PLCs, NF-κB pathway inhibitor and vesicular transport
LOF, are shown in the diagram. To avoid missing possible predicted functions of formulated curcumin,
we used an intersection-driven approach to broadly cover these PCLs (score > 70). (C) The top
30 compounds (CP) are representative, while the complete list is provided in the Supplementary
Information (score > 90). Details are in Supplementary Figure S3. (D) Intersection compounds
using L1000 array analysis of formulated curcumin by CLUE. The connectivity score is based on the
Kolmogorov–Smirnov enrichment statistical evaluation of each gene expression profile. The results
provided from CLUE are expressed as a comprehensive connectivity score, showing that the same
drug has a similar MOA on different cancer cells in CLUE, Connectivity Map and Library of Integrated
Network-Based Cellular Signatures (LINCS) unified environment; PCL, perturbagen class; MOA,
mechanism of action.
Figure 4. Possible pathways of formulated curcumin predicted by CPDB. Genes in two datasets were
used to query CPDB in order to predict the pathways in which these genes were likely participating.
The Venn diagram shows the intersecting PCLs (top, right). We focused on intersection results indicated
by red circles. The results contained two PCLs, NF-κB pathway inhibitors and vesicular transport
LOF and used their targets and member gene lists (total 22 genes) to query CPDB in order to analyze
interaction network modules, biochemical pathways, and functional information. Top 50 prediction
pathways are listed in Supplementary Figure S2, and top 20 pathways identified by CPDB analysis
(q < 0.001) are shown at the bottom of the figure. The size of each dot denotes the entity number of
genes in the pathway. The line between two dots was calculated by the function of these two pathways
to indicate the number of genes overlapping said pathways. The breadth of the line denotes the
strength of the correlation between two dots. The apoptosis was analyzed in this study (highlighted
in yellow, Supplementary Figure S2). CPDB, ConsensusPathDB; PCL, perturbagen class; shRNA,
short hairpin RNA.
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Figure 5. Heatmaps showing the top 50 up/down L1000 probes with similar expression patterns
between conventional and formulated curcumin in HepG2 and HT29 cells, respectively. The horizontal
axis denotes the treatments in three groups: (1) DMSO, (2) conventional curcumin, and (3) formulated
curcumin. The vertical axis denotes the L1000 probe IDs and their corresponding gene names.
3.4. Formulated Curcumin Displays Stronger Inhibition on Population Growth of Huh7 Cells
To determine whether formulated curcumin retains the biological functions of conventional
curcumin, we performed MTT assay to assess the cell proliferation and cell viability of conventional
curcumin and formulated curcumin-treated Huh7 cells. As shown in Supplementary Figure S4,
when the concentration of conventional or formulated curcumin increased, cell viability decreased
after treatment with curcumin for 24–120 h. We also observed cytotoxicity of curcumin in Huh7 cells.
The 50% inhibitory concentration (IC50) value for conventional curcumin at 24, 48, 72, 96, and 120 h
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was around 90, 90, 60, 45, and 30 μM, respectively, while the IC50 value for formulated curcumin was
around 60, 60, 30, 10, and 10 μM, respectively.
3.5. Cytotoxic Effect of Curcumin on Other HCC Cell Lines
To determine whether conventional and formulated curcumin could mediate the survival of
other HCC cell lines, we first examined the effect of conventional and formulated curcumin on the
viability of Huh7, Mahlavu, and PLC5 cells using MTT assay. While Huh7 cells are well differentiated,
Mahlavu and PLC5 cells are poorly differentiated and carry p53 mutations. To explore the cytotoxic
activity of conventional and formulated curcumin against these HCC cell lines, we initiated an in vitro
study by treating Huh7, Mahlavu, and PLC5 cells each with increasing dosages of conventional
and formulated curcumin (0, 1, 3, 10, 30, 60, and 90 μM) for 72 h. MTT assay results indicated that
both conventional and formulated curcumin significantly inhibit the viability of Huh7 (Figure 6A),
Mahlavu (Figure 6B), and PLC5 (Figure 6C) cells. After 72 h post-treatment, formulated curcumin
caused cytotoxicity in Huh7, Mahlavu, and PLC5 cells with an IC50 value of 38.1, 10.1, and 60.9 μM,
respectively, while the IC50 values of conventional curcumin were 53.3, 35.4, and 82.5 μM, respectively
(Figure 6A–C). Taken together, the results showed that both conventional and formulated curcumin
inhibited the survival and proliferation of HCC cell lines in a dose-dependent manner. In addition,
formulated curcumin was more effective than conventional curcumin.
Figure 6. Cytotoxic effect of curcumin and formulated curcumin on other HCC cell lines (Huh7,
Mahlavu, and PLC5). After separate treatment with 1, 3, 10, 30, 60, and 90 μM of conventional and
formulated curcumin for 72 h, cell viability was determined by MTT assay and expressed as a percentage
relative to the control group. Formulated curcumin was more effective than conventional curcumin on
the basis of cell viability in the three cell lines tested. Formulated curcumin has higher cytotoxicity
in (A) Huh7, (B) Mahlavu, and (C) PLC5 compared to conventional curcumin. #p < 0.05; ##p < 0.01;
###p < 0.005 compared to the control group (formulated curcumin). *p < 0.05; **p < 0.01; ***p < 0.005
compared to the control group (conventional curcumin). MTT, 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide.
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3.6. Effects of Curcumin on Apoptosis-Related Protein Expression
MTT assay indicated that both conventional and formulated curcumin suppress cell viability.
To determine whether cell viability inhibition is due to apoptosis, we examined the degree of apoptosis
by PI and annexin V staining using flow cytometry. The results clearly demonstrated that 24 h
post-treatment with 10–60 μM of conventional and formulated curcumin, the percentage of cells
undergoing early apoptosis (annexin V+/PI–) and late apoptosis (annexin V+/PI+) increased, while the
percentage of viable cells decreased (annexin V–/PI–) in a dose-dependent manner (Figure 7A).
Comparison of effectiveness between conventional and formulated curcumin showed no significant
statistical difference.
Caspase-3 activation is crucial for mitochondrial-dependent and mitochondrial-independent
apoptotic pathways. Therefore, we examined the activity of caspase-3 by observing its active form
(cleaved form) by western blotting in Huh7 cells (Figure 7B). Both conventional and formulated
curcumin increased caspase-3 activity in Huh7 cells in a dose-dependent manner (Figure 7B). Caspase-3
activation led to cleavage of several substrates, including PARP. PARP cleavage was also determined
by western blotting (Figure 7B). Therefore, conventional and formulated curcumin separately induced
apoptosis by activating caspase-3 (Figure 7B).
Many antineoplastic drugs induce apoptosis of cancer cells via mitochondrial apoptotic
pathways [34–36]. A hallmark of apoptosis induction via these pathways is a rapid, early breakdown
of the mitochondrial membrane potential. Therefore, in this study, we also analyzed the mitochondrial
function integrity posttreatment with conventional and formulated curcumin. Both conventional and
formulated curcumin significantly induced mitochondrial membrane potential breakdown (ΔΨm) in
a concentration-dependent manner (Figure 7C), as determined by ELISA using the potential-sensitive
dye JC-1.
Previous studies have shown that curcumin inhibits cancer cell proliferation via suppression of
the ERK signaling pathway [37–39]. To investigate whether the ERK signaling pathway is involved
in curcumin-induced apoptosis, ERK activation was evaluated by detecting ERK phosphorylation.
Huh7 cells were exposed to 10–60 μM of conventional curcumin and formulated curcumin separately
for 48 h, and ERK activation was determined by western blotting. As shown in Figure 7D, both
conventional and formulated curcumin-induced phosphor-ERK down-regulation but with little change
in the total ERK protein in Huh7 cells.
Recent studies have suggested that a curcumin-induced mitotic spindle defect and cell cycle
arrest in human cancer cells occur through Aurora kinase inhibition [40–42]. To determine whether
conventional and formulated curcumin inhibit Huh7 cell proliferation via down-regulation of Aurora-A
expression, Huh7 cells were incubated with 0–60 μM of conventional and formulated curcumin
separately for 48 h. We observed a significant decrease in the level of Aurora-A by western blotting
(Figure 7D). These data suggested that the biological function of both conventional and formulated
curcumin involves caspase-3 activation and ERK and Aurora-A down-regulation.
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Figure 7. Both conventional and formulated curcumin caused apoptosis of Huh7 cells. (A) The cells
were incubated and treated with conventional and formulated curcumin. After 24 h, the cells were
subjected to annexin V/PI staining and analyzed by flow cytometry. Quantitative analysis of PI- or
annexin V-positive cells is shown (n = 3). **p < 0.01 and ***p < 0.005 compared to the live-cell group
without treatment. ##p < 0.01 and ###p < 0.005 compared to the apoptotic cell group without treatment.
(B) Huh7 cell lysates treated with conventional and formulated curcumin separately were subjected
to immunoblot analysis. The expression levels of cleaved caspase-3, caspase-9, and PARP increased,
demonstrating that the cells had undergone apoptosis. (C) The mitochondrial membrane potential
(ΔΨm) in Huh7 cells was analyzed using the JC-1 mitochondrial membrane potential assay. ΔΨm was
lower in HCC cell lines treated with different concentrations (10, 30, and 60 μM) of conventional or
formulated curcumin compared to control HCC cell lines (n = 3). *p < 0.05; **p < 0.01; and ***p < 0.005
compared to the group without conventional curcumin treatment. #p < 0.05; ##p < 0.01; and ###p < 0.005
compared to the group without formulated curcumin treatment. (D) P-ERK and AURKA expression
was down-regulated by conventional and formulated curcumin in a concentration-dependent manner,
as shown by immunoblot analysis results with anti-ERK, anti-P-ERK, and anti-AURKA antibodies. PI,
propidium iodide; PARP, poly (ADP-ribose) polymerase; ERK, extracellular regulated protein kinase;
AURKA, aurora kinase A.
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3.7. Effects of Combination of Curcumin and Sorafenib
Sorafenib and curcumin both inhibited cell viability of two HCC cell lines (Huh7 and Hep3B) in
a dose-dependent manner (Supplementary Figures S5 and S6). Therefore, we explored the potential
effects of sorafenib in combination with conventional or formulated curcumin on Huh7, Mahlavu,
and Hep3B cell proliferation. The cells were treated with various concentrations of sorafenib in
combination with conventional or formulated curcumin for 48 h (Supplementary Figures S5A and S6).
The results indicated that the combination of conventional or formulated curcumin with sorafenib has
a stronger inhibitory effect on the population growth of HCC cell lines.
In this study, we demonstrated that both conventional and formulated curcumin inhibit Aurora
kinase, preferentially suppress proliferation, and induce apoptosis of HCC cell lines. A previous
study also indicated that curcumin induces apoptosis-associated autophagy [43,44]. Therefore,
we investigated whether the combination of sorafenib and conventional or formulated curcumin can
increase apoptosis of HCC cell lines. Cell cycle analysis revealed that adding conventional curcumin
for 48 h leads to an apoptosis rate of 13.5% (sub-G1 population), similar to the 10.9% rate induced by
sorafenib. We further examined whether conventional curcumin induces apoptosis of Hep3B cells.
We found that the levels of cleaved caspase-3 proteins increased in conventional curcumin-treated,
sorafenib-treated, and combination-treated cells (Supplementary Figure S5C). There was no notable
difference between the three groups. Conventional curcumin and its combination with sorafenib both
significantly induced accumulation of LC3-II (Supplementary Figure S5D), a lipidated form of LC3 that
is considered an autophagosomal marker in mammals. Similar results were found with formulated
curcumin treatment (data not shown). These results suggested that the combination of conventional
curcumin and formulated curcumin separately with sorafenib induces apoptosis-associated autophagy
in HCC cell lines.
4. Discussion
In this study, we reported that (i) both conventional and formulated curcumin induce apoptosis
of HCC cell lines and down-regulate Aurora-A and (ii) a combination of conventional or formulated
curcumin with sorafenib has a stronger inhibitory effect on HCC cell viability, demonstrating a possible
prevention and therapeutic application for formulated curcumin to be used as a food supplement and
medical food.
HCC most often develops and progresses with a lot of oxidative stress and inflammation.
Phytochemicals, such as dietary polyphenols, endowed with potent antioxidant and anti-inflammatory
properties, provide a suitable alternative for alleviation of HCC. Previous studies have reported that
systemic bioavailability of curcumin in humans is very poor [45,46]. Solid dispersion manufacturing
of poorly soluble drugs by spray-drying is a practical commercialization strategy to improve solubility
and dissolution rates because of the reasonable cost of required materials and ease of scale-up [47].
Several methods have been developed to solve issue of low oral bioavailability of curcumin.
One method is the use of a natural enhancer, such as alkaloid piperine. When 20 mg of piperine was
given concomitantly with 2 g of curcumin, the serum curcumin increased by 20 times in humans
and 1.56 times in rats. However, because piperine is a relatively selective CYP3A inhibitor [14],
drug and food interactions with piperine are a concern. Some studies have used phospholipids as
a delivery vehicle for curcumin. The oral bioavailability of curcumin-silica-coated flexible liposomes
(curcumin-SLs) and curcumin-flexible liposomes (curcumin-FLs) was found to be 7.76- and 2.35-fold
higher, respectively, compared to curcumin suspensions [20]. However, large-scale manufacturing will
incur a substantial cost.
In the pharmaceutical industry, solid dispersion pellets are one of the drug delivery solutions
for poorly soluble drugs. Solid dispersion pellets increase the solubility and release rate of a drug.
For example, itraconazole is a triazole antifungal agent with low solubility. In some itraconazole
solid dispersion pellets, the formulated itraconazole showed around 30- and 70-fold increase in the
dissolution rate compared to pure drug [48]. Tanshinone IIA (TA), one of the liposoluble bioactive
90
Nutrients 2019, 11, 2982
constituents extracted from the root of Salvia miltiorrhiza Bunge, has positive cardiovascular functions
such as vasorelaxation and cardioprotective effects. The oral bioavailability of TA tSD pellets (a solid
dispersion of a combination of PVP and poloxamer 188) in rabbit increased by 5.4 times compared
to TA [49]. In this study, the oral bioavailability of formulated curcumin (solid dispersion pellets)
increased significantly compared to conventional curcumin. Except for curcumin itself, all the materials
used are inert and safe. In addition, because of the simple manufacturing process, solid dispersion
pellets are also suitable for continuous and large-scale manufacturing, and the formulated curcumin
can be used as a food supplement and medical food.
As mentioned in Section 3.1, 830–1000 μm is the size distribution of the pellets (formulated
curcumin) determined by the sieving method. These pellets were formed by spraying ethanol solution
of curcumin and PVP-K30 onto sugar spheres in a fluid-bed granulator machine. After re-dispersion
in water, they were disintegrated to release free curcumin into the water as nanoparticles. The size
of the curcumin particles (Z-average) measured using Zetasizer Nano ZS90 was determined to be
141.9 ± 5.1 nm, which could be filtered by a 0.45-μm pore filter. The nano size of the curcumin particles
made it possible for them to be dissolved quickly in the dissolution medium. This was compatible
with the data of the dissolution test.
In addition, using 1% SDS solution as the media for the dissolution test is mentioned in the US
Pharmacopeia for curcuminoid tablets or curcuminoid capsules. Therefore, we used SDS in the medium
to evaluate how well our newly formulated curcumin was improved in its dissolution by comparison
with conventional curcumin. The results showed that dissolution of conventional curcumin in 1% SDS
solution was only about 20% after 60 minutes, whereas that of the formulated curcumin was more than
85% after 10 minutes.
Supplementary Table S1 summarizes several studies that have reported techniques for enhancing
curcumin oral bioavailability. While the formulated curcumin increases bioavailability over 800-fold,
only approximately 5–100-fold increases have been achieved by other formulations. To clarify this
difference, we investigated several pharmacokinetic parameters of conventional curcumin from these
studies (supplementary Table S2) ([50–52]). In our study, administration of 500 mg/kg of curcumin
resulted in a very low amount of curcumin in rat plasma: AUC0-t (h × ng/mL) was 1.1, whereas in other
studies the AUC0-t (h × ng/mL) were 8.76, 80, and 60 after doses of 50, 340, and 500 mg/kg, respectively,
were administered. If we used these AUC0-t (h × ng/mL) from un-formulated curcumin to calculate the
AUC for the formulated curcumin, an approximately 8–16-fold increase in bioavailability was obtained.
In short, this study showed that oral administration of a novel solid dispersion of curcumin significantly
increased its oral bioavailability compared with that of conventional curcumin. Although the Cmax
of the formulated curcumin is far below the effective concentrations of our cell culture experiments,
administration of conventional curcumin (200 mg/kg) for days or weeks has been reported to exhibit
significant biological activity against both chemically induced and xenograft hepatocarcinogenesis [53].
Because the formulated curcumin (single administration of 60 mg/kg) significantly increased the oral
bioavailability compared with conventional curcumin (single administration of 500 mg/kg), repeating
administration of the formulated curcumin at a higher dosage for a longer period of time can be
expected to achieve a much higher Cmax, and especially AUC, to display the biological effect of
curcumin observed in vitro. It is noteworthy that the formulated curcumin, as expected, retains similar
characteristics to conventional curcumin at the cellular level.
It is well known that the low oral bioavailability of curcumin is due to its poor solubility,
poor intestinal permeability and extensive metabolism. In another study [52], authors have used
phospholipid to formulate liposome of curcumin in order to enhance intestinal absorption of curcumin.
In the fasted rat model (rats were fasted overnight to avoid interference by food), they proved that
the AUC for liposome of curcumin increased about 5.5-fold compared with that for the conventional
curcumin after administration of 340 mg/kg dose; the AUC 26.7 μg ×min/mL is equivalent to 445 h
× ng/mL. In our study, rats had free access to food and water. After administrating 60 mg/kg of the
formulated curcumin, the AUC recorded was approximately 111 h × ng/mL. In addition, AUC/dose
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calculated in our study was higher than that in the previous study. Although we enhanced solubility of
curcumin, we suggest that after administration of our formulation, curcumin was quickly released as
nano particles then dissolved in gastric fluid or tiny oil droplet in food. Therefore, a part of curcumin
was absorbed as free form and the rest was absorbed by pathway of oil absorption supported by bile
salts. This was one of the advantages of the formulated curcumin which can be prepared easily and
scaled up in industry. In future, we will conduct more experiments to verify this conclusion.
Both conventional and formulated curcumin were effective in decreasing proliferation and
viability of HCC cell lines in a dose-dependent manner and induced apoptosis of HCC cell lines via
mitochondria dysfunction in vitro. In the cell culture study, both forms of curcumin were dissolved
completely before experiments, thus the benefits of formulated curcumin with improved solubility
and dissolution rates could not be displayed. The in vitro study was carried out mainly to determine if
the formulated curcumin retained similar characteristics of conventional curcumin at the cellular level.
Mitochondrial hyperpolarization is a prerequisite for curcumin-induced apoptosis, and mitochondrial
DNA (mtDNA) damage might be a probable mechanism for curcumin-induced apoptosis of HepG2
cells and might serve as the initial event triggering a chain of events leading to apoptosis [12]. Aurora
kinases, such as Aurora-A, Aurora-B, and Aurora-C, comprise a family of centrosome-associated
serine/threonine kinases that are overexpressed in various cancers and are potentially correlated with
chemoresistance [54–56]. Curcumin administration [57] or Aurora-A inhibition by short interfering RNA
(siRNA) [58] induces apoptosis. Curcumin has also been shown to down-regulate Notch1, the janus
kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, and multidrug resistance
protein 1 (MDR1) expression and to inhibit histone deacetylase 1 (HDAC1) activity [12,13,42,59,60].
Sorafenib is the only chemotherapeutic drug that has been shown to be effective in prolonging the
survival of HCC patients. However, the low rate of tolerance to sorafenib among HCC patients
limits its use [31,32]. Recent preclinical studies have reported that combining sorafenib with other
chemotherapeutic agents exerts synergistic effects [61,62], which could provide a promising strategy
for the treatment of advanced HCC. In this study, conventional or formulated curcumin in combination
with sorafenib inhibited the proliferation of HCC cell lines and exhibited a stronger inhibitory effect
on HCC cell lines. Taken together, the formulated curcumin appeared to have properties similar to
conventional curcumin, raising the possibility that our formulated curcumin could enhance cytotoxicity
against HCC.
In addition, our bioinformatics screening platform effectively identified the molecular mechanisms
of a phytochemical via gene expression profiles. C-Map can be queried to identify specific gene
signatures from small molecules, including FDA-approved drugs. CLUE is similar to C-Map but
considerably larger, with > 1.1 million L1000 profiles; therefore, similarity scores for compounds
in CLUE can be obtained to identify their molecular actions. Similar results for conventional and
formulated curcumin suggested that only solubility and oral bioavailability have been altered in
formulated curcumin. Curcumin is known to exert strong anti-inflammatory effects by interrupting
NF-κB signaling at multiple levels. Based on CLUE analysis, formulated curcumin can be predicted
to have a similar action as NF-κB pathway inhibitors. Furthermore, analysis via CPDB suggests
that curcumin can be linked to TNF related weak inducer of apoptosis as well as TNF mediated
NF-κB pathway. Therefore, our screening platform not only confirms that the formulated curcumin
has similar mechanism with unformulated curcumin, but it also predicts the novel mechanism of
formulated curcumin, such as suppression of HMGB1 mediated inflammation by THBD (label in red
in Supplementary Figure S2).
In conclusion, our curcumin was formulated in pellet form, which not only improved its oral
bioavailability but also provided high flexibility of use. For example, it would be easy to adjust the
dosage and combine the pellets with other ingredients. In addition, as a functional food and alternative
medicine, it would be suitable for those who cannot swallow tablets or capsules.
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Supplementary Materials: The following are available online: http://www.mdpi.com/2072-6643/11/12/2982/s1.
Figure S1. The dissolution rates of conventional and formulated curcumin in 1% sodium dodecyl sulfate medium,
Figure S2. Prediction of highly correlated pathways, Figure S3. The output data of compounds (CP, score ≥ 90)
was analyzed via CLUE, and detected their similarity among these gene expression profiles, Figure S4. Curcumin
and the formulated curcumin affect the cell viability of Huh7 cells, Figure S5. Inhibitory effect of the combination
of sorafenib and conventional or formulated curcumin on HCC cell lines, Figure S6. Effect of sorafenib with or
without curcumin/formulated curcumin on Mahlavu and Hep3B cell viability, Table S1. Comparison between
our study and previous studies on the improvement of solubility/oral bioavailability of curcumin formulation,
Table S2. Comparison of pharmacokinetic parameters of curcumin in rat plasma following oral administration.
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area under curve AUC
aurora kinase A AURKA
bioavailability BA
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enhanced chemiluminescence ECL
extracellular regulated protein kinases ERK
hepatocellular carcinoma HCC
high performance liquid chromatography HPLC
histone deacetylase 1 HDAC1
janus kinase JAK
limit of quantification LOQ
limits of detection LOD
multidrug resistance protein 1 MDR1
platelet-derived growth factor receptor beta PDGFR-β
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The Food and Drug Administration FDA
vascular endothelial growth factor receptor VEGFR
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Abstract: Background and aim: We previously reported the anti-atherogenic properties of wild rice
in low-density lipoprotein receptor knockout (LDL-r-KO) mice. The present study aimed to discover
the mechanism of action for such effects. Materials: Fecal and plasma samples from the wild rice
treated and control mice were used. Fecal bacterial population was estimated while using 16S rDNA
technology. The plasma samples were used to estimate the levels of 35 inflammatory markers and
metabolomics, while using Meso Scale multiplex assay and liquid chromatography-mass spectrometry
(LC-MS/MS) techniques. Results: Many bacteria, particularly Anaeroplasma sp., Acetatifactor sp.,
and Prophyromonadaceae sp., were found in higher quantities in the feces of wild rice fed mice as
compared to the controls. Cytokine profiles were significantly different between the plasma of treated
and control mice. Among them, an increase in the level of IL-10 and erythropoietin (EPO) could
explain the anti-atherogenic properties of wild rice. Among many metabolites tested in plasma
of these animals, surprisingly, we found an approximately 60% increase in the levels of glucose
in the wild rice fed mice as compared to that in the control mice. Conclusion: Additional studies
warrant further investigation of the interplay among gut microbiome, inflammatory status, and
macronutrient metabolism.
Keywords: wild rice; microbiome; metabolomics; atherosclerosis; LDL-r-KO mice; cytokines; 16S
rDNA; plasma; feces; proteins; carbohydrates; functional food
1. Introduction
Appropriate types of diets and levels of physical activities are believed to be major determinants
of maintaining optimal health [1,2]. Many studies have reported that regular consumption of certain
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foods, particularly plant-based foods, such as whole grains, fruits, and vegetables, as well as fish,
are associated with decreased prevalence of chronic diseases, specifically cardiovascular disease [3,4].
Phytochemicals that are contained within these foods are believed to mediate these health benefits and
include phytosterols, dietary fiber, dietary antioxidants, oleic acid, and docosahexaenoic acid (DHA).
On the other hand, food ingredients, such as saturated fat, heavy metals, and other contaminants,
may increase the risk of cardiovascular disease [5,6]. One of the common chronic diseases with a
significant negative impact on the quality of life is atherosclerotic vascular disease, which remains
the main cause of global morbidity and mortality [7]. A fundamental contributor in the pathogenesis
of atherosclerosis is the oxidation of low-density lipoprotein (LDL) particles, which are taken up
by macrophages, initiating foam cell formation in the arterial wall [8]. Therefore, foods with an
ability to lower LDL cholesterol and prevent LDL oxidation have been at the center of atherosclerosis
prevention [3].
Wild rice has many health benefits when consumed, as noted in historical documents of the
indigenous peoples of North America for centuries, as well as other nations, including Chinese
and Europeans [9]. Although it is not a grain, wild rice is recognized as a ‘whole grain’ [10].
Unlike conventional rice, wild rice is usually consumed unprocessed, meaning that wild rice maintains
its natural outer layers and contains significantly higher amounts of dietary fiber, micronutrients,
and phytochemical compounds. Another important difference between wild rice and conventional
white rice is the type of starch they produce [9]. Wild rice contains resistant starch, being often
considered to act like a prebiotic; prebiotics are compounds within foods that beneficially affect gut
bacterial population and diversity [11]. Gut bacteria produce many metabolites that can either benefit
or harm the cardiovascular system [12].
We have previously reported cholesterol-lowering effects and anti-atherosclerotic properties of
plant sterols in apolipoprotein E knockout (apo E-KO) mice [13,14]. Over the past few years, we also
tested the potential anti-atherosclerotic effects of wild rice in LDL receptor knockout (LDL-r-KO)
mice [15,16]. In these studies, we observed significant anti-atherogenic effects of wild rice; however,
we were not able to identify a mechanism of action. Atherosclerosis is a multi-factorial disease, in
which alterations in inflammatory pathways and oxidative stress, including LDL particle oxidation,
play a major role [17]. Furthermore, recent studies reported an association between gut microbiome
biology and atherogenesis [18]. Therefore, this study aimed to investigate the impact of wild rice on
bacterial species abundance and diversity from 16S rDNA data analysis collected from mouse feces
and monitor the metabolic products from the feces and plasma of LDL-r-KO mice.
2. Materials and Methods
2.1. Animals and Diets
Sixteen male, four week old LDL-r-KO mice were purchased from the Jackson Laboratory, USA.
The animals were kept in pairs while using standard cages and fed regular mouse chow in a controlled
environment for one week. After a week of chow adaptation, fasting blood samples were taken from
the jugular vein under light anesthesia; body weight was also recorded. Plasma total cholesterol
was estimated, and the animals were divided into two groups of treated (n = 8) and controls (n = 8),
as previously reported [15]. The treated group was fed an atherogenic diet that contained 60% (w/w)
wild rice powder, whereas the control group received the same atherogenic diet without wild rice
powder, as previously reported [15]. Briefly, the mouse chow diet contained 9% fat that was purchased
from Ren’s Feed & Supplies Ltd. (Whitby, ON, Canada). This diet was supplemented with 0.06% (w/w)
cholesterol to make it atherogenic; the atherogenic diet was further supplemented with or without
60% (w/w) wild rice powder and then used for this study. This supplementation was performed by
replacing the atherogenic diet by the ground wild rice at 60%. Therefore, the amounts and types of
dietary fiber in the control diet and the wild rice diet were not identical. The experiments lasted for
24 weeks.
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2.2. Sample Collection
The blood samples were taken every four weeks. Fecal samples were collected and stored at −80◦C
until analysis. At autopsy, final blood samples were taken from the hearts and animals were euthanized
while using CO2 gas followed by cardiac puncture [15]. The hearts and aortae were collected for the
assessment of atherosclerotic lesion development [15]. The Animal Care Committee approved the
study at the University of Manitoba, Winnipeg, Canada; refer to Protocol number 18-048 [15].
2.3. Plasma Cytokine Levels
Plasma samples that were taken at week 16 of the experiments were used for the estimation
of 35 inflammatory biomarkers, using Meso Scale Discovery U-PLEX multiplex assay kit for a
mouse (Meso Scale Diagnostics, Rockville, MD 20850-3173, USA) [19]. These markers include
interleukins (IL-2, IL-4, IL-9, IL-10, IL-13, IL-17A, IL-17E/IL 25, IL-17F, IL-21, IL-22), tumor necrosis
factor-alpha (TNF-α)), TH1/TH2 Combo (IL-1β, IL-5, and IL-12p70A), TH17 Combo 1 (IL-17C, IL-23, and
IL-33),TH17 Combo 2 (IL-6, erythropoietin (EPO), IL-27p28/IL-30, vascular endothelial growth factor A
(VEGF-A), IL-15, IL-16, and IL-17A/F), interferon gamma-induced protein-10 (IP-10), growth regulated
oncogenes (KC/GRO), monocyte chemo-attractant protein-1 (MCP-1), macrophage inflammatory
proteins (MIP-1α, MIP-1β, MIP 2, and MIP-3α), granulocyte-macrophage colony-stimulating factor
(GM-CSF), and interferon-gamma (IFN-γ). This cytokine analysis was performed on the pooled
samples (n = 4). MSD SI2400 Imager device and MSD Workbench 3.0 software were used to detect
and analyze the standard curves and intensity of the cytokines. The intensity for each biomarker was
included in statistical analysis and then reported herein.
2.4. Fecal Microbiome Analysis
Microbial diversity and species changes in mice that were fed wild rice as compared to controls
were estimated based on extracted 16S rDNA from fecal samples that were collected from pairs of
mice at weeks, 0, 4, 16, and 24 during the study. Feces from four cages, where each cage contained two
mice (eight mice total), were collected (n = 4) for each experimental diet group and stored at −80 ◦C.
Microbial genomic DNA from each thawed fecal sample were extracted with a QIAamp Fast DNA Stool
Mini kit (51604, QIAGEN Inc., Germantown, MD, USA), according to its recommended DNA extraction
procedures. Fecal DNA was resuspended in nuclease-free water, where the DNA quantity and quality
were assessed while using a Qubit™ dsDNA BR Assay Kit (Q32853, Life Technologies, Carlsbad, CA,
USA). Fecal DNA samples were stored at −20 ◦C until they were shipped on dry ice to LC Sciences,
LLC (Houston, TX, USA) for 16S rDNA sequencing services. The sequencing methodology that was
used by this service and for this study was described previously [20]. Briefly, 16S rDNA sequencing
with an Illumina MiSeq platform was carried out, using 338F/806R primers. Further amplification of
V3 and V4 regions (around 469 bp in length) was performed by the polymerase chain reaction (PCR).
Bioinformatics analysis of 16S rDNA sequence data was assisted by LC Sciences LLC (Houston, TX,
USA). Briefly, QIIME software 1.9.1 was used to analyze paired-end reads that were merged into single
tags, according to the overlapped region between pairs. The tags were filtered based on their Phred
quality score (Q20 and Q30). Chimera sequences that were generated during PCR amplification of the
16S rDNA gene were also excluded, resulting in the final dataset for analysis. This 16S rDNA sequences
in the dataset were mapped to the ribosome database project (RDP; http://rdp.cme.msu.edu/) and NCBI
16S rDNA Microbial databases (NT-16S; ftp://ftp.ncbi.nlm.nih.gov/blast/db/nt.gz; as of August 2018)
to produce taxonomically annotated sequences, which are referred to as operational taxonomic units
(OTUs), described herein. The sequence dataset was grouped using the UCLUST algorithm program.
A minimum sequence identity of 99% was used to align the most abundant sequences within each
OTU against the reference database sequences, and the hypervariable regions were removed and used
to classify the OTUs.
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2.5. Metabolomics Studies
Metabolites from fecal and plasma samples from week 18 of the study were analyzed by a
previously described the liquid chromatography (LC)-mass spectrometry (MS/MS) analysis method [21].
This method combines derivatization and extraction of analytes from the samples, and the selective
mass-spectrometric detection using multiple reaction monitoring pairs. The isotope-labeled internal
standards were used for metabolite quantification. A total of 133 metabolites were included in the full
panel. This analysis was performed through a service contract with The Metabolomics Innovation
Centre (TMIC) at the University of Alberta, Edmonton, Canada. It is acknowledged that the use of
fecal samples from two mice that were housed in one cage is a limitation for microbiome studies as
each mouse can behave as a single ecosystem; however, the average changes among multiple mice
were the objective of this study.
2.6. Atherosclerotic Lesion Assessment
Sections from the beginning of the aortae were cut and processed for morphological evaluation of
the atherosclerotic lesions, as previously described [15]. The sections were stained with hematoxylin
and eosin (H&E) and trichrome. Light microscopy techniques were used for semi-quantitative analysis
of atherosclerotic lesions in the wild rice treated and control mice [15].
2.7. Statistical Analysis
Non-parametric Mann–Whitney tests (also known as the Wilcoxon rank-sum test) and
Kruskal–Wallis rank-sum tests were used to calculate the p-values and identify significant differences
between the two groups of wild rice fed and control mice with an n = 4. These statistical analyses
were also used to identify significant differences between time course measurements for each animal
group when appropriate. Statistical analyses of fecal microbial composition differences were assessed
by non-parametric tests, as described by White et al. 2009 [22]. The Venn diagrams of OTUs
determined from these analyses were generated while using ‘R’ statistics software (version 3.6.1,
https://www.r-project.org/) ‘Venn Diagram’ package to show the number of common OTUs in feces
of control and wild rice diet groups. Data are presented as means and standard deviations, where
p-values ≤ 0.05 were deemed to be significantly different based on the degrees of freedom for each
sample group. All of the statistical analyses were performed, while using either Microsoft Office Excel
(365, Microsoft, Redmond, USA) or the comprehensive ‘R’ Archive Network (CRAN) statistics software
(version 3.6.1, https://www.r-project.org/), with the ‘PMCMR’ analysis package, using ‘kruskal.test’
and ‘wilcox.test’ functions.
3. Results
3.1. Consumption of Wild Rice Was Associated with Changes in Fecal Bacterial Species Populations
Insights into microbial taxonomic alterations could only be confidently determined for high
abundance OTUs due to the small number of fecal samples (n = 4) examined in this analysis.
Microbial 16S rDNA analysis identified more than 200,000 bacterial species (OTUs) in the mouse fecal
samples. Figure 1A shows a Venn diagram comparing similar OTUs that were observed between the
control and wild rice fed fecal samples collected at various weeks 0, 4, 16, and 24. The majority of all
OTUs (732 total) shown in the center of the Venn diagram were identical among all diet treatments,
as would be expected in a study involving similar mouse breeds and housing conditions. The wild rice
diet fecal samples showed a decrease in the number of unique OTUs over time, where 135 unique
OTUs at week 0 reduced to 73 OTUs by week 24. The control samples showed no differences in unique
OTUs over time, suggesting that the introduction of the wild rice diet reduced species diversity as
compared to the control diets.
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Figure 1. (A) Venn diagram comparing 16S rDNA operational taxonomic units (OTUs) from the feces
of wild rice and control diet fed mice at weeks 0, 4, 16, and 24. The red curved arrow highlights the
decrease in the unique total OTUs in the wild rice fed mice from week 0 to week 24 of the study. (B) The
relative abundance of the top 20 most abundant bacterial OTUs identified from wild rice or control diet
fecal samples at weeks 0 to 24. Identified OTUs are listed according to their order (bottom to top) and
color within the bar chart.
Microbial composition changes were further investigated by performing 16S rDNA sequence
clustering, where the top 20 most abundant OTUs determined from each fecal sample are shown as a
stacked bar chart (Figure 1B). No significant differences were detected between the two major taxa,
unclassified Porphyromonadales and Lachnospirales, over time (weeks 0–16 or weeks 0–24) between
the control and wild rice diet fecal samples (Figure 1B). Wild rice diets significantly increased (p <
0.05) the proportion and appearance of a number of major OTUs when comparing week 0 to week 24
fecal samples; specifically, uncultured Anaeroplasma sp. (8.8-fold increase), Acetatifactor muris (4.4-fold
increase), uncultured Lactobacillus sp. (3-fold increase), uncultured Oscillospira sp. (3-fold increase),
and Dubosiella newyorkensis (0.07% appearance) increased (Figure 1B). Losses or significant reductions
(p < 0.05) in OTUs within the fecal wild rice diet microbiomes after comparing them to the control diet
microbiomes were also noted over time (weeks 4 and/or 24). Specifically, reductions in unclassified
Barnesiella sp. (2-fold reduction), uncultured Butyrivibrio sp. (2-fold reduction), and unclassified
Oscillibacter sp. (2-fold reduction;) were detected. Bifidobacterium choerinium was also undetectable in
the wild rice diet samples at weeks 4 and 24 as compared to control diet (Figure 1B). Altered proportions
of OTUs were also noted within the control diet fecal samples over time (weeks 0 to 16); significant (p
< 0.05) reductions in uncultured Anaeroplasma sp. (undetectable at week 16), uncultured Ruminococcus
sp. (2-fold reduction), and uncultured Filifactor sp. (undetectable at week 16) were noted, as well as
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significant increases (p < 0.05)in Ileibacterium valens (2–5% appearance) and Bifidobacterium choerinum
(43-fold increase). It is noteworthy that the control diet OTUs, as mentioned above, were either low or
completely absent in the wild rice diet fecal samples (Figure 1B). Overall, fecal microbiome analyses
indicate that the wild rice diet significantly alters many high abundance bacterial species.
Figure 2 shows values for three OTUs that reached statistically significant differences (p < 0.05)
between the treated and control animals. The abundance of unclassified Prophyromonadaceae sp. and
uncultured Anaeroplasma sp. in wild rice fed mice were approximately 5000 and 1000, respectively,





















Wild rice vs. Control
Wild rice group
Control group
Figure 2. The abundance of OTUs for selected species identified from 16S rDNA analysis of wild
rice fed and control fecal samples. All samples were collected at week 16 of the study with an n = 4
per group. OTU 4: Acetatifactor sp. unclassified; OTU 1064: Porphyromonadaceae sp. unclassified;
OTU 104999: uncultured Anaeroplasma sp. *: p < 0.05 as compared with the controls.
3.2. Wild Rice Consumption Is Associated with Changes in Plasma Inflammatory Markers
Our analysis included an estimation of 35 different markers in inflammatory pathways.
Statistical analyses between data from the wild rice fed and control groups only identified five
markers with a significant change in their mean values (Table 1). The levels of EPO and interleukin
10 (IL-10) increased by approximately 109% and 130%, respectively, in the wild rice diet mice.
In contrast, wild rice diet mice had reduced markers of approximately 18%, 18%, and 35% of tumor
necrosis factor-alpha (TNF-α), vascular endothelial growth factor (VEGF), and interleukin-16 (IL-16),
respectively, as compared with the control animals.




Control Group (n = 4) Wild Rice Group (n = 4) % Change
EPO 6.69 ± 2.7 14.01 ± 4.7 * ↑109
TNF-α 6.77 ± 0.7 5.57 ± 0.5 * ↓18
VEGF 6.06 ± 0.6 5.0 ± 0.5 * ↓18
IL10 4.32 ± 1.77 9.94 ± 3.14 * ↑130
IL16 645.83 ± 14.4 422.07 ± 64.3 * ↓35
Data are presented as means ± standard deviation. Statistical analyses were performed using the Mann Whitney
test; *: p < 0.05 as compared with the controls. EPO: erythropoietin, TNF-α: tumor necrosis factor-α, VEGF: vascular
endothelial growth factor, IL-16: interleukin-16. ↓: Decrease. ↑: Increase
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3.3. Wild Rice Diets Show Differences in Fecal and Plasma Metabolites
LC-MS/MS analysis of metabolites that were extracted from wild rice and control diet fecal and
plasma samples identified a total of 133 metabolites. We performed a Mann-Whitney rank-sum test on
metabolite values between the sample groups to improve the confidence in metabolite analyses due to
our lower sampling numbers (n = 4). We focused our results on metabolites with significant differences
from the control diet group (p < 0.05). Table 2 show significant changes in the levels of 11 plasma
metabolites that were differentially detected. Glucose increased in wild rice fed mice by approximately
61%, whereas 10 metabolites, including short-chain fatty acids (C8, C10, and C12), medium-chain fatty
acids (C14:1, and C16), and long-chain fatty acids (C18 and C18:1) decreased by 17–48% in the wild
rice diet plasma samples as compared to those in the controls.
Table 2. Metabolomics data from plasma samples of mice fed wild rice and control diets.
Plasma Metabolomics Control Group
(n = 4) (μM)
Wild Rice Group
(μM) (n = 4)
% Change from
Control DietNutrients Metabolites
Proteins Putrescine 1.21 ± 0.19 0.83 ± 0.16 * ↓32%
Carbohydrates Glucose 10,208.17 ± 2575.4 16,405.98 ± 2966.73 * ↑61%
Short Chain Fatty
Acids
Caprylic acid 0.06 ± 0.009 0.05 ± 0.007 * ↓25%
Capric acid 0.09 ± 0.009 0.06 ± 0.010 * ↓30%
Lauric acid 0.08 ± 0.014 0.05 ± 0.0002 * ↓41%
Medium Chain
Fatty Acids
Myristic acid (C14) 0.17 ± 0.026 0.10 ± 0.008 * ↓41%
3-Hydroxytetradecenoyl-carnitine
(C14:1-OH) 0.03 ± 0.0047 0.02±0.0027 * ↓29%
Palmitic acid (C:16) 0.51 ± 0.158 0.32 ± 0.032 * ↓38%
Hydroxyhexadecadienyl-l-Dcarnitine
(C16:2OH) 0.01 ± 0.0026 0.01 ± 0.002 * ↓35%
Long Chain Fatty
Acids
Stearic (C18) 0.18 ± 0.0205 0.12 ± 0.012 * ↓31%
Hydroxy-Oleyl-l-Carnitine
(C18:1OH) 0.05 ± 0.011 0.03 ± 0.002 * ↓34%
Data are presented as means ± standard deviation. Statistical analyses were performed using the Mann-Whitney
test; *, p < 0.05 as compared with controls. ↓: Decrease. ↑: Increase
Among 24 fecal metabolites listed in Table 3, only four metabolites, butyric acid and three
phospholipids increased by 51–323%. The remaining metabolites, which included amino acids,
short-chain fatty acids (except butyric acid), and long-chain fatty acids, showed a decrease of 30–70%
by wild rice fed fecal samples as compared to those in the control group (Table 3).
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3.4. Wild Rice Consumption Prevents Atherogenesis
In agreement with our previous findings [15,16], we report that the mice fed with wild rice had
much smaller atherosclerotic lesions in their aortae as compared to that in the control animals. Figure 3
illustrates advanced atherosclerotic lesions at the beginning of aortae in the control animals (arrows),
but similar lesions were absent or minimal in the similar anatomical region of aortae of the wild rice
fed mice.
Figure 3. Representative photomicrographs were taken at the beginning of aorta from one control
mouse (A,B) and one wild rice fed mouse (C,D) illustrating atherosclerotic lesions (arrows). As it is
seen in (A,B), atherosclerotic lesions are large and well established in the control mouse (arrows), while
such advanced lesions are missing in the wild rice fed mouse (C,D). H&E staining (A,C); trichrome
staining (B,D).
4. Discussion
We have previously shown that wild rice consumption is associated with the prevention of
atherosclerotic vascular disease in LDL-r-KO mice [15,16]. This effect could be related to reductions in
plasma cholesterol levels. We have shown alterations in LDL-r-KO mice microbiomes may influence
the detection of inflammatory markers, and alter concentrations of metabolites when fed a diet rich in
wild rice based on the results of our study. LDL-r-KO mice exhibit atherosclerosis, which is known
to be an inflammatory disease [23]. Therefore, treatment with agents that possess pro-inflammatory
properties are expected to increase the risk for this disease and anti-inflammatory states should prevent
atherosclerosis [24]. LDL-r-KO mice fed a wild rice diet had approximately 75% lower atherosclerotic
lesions (0.46 ± 0.11 vs. 1.95 ± 0.16 mm2) in their aortic roots as compared to the control diet mice [15].
The results from the current study have identified that wild rice feeding is associated with a 130%
change increase in IL-10; IL-10 was shown in previous studies to possess anti-atherogenic activities [25].
Another interesting observation was a 109% increase in the levels of EPO in plasma of wild rice fed
mice. Recent studies have shown the anti-atherogenic properties for EPO [26]. The mechanism by
which IL-10 and EPO levels were increased in wild rice treated animals is not presently understood,
but it may be associated with changes in gut microbiome composition. We have reported a beneficial
change in the inflammatory pathways of mice that were fed either wild rice or Saskatoon berries [27,28].
Additionally, a recent study monitoring dietary changes in mice demonstrated that specific microbes
can alter gut T-cell responses [29]. It is possible that the changes in cytokine concentrations that we
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observed in wild rice fed LDL-r-KO mice may indirectly influence plasma when phytochemicals
produced by altered gut microbiome species reach the blood.
We also reported that starch from wild rice is different in nature from the starch found in
conventional white rice; wild rice also contains a significant amount of dietary fiber [9,16]. These forms
of carbohydrates may act as prebiotics, which thereby alters the diversity and population of the gut
microbiome [11,12]. In the present study, we observed that unclassified Prophyromonadaceae decreased
in the fecal samples of wild rice fed mice (Figure 1B). When we examined different OTUs associated
with unclassified Prophyromonadaceae, we observed that many OTUs increased in wild rice group as
compared to those in the control (Figure 2). This suggests that specific Prophyromonadaceae, such as
unclassified Barnesiella sp., differ between control and wild rice fed mice (Figure 1B). Previous studies
examining changes in mouse gut microbial species showed that mice that were fed with polysaccharides
from the mushroom Auricularia auricular altered quantities of Prophyromonadaceae in their intestine
as compared to control diet animals [30]. This study highlights the importance of carbohydrates on
microbial species diversity. In the same mushroom study, the treated animals showed higher serum
IgA and IgG, indicating changes in gut microbiome due to mushroom carbohydrate consumption
also modulated the immune system of the mice [30]. Another noteworthy observation was the
difference in Anaeroplasma sp. between the wild rice fed and control fecal samples. A study by Zeng
et al. [31] reported an increased abundance of Anaeroplasma species in the intestines of wild type
mice that were fed a high-fat diet. These authors concluded that high-fat diets promoted colonic
aberrant crypt formation accompanied by an increase in the abundance of opportunistic pathogens,
such as Anaeroplasma sp. in the colon of C57BL/6 mice [31]. Acetatifactor sp. was also identified
in high abundance over time within the wild rice fed fecal samples. Although not much is known
about Acetatifactor species’ influence on murine microbiomes, Pfeiffer et al. [32] suggested the name
Acetatifactor muris due to its isolation from the cecum of mice fed a high-fat diet, which we also observed
in our study only among control diet LDL-r-KO mice (Figure 1B). Acetatifactor species are not known to
metabolize glucose and they are associated with higher phenylalanine arylamidase activities. In our
study, we identified that wild rice diets reduced the Acetatifactor muris levels, suggesting that this
species, might indirectly influence atherosclerosis in an LDL-r-KO mouse model.
Analysis of fecal metabolic compounds revealed that wild rice consumption was associated
with altered metabolite abundances, particularly metabolites that are associated with amino acids,
carbohydrates, and fats. All amino acids that were detected in fecal samples were significantly reduced
from mice fed wild rice diets. Wild rice diets may promote the growth and predominance of these
amino acid utilizing species to catabolize more amino acids, since the most abundant bacterial species
Anaeroplasma sp., Acetatifactor sp., and Prophyromonadaceae sp. significantly differed in wild rice as
compared to the control group. For example, Acetatifactor muris may be a species promoting greater
amino acid usage, as it possesses phenylalanine arylamidase, which breaks down L-phenylalanine
from peptides [32]. This might suggest that a significant reduction in the concentrations of several
amino acids could be associated with bacteria containing this and other relevant enzymes.
Among several short-chain fatty acids and their derivatives, butyric acid was found in the
fecal materials from the wild rice fed mice 81% more than that in the control animals. This finding
coincides with specific and significant increases in butyric acid-producing uncultured Butyrivibrio
species identified from 16S rDNA wild rice fed fecal microbiomes (Figure 1B). Butyrivibrio sp. is
commonly enriched in the guts of ruminant animals, where they produce butyrate from the breakdown
of plant fibers and structural carbohydrates, specifically hemicellulose [33,34]. Many studies have
reported the metabolic benefits of short-chain fatty acids [35,36]. Analysis of blood plasma samples
did not correlate well to metabolic and microbiome changes despite increases in butyrate in the
intestine of wild rice fed mice. Plasma concentrations of other short-chain fatty acids, such as caproic
acid and caprylic acid, were significantly lower in the wild rice fed mice as compared to those in
the controls. However, there was an association between the levels of long-chain fatty acids in
the fecal and plasma samples, as these levels were increased in both samples from the wild rice
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fed mice as compared to those in the controls. Another observation was a significant increase in
plasma glucose concentrations in the wild rice fed mice as compared to that in the control group.
Increased plasma glucose levels are seen during diabetes or insulin resistance in animals as well as
humans [37,38]. However, the consumption of high fiber diets is generally recommended to combat
complications that are caused by diabetes [39,40]. Wild rice is a rich source of dietary fiber; therefore,
this observation seems to be in contrast with our general knowledge and it certainly begs more
investigation. To conclude, additional investigations examining the interplay between changes in
intestinal microflora, inflammatory response, and metabolic biomarkers are warranted, as they may
play a role in the pathogenesis of chronic diseases, like atherosclerosis. Overall, it should be mentioned
that a low number of animals, pooled fecal, and plasma samples, as well as a lack of different doses of
wild rice, could be viewed as limitations of the present study.
5. Conclusions
In conclusion, we hereby report that the long term consumption of wild rice at 60% (w/w) in
LDL-r-KO mice is associated with the prevention of atherosclerosis. This effect was accompanied by
significant alterations in the fecal bacterial population and diversity, as well as significant changes
in several inflammatory and metabolic biomarkers. Of particular interest was an increase in the
plasma glucose levels in the wild rice fed mice; currently, we have no explanation for this finding.
Other findings that can support anti-atherogenic properties of wild rice are increases in the plasma levels
of anti-inflammatory marker IL-10 and EPO. Altogether, this study provides preliminary evidence
in support of additional studies on this animal model and others to improve our understanding of
how gut bacterial species, plasma inflammatory markers, and metabolic biomarkers may prevent
atherosclerosis. Furthermore, a dose-response study can help to establish whether lower doses of wild
rice can result in similar findings in this animal model.
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Abstract: Platycodon grandiflorus root extract (PGE) has shown various properties, such as
anti-hyperlipidemia, anti-diabetic, and anti-obesity, but mostly in animal studies. Therefore, we
conducted a preliminary study on the anti-obesity effect of PGE in 108 Korean adults (aged 20–60 years,
30 kg/m2 ≥ body mass index≥ 23 kg/m2). The participants were randomly assigned to four groups and
were administered the placebo, PGE571 (571 mg as PGE), PGE1142 (1142 mg as PGE), and PGE2855
(2855 mg as PGE), independently, for 12 weeks. Body composition, nutrient intake, computed
tomography scan, and plasma adipokines, as well as hepatic/renal function markers, were assessed.
The PGE571 group revealed a significant decrease in body fat mass and body fat percentage when
compared with the placebo group. Moreover, the total abdominal and subcutaneous fat areas were
significantly decreased following PGE (PGE2855 group) supplementation. These results provide
useful information on the anti-obesity effect of PGE for overweight and obese adult humans.
Keywords: Platycodon grandiflorus root; BMI; body fat mass; abdominal fat area
1. Introduction
Obesity is associated with the morbidity and mortality of diabetes and cardiovascular disease, and
it is a major public health problem that is increasing in prevalence worldwide [1]. Obesity increases
the risk of metabolic abnormalities, associated insulin resistance, hyperglycemia, type 2 diabetes, and
dyslipidemia, which generate high medical costs [2,3]. Obesity leads to the accumulation of body fat
mass, as well as the loss of skeletal muscle mass. Recently, a new concept of sarcopenic obesity has
emerged, reflecting a combination of sarcopenia and obesity, which describes the process of muscle
loss combined with increased body fat as people age—a condition associated with the loss of muscle
strength and function, reduced quality of life, and even mortality [4,5].
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Platycodon grandiflorus (PG) root is widely used in traditional Chinese medicine. It contains
many active constituents, such as steroidal saponins, flavonoids, phenolic acids, and sterols, among
which, the saponins are regarded as the major active compounds [6]. Numerous studies have proven
that the saponins of P. grandiflorus exhibit diverse pharmacological activities, such as antioxidant [7],
anti-inflammatory [8], and anti-apoptosis effects [9]. These saponins are also believed to have
protective effects against some chemically-induced hepatotoxic reactions. Indeed, platycodin D,
the major triterpenoid saponin found in PG, was recently suggested for protecting against liver damage
caused by ethanol and carbon tetrachloride [10]. In addition, PG is considered to be a legal medicine
and dietary supplement; it is also frequently used as an ingredient in health foods and vegetable
dishes [11].
Many studies have reported the effects of PG fractions or extracts on lipid metabolism regulation
and insulin resistance improvement, but mostly in animal models [11–13]. Therefore, we conducted a
preliminary study on the anti-obesity effect of PG extract (PGE) in overweight and obese adult humans.
This is the first study to investigate the body fat loss effects of PGE in humans. In particular, this
preliminary study provides information on the approximate daily dosage of PGE for the upcoming
main study, which will be performed using dual-energy X-ray absorptiometry (DEXA) equipment for
body fat measurement.
2. Materials and Methods
2.1. Participants
Volunteers (20–60 years old) were recruited from Daegu and among employees of Kyungpook
National University in the Republic of Korea, in March 2017. After an initial screening, 108 participants
with a body mass index (BMI) of 23–30 kg/m2 were selected. The exclusion criteria were as follows:
(1) taking diuretics for hypertension; (2) taking oral hypoglycemic agents or insulin injection; (3) serious
cardiac, renal, hepatic, thyroid, or cerebrovascular disease; (4) serious cystic or gastrointestinal disease,
gout, or porphyria; (5) psychiatric problems, such as depressive disorder, schizophrenia, alcoholism,
and drug intoxication; (6) cancer diagnosis and treatment; (7) asthma or other allergies; (8) a history of
surgery within the past 6 months; (9) pregnant or in lactation period. The study was approved by the
Kyungpook National University Human Research Committee (KNU 2017-0113). All participants gave
their written informed consent for inclusion before they participated in the study.
2.2. Sample Size
In order to eliminate the effects of gender differences, the gender of the participants was assigned
by replicated randomized complete block design. The sample size was estimated using G* Power
3.1.9.2. Assuming a 95% statistical power, 0.05 significance level, and 0.40 effect size (Cohen’s standard
for a large effect), it was estimated that at least 120 participants were required to show a statistically
significant difference in biomarkers of body fat among four groups.
2.3. Design
This single institution, randomized, double-blinded, and placebo-controlled study was conducted
to confirm the effect of PGE supplementation on body fat loss in obese or overweight participants.
The random assignment code was generated using the permed-block randomization method with
the assistance of SAS Proc Plan (SAS Institute, Cary, NC, USA). All participants were randomly
assigned in into four groups in a 1:1:1:1 ratio: placebo, PGE571 (571 mg as PGE), PGE1142 (1142 mg
as PGE), and PGE2855 (2855 mg as PGE). The total content of test product for one tablet was 900 mg
(including 571 mg of Platycodon grandifloras extract); all participants received two pouches per day of
the placebo (including 666 mg of crystalline cellulose) and each PGE (PGE571, PGE1142, PGE2855),
according to their assigned group, which were consumed from baseline (0 days) to the end of the
12-week experiment, at 30 min after breakfast and dinner. The placebo and PGEs were supplied by
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GC WellBeing (Seongnam, Korea). All participants were instructed to maintain their routine food
intake and physical activity during the study. Moreover, during the study period, we monitored the
participants’ compliance with the nutritional intervention and capsule consumption every week by
telephone. At the end of the study, the participants were asked to return any pouches not consumed.
The doses of PGE were selected by extrapolated calculations on the basis of a previous animal study [14].
2.4. Anthropometric and Biochemical Analyses
For anthropometric and physiological measurements at baseline and 4, 8, and 12 weeks
post-test material supplementation, the participants visited the Science Research Center Laboratory
at Kyungpook National University between 07:00 and 11:00 h after a 12 h overnight fast. The BMI,
height, weight, and body composition were measured using an X-Scan Plus II body composition
analyzer (Jawon Medical Co., Daejeon, Korea). Abdominal computed tomography (CT; Brivo CT385,
GE Healthcare, Chicago, IL, USA) scans that included the lumbar spine were acquired at baseline
and during follow-up [2,4]. The CT scans were taken at the Doctors Radiology Clinic, located in
Daegu city (Korea). The waist and hip circumferences were measured with an anthropometric tape.
The waist circumference was measured as the minimum circumference between the iliac crest and rib
cage, and the hip circumference was measured as the maximum width over the greater trochanters.
The waist-to-hip ratio was calculated by dividing the waist measurement by the hip measurement.
Blood samples were collected in ethylenediaminetetraacetic acid-coated tubes and centrifuged at
1000× g for 15 min at 4 ◦C for plasma assays. To determine the dietary intake, 24 h dietary recalls were
administered in face-to-face interviews at the participants’ homes before and during the preliminary
trial by dieticians. Three day dietary recalls were performed twice at baseline and during follow-up. We
presented the mean of the 3 day dietary intake at each point. During the interview, the participants were
asked what kinds of food they ate and drank on their dietary recall sheet. Food replicas were provided
to help the participants estimate their dietary intakes and exact portions. Nutritional analysis was
performed using CAN-Pro 3.0 software (The Korean Nutrition Society, Seoul, Korea), which provides a
comprehensive database for the nutritional content of general foods and specific Korean foods.
2.5. Biochemical Analyses
Before and after the test, fasting blood was collected and analyzed by Seegene Co. Ltd.
(Daegu, Korea). The levels of plasma adiponectin, leptin, interleukin-6, tumor necrosis factor-alpha, and
monocyte chemoattractant protein-1 were determined using a Cobas 8000 analyzer (Roche Diagnostics,
Mannheim, Germany). For the safety evaluation of the test material, the liver and renal function
markers (albumin, blood urea nitrogen, total bilirubin, aspartate transaminase, alanine transaminase,
and alkaline phosphatase (ALP)) were measured using a Hitachi LABOSPECT 008 AS (Hitachi,
Tokyo, Japan).
2.6. Statistical Analysis
Data were analyzed using SPSS (IBM SPSS, version 21) and expressed as mean ± standard
deviation. Statistical analysis was performed using the analysis of covariance (ANCOVA) test for
comparison between the placebo control group (placebo) and the test groups. In the questionnaire,
it was confirmed that there was a large difference in physical activity and drinking among the
participants. Given that there is a high correlation between alcohol consumption and obesity rate [15],
participants who frequently consumed alcohol (more than two bottles per week) and reported a very
low physical activity (sedentary behavior) were excluded (Table 1). Paired t-test was used to verify
the difference before and after ingestion at p < 0.05. Statistical analysis was also performed on all
participants (23 kg/m2 ≤ BMI ≤ 30 kg/m2) without any discrimination of physical activity and alcohol
consumption for safety assessment.
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Table 1. Survey of physical activity and alcohol drinking status of subjects.
Score Physical Activity Drinking Behavior
1 Sedentary behavior 1–2 glasses/week
2 Light activity Less than 1 bottle/week
3 Moderate activity 1–2 bottles/week
4 Vigorous activity More than 2 bottles/week
3. Results
3.1. Study Flow
This study had an initial 130 candidates, and had 108 eligible individuals who were enrolled
in this study through the eligibility tests. After 12 weeks, eight people dropped out for personal
reasons. Participants with factors affecting obesity, very low physical activity, and frequent alcohol
consumption were excluded. Physical activity and alcohol consumption were assessed through the
questionnaire (Table 1). Thus, data from 72 participants were analyzed for evaluating the efficacy of
PGE supplementation. Serious adverse effects were not reported by the participants consuming the
PGEs or placebo supplements.
3.2. Baseline Clinical Characteristics and Nutrient Intake
The baseline characteristics of volunteers who completed the randomized controlled trial are
shown in Table 2. There were no significant differences among all groups in terms of age, height,
systolic blood pressure, diastolic blood pressure, and fasting blood glucose. Nutritional intake of
the participants before and after the test food intake was measured six times (three times before the
test, three times after the test) using the 24 h recall method. The energy and carbohydrate intake of
the PGE1142 and PGE2855 groups were significantly higher than that of the placebo group. In other
nutrients, no significant difference was found among all groups (Table 3).
Table 2. Baseline characteristics of 4 groups with overweight or obesity subjects who participated in
efficacy test of Platycodon grandiflorus root extract (PGE).
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Age (years) 40.89 ± 3.44 42.63 ± 2.52 44.95 ± 2.56 48.00 ± 2.03
Height (cm) 168.58 ± 2.79 163.59 ± 2.37 165.26 ± 1.73 162.49 ± 1.82
Body weight (kg) 74.07 ± 2.64 72.48 ± 2.40 70.14 ± 1.93 69.32 ± 1.75
BMI (kg/m2) 25.98 ± 0.44 26.99 ± 0.44 25.62 ± 0.41 26.24 ± 0.48
Waist (cm) 93.34 ± 1.21 92.26 ± 1.12 91.76 ± 1.41 90.67 ± 0.84
Hip (cm) 103.00 ± 1.10 101.84 ± 1.00 101.16 ± 0.91 100.64 ± 0.97
WHR 0.91 ± 0.01 0.91 ± 0.01 0.91 ± 0.01 0.90 ± 0.01
Systolic BP (mmHg) 124.69 ± 3.68 133.95 ± 3.95 130.42 ± 3.50 139.11 ± 4.24
Diastolic BP (mmHg) 82.44 ± 2.97 90.21 ± 2.75 85.74 ± 2.27 87.83 ± 2.90
Values are the mean ± SD; PGE571: 571 mg administered as PGE, PGE1142: 1142 mg administered as PGE, PGE2855:
2855 mg administered as PGE, BMI: body mass index, WHR: waist hip ratio, BP: blood pressure, M: male, F: female.
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Table 3. Comparison of physical activity and nutrients intake in four groups with overweight or obesity
by 24 h dietary recall performed before and in a follow-up of the trial.
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Energy
(kcal/day)
Baseline 1571.86 ± 8.31 1680.07 ± 16.89 1520.09 ± 13.74 1747.36 ± 14.15
Follow-up 1384.56 ± 9.83 * 1545.68 ± 14.12 1706.26 ± 15.32 1757.60 ± 10.76
CFB −187.30 ± 9.45 −134.4 ± 13.21 186.18 ± 12.04 10.24 ± 16.00
p-Value 0.437 0.013 0.045
Carbohydrate
(d/day)
Baseline 226.34 ± 1.32 222.70 ± 1.81 221.81 ± 1.85 244.70 ± 1.99
Follow-up 186.23 ± 1.82 ** 211.71 ± 2.23 241.07 ± 1.71 245.17 ± 1.80
CFB −40.12 ± 1.56 −10.99 ± 1.60 19.26 ± 1.89 0.46 ± 2.23
p-Value 0.185 0.007 0.021
Fat (g/day)
Baseline 43.80 ± 0.46 53.95 ± 1.11 43.55 ± 0.68 51.61 ± 0.68
Follow-up 45.17 ± 0.53 48.84 ± 0.57 46.85 ± 0.64 52.97 ± 0.42
CFB 1.37 ± 0.58 −5.11 ± 1.13 3.30 ± 0.52 1.36 ± 0.80
p-Value 0.823 0.790 0.358
Protein (g/day)
Baseline 64.13 ± 0.46 65.61 ± 0.81 57.33 ± 0.55 68.57 ± 0.63
Follow-up 58.72 ± 0.48 57.80 ± 0.55 65.03 ± 0.71 67.96 ± 0.43
CFB −5.41 ± 0.63 −7.81 ± 0.61 7.70 ± 0.54 −0.61 ± 0.72
p-Value 0.804 0.145 0.242
Cholesterol
(mg/day)
Baseline 239.95 ± 3.79 213.90 ± 3.41 203.86 ± 3.40 274.73 ± 3.94
Follow-up 218.46 ± 3.32 234.29 ± 3.71 246.74 ± 3.44 244.84 ± 3.06
CFB −21.48 ± 4.31 20.39 ± 3.10 42.87 ± 4.83 −29.89 ± 4.20
p-Value 0.564 0.341 0.692
p-Value: Analysis of covariance (ANCOVA) model with independent variable as baseline and treatment; * p < 0.05,
** p < 0.01 derived from paired t-tests performed for values obtained before and after the trial. CFB: changes
from baseline.
3.3. Body Composition
Body composition, such as body weight, BMI, body fat mass, body fat percentage (BFP), and
muscle weight, were analyzed by using data that considered drinking and exercise activities (n = 72)
(Table 4). Body fat (ANCOVA, p < 0.028) and BFP (ANCOVA, p < 0.001) were significantly decreased
in the PGE571 group compared with the placebo. Also, supplementation of PGE2855 led to a decrease
in the body fat mass (ANCOVA, p < 0.036) and BPF (ANCOVA, p < 0.035). In contrast, muscle mass
was significantly increased in the PGE571 (ANCOVA, p < 0.002)-supplemented group compared with
the control (placebo) group (Table 4).
Moreover, we performed CT scans at baseline and after (follow-up) to observe the effects of PGE
supplementation on the participants’ abdominal fat area. The high-dose PGE group (PGE2855) was
observed to have a significant effect when compared with the placebo group. In particular, the PGE2855
led to a significant decrease in the L4 total abdominal fat area (ANCOVA, p = 0.029) and subcutaneous
fat area (ANCOVA, p = 0.035) (Table 5).
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Table 4. Effect of PGE supplementation for 12 weeks on change of body composition measured by
bioelectrical impedance analysis (BIA), WHR-related body measurements, and blood pressure in groups
with overweight or obesity.
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Body weight (kg)
Baseline 74.07 ± 2.64 72.48 ± 2.40 70.14 ± 1.93 69.32 ± 1.75
Follow-up 73.61 ± 2.70 72.12 ± 2.42 69.73 ± 1.95 68.03 ± 1.60 **
CFB −0.46 ± 0.40 −0.36 ± 0.39 −0.42 ± 0.42 −1.28 ± 0.36
p-Value 0.901 0.969 0.128
BMI (kg/m2)
Baseline 25.98 ± 0.44 26.99 ± 0.44 25.62 ± 0.41 26.24 ± 0.48
Follow-up 25.71 ± 0.46 * 26.69 ± 0.42 25.39 ± 0.44 25.69 ± 0.46 ***
CFB −0.27 ± 0.13 −0.30 ± 0.16 −0.23 ± 0.16 −0.54 ± 0.11
p-Value 0.933 0.924 0.213
Body fat mass (kg)
Baseline 21.02 ± 0.95 22.76 ± 0.75 21.91 ± 0.85 22.11 ± 0.98
Follow-up 21.46 ± 0.93 22.12 ± 0.77 21.96 ± 0.91 21.54 ± 0.99 **
CFB 0.44 ± 0.30 −0.64 ± 0.38 0.05 ± 0.30 −0.57 ± 0.20
p-Value 0.028 0.432 0.036
BFP (%)
Baseline 28.73 ± 1.45 31.95 ± 1.18 31.41 ± 1.12 31.97 ± 1.27
Follow-up 29.52 ± 1.42 * 31.11 ± 1.25 * 31.67 ± 1.17 31.73 ± 1.30
CFB 0.79 ± 0.30 −0.85 ± 0.41 0.26 ± 0.30 −0.24 ± 0.17
p-Value 0.001 0.273 0.035
Muscle weight (kg)
Baseline 48.79 ± 2.41 45.61 ± 2.12 44.25 ± 1.68 43.24 ± 1.53
Follow-up 47.94 ± 2.42 ** 45.91 ± 2.21 43.82 ± 1.67 42.62 ± 1.43 **
CFB −0.85 ± 0.26 0.29 ± 0.25 −0.43 ± 0.26 −0.62 ± 0.19
p-Value 0.002 0.251 0.551
p-Value: ANCOVA model with independent variable as baseline and treatment; * p < 0.05, ** p < 0.01, *** p < 0.001
derived from paired t-tests performed for values obtained before and after the trial; CFB: changes from baseline;
BFP: body fat percentage.
Table 5. Effect of PGE supplementation for 12 weeks on change of abdominal fat area assessed by
computed tomography (CT) in subjects with overweight or obesity.
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
L4 Total abdominal fat (cm2)
Baseline 305.72 ± 21.54 363.49 ± 15.51 331.80 ± 18.78 318.07 ± 14.08
Follow-up 316.84 ± 19.81 362.35 ± 15.12 331.36 ± 17.47 299.11 ± 11.53 *
CFB 11.12 ± 12.81 −1.13 ± 8.54 −0.44 ± 8.50 −18.95 ± 7.91
p-Value 0.959 0.651 0.029
L4 Subcutaneous fat (cm2)
Baseline 184.00 ± 20.17 215.13 ± 14.95 195.32 ± 13.65 179.18 ± 11.76
Follow-up 197.10 ± 18.16 222.43 ± 13.87 196.80 ± 12.28 171.04 ± 10.41
CFB 13.10 ± 11.17 7.30 ± 6.19 1.48 ± 7.15 −8.14 ± 6.73
p-Value 0.911 0.382 0.035
L4 Visceral fat (cm2)
Baseline 121.71 ± 7.32 148.35 ± 9.89 136.48 ± 10.37 138.88 ± 11.16
Follow-up 119.74 ± 8.96 139.92 ± 10.52 134.56 ± 10.88 128.07 ± 9.56 **
CFB −1.97 ± 4.62 −8.43 ± 6.03 −1.92 ± 3.62 −10.81 ± 3.60
p-Value 0.561 0.828 0.245
p-Value: ANCOVA model with independent variable as baseline and treatment; * p < 0.05, ** p < 0.01 derived from
paired t-tests performed for values obtained before and after the trial; CFB: changes from baseline.
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3.4. Plasma Adipokines
Table 6 shows the levels of plasma adipokines. When ANCOVA was used, there were no
significant differences in adipokine levels among the four groups. However, PGE571 supplementation
significantly reduced leptin levels after 12 weeks from baseline. Also, the leptin:adiponectin (L:A)
ratio was significantly lower after supplementation with PGE2855 compared with the baseline (before
supplementation) measurement. In comparison to the baseline, PGE supplementation led to a
significant decrease in leptin levels in the PGE571 (paired t-test, p < 0.01) and the L:A ratio in the
PGE2855 (paired t-test, p < 0.05) after the 12 week experiment. In addition, when all participants were
analyzed (n = 100), adiponectin levels (ANCOVA, p < 0.059) tended to decrease in the PGE571 group
compared with the placebo (data not shown).
Table 6. Effect of supplementation of PGE for 12 weeks on changes of serum adipokine levels in subjects
with overweight or obesity.
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Leptin (ng/mL)
Baseline 3.58 ± 0.61 6.22 ± 0.96 4.15 ± 0.66 5.47 ± 0.84
Follow-up 3.11 ± 0.46 5.00 ± 0.78 ** 4.24 ± 0.62 4.19 ± 0.67
CFB −0.48 ± 0.42 −1.22 ± 0.35 0.09 ± 0.46 −1.16 ± 0.58
p-Value 0.776 0.133 0.888
Resistin (ng/mL)
Baseline 31.66 ± 8.05 21.83 ± 1.84 19.16 ± 2.57 26.69 ± 4.51
Follow-up 23.65 ± 3.03 21.03 ± 2.79 17.74 ± 2.38 23.17 ± 2.80
CFB −8.01 ± 6.22 −0.80 ± 2.07 −1.42 ± 2.39 −4.37 ± 2.91
p-Value 0.724 0.968 0.726
Adiponectin (ug/mL)
Baseline 9.74 ± 1.28 8.44 ± 1.61 8.27 ± 1.28 13.53 ± 2.97
Follow-up 9.00 ± 1.37 13.38 ± 4.51 9.84 ± 1.64 11.95 ± 2.16
CFB −0.74 ± 0.43 4.94 ± 4.60 1.58 ± 1.39 −0.70 ± 1.18
p-Value 0.174 0.633 0.792
L:A ratio
Baseline 0.42 ± 0.07 1.14 ± 0.23 0.84 ± 0.22 0.75 ± 0.22
Follow-up 0.39 ± 0.05 0.74 ± 0.16 0.74 ± 0.20 0.53 ± 0.16 *
CFB −0.02 ± 0.05 −0.40 ± 0.22 −0.10 ± 0.13 −0.24 ± 0.10
p-Value 0.789 0.466 0.758
p-Value: ANCOVA model with independent variable as baseline and treatment; * p < 0.05, ** p < 0.01 derived
from paired t-tests performed for values obtained before and after the trial; CFB: changes from baseline, L:A:
leptin:adiponectin.
3.5. Lipids Metabolism
Table 7 shows the changes in the indirect markers of lipids metabolism. There were no significant
changes in lipids metabolism. When all participants were analyzed, there were no significant changes
among the four groups in terms of cholesterol, triglyceride, high density lipoprotein cholesterol
(HDL-C), low density lipoprotein cholesterol (LDL-C), and phospholipid. The changes were within the
normal range and were considered to have no clinical implications in terms of the safety assessment.
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Table 7. Effect of supplementation of PGE for 12 weeks on changes of lipids metabolism in subjects
with overweight or obesity.
Placebo
(M: 9, F: 7)
PGE571
(M: 6, F: 13)
PGE1142
(M: 5, F: 14)
PGE2855
(M: 6, F: 12)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Cholesterol (mg/dL): normal range 0~240 mg/dL
Baseline 201.38 ± 10.42 210.25 ± 9.18 204.43 ± 7.70 198.84 ± 7.30
Follow-up 199.75 ± 10.56 204.55 ± 7.22 208.05 ± 9.69 195.72 ± 8.06
CFB −1.63 ± 4.34 −5.70 ± 7.40 3.62 ± 5.46 −1.89 ± 5.65
p-Value 0.837 0.517 0.904
TG (mg/dL): normal range 36~150 mg/dL
Baseline 96.00 ± 8.34 119.40 ± 10.81 116.38 ± 9.12 125.79 ± 25.42
Follow-up 119.38 ± 16.70 137.75 ± 15.98 112.00 ± 10.85 116.22 ± 17.78
CFB 23.38 ± 13.33 18.35 ± 11.36 −4.38 ± 8.13 −7.61 ± 21.67
p-Value 0.733 0.279 0.324
HDL-C (mg/dL): normal range 40~60 mg/dL
Baseline 49.88 ± 2.50 53.80 ± 3.06 57.86 ± 2.95 50.11 ± 2.52
Follow-up 46.38 ± 2.49 * 50.95 ± 2.74 56.24 ± 2.23 45.56 ± 2.25 *
CFB −3.5 ± 1.63 −2.85 ± 2.07 −1.62 ± 1.66 −4.39 ± 1.61
p-Value 0.299 0.088 0.704
LDL-C (mg/dL): normal range 0~130 mg/dL
Baseline 131.69 ± 8.52 134.50 ± 8.47 123.38 ± 6.40 125.68 ± 7.12
Follow-up 130.25 ± 8.01 125.65 ± 6.42 128.38 ± 8.73 124.11 ± 6.50
CFB −1.44 ± 3.77 −8.85 ± 7.87 5.00 ± 5.02 −0.39 ± 5.78
p-Value 0.427 0.563 0.877
Phospholipid (mmol/L): normal range 150~250 mg/dL
Baseline 225.31 ± 8.88 242.40 ± 7.67 237.90 ± 6.50 229.74 ± 7.13
Follow-up 229.38 ± 8.56 241.85 ± 6.53 246.81 ± 6.78 226.17 ± 7.56
CFB 4.06 ± 5.87 −0.55 ± 6.92 8.9 ± 5.05 −2.11 ± 7.32
p-Value 0.812 0.333 0.560
p-Value: ANCOVA model with independent variable as baseline and treatment; * p < 0.05 derived from paired
t-tests performed for values obtained before and after the trial; CFB: change from baseline; TG: triglyceride; HDL-C:
high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol.
3.6. Safety Assessment and Indirect Markers of Hepatic and Renal Function Test
Hepatic and renal function markers in plasma were analyzed for safety assessment. When all
participants were analyzed (n = 100), there were no significant changes in the safety-related markers of
liver or renal function among the four groups. Table 8 shows the changes in the indirect markers of
liver and renal function due to PGE supplementation. PGE1142 supplementation was observed to
lower the glutamic-pyruvic transaminase (GPT) (ANCOVA, p < 0.006) levels more than the placebo.
The changes were within the normal range and were considered to have no clinical implications.
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Table 8. Effect of PGE supplementation for 12 weeks on plasma albumin, total bilirubin, alanine
aminotransferase (ALP), glutamic oxalacetic transaminase (GOT), glutamic pyruvate transaminase (GPT),
blood urea nitrogen (BUN), and creatinine levels in subjects with overweight or obesity (n = 100).
Placebo
(M: 15, F: 10)
PGE571
(M: 10, F: 16)
PGE1142
(M: 10, F: 15)
PGE2855
(M: 8, F: 16)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
ALB (g/dL): normal range 3.5~5.2 g/dL
Baseline 4.45 ± 0.04 4.37 ± 0.06 4.37 ± 0.05 4.39 ± 0.04
Follow-up 4.51 ± 0.05 ** 4.38 ± 0.05 4.46 ± 0.04 *** 4.42 ± 0.04
CFB 0.06 ± 0.03 0.02 ± 0.04 0.08 ± 0.02 0.03 ± 0.03
p-Value 0.080 0.991 0.205
Total bilirubin (mg/dL): normal range <1.3 mg/dL
Baseline 0.82 ± 0.05 0.73 ± 0.06 0.74 ± 0.06 0.78 ± 0.07
Follow-up 0.84 ± 0.04 0.73 ± 0.06 0.67 ± 0.04 0.76 ± 0.07
CFB 0.01 ± 0.03 0 ± 0.06 −0.07 ± 0.04 −0.02 ± 0.05
p-Value 0.438 0.052 0.411
ALP (U/L): normal range 40~160 U/L
Baseline 56.8 ± 3.20 56 ± 2.23 55.84 ± 2.74 61.08 ± 2.91
Follow-up 57.84 ± 2.99 55.04 ± 2.12 56.08 ± 2.94 59.5 ± 2.99
CFB 1.00 ± 1.37 −0.96 ± 1.80 0.23 ± 1.76 −1.52 ± 2.87
p-Value 0.412 0.696 0.608
GOT (AST) (U/L): normal range <40 U/L
Baseline 32.88 ± 5.10 29.15 ± 3.46 26.68 ± 1.79 26.00 ± 1.87
Follow-up 30.24 ± 4.49 26.92 ± 2.88 23.16 ± 1.13 * 26.75 ± 2.40
CFB −2.54 ± 3.35 −2.23 ± 4.30 −3.38 ± 1.44 0.72 ± 1.78
p-Value 0.668 0.258 0.959
GPT (ALT) (U/L): normal range <40 U/L
Baseline 31.44 ± 8.21 26.54 ± 3.94 27.08 ± 3.38 24.21 ± 3.06
Follow-up 36.08 ± 9.47 26.46 ± 4.47 21.68 ± 2.25 * 23.17 ± 3.65
CFB 4.46 ± 2.07 −0.08 ± 2.80 −5.19 ± 2.08 −1 ± 2.84
p-Value 0.188 0.006 0.121
BUN (mg/dL): normal range 8~22 mg/dL
Baseline 13.12 ± 0.58 13.31 ± 0.66 12.96 ± 0.49 15.04 ± 0.82
Follow-up 14.24 ± 0.79 12.85 ± 0.66 13.64 ± 0.55 14.08 ± 0.83
CFB 1.08 ± 0.55 −0.46 ± 0.61 0.65 ± 0.50 −0.92 ± 0.78
p-Value 0.070 0.550 0.118
Creatinine (mg/dL): normal range 0.5~1.30 mg/dL
Baseline 0.74 ± 0.03 0.70 ± 0.04 0.70 ± 0.03 0.68 ± 0.03
Follow-up 0.79 ± 0.03 *** 0.74 ± 0.04 *** 0.77 ± 0.04 *** 0.71 ± 0.03
CFB 0.05 ± 0.01 0.04 ± 0.01 0.06 ± 0.02 0.04 ± 0.02
p-Value 0.540 0.630 0.365
p-Value: ANCOVA model with independent variable as baseline and treatment; * p < 0.05, ** p < 0.01, *** p < 0.001
derived from paired t-tests performed for values obtained before and after the trial; ALB: albumin, ALP: alanine
aminotransferase, GOT: glutamic oxalacetic transaminase, GPT: glutamic pyruvate transaminase, BUN: blood urea
nitrogen, CFB: changes from baseline.
4. Discussion
Many studies have reported on the health benefits of the extracts and saponin fractions of
P. grandiflorus, such as anti-obesity and anti-lipid metabolism, but most of them have demonstrated
efficacy in animal models. Our preliminary study also confirmed the weight loss and body fat loss
efficacy of PGE in animal models of obesity. Indeed, PG extract increased thermogenic gene expression
(such as SIRT1, PPARα, UCP1, PGC1α), thereby inducing the browning of white adipose tissue,
resulting in an anti-obesity effect. Thus, this study was conducted to verify the effect of PGE in humans.
Through the questionnaire, we found that there was a significant difference in the level of alcohol
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drinking and physical activity among the participants. Accordingly, the following statistics were used
in this study: an analysis, excluding dropouts, but including the participants with very low physical
activity and frequent drinking activities (more than two bottles per week).
This study was a small-scale experiment to set the effective dose of PGE in humans by confirming
the anti-obesity effect. We conducted bioelectrical impedance analysis (BIA), which is generally highly
correlated with body weight and body fat mass, although we did not measure body fat mass by DEXA.
In particular, we screened participants who frequently consumed alcohol and had a very low
physical activity, two factors closely associated with obesity, to confirm the anti-obesity effect of PGE.
Energy and carbohydrates were significantly higher in the PGE1142 and PGE2855 supplement groups
compared with the placebo. Body composition changes induced by PGE revealed that supplementation
of PGE571 and PGE2855 significantly reduced body fat mass and BFP, but also led to an increase
in muscle mass in the PGE571 group. In our previous study [14], we found increased muscle mass
associated with increased energy expenditure following supplementation of PGE in animal models of
obesity. Similarly, in this study, PGE supplementation significantly increased the muscle mass of the
participants. Therefore, this increase is considered to be an important candidate in obesity treatment or
prevention. We performed abdominal CT, as well as BIA, to confirm the effect of PGE on body fat loss.
Consistent with the BIA results, PGE2855 supplementation significantly lowered the subcutaneous fat
and abdominal fat area of L4 when compared with the placebo, suggesting the association of BFP and
fat mass reduction by PGE2855 supplementation. Although there was no change in the abdominal
fat area in the PGE571 group, this may have been due to the relatively high baseline abdominal fat
area, as the PGE571 group showed a high level of leptin in the blood, which is proportional to the
amount of fat [16]. PGE571 not only significantly decreased body fat and BFP, but also significantly
increased muscle mass when BIA was performed, regardless of the statistical method. This was similar
to our previous studies that showed increased muscle mass by PGE, which is closely associated with
increased energy expenditure [17]. When all participants were analyzed in terms of lipids metabolism
and markers of hepatic and renal function test, there were no significant changes among the four
groups in terms of cholesterol, triglyceride, HDL-C, LDL-C, phospholipid, and markers of liver and
renal function. The changes were within the normal range and were considered to have no clinical
implications for the safety assessment. In this context, it is considered that the increase of muscle
mass can act as an important marker in obesity (or sarcopenic obesity) research. In this study, DEXA,
which is highly correlated with BIA [18] and provides more accurate levels of body fat mass, was not
measured. Therefore, it is presumed that DEXA measurement may be able to confirm the change of
abdominal fat area due to PGE571 supplementation in future studies.
The limitations of this trial should be emphasized. Given that the participants of this study were
restricted to volunteers, it was difficult to represent the general population with this small sample size.
As the study was conducted on overweight or moderately obese adults who had BMI measurements
ranging between 23 and 30, part of the results that we obtained via clinical trial were difficult to identify
and generate statistically meaningful data. Hence, to have more statistical meaningful data, it would be
prudent to conduct the trial in obese adults. This study was a clinical trial to determine whether PGE
could improve obesity and estimate the appropriate daily dose of PGE for overweight or obese adult
humans. In addition, we used CT scans to improve the accuracy of the body composition measurements,
but this technique only measured the abdominal fat area. Therefore, a further experiment is underway
to confirm the body fat reduction function of PGE571 using DEXA.
5. Conclusions
In conclusion, despite some limitations, we demonstrated that PGE is able to reduce body fat mass
and body fat percentage, which is an anti-obesity marker, in overweight or obese adult humans. PGE
supplementation significantly increased the muscle mass when compared with the placebo, indicating
an excellent anti-obesity effect.
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Abstract: For centuries, frankincense extracts have been commonly used in traditional medicine,
and more recently, in complementary medicine. Therefore, frankincense constituents such as boswellic
and lupeolic acids are of considerable therapeutic interest. Sixteen frankincense nutraceuticals
were characterized by high-performance liquid chromatography with tandem mass spectrometry
(HPLC-MS/MS), revealing major differences in boswellic and lupeolic acid compositions and total
contents, which varied from 0.4% to 35.7%. Frankincense nutraceuticals significantly inhibited the
release of proinflammatory cytokines, such as TNF-α, IL-6, and IL-8, by LPS-stimulated peripheral
blood mononuclear cells (PBMC) and whole blood. Moreover, boswellic and lupeolic acid contents
correlated with TNF-α, IL-1β, IL-6, IL-8, and IL-10 inhibition. The nutraceuticals also exhibited toxicity
against the human triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-453, and CAL-51
in vitro. Nutraceuticals with total contents of boswellic and lupeolic acids >30% were the most active
ones against MDA-MB-231 with a half maximal inhibitory concentration (IC50)≤ 7.0 μg/mL. Moreover,
a frankincense nutraceutical inhibited tumor growth and induced apoptosis in vivo in breast cancer
xenografts grown on the chick chorioallantoic membrane (CAM). Among eight different boswellic
and lupeolic acids tested, β-ABA exhibited the highest cytotoxicity against MDA-MB-231 with an
IC50 = 5.9 μM, inhibited growth of cancer xenografts in vivo, and released proinflammatory cytokines.
Its content in nutraceuticals correlated strongly with TNF-α, IL-6, and IL-8 release inhibition.
Keywords: frankincense; Boswellia; boswellic acid; lupeolic acid; AKBA; cytokine; breast cancer;
pentacyclic triterpenic acid; triterpenoid; chorioallantoic membrane assay
1. Introduction
Frankincense is an oleogum resin from trees of the genus Boswellia Roxb. ex Colebr., which belong
to the Burseraceae family. Herbal preparations from frankincense have been used for centuries in
traditional Ayurvedic, African, Arab, and Chinese medicine for the treatment of skin ailments, infectious
diseases, and other conditions, which today could be assigned to various chronic inflammatory diseases
and cancer [1,2]. Likewise, modern medicine has rediscovered frankincense and its pain-relieving,
sedative, anti-inflammatory, antimicrobial effects, and even potential anticancer properties [3–5].
Boswellia trees grow mainly in dry areas in India, the Arabian Peninsula, and the Horn of Africa and
often have a shrubby appearance with an average high of 2–6 m [6,7], whereby, the main representative
Nutrients 2019, 11, 2341; doi:10.3390/nu11102341 www.mdpi.com/journal/nutrients123
Nutrients 2019, 11, 2341
species are Boswellia sacra (Oman and Yemen), Boswellia carterii (Somalia), and Boswellia serrata (India).
However, there are about 25 Boswellia species reported, but it is still not clear whether this number
contains some double-counted species [8]. Frankincense, the oleogum resin of Boswellia trees, which
contains potential biologically-active compounds, emerges from cuts in trunks and branches as a
sticky-milky liquid, which dries quickly in the air, yielding an oleogum resin containing 15–20%
boswellic acids and lupeolic acids [9] (Figure 1). These pentacyclic triterpenic acids are believed to be
effective in the prevention and treatment of chronic inflammatory diseases and cancer [3,5]. Previous
studies have demonstrated that boswellic acids inhibit essential pathways of inflammatory responses
by interaction with IκB kinases and therefore inhibition of proinflammatory gene expression or by
inhibition of 5-lipoxygenase and leukotrienes biosynthesis [10,11]. Moreover, also recent clinical pilot
studies claimed therapeutic efficacy of extracts containing boswellic acids in the treatment of chronic
inflammatory diseases like asthma, rheumatoid arthritis, Crohn’s disease, osteoarthritis, collagenous
colitis, or colitis ulcerosa [12,13]. Furthermore, Boswellia serrata extracts as well as boswellic and lupeolic
acids induce apoptosis in various cancer cell lines, such as leukemia, brain, and prostate [5,14–17].
There have also been reports indicating the efficacy of boswellic acids against breast cancer [18,19].
 
Figure 1. Production of frankincense nutraceuticals. Boswellia tree grown in Somalia (a), harvesting
of the frankincense oleogum resin by bark incisions (b), commercial frankincense nutraceuticals (c).
Pictures with permission from Georg Huber [20].
With 24.2%, breast cancer is the most common cancer of all female cancer cases, causing 15.0% of
all female cancer deaths in 2018 [21]. Particularly, triple-negative breast cancer (TNBC) is an aggressive,
highly metastatic breast cancer subtype affecting mainly younger women. TNBC is characterized by
the lack of expression of hormone receptors (estrogen and progesterone) and the human epidermal
growth factor receptor 2 (HER2), which countervails targeted therapy [22]. First, in 2011, Suhail et al.
described the induction of apoptosis in human breast cancer cells in vitro by essential oil derived
from Boswellia sacra [19]. In a later study, we demonstrated that mainly the acidic components of
frankincense, i.e., boswellic and lupeolic acids, exhibit cytotoxic efficacy against the TNBC cell line
MDA-MB-231 [18].
The global market size of dietary supplements and nutraceuticals was estimated to be worth USD
115 billion in 2018 with an expected compound annual growth rate (CAGR) of 7.8% till 2025 [23]. This
demonstrates the strong aptness of the general public to use natural products to maintain good health
and to prevent or treat diseases. However, due to insufficient regulation regarding quality and lack
of standardization of dietary supplements and nutraceuticals, several questionable or even harmful
products are on the market [24].
The aim of this study is to compare frankincense nutraceuticals (FNs) regarding their chemical
composition, their efficacies in inhibiting production of inflammatory cytokines, and their cytotoxic
efficacy against metastatic TNBC cells.
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2. Materials and Methods
2.1. Materials
All solvents and chemicals were of analytical reagent grade. Dimethyl sulfoxide (DMSO) for sample
preparation was purchased from Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA). The solvents
used for HPLC-MS/MS analysis were methanol, acetic acid (both HiPerSolv Chromanorm, VWR
chemicals, Fontenay-sous-Bois, France) and ultrapure water (reverse-osmosis type water (pureAqua,
Schnaitsee, Germany) coupled to a Milli-Q station (Millipore, Eschborn, Germany). The reference
substances, acetyl-α-boswellic acid (α-ABA), acetyl-β-boswellic acid (β-ABA), α-boswellic acid (α-BA),
β-boswellic acid (β-BA), acetyl-11-keto-β-boswellic acid (AKBA), and 11-keto-β-boswellic acid (KBA)
were purchased from Extrasynthese (Genay Cedex, France). Acetyl-lupeolic acid (ALA) and lupeolic
acid (LA) were isolated and characterized as previously published [9,25]. Samples of frankincense
nutraceuticals (FNs) were purchased from the respective distributors (see Table A1). Stock solutions of
FNs and pure boswellic (BAs) and lupeolic acids (LAs) were prepared in DMSO and further diluted in
RPMI 1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). In all experiments, the final
DMSO concentration did not exceed 0.5%.
2.2. Quantification of Boswellic and Lupeolic Acids by HPLC-MS/MS Analysis
The method development, chromatographic separation, mass spectrometry detection, and method
validation for quantification of boswellic and lupeolic acids by HPLC-MS/MS have been previously
published by us [18]. The quantification by HPLC-MS/MS analysis was performed on an Agilent
1260 Infinity system (Agilent, Santa Clara, CA, USA) coupled with an AB API 2000 triple quadrupole
mass spectrometer (Applied Biosystems, Foster City, CA, USA). For chromatographic separation,
an analytical reversed-phase HPLC column (Dr. Maisch ReproSil-Pur Basic-C18 HD, 3 μm, 125 × 3
mm; Dr. Maisch GmbH, Ammerbruch, Germany) with a precolumn (Dr. Maisch ReproSil Universal
RP, 5 μm, 10 × 4 mm) were used. For sample preparation, contents were removed from the capsules,
weighted, and dissolved in DMSO (β = 1 mg/mL, w/v), whereas pills were beforehand grounded.
Samples were filtered through a 0.45 μm regenerated cellulose filter before injection. For quantification,
three different capsules or pills were analyzed per product, each in duplicates.
2.3. Analysis of Cytokine Release
Whole human blood was collected from the antecubital vein of healthy male donors and incubated
with FNs in concentrations of 30 μg/mL for 20 min followed by a stimulation with LPS (10 ng/mL) for
18 h. Plasma was separated by centrifugation and analyzed for IL-10 and TNF-α using ELISA Duo-Set
Human from R&D Systems (Minneapolis, MN, USA). Peripheral blood mononuclear cells (PBMC) were
isolated from whole venous blood from healthy male donors via density gradient centrifugation using
Biocoll (Biochrom GmbH, Berlin, Germany). The collection and analysis of whole blood and peripheral
blood mononuclear cells used in this study were approved by the Institutional Ethics Committee
(# 177/18). The participating volunteers provided written informed consent to participate in this study.
Cells were seeded into a 96-well plate (4 × 105 cells in 200 μL RPMI 1640 supplemented with 1% FCS
and 100 U/mL penicillin, 100 μg/mL streptomycin (all from Gibco)). Cells were treated with FNs in
concentrations of 10 μg/mL and pure BAs or LAs in final concentrations of 3 μg/mL for 20 min followed
by a stimulation with LPS (10 ng/mL) and an 18 h incubation at 37 ◦C and in a 5% CO2 atmosphere.
After incubation, cells were centrifuged and supernatants were analyzed. The amounts of IL-12p70,
TNF-α, IL-10, IL-6, IL-1β, and IL-8 were quantified by flow cytometry using Cytometric Bead Array
(CBA) from Becton Dickinson (Franklin Lakes, NJ, USA) according to manufacturer’s instructions.
2.4. Analysis of Antiproliferative and Cytotoxic Effects In Vitro
To verify that the concentrations of the FNs and pure BAs and LAs used, are not cytotoxic
to PBMC but cytotoxic to cancer cells, analysis of lactate dehydrogenase (LDH) release (Roche,
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Basel, Switzerland), XTT assay of cell viability and proliferation (Roche), and analysis of cell
membrane integrity by propidium iodide staining [26] were carried out. Triple-negative human
breast cancer cells MDA-MB-231 (ATCC, Rockville, MD, USA), CAL-51 and MDA-MB-453 (both from
DSMZ, Braunschweig, Germany), and PBMC were analyzed. MDA-MB-231 cells were cultured in
Dulbecco’s Modified Eagle Medium (4.5 g/L glucose, GlutaMax; Life Technologies, Carlsbad, CA,
USA) supplemented with 10% FCS, 0.1 mM MEM non-essential amino acids, 100 U/mL penicillin,
and 100 mg/mL streptomycin. CAL-51 cells were cultured in Dulbecco’s Modified Eagle Medium
(4.5 g/L glucose; Life Technologies) supplemented with 10% FCS, 100 U/mL penicillin, and 100 mg/mL
streptomycin. The MDA-MB-453 cells were cultured in Leibovitz’s L-15 medium (Life Technologies)
containing 10% FCS, 100 U/mL penicillin, and 100 mg/mL streptomycin and kept at atmospheric
CO2. When cancer cells reached 80% confluence, they were subcultured according to the supplier’s
recommendations. MDA-MB-231 and CAL-51 cells were treated 24 h after seeding. MDA-MB-453 cells
were allowed to adhere for 72 h, because of slow adhesion. Subsequently, treatment with the respective
compounds for 72 h followed. Different concentrations of the respective samples were applied using a
Tecan D300e Digital Dispenser (Tecan, Männedorf, Switzerland). Absorbance was measured using
an Infinite M1000 PRO Tecan plate reader. For analysis of viability, the blank values containing the
respective compounds in the according concentration were subtracted and the percentage of viable cell
was calculated by normalization to the vehicle control.
2.5. Human Tumor Xenografts on the Chick Chorioallantoic Membrane
TNBC xenografts were established by seeding 0.7 × 106 MDA-MB-231 cells in medium/matrigel
(1:1) onto the chick chorioallantoic membrane (CAM) of fertilized chick eggs 7 days after fertilization.
For the next 3 consecutive days, cells were treated topically with 20 μL of the respective FN or pure
compounds dissolved in 0.9% NaCl (vehicle control: 0.5% DMSO). FN16 was used in concentrations of
5 and 10 μg/mL; AKBA and β-ABA were used in concentrations of 5 μg/mL (10 μM); and doxorubicin
was used in a concentration of 1 μM. On day 4 after treatment initiation, tumors were collected, imaged,
fixed, and embedded in paraffin for analysis by immunohistochemistry. Tumor volume (mm3) was
calculated with the formula length (mm) ×width2 (mm) × π/6. For immunohistochemical analysis,
5-μm slices of the collected tumors were stained using antibodies against the proliferation marker Ki-67.
For analysis of apoptosis in vivo, DNA strand breaks were visualized by deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) according to the manufacturer’s recommendations (Roche). Images
were recorded with an Axio Lab.A1 microscope (Carl Zeiss, Göttingen, Germany) and a Zeiss 2/3”
CMOS camera using Progres Gryphax software (Carl Zeiss).
2.6. Statistical Analysis
Each experiment was repeated at least three times and the data are expressed as mean ± standard
deviation (SD) or standard error of the mean (SEM) as indicated. Statistical analysis was performed
using Minitab 18 software (Minitab, Munich, Germany) and SigmaPlot 14.0 (Systat Software Inc., San
Jose, CA, USA). All data were tested for normal distribution by the Anderson-Darling test and equality
of variances by Levene’s test. Sample groups were compared by one-way analysis of variance (ANOVA)
and post-hoc by Dunett’s test for parametric data. Non-parametric data were either transformed prior
to analysis by Box-Cox transformation or compared directly by Kruskal-Wallis one-way ANOVA on
ranks and post-hoc by Dunn’s test. Spearman’s rank correlation was used to investigate correlations
of non-parametric data. Cluster analysis was performed with hierarchical agglomerative clustering,
complete-linkage, and Euclidean distances. Principal component analysis (PCA) was derived from a
covariance matrix of the data.
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3. Results
3.1. Compositions of Boswellic and Lupeolic Acids in Frankincense Nutraceuticals
Quantification of eight BAs and LAs including α-boswellic acid (α-BA), acetyl-α-boswellic acid
(α-ABA), β-boswellic acid (β-BA), acetyl-β-boswellic acid (β-ABA), 11-keto-β-boswellic acid (KBA),
acetyl-11-keto-β-boswellic acid (AKBA), lupeolic acid (LA), and acetyl-lupeolic acid (ALA), in 16
frankincense nutraceuticals (FNs) was performed by HPLC-MS/MS. The total contents (w/w) of BAs
and LAs varied from 0.4% to 35.7% (Table 1). Related to the mass of a capsule or a pill, the total BA and
LA contents varied from 3.5 to 157.3 mg/unit (Table S1). Many manufacturers and distributers promote
their products as those with boswellic acids contents over 80%. Interestingly, these concentrations
could not be confirmed. Manufacturers usually determine the boswellic acid content of their products
by non-aqueous titration, for example, using 0.1 N potassium methoxide and 0.3% (w/v) thymol blue
as the indicator [27]. These methods estimate unselectively all acidic compounds, not only boswellic
acids. Here, a highly selective and accurate quantification method for analysis of BAs and LAs by
HPLC-MS/MS was applied (Figure 2a,b). Consequently, the precise contents of the individual BAs and
LAs in nutraceuticals could be determined (Table 1 and Table S1).




Concentrations of Boswellic and Lupeolic acids
Deacetylated Compounds (μg/mg) Acetylated Compounds (μg/mg)
Σ (%)
(w/w)
KBA LA α-BA β-BA AKBA ALA α-ABA β-ABA
FN9 34.1 17.2 46.5 120.7 36.9 13.8 24.4 63.6 35.7
FN16 42.3 16.4 47.7 118.8 36.9 11.9 20.3 55.7 35.0
FN13 43.9 16.5 45.6 117.2 31.8 11.2 19.2 50.7 33.6
FN6 38.1 15.0 38.8 109.0 7.7 5.9 11.8 36.7 26.3
FN14 38.9 14.4 34.9 98.3 4.2 3.5 6.6 20.8 22.1
FN2 36.9 11.3 32.0 85.9 5.6 4.0 7.9 24.0 20.8
FN4 9.7 6.6 19.9 62.9 18.6 7.8 14.7 46.3 18.6
FN1 25.7 6.8 20.5 57.6 3.6 2.4 4.9 14.8 13.6
FN3 21.8 6.3 18.3 53.1 4.3 2.4 4.6 13.9 12.5
FN15 14.2 6.1 15.6 42.4 11.8 4.1 6.7 17.7 11.9
FN11 4.8 2.5 6.8 20.1 30.0 5.7 10.1 16.7 9.7
FN8 1.3 0.5 1.1 3.2 75.5 1.1 1.6 4.6 8.9
FN10 5.9 2.2 5.6 12.7 33.6 5.3 8.2 12.2 8.6
FN12 4.5 2.1 5.3 14.2 31.4 5.4 8.0 13.2 8.4
FN5 3.4 1.3 3.5 9.2 2.9 0.8 1.9 5.7 2.9
FN7 0.3 0.1 0.3 0.5 1.2 0.3 0.6 1.1 0.4
Samples are arranged by descending total contents of BAs and LAs (Σ in percent, w/w). KBA, 11-keto-β-boswellic
acid; LA, lupeolic acid; α-BA, α-boswellic acid; β-BA, β-boswellic acid; AKBA, acetyl-11-keto-β-boswellic acid;
ALA, acetyl-lupeolic acid; α-ABA, acetyl-α-boswellic acid; β-ABA, acetyl-β-boswellic acid.
In a previous study, we showed that oleogum resins of the species B. serrata are characterized by
higher proportions of deacetylated compounds compared to acetylated compounds [18]. This pattern
was also observed in the FN samples analyzed here, which contained mainly extracts from B. serrata.
Unusually, particularly for B. serrata, sample FN8 exhibited an exceptionally high content of AKBA.
Especially, the concurrence of the high content of AKBA and very low contents of the other BAs and
LAs indicated a special enrichment procedure putting FN8 apart from the other samples. Meins et
al. observed the same uncommon ratio between AKBA content and total BAs content in a product
containing the same 5-Loxin® extract [28]. FN5 and FN7 showed the lowest contents of BAs and LAs
of all investigated samples, with total BAs and LAs contents of 2.9% for FN5 and only 0.9% for FN7.
In addition to the exceptionally low BAs and LAs contents, the large difference between the stated
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extract content of 400 mg for FN7 and the determined pill mass of 809.8 ± 5.0 mg points also to an oddly
high amount of additives in FN7 (Table 1 and Table S1). According to the manufacturer, the AKBA
content of FN7 is 52 mg per pill. However, analysis revealed an AKBA content <1 mg per pill. Hence,
it can be assumed that either less Boswellia extract than stated was processed or other Boswellia oleogum
resins containing little or no BAs and LAs were used like, for example, B. frereana [18,29].
Figure 2. Chromatograms of HPLC-DAD-MS/MS analysis of sample FN9 and multivariate statistical
analysis of BAs and LAs contents in different FNs. (a) Total wavelength chromatogram with detection
at 210 nm, 254 nm, and 280 nm. (b) Multiple-reaction monitoring chromatogram and structures of
BAs and LAs present in FNs. (c) The dendrogram shows FNs assigned to three different clusters
according to their BAs and LAs composition: Cluster A >30%, Cluster B with 15–30%, and Cluster
C <15% of total BAs and LAs. (d) Samples within clusters exhibit similarity in their individual BAs
and LAs compositions. Biplot of principal component analysis is shown. Sample FN8 shows the
highest deviation due to its unusually high AKBA content concomitantly with very low levels of all
other BAs and LAs. Numbered scores visualize the individual FN1-16 in the biplot and dashed lines
demonstrating the loadings of the individual BAs and LAs.
Multivariate statistical methods, cluster analysis and principal component analysis (PCA) were
applied to the datasets to visualize the data and discover patterns of the BAs and LAs compositions in
different FNs. Cluster analysis assigned the samples to three different clusters (Figure 2c). Cluster
A contained samples FN9, FN13, and FN16 with the highest total BAs and LAs contents of over
30%. Furthermore, these FNs showed high similarity regarding the composition of the individual
components (Figure 2d). Cluster B (samples FN2, FN4, FN6, and FN14) comprised samples with total
BAs and LAs contents between 15% and 30%, and Cluster C (samples FN1, FN3, FN4, FN5, FN7, FN8,
FN10, FN11, and FN12) contained less than 15% BAs and LAs. FN8 showed the lowest similarity to
Cluster C (<50%) due to its unusual chemical composition with high AKBA concentration. Moreover,
samples FN10, FN11, and FN12, which contained non-extracted oleogum resin, formed an additional
subcluster, due to their similarity. Interestingly, these three samples contained oleogum resins of
different Boswellia species. According to the manufacturers, sample FN10 was made of B. sacra, FN11
of B. serrata, and FN12 of B. carterii. Comparing with the BAs and LAs compositions determined in
our previous studies [9,18], FN11 exhibited indeed general BAs and LAs patterns typical for B. serrata
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resins, with a higher proportion of deacetylated BAs and LAs than acetylated ones. However, FN10
and FN12 showed BAs and LAs patterns untypical for B. sacra or B. carterii resins, but more similar to
B. serrata, too. Because these samples contain no extracts but untreated oleogum resin, these differences
could not be caused by an extraction procedure. Therefore, it cannot be excluded that instead of B.
sacra or B. carterii, possibly B. serrata oleogum resin might have been used for manufacturing of FN10
and FN12.
3.2. Inhibition of Proinflammatory Cytokine Release by Frankincense Nutraceuticals
For comparative investigation of the immunomodulatory activities of the FNs, whole blood of
healthy donors was treated with lipopolysaccharide (LPS) to initiate an acute inflammatory response
and to induce the release of proinflammatory cytokines. Pretreatment with FNs significantly decreased
the expression of the proinflammatory cytokine TNF-α compared to the LPS-treated control group
(Figure 3a). Interestingly, the production of the anti-inflammatory cytokine IL-10 was inhibited by
the FNs, too. IL-10 acts to limit inflammatory responses by damping the uncontrolled production of
proinflammatory cytokines including TNF-α [30]. However, also TNF-α regulates the production of
IL-10. Thereby, the chronological sequence of cytokine expression during inflammation is essential.
While high levels of proinflammatory cytokines IL-1, IL-6, IL-8, and TNF-α are released already 4–8 h
after LPS stimulation, maximal levels of the anti-inflammatory IL-10 are observed only 24–48 h after
stimulation [31]. Moreover, about 50–75% of IL-10 released by LPS-stimulated monocytes can be
inhibited by anti-TNF-α [32], indicating that TNF-α is responsible for the majority of the released IL-10.
Therefore, the decreased production of TNF-α by blood treated with FNs would decrease the later
IL-10 release (Figure 3a).
The strong albumin-binding affinity of BAs complicates an accurate analysis of their
immunomodulatory activity in whole blood [33]. In addition, blood contains varying amounts
of different lipids aiding samples’ solubility. Hence, analysis of variance (ANOVA) exhibited no
significant differences between the samples or sample groups when analyzed in whole blood. As
monocytes are the major producers of TNF-α and IL-10 in blood [34], for further analysis, peripheral
blood mononuclear cells (PMBC) were used and the effects of the FNs on the production of a panel of
cytokines including TNF-α, IL-1β, IL-6, IL-8, IL-10, and IL-12p70, were analyzed. Contents of IL-12p70
were too low for an adequate evaluation and are not presented. FNs were used at a concentration of
10 μg/mL, which did not affect cell viability as analyzed by XTT and lactate dehydrogenase release
(LDH) assays and by propidium iodide staining.
FNs with BAs and LAs contents >30% (Cluster A: FN9, FN13, and FN16) exhibited a significant
inhibition of TNF-α, IL-6, and IL-8 expression compared to the control LPS group (Figure 3b–f and Table
S2). Moreover, FN4 and FN6 from Cluster B showed considerable inhibitory activity towards TNF-α,
IL-6, and IL-8, too. The most potent five nutraceuticals, FN4, FN6, FN9, FN13, and FN16, decreased the
release of proinflammatory cytokines to 20.7% for TNF-α, 9.2% for IL-6, and 16.8% for IL-8 (average
values for all five FNs). Interestingly, these five samples also had the highest concentrations of ALA,
α-ABA, and β-ABA. The proteasome inhibitor MG132 used as a positive control decreased cytokine
release to 15.5% ± 7.2% for TNF-α, 18.5% ± 7.7% for IL-1β, 5.2% ± 3.5% for IL-6, 20.2 ± 7.2% for IL-8,
and 37.5% ± 14.8% for IL-10 compared to the control group. Differently, samples FN5 and FN7, that
were previously shown to contain the lowest BAs and LAs contents, exhibited no inhibitory effects on
cytokine production at all but even enhanced the expression of the proinflammatory cytokines TNF-α,
IL-6, and IL-8 with average values of 142.4% for FN5 and 210.7% for FN7 compared to the control
group. The reason for the increased secretion of cytokines might be contamination of these FNs with
bacterial products.
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Figure 3. FNs inhibit cytokine production by LPS-stimulated blood and PBMC. (a) Inhibition of TNF-α
and IL-10 expression by FNs (each at 30 μg/mL) in LPS-stimulated whole blood. Data are mean± SEM of
16 FNs; each FN was analyzed in five independent experiments/donors, Wilcoxon test. (b–f) Inhibition
of TNF-α, IL-1β, IL-6, IL-8, and IL-10 production by LPS-stimulated PBMC by the respective FN (each
at 10 mg/mL). Samples are arranged according to β-ABA content in a descending order. Clusters are
from cluster analysis of BAs and LAs compositions in Figure 2c,d: Cluster A (light red) >30%, Cluster
B 30–15% (yellow), and Cluster C (green) <15% total contents of BAs and LAs. Box-Cox transformation
followed by one-way ANOVA and post-hoc Dunnett’s test. All data are mean ± SEM. n = 7 donors; *
p < 0.05, ** p < 0.01, *** p < 0.001 compared to LPS-stimulated control groups (Ctrl).
Investigation of the correlation between the chemical composition and cytokine expression
revealed that the total amount of BAs and LAs correlate positively with the inhibition of TNF-α, IL-6,
IL-8, and IL-10 (Table 2 and Figure S1). Especially, the acetylated compounds ALA, α-ABA, and β-ABA
exhibit the highest correlation coefficients, while the acetylated compound with keto group AKBA
shows the lowest correlation. However, when FN8 with the extraordinarily high AKBA content was
removed as an outlier (Grubbs test), AKBA contents in FNs exhibited significant correlation with
all cytokines with p = 0.007 for TNF-α, p < 0.001 for IL-1β, p = 0.011 for IL-6, p = 0.006 for IL-8,
and p = 0.001 for IL-10. Inhibition of IL-1β correlated only with AKBA, ALA, and α-ABA contents in
FNs. Moreover, the inhibition of all five investigated cytokines correlated with each other. Whereby,
IL-1β, the only cytokine in the panel activated by the NLRP3 inflammasome [35], showed the lowest
correlation (Table 2 and Figure S1).
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Table 2. Correlation between BAs and LAs contents and inhibition of cytokine production by
LPS-stimulated PBMC.
Compound
TNF-α IL-1β IL-6 IL-8 IL-10
R p R p R p R p R p
KBA −0.621 * −0.241 > 0.05 −0.744 *** −0.665 ** −0.656 **
LA −0.721 ** −0.341 > 0.05 −0.832 *** −0.791 *** −0.765 ***
α-BA −0.709 ** −0.356 > 0.05 −0.815 *** −0.774 *** −0.774 ***
β-BA −0.735 *** −0.359 > 0.05 −0.850 *** −0.815 *** −0.794 ***
AKBA −0.537 * −0.714 ** −0.430 > 0.05 −0.530 * −0.511 *
ALA −0.867 *** −0.784 *** −0.884 *** −0.890 *** −0.918 ***
α-ABA −0.879 *** −0.797 *** −0.891 *** −0.897 *** −0.932 ***
β-ABA −0.847 *** −0.447 > 0.05 −0.932 *** −0.903 *** −0.900 ***
Σ BAs and LAs −0.753 *** −0.318 > 0.05 −0.835 *** −0.818 *** −0.785 ***
TNF-α 0.612 * 0.959 *** 0.968 *** 0.944 ***
IL-1β 0.535 * 0.600 * 0.624 **
IL-6 0.976 *** 0.947 ***
IL-8 0.947 ***
Spearman’s rank correlation; R, correlation coefficient, * p < 0.05, ** p < 0.01, and *** p < 0.001, n = 16. PBMC,
peripheral blood mononuclear cells.
3.3. Cytotoxic Efficacy of Frankincense Nutraceuticals Against Triple-Negative Breast Cancer Cells In Vitro
FN16, one of the most potent nutraceuticals with respect to cytokine release,
concentration-dependently inhibited the viability of the highly metastatic, treatment-resistant breast
cancer cell line MDA-MB-231 in vitro. Interestingly, cancer cells were more sensitive to FN16 compared
to normal human PBMC, providing evidence for selectivity against cancer cells (Figure 4a). Also, FN1
with low contents of BAs and LAs, exhibited higher toxicity against MDA-MB-231 cells compared to
PBMCs (Figure S2a), though the difference was not as strong as for FN16. Therefore, all FNs were
investigated for their toxicity against MDA-MB-231 breast cancer cells and the half maximal inhibitory
concentrations (IC50) were determined (Table 3 and Figure 4b). The FNs exhibited cytotoxicity against
MDA-MB-231 cells with an average IC50 of 15.9 μg/mL. The samples FN9, FN13, and FN16 (Cluster A)
with the highest BAs and LAs contents exhibited also significantly higher cytotoxicity with IC50 values
for FN9, FN13, and FN16 of 7.0 μg/mL, 6.6 μg/mL, and 6.0 μg/mL, respectively, compared to the average
IC50 value of 15.9 μg/mL (Figure 4b). Samples FN5 and FN7 (Cluster C) demonstrated the lowest
cytotoxicity against MDA-MB-231 with an IC50 = 44.3 μg/mL for FN5 and an IC50 = 30.7 μg/mL for FN7.
Thus, FN5 and FN7 not only exhibited the lowest contents of BAs and LAs and the poorest cytokine
modulatory properties, but also the cytotoxic efficacies against MDA-MB-231 were significantly below
average. Hence, this points to a correlation between BAs and LAs compositions and cytotoxicity
against breast cancer cells. A combination of principal component analysis (PCA) of the BAs and LAs
concentrations with a contour plot that visualizes the IC50 values revealed correlation between the BAs
and LAs contents and cytotoxic efficacy (Figure 4c). Interestingly, in addition to similar total BAs and
LAs contents and similar effects on cytokine release, the compositions of the individual BAs and LAs
in the most potent nutraceuticals FN9, FN13, and FN16 were highly alike. Spearman’s rank correlation
analysis revealed that contents of BAs and LAs without a keto group exhibit the highest correlation to
FN cytotoxic efficacy (Figure S1). In this regard, the content of the boswellic acid β-ABA shows the
highest correlation to cytotoxicity against MDA-MB-231.
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Figure 4. FNs are toxic to a TNBC cell line. (a) MDA-MB-231 cancer cells and peripheral blood
mononuclear cells (PBMC) were treated for 72 h with FN16, and cell viability was analyzed by XTT
assay (n = 3). (b) Half maximal inhibitory concentrations (IC50) of FNs against MDA-MB-231 cell line.
Comparison of IC50 values of individual FNs with the average IC50 value for all FNs (15.9 μg/mL) by
Box-Cox transformation, one-way ANOVA, and post-hoc Dunnett’s test. All data are mean ± SEM,
n = 3 for the respective FN, n = 16 for the average value, * p < 0.05, ** p < 0.01, and *** p < 0.001.
(c) Principal component analysis (PCA) and contour plot visualizing the correlation between toxicity of
different FNs and their BAs and LAs contents.
Furthermore, a principal component regression analysis (PCR) based on known BAs and LAs
contents in FNs was used, to avoid biases caused by multicollinearity. Sample FN5 was identified
as an outlier by the Grubbs test and excluded from the regression analysis. The resulting regression
model exhibited a R2 of 96.5% and a significance of correlation of p < 0.001. The regression analysis
yielded the following equations:
IC50(μg/mL) = 31.6− 0.223 PC1− 0.668 PC2 + 0.000586 PC12 + 0.00737 PC22 + 0.00166 PC1× PC2 (1)
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with
PC1 = 0.289 [KBA] + 0.115 [LA] + 0.316 [α-BA] + 0.830 [β-BA] − 0.026 [AKBA] + 0.056 [ALA]
+0.103 [α-ABA] + 0.316 [β-ABA]
(2)
and
PC2 = −0.115 [KBA] − 0.002 [LA] + 0.008 [α-BA] − 0.064 [β-BA] + 0.936 [AKBA] + 0.088 [ALA]
+0.136 [α-ABA] + 0.285 [β-ABA]
(3)
with concentrations of corresponding BA or LA in μg/mg FN given in square brackets.
The IC50 values calculated by the regression model exhibited an average absolute residue of
only ± 1.0 μg/mL compared to the experimentally-derived values (Table 3). Hence, the regression
equation could be used as a tool to predict cytotoxic efficacy of FNs and other frankincense herbal
preparations with known BAs and LAs content. By expanding the data set, one could achieve an even
more accurate prediction.
Table 3. Cytotoxic efficacy of FNs against MDA-MB-231 cell line.
FN Sample
XTT: IC50 (μg/mL) Regression: IC50 (μg/mL) ]vspace3ptAbsolute
Residue (μg/mL)
Mean SEM Value SE
FN16 6.0 0.9 6.7 0.9 0.7
FN13 6.6 0.6 5.7 0.8 1.0
FN9 7.0 0.4 7.5 1.0 0.5
FN4 9.5 0.9 8.4 0.9 1.1
FN6 11.0 1.8 9.2 1.1 1.8
FN14 11.6 0.7 13.7 0.9 2.0
FN2 12.2 1.6 13.1 0.7 0.9
FN15 13.2 1.1 15.4 0.7 2.2
FN12 13.2 0.6 14.5 0.8 1.3
FN11 13.9 0.5 13.6 0.8 0.3
FN10 15.0 0.9 14.4 0.9 0.6
FN1 19.4 2.7 18.1 0.8 1.3
FN3 19.5 1.0 18.4 0.8 1.1
FN8 21.5 3.6 21.4 1.5 0.2
FN7 30.7 6.7 30.4 1.4 0.3
FN5 44.3 8.5 / / /
XTT, IC50 values were determined experimentally by XTT assay (72 h, n = 3). Regression, IC50 values were
determined by principal component regression (PCR). Data are mean± standard error of the mean (SEM) or standard
error of the regression model (SE). Sample FN5 as an outlier (Grubbs test) was excluded from the regression analysis.
Absolute residue is the difference between experimentally determined values and those determined by regression
analysis. Samples are arranged by cytotoxicity (XTT) in a descending order.
Further, the three FNs, FN9, FN13, and FN16, showing the highest cytotoxicity against
MDA-MB-231 cells, were investigated for their cytotoxic efficacy against two additional TNBC
cell lines, MDA-MB-453 and Cal-51. Likewise, the investigated samples exhibited considerable
cytotoxicity against MDA-MB-453 with IC50 values between 12.9 μg/mL and 17.3 μg/mL, and against
Cal-51 with even lower IC50 values between 3.8 μg/mL and 4.0 μg/mL (Table 4). This indicates that
FNs exhibit cytotoxic efficacy against different triple-negative treatment-resistant breast cancer cells.
The non-halogenated anthracycline doxorubicin, a chemotherapeutic agent used to treat patients
with breast cancer, was analyzed as a positive control for FNs. Doxorubicin exhibited an IC50 = 0.41
± 0.03 μg/mL for MDA-MB-231, an IC50 = 0.26 ± 0.02 μg/mL for MDA-MB-453, and an IC50 = 0.033
± 0.004 μg/mL for Cal-51. However, for doxorubicin, severe adverse effects including cardio- and
nephrotoxicity have been reported [36,37]. Differently, for frankincense extracts, only mild adverse
effects, like heartburn or nausea, have been described [38].
133
Nutrients 2019, 11, 2341




Mean SEM Mean SEM
FN9 14.5 0.9 3.8 0.5
FN13 12.9 0.6 3.9 0.6
FN16 17.3 0.5 4.0 0.3
XTT assay, 72 h, n = 3.
3.4. Boswellic and Lupeolic Acids Inhibit Cytokine Release and Are Cytotoxic for TNBC Cells
Cytotoxicity of FNs against MDA-MB-231 cells correlated significantly to the total contents of BAs
and LAs as well as to individual BAs and LAs contents, except for AKBA, in FNs (Spearman’s rank
correlation, p < 0.001) (Figure S1). The highest correlation coefficient exhibited β-ABA, whereas no
significant correlation was detected for AKBA. The poor correlation of AKBA was caused mainly by the
unusual chemical composition of the sample FN8 with unexpectedly high AKBA content concomitantly
with very low contents of other BAs and LAs. After rejecting sample FN8 from the statistical analysis,
the AKBA contents of the remaining samples correlated significantly with the cytotoxicity against
MD-MB-231 cells (p = 0.004). Hence, we further investigated the cytotoxic efficacies of the pure
individual BAs and LAs against MDA-MB-231 (Table 5). The acetylated forms of boswellic acids
were more effective against MDA-MB-231 cells than their deacetylated forms; and the most cytotoxic
compounds were AKBA with IC50 = 6.6 μM, α-ABA with IC50 = 7.2 μM, and β-ABA with IC50 = 5.9 μM.
Differently, for lupeolic acids, LA was more cytotoxic compared to ALA. We have previously shown
that acetylated BAs, similar to anticancer drugs such as camptothecins and podophyllotoxins, inhibit
activities of human topoisomerases [39]. Acetylated BAs also inhibit the activation of transcriptional
factor NF-κB which regulates the synthesis of antiapoptotic proteins [11,17], whereas ALA is an
inhibitor of the AKT kinase [16]. These molecular targets might explain the high cytotoxicity of BAs
and LAs against proliferating cancer cells.




Mean SEM Mean SEM
KBA 12.0 0.4 25.4 0.9
LA 5.6 0.1 12.3 0.2
α-BA 5.0 0.4 10.8 0.9
β-BA 4.2 0.1 9.3 0.2
AKBA 3.4 0.1 6.6 0.2
ALA 13.4 0.5 26.9 1.0
α-ABA 3.6 0.5 7.2 1.0
β-ABA 2.9 0.4 5.9 0.8
XTT assay, 72 h, n = 3. Acetylated boswellic acids (AKBA, α-ABA, and β-ABA) are more potent compared to their
deacetylated forms (KBA, α-BA, and β-BA). Differently, LA is more potent than ALA.
Interestingly, similar to FN1 and FN16, AKBA, and in particular, β-ABA, showed higher toxicity
against cancer cells compared to PBMC (Figure S2b,c), suggesting selectivity against cancer cells.
Moreover, toxicity against breast cancer cells strongly correlated with cytokine inhibition with
p= 0.023 for IL-1β and p< 0.001 for TNF-α, IL-6, IL-8, and IL-10 (Figure S1). Cluster analysis of variables
confirmed the correlation between toxicity against breast cancer cells and cytokine inhibition (Figure 5).
In addition to the activation of genes coding for antiapoptotic proteins and for those necessary for
continuous cell proliferation, NF-κB activation is central to the activation of cytokine and chemokine
gene expression [40]. In previous studies, we have shown that acetylated boswellic acids AKBA and
β-ABA specifically inhibited the activities of human IκB kinases (IKK) and the subsequent release of
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proinflammatory cytokines by human monocytes [11]. Moreover, intercepting the IKK activity by
AKBA and β-ABA inhibited proliferation and promoted apoptosis in androgen-independent PC-3
prostate cancer cells in vitro and in vivo [17]. Hence, inhibition of NF-κB by boswellic acids might
represent a clue as to why these compounds inhibit both inflammatory processes and cancer growth.
 
Figure 5. Heatmap visualizing correlations between BAs and LAs compositions in FNs and FN efficacies
with respect to inhibition of cytokine release and cancer cell toxicity. Cluster analysis of variables (BAs, LAs,
cytokines, IC50) was performed with distances of correlation coefficients and complete linkage. Cluster
analysis of objects (FN1-16) was performed with standardized variables, Euclidean distances, and complete
linkage. All data were standardized and efficacy values were additionally inverted. +1 indicates high
contents of BAs and LAs in FNs or high efficacies of FNs, −1 indicates low contents or efficacies. BAs
and LAs contents were analyzed by HPLC-MS/MS; IC50 toxicity against MDA-MB-231 breast cancer cells
was determined by XTT (72 h); and inhibition of cytokine release by PBMC was analyzed after 18 h by
flow cytometry.
Interestingly, chronic inflammation is known to increase cancer risk. Particularly, activation of
NF-κB and production of inflammatory cytokines by tumor-associated immune cells are important
components aiding tumor initiation, growth, malignant transformation, invasion, and metastasis [41].
Hence, inhibition of inflammatory mediators prevents the development of experimental cancers,
and treatment with anti-inflammatory drugs reduces cancer risks and progression [42]. Hence,
inhibition of inflammation by frankincense constituents could benefit anticancer therapy.
Similar to FNs, pure BAs and LAs, in concentrations which do not affect PBMC viability, inhibited
cytokine production by LPS-activated PBMC, but not as efficiently as FNs (Table S3). Although BAs
and LAs are identified here as the active principle of FNs, frankincense extracts also contain a rather
complex lipidome including a large number of different fatty acids [43]. The lipids are extracted from
frankincense during extract preparation and are persistent components of FNs. Such lipids can act as a
natural emulsifier for nonpolar compounds like BAs and LAs and increase their bioavailability [44].
Accordingly, the intake of a FN in combination with a high-fat meal improved the bioavailability of
BAs in humans [45]. Hence, the intake of pure BAs and LAs in the absence of solubility enhancers
might decrease their bioavailability and worsen the therapeutic response. This should be considered in
the development of drugs based on BAs and LAs. Formulations with lecithin for oral administration
and complexation with cyclodextrins or liposomes for injections can be beneficial [46,47].
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3.5. Inhibition of Proliferation and Induction of Apoptosis in Breast Cancer Xenografts
The antitumor activity of FNs and BAs was further verified in vivo, in MDA-MB-231 breast
cancer xenografts grown on the chorioallantoic membrane (CAM) of fertilized chick eggs. Xenografts
were treated with FN16, because it contains high amounts of BAs and LAs and exhibited the highest
cytotoxicity against MDA-MB-231 cells in vitro. Also, two acetylated BAs, AKBA and β-ABA, which
exhibited the highest cytotoxic efficacy in vitro, were tested in an in vivo model.
Treatment of cancer xenografts with FN16 reduced dose-dependently and significantly the tumor
volume compared to the control group (Figure 6a,b). Also, treatment with β-ABA significantly
reduced the tumor volume. AKBA-treated xenografts were only non-significantly smaller than control.
Immunohistochemical analysis of the tumors revealed that FN16 had a dose-dependent inhibitory
effect on cancer cell proliferation (Figure 6c). Also, AKBA and β-ABA significantly inhibited cancer
cell proliferation. FN16, AKBA, and β-ABA all induced apoptosis in TNBC xenografts as shown by
analysis of apoptosis by using the TUNEL technique (Figure 6d). Whilst the chemotherapeutic drug
doxorubicin exhibited eminent cytotoxicity against MDA-MB-231 cells in vitro, in vivo its efficacy
was not sufficient to induce a significant reduction of tumor size or to induce apoptosis during the
treatment period. Notably, no systemic toxicity of the FN16 or BAs on the chick embryos was observed.
Figure 6. FNs and BAs inhibit growth and induce apoptosis in TNBC breast cancer xenografts in vivo.
MDA-MB-231 cells were grafted on the chorioallantoic membrane (CAM) of fertilized chick eggs and treated
for 3 consecutive days with either FN16 (5 mg/mL and 10 mg/mL), the boswellic acids AKBA orβ-ABA (each
10 μM), doxorubicin (1 μM), or DMSO (0.5%) as control. (a) First row: tumor photographs immediately after
extraction (original magnification 50×). Second row: hematoxylin and eosin staining. Third row: staining for
proliferation marker Ki-67 (red-brown nuclear stain, original magnification 200×). Fourth row: staining for
the apoptosis marker TUNEL (brown, original magnification 200×). (b) FN16 and β-ABA inhibit the tumor
growth. (c) FN16, AKBA, and β-ABA inhibit cancer cell proliferation. (d) FN16, AKBA, and β-ABA induce
apoptosis in cancer xenografts. All data are mean ± SEM, n = 4. Comparison with control by Kruskal-Wallis
one-way ANOVA on ranks and post-hoc by Dunn’s test with * p < 0.05, ** p < 0.01, and *** p < 0.001.
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4. Conclusions
A comparative analysis of 16 frankincense nutraceuticals (FNs) revealed major differences in
chemical compositions, cytokine modulatory properties, and cytotoxicities against triple-negative
breast cancer cells. FNs with total boswellic and lupeolic acids (BAs and LAs) contents over 30%
and/or β-ABA contents over 36 μg/mg significantly inhibited the expression of the proinflammatory
cytokines TNF-α, IL-6, and IL-8. Moreover, FNs exhibited cytotoxic efficacy against triple-negative
breast cancer cell lines MDA-MB-231, MDA-MB-453, and CAL-51 in vitro. In this regard, FNs with
BAs and LAs contents over 30% and β-ABA contents over 50 μg/mg proved to be the most potent
ones. A FN from this group and pure β-ABA inhibited growth and induced apoptosis in breast cancer
xenografts in vivo. Moreover, a remarkable correlation between BAs and LAs contents, cytokine
inhibition, and cytotoxicity against breast cancer cells could be observed. The contents of β-ABA
exhibited the highest average correlation to inhibition of TNF-α, IL-6, and IL-8 cytokine release as well
as cytotoxicity against breast cancer cells. Furthermore, pure β-ABA showed high cytotoxic efficacy
against breast cancer cells in vitro and in vivo. Therefore, β-ABA should be considered as a compound
for standardization of frankincense nutraceuticals and herbal preparations and it deserves further
studies aiming at the development of new anticancer drugs.
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Appendix A
Table A1. Frankincense nutraceuticals (FNs) analyzed in the study.
FN Sample Manufacturer/Distributor
Manufacturer’s Specifications
Product Batch Stated Content RDA 1
FN1 Gall Pharma (Judenburg,Austria)
Boswellia serrata
200 mg GPH Kapseln 5260.53
200 mg B. serrata
extract 2




2260.52 350 mg B. serrataextract 1 × 1
FN3 Hecht Pharma(Bremervörde, Germany)
H15® Weihrauch
Kapseln 200 mg
5260.53 200 mg B. serrataextract 1 × 2
FN4 Heidelberg Pharmacy(Bisingen, Germany)
Weihrauch-Extrakt-
Kapseln HBMI07
300 mg B. serrata
extract 3 × 1–2
FN5 The Nutri Store (Mauren,Liechtenstein)
Boswellia carterii
Extrakt Kapseln #7779529-1612
400 mg B. carterii
extract 1 × 1
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Product Batch Stated Content RDA 1
FN6 Wellnest Nutrazeutika (EastGrinstead, England)
Boswellia
Weihrauchextrakt NB/BOS-1215189







400 mg B. serrata
extract 2




#703657 150 mg B. serrataextract 2
FN9 Schloss Pharmacy (Koblenz,Germany)
Indische
Weihrauchkapseln 611142B
400 mg B. serrata
extract
FN10 Heilsteine Methusalem(Neu-Ulm, Germany)
Sacra Weihrauch
Gold WS/102017/NT
430 mg B. sacra
gum resin 2 × 2
FN11 Heilsteine Methusalem(Neu-Ulm, Germany)
Weihrauch
Boswellia serrata WBS/2425/12AS
500 mg B. serrata
gum resin 2 × 1








400 mg B. serrata
extract 1
FN14 Gall Pharma (Judenburg,Austria)
Boswellia serrata
Tabletten 400 mg 261.29
400 mg B. serrata
extract 3 × 1
FN15 Gufic Biosciences Ltd.(Mumbai, India)
Sallaki® Tablets
400 mg
AB17019 400 mg B. serrataextract
FN16 Delphin Pharmacy(Langenau, Germany) Weihrauch-Kapseln
BBD 2
05.04.2018
400 mg B. serrata
extract
1 Recommended daily allowance; 2 Best-before date.
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Abstract: Previous literature has shown that complementary and alternative medicine (CAM) is
steadily increasing in autism spectrum disorder (ASD). However, little data is currently available
regarding its use, safety, and efficacy in children with ASD. Thus, the purpose of this study is to describe
the use of supplement-based CAM therapies in children between the ages of 4 to 17 years with ASD.
This population-based, cross-sectional study evaluated children with ASD regarding supplement
use. A total of 210 participants were recruited from a variety of sources including educational
and physical activity programs, and social media to complete a questionnaire. Primary caregivers
provided information on current supplement based CAM use. Data evaluated the proportion of
children that used supplement therapies, the types of supplements used, reasons for use, perceived
safety, and demographic factors associated with use (e.g., income, parental education, severity of
disorder). Seventy-five percent of children with ASD consumed supplements with multivitamins
(77.8%), vitamin D (44.9%), omega 3 (42.5%), probiotics (36.5%), and magnesium (28.1%) as the most
prevalent. Several supplements, such as adrenal cortex extract, where product safety has not yet
been demonstrated, were also reported. A gluten free diet was the most common specialty diet
followed amongst those with restrictions (14.8%). Health care professionals were the most frequent
information source regarding supplements; however, 33% of parents reported not disclosing all their
child’s supplements to their physician. In conclusion, the use of supplement therapies in children
with ASD is endemic and highlights the need for further research concerning public health education
surrounding safety and efficacy.
Keywords: Autism spectrum disorder; dietary supplements; pediatric; physician communication
1. Introduction
Autism spectrum disorder (ASD) is a group of heterogeneous chronic neurodevelopmental
disorders characterized by qualitative impairments in social interaction, communication, and repetitive
stereotyped patterns of behavior [1]. The etiology of these conditions is thought to be multifactorial,
involving genetic, prenatal, and postnatal factors [2]. The Centre for Disease Control (CDC) reports
that 1 in 59 children are diagnosed with ASD, with boys 4 times more likely to be diagnosed than girls.
As such, ASD is the fastest growing developmental disorder in the United States [3].
Treatment for ASD focuses on educational and behavioral interventions such as applied behavioral
analysis [4]. Psychotropic drugs are commonly prescribed to treat core behavioral symptoms, decrease
maladaptive behavior, and support learning and development [5]. In addition to conventional treatment
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options, some parents of children with ASD seek out complementary and alternative medicine (CAM)
to treat symptoms. The National Centre for Complementary and Integrative Health defines CAM as
“a diverse group of medical and health care systems, practices, and products that are not generally
considered part of conventional Western medicine” [6]. Complementary approaches fall broadly into 3
categories: Natural products such as dietary supplements and special diets, mind and body practices,
and other complementary health approaches [7].
Evidence regarding the use of CAM in the general pediatric population is limited. Studies in the
United States have shown that the prevalence of pediatric CAM use in populations with illness or
disease can range up to 76% [8]. However, these studies are limited in several ways. First, while many
employ sound methodologies, they often provide differing definitions of what constitutes a CAM
therapy. For example, in their review of 136 studies on alternative medicines, Surette et al. [9] found 39
studies that included vitamins, 13 studies that excluded vitamins, and 41 studies that made no mention
of their inclusion or exclusion criteria. Further, many of the pediatric CAM studies are characterized by
wide variation in study populations and size, prevalence measurements, and research methodologies,
all of which hinder the formulation of evidence-based recommendations.
Though limited in number, some studies have examined CAM effects in ASD. Levy et al. [10]
found that greater than 9% of children with ASD used potentially harmful CAM, such as chelation,
antibiotics, or excessive amounts of vitamins. These findings are consistent with anecdotal evidence of
dangerous products used to “cure” ASD. For example, in 2014, the supplementation market saw an
explosion of Miracle Mineral Solution, a solution of sodium chlorite and hydrochloric acid (i.e., bleach)
as a treatment option for ASD. The US Food and Drug Administration has issued several warnings
about the product and the treatment has been linked to 1 death and several serious injuries; however,
Miracle Mineral Solution is still widely available, with 1000 + followers on social media promoting its
use [11].
From a public health perspective, supplement-based therapies and specialty diets, a subcategory
of CAM, requires further evaluation. While many supplements such as melatonin, vitamins,
gluten-casein-free diet, and omega 3 fatty acids may have few adverse effects, their safety and
effectiveness in reducing ASD symptomology have not been reliably established [2,12,13]. Research
estimates that up to 74% of children with ASD have been provided with CAM and that supplement-based
therapies make up approximately 50% of CAM therapies used by this population [14].
Despite its popularity, disclosure of CAM use to physicians is often poor, with rates as low as
23% [15]. Concurrent use of CAM and prescription medications is widespread and poses a possible
risk to patients who may be unaware of the potential for interactions [16]. Further, research has
documented that knowledge of CAM use is important for health care professionals, as it provides
insight into patient values and health beliefs. Importantly, considering patient values may assist in
providing optimum care, especially in the context of supplements that pose a safety risk to patients [15].
Given the rates of concurrent use, in conjunction with lack of disclosure, there is a pressing need to
assess pediatric CAM use and parental perceptions of these therapies.
As the prevalence of supplements and specialty diets are high and many are unsupported by
research, a better understanding of the use of supplementation in pediatric ASD could help provide
better integrative care by (1) informing the public and health care professionals about the prevalence
and types of supplement therapies and specialty diets used in children with ASD; (2) assessing
patient-physician communication and interactions surrounding supplement and specialty diet use;
and (3) highlighting priorities for evidence-based clinical trials for supplements in ASD. Therefore, this
study seeks to describe the use of supplement-based CAM therapies in children with ASD.
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2. Materials and Methods
2.1. Participants
This study was approved by the Conjoint Health Research Ethics Board at the University of
Calgary (REB17-0970). Inclusion criteria for this population-based cross sectional study included (1)
a physician-confirmed diagnosis of autism spectrum disorder (including previous diagnostic labels
of Asperger’s syndrome, pervasive developmental disorder—not otherwise specified, childhood
disintegrative disorder, or Rett syndrome) and (2) between the ages of 4 and 17.99 years inclusive. A
sample size calculation (margin of error 8% and 95% confidence interval) revealed 150 participants
were required [17]. Many of the children were cognitively and/or developmentally delayed; therefore,
the parents/legal guardians served as a proxy for describing their child’s use of supplements, in order to
maintain consistency between responses. The parents/legal guardians of children with ASD provided
written informed consent and completed the questionnaire on their behalf.
2.2. Dietary Supplement Questionnaire
Data about supplement use with regards to ASD was collected via self-report online and paper
form questionnaires. A validity and reliability tested supplement use questionnaire [18,19] was
modified for children with ASD. Supplements were defined as a product that contains a vitamin,
mineral, herb or botanical, amino acid, concentrate, metabolite, or other dietary ingredients intended
to add further nutritional value to the diet. Supplements may be found in many forms such as tablets,
capsules, soft gels, liquids, or powders. Examples include multivitamins, supplementary minerals,
protein powders, energy drinks, meal replacements, etc. This definition was based on the definition
provided by the National Centre for Complementary and Integrative Health [6]. Specialty diets such
as the ketogenic diet, low-carb diet, and gluten free diet were also evaluated. The response format for
the survey contained several closed-ended questions, short answer, and 5 item Likert scale questions.
Several questions provided participants with answers to select from as well as short answer boxes
to provide their answers. A pilot-test was conducted on a small sample of parents (n = 34) to ensure
clarity of content. A sample of the questionnaire can be found in Supplementary Data File S1, Table S1.
2.3. Measures
The key outcomes were the demographic variables of the child (i.e., age, sex, ethnicity, medical
characteristics) and parent (i.e., income, education level), and the types of therapies (i.e., gluten free
diet, omega 3 fatty acids, probiotics) used. Secondary outcomes included reasons why parents have or
have not used supplement therapies for their children, the information sources consulted by parents
regarding therapies, and the proportion of parents who perceive the therapies used as being safe. In
addition, parent perceived satisfaction with their child’s family physician or pediatrician, comfort
level in discussing nutrition and supplements, number of supplements/dietary patterns disclosed to
the physician (if applicable), and reasons why they might have chosen not to disclose supplements
were quantified.
2.4. Procedures
Children were recruited from clinics at the Alberta Children’s Hospital, Autism Calgary, and
physical literacy programs around the city. Researchers also utilized schools that focus on inclusive and
accessibility programs to recruit eligible participants. Recruitment posters were displayed throughout
the facilities to describe the study, explain eligibility criteria, and provide contact information should
parents of children with ASD want to participate. Researchers also contacted program organizers and
asked permission to approach parents directly during recreation and instructional sessions and enroll
them in the study. Many of these organizations promoted the study on their social media platforms,
which provided an online consent form and a link to complete the survey.
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2.5. Statistical Analysis
Data from the question ‘has your child previously taken or currently taking any dietary
supplements’ was categorized as yes or no. Dietary supplement use data were categorized into
groups based on sex, age (4 to 8 years, 9 to 13 years, and 14 to 17 years), and abilities. The age groups
were based on dietary reference intake (DRI) values [20]. Ability groups were based on 4 ability
categories (verbal, intellectual, social, and physical) in which parents ranked their child as “very
weak/weak,” “neutral,” or “strong/very strong. Differences between sex, age, and ability groups were
determined by a Fisher’s exact test. All analyses were performed using SPSS statistics version 25 (IBM
Corporation, Armonk, NW, USA).
3. Results
3.1. Participant Characteristics
A total of 210 parents agreed to participate in the study on behalf of their child(ren) and completed
the questionnaire. Descriptive characteristics and demographic characteristics of the participants are
outlined in Tables 1 and 2, respectively.
Table 1. Descriptive characteristics.
Descriptive Characteristics All Males Females
Participants 210 157 (74.8%) 53 (25.2%)
Age, years 9.2 (3.6) 9.0 (3.6) 9.5 (3.7)
Year of Diagnosis
2003–2007 16 (7.8%) 14 (6.8%) 2 (1.0%)
2008–2012 42 (20.5%) 28 (13.7%) 14 (6.8%)
2013–2018 147 (71.7%) 113 (55.1%) 34 (16.6%)
Participants and year of diagnosis are listed as a count (percentage of total); age is listed as a mean (standard deviation).
Table 2. Demographic characteristics.
Characteristic All n (%) Males n (%) Females n (%)
Ethnicity
Caucasian 170 (81.3) 124 (59.3) 46 (22.0)
Asian/Pacific Islander 13 (6.2) 11 (5.3) 2 (1.0)
Hispanic or Latino 2 (1.0) 2 (1.0) 0 (0.0)
Black or African American 5 (2.4) 2 (1.0) 3 (1.4)
First Nations or Metis or Inuit 6 (2.9) 5 (2.4) 1 (0.5)
Multiracial 13 (6.2) 12 (5.7) 1 (0.5)
Household Income
>$20,000 10 (4.8) 7 (3.3) 3 (1.4)
$20,000–40,000 23 (11.0) 18 (8.6) 5 (2.4)
$40,000–60,000 23 (11.0) 17 (8.1) 6 (2.9)
$60,000–80,000 33 (15.7) 25 (11.9) 8 (3.8)
$80,000–$100,000 35 (16.7) 23 (11.0) 12 (5.7)
$100,000+ 75 (35.7) 60 (28.6) 15 (7.1)
Not Applicable 11 (5.2) 7 (3.3) 4 (1.9)
Parent Level of Education
High School Diploma 17 (8.2) 13 (6.3) 4 (1.9)
Trade School Diploma 4 (1.9) 3 (1.4) 1 (0.5)
Some College 17 (8.2) 13 (6.3) 4 (1.9)
College Diploma 51 (24.5) 41 (19.7) 10 (4.8)
Some University 19 (9.1) 17 (8.2) 2 (1.0)
University Degree 52 (25.0) 40 (19.2) 12 (5.8)
Master’s Degree 30 (14.4) 21 (10.1) 9 (4.3)
Professional Degree 11 (5.3) 5 (2.4) 6 (2.9)
Ph.D. 7 (3.4) 3 (1.4) 4 (1.9)
The category “Multiracial” was created as a result of multiple parents indicating this option in the “other” category
to reflect the demographic of our sample. Data is presented as a count (percentage of total).
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3.2. Dietary Supplement Use
A total of 167 parents (79.5%) indicated that their child had previously taken or was currently
taking at least 1 supplement (males 77.1%; females 86.8%, p = 0.168). Eighty-three percent (83%) of
parents reported thinking supplements were safe, 3.8% reported that they did not consider them
safe, and 13.3% were undecided or perceived supplements as safe under certain conditions (i.e.,
evidence-based, supervised by a health care professional, etc.). There were no statistical differences
between sexes in perceived safety of dietary supplement use (p = 234).
The top 10 previous and current pediatric supplement use is summarized in Figure 1. A more
extensive list of the supplements listed by the questionnaire can be found in Supplementary Data,
Table S2. The 5 most common supplements were multivitamins (77.8%), vitamin D (44.9%), omega
3 (42.5%), probiotics (36.5%), and magnesium (28.1%). Other supplements such as alpha lipoic acid,
sodium butyrate, N-Acetyl Cysteine, 5HTP, fluoride, methylfolate, adrenal cortex extract, selenium,
milk thistle, liposomal curcumin, cannabidiol, and melatonin were also mentioned. Differences
between sexes were found in calcium (male = 9.1%, female = 21.7%, p = 0.037) and vitamin K (male =
1.7%, female = 10.9%, p = 0.018). When analyzed by age group, significant differences were found in
calcium (p = 0.049), vitamin B (p = 0.010), and energy drinks (p = 0.027). The percentage of children who
have/are taking more than 1 supplement was 88.6%. In addition, a Pearson’s correlation determined
that there was no relationship between number of supplements used and years since diagnosis (p =
240). The average number of supplements per child was 4.49 and the mean year of diagnosis was 2013.













Figure 1. Dietary supplements commonly used in pediatric autism spectrum disorder (ASD). Male and
female is percent within sex.
Of the 167 parents who indicated their child has or is currently taking supplements, 126 rated the
perceived degree of change on their child’s overall well-being between neutral and positive (69.1 ±
15.9) on a scale of 1 (negative impact) to 100 (positive impact). The most common supplements cited
to have the largest impact on the child’s health were melatonin, multivitamins, omega fatty acids,
and magnesium.
3.3. Dietary Supplement Reasons for Use
Parental reasons for providing their children with supplements are outlined in Table 3. The top 3
reasons for consuming supplements were to enhance the child’s diet, promote immune system function,
and increase quality/duration of sleep. Improvement in gut health was listed 7 times under the
“other” section. Parents also indicated several reasons for omitting supplements including: Inadequate
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knowledge/information (n = 14), too expensive (n = 8), and may be considered harmful (n = 5). Six
parents indicated that supplements were not necessary, as their child eats a balanced diet.
Table 3. Reasons for and against dietary supplement use.
All n (%) Males n (%) Females n (%) p
Reasons for Use
Enhance diet 127 (76.0) 94 (56.3) 33 (19.8) 0.424
Promote immune system function 88 (52.7) 66 (39.5) 22 (13.2) 0.490
Increase quality/duration of sleep 76 (45.5) 53 (31.7) 23 (13.8) 0.602
Improve cognitive ability 54 (32.3) 34 (20.4) 20 (12.0) 0.066
Decrease repetitive or restrictive behavior 21 (12.6) 16 (9.6) 5 (3.0) 0.798
Promote sociability 18 (10.8) 12 (7.2) 6 (3.6) 0.581
Increase interactions with others 13 (7.8) 8 (4.8) 5 (3.0) 0.349
Enhance motor skills 12 (7.2) 9 (5.4) 3 (1.8) 1.000
Reasons Against Use
Inadequate knowledge/information 14 (32.6) 12 (27.9) 2 (4.7) 1.000
Too expensive 8 (18.6) 7 (16.3) 1 (2.3) 1.000
May be considered harmful 5 (11.6) 5 (11.6) 0 (0.0) 0.574
Based on suggestion from close
family/friends 4 (9.3) 4 (9.3) 0 (0.0) 1.000
Read in scholarly article 4 (9.3) 4 (9.3) 0 (0.0) 1.000
Reasons for use are listed for the parents who indicated that their child had taken supplements (n = 167). Reasons
against use are listed for the parents who indicated that their child had not taken supplements (n = 43). Data is
presented as a count (percentage of total).
3.4. Special Diets and Information Sources
Current diet information is summarized in Table 4. The top 4 diets followed in our sample
included no restrictions, gluten free, high carbohydrate, and lactose free, with a significant difference
between sex in diets with no restrictions (male = 72.0%, female = 54.7%, p = 0.027), gluten free (male
= 5.1%, female = 24.5%, p < 0.001), and lactose free (male = 4.5%, female = 17.0%, p = 0.006). Other
diets such as the paleo diet, nut-free, dye-free, and low sugar diets were also mentioned. In addition, 6
parents also stated that their children were picky eaters and had “very limited diets.”
Table 4. Special diet use in pediatric autism.
All n (%) Males n (%) Females n (%) p
No restrictions 142 (67.6) 113 (72.0) 29 (54.7) 0.027
Gluten free 21 (10.0) 8 (5.1) 13 (24.5) <0.001
High carb 17 (8.1) 14 (8.9) 3 (5.7) 0.570
Lactose free 16 (7.6) 7 (4.5) 9 (17.0) 0.006
Casein free 12 (5.7) 8 (5.1) 4 (7.5) 0.734
High protein 8 (3.8) 4 (2.5) 4 (7.5) 0.206
Ketogenic diet (i.e., high fat, low card) 7 (3.3) 6 (3.8) 1 (1.9) 0.682
Vegetarian 4 (1.9) 2 (1.3) 2 (3.8) 0.574
Vegan 0 (0.0) 0 (0.0) 0 (0.0) n/a
Diet data is presented as a count (percentage within sex) who follow each diet. Differences between sex were
determined using a Fisher’s exact test. p < 0.05 was considered significant. Significant differences are bolded. n/a,
not applicable.
The primary information sources regarding dietary supplements used by parents are shown in
Figure 2. Sixty-five percent (65%) of parents indicated that health care professionals (e.g., physician,
nurse, nutritionist) were their primary source of information regarding dietary supplements. Published
literature and media (e.g., news, magazines, journals) were listed as the second and third most popular
sources of information. Social media was the least utilized source, with only 5.8% of parents indicating
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use. Two participants did not indicate a primary information source and two other participants
indicated “knowledge over the years,” and “myself (pharmacist)” in the “other” section.
Figure 2. Primary information sources about dietary supplements. Data is presented as % of respondents.
Participants could only choose one source or answer in the “other” section. One participant indicated
in the “other” section that they use a combination of social media and health care professionals, so a
“yes” was put into each category.
3.5. Physician Communication
Nearly all families (98.1%) indicated that they have a family doctor and/or a pediatrician. Eleven
percent (11%) of families (n = 21) rated their overall level of satisfaction with the primary care physician
as not satisfied or partially unsatisfied on a scale of 1 (not satisfied) to 5 (very satisfied), whereas 87% of
parents (n = 169) rated their level of comfort in discussing supplements with physicians as comfortable
or very comfortable. A large majority (72.4%; n = 152) had never met with a dietician. The frequency
of disclosure of supplement use to a physician is summarized in Table 5. Results revealed that 33.5% of
parents did not disclose all supplements to their physician. Several reasons were reported for omitting
disclosure of supplementation use to primary care physicians including perceived “physician lack of
knowledge”, “no benefit”, “too time consuming”, and “scared of judgment”.
Table 5. Disclosure of supplement use to physician.
Disclosure of Number of Supplements (%) Frequency n (%)
None (0) 11 (6.6)
Some (1–49) 14 (8.4)
Half (50) 8 (4.8)
Most (51–99) 23 (13.8)
All (100) 111 (66.5)
Frequency data is presented as a count (percentage of total).
4. Discussion
The use of complementary and alternative medicine (CAM) is increasing among children and is
common in those with chronic illness or disorders, such as ASD [13]. Critically, however, a complete
profile of dietary supplement use in children with ASD is lacking; making it difficult to develop
educational strategies. The present study is impactful, as it provides a fully powered assessment of
supplement-based CAM therapies in children with ASD.
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4.1. Dietary Supplement Patterns and Special Diet Use
In this study, 75.9% of the children sampled have consumed dietary supplements, supporting the
upper end of the prevalence range of supplement use in pediatric ASD cited in previous literature [14].
As the most recent studies evaluating supplement use in children with ASD were conducted several
years ago, it is possible that the high prevalence reported here reflects a continued increase in
supplement use. Additionally, this study utilized a broad definition of supplements when compared
to other studies, therefore, it is likely we captured a wider variety of supplements used by children
with autism. Nevertheless, the reported high rates of dietary and supplement use in this study would
indicate these products continue to be of interest as a complementary approach to standard treatment
of care.
Multivitamins, vitamin D, omega 3 fatty acids, probiotics, and magnesium were the most common
supplement therapies used. Research regarding the efficacy of these supplements in ASD populations
requires further evaluation [21]. Multivitamins, for example, are considered a popular CAM therapy
in ASD [22]. The rationale for this treatment is based on the frequently observed dietary deficiency of
vitamins and micronutrients in children with ASD. Children with ASD are often deficient in calcium,
vitamin D, vitamin K, vitamin A, vitamin E, zinc, vitamin B6, and tetrahydrobiopterin [21]. These
deficiencies could be the result of food selectivity or altered gastrointestinal absorption. Adams
et al. [23] conducted a double-blind randomized control trial to examine the effect of a common
commercial vitamin supplement on observed improvements in parent-rated pre and post autism
symptomatology. They found significant improvements in hyperactivity, tantrumming, overall, and
receptive language, suggesting it as a reasonable adjunct therapy for children with ASD. However, no
other study has evaluated or been able to replicate the effectiveness or safety of this biological therapy.
Similarly, preliminary studies on probiotics have shown improvement in core symptomatology in
ASD [21], but they have been minimally replicated and several other studies have denounced their
effects. It is also possible that there are responders and non-responders to individual treatments,
further complicating interpretation.
Recently, vitamin D has been proposed as a potential treatment for ASD [24]. In 2015, an open
trial demonstrated significant improvements in autism rating scales following 3 month vitamin D3
supplementation [25]. However, this small sample study has been the only experimental study to
demonstrate the potential efficacy of vitamin D in children with ASD, highlighting the need for more
wide-scale studies to critically validate the efficacy of vitamin D before drawing any definite conclusions.
Collectively, these supplements require more systematic and rigorous research. As a result, there
is little evidence to support the use of any nutritional supplement or dietary therapy for children with
ASD [26]. Furthermore, some of the other supplements reported in this study confirm anecdotal reports
regarding the consumption of dangerous biological therapies. The Food and Drug Administration
has issued several health warnings about adrenal cortex extract, for example, and has deemed it
“unsafe and ineffective for labeled indications for human use” [27–29]. Evidently, there are gaps in
the transmission of scholarly literature to quality educational materials for families, as many children
continue to consume dietary supplements that are unsupported by research. In addition, several
parents indicated that they were undecided about the safety of supplements and listed inadequate
knowledge about supplements as the number one factor barring use.
Research evaluating specialty diets (e.g., gluten free casein free, lactose free, etc.) shows similar
ambiguity. More specifically, there are few studies that demonstrate conclusive results in the gluten
free and casein (or lactose) free diets reported in this study [30]. Many are small in size and lack strict
dietary controls, both common problems in conducting dietary research in children, which limits the
ability of researchers to drawn firm conclusions. Consequently, many studies regarding specialty diets
point to the need for further research and illustrate how clinicians often find themselves unable to offer
the most up-to-date and scientifically credible information to their patients. Of note, the ketogenic diet
has emerged as a leader in specialty diets for ASD in the past several years and has offered promising,
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though preliminary, results in both animal and human studies [31–33]. Seven participants reported
utilizing this diet.
4.2. Physician-Patient Communication
Sixty-five percent (65%) of parents disclosed that their primary source of information regarding
supplements were health care providers. In addition, 72% of families indicated that they had never
met a dietician, signifying that many are relying on their physician for quality information regarding
supplements and special diets. However, 33% admitted to not disclosing all supplements to their
physician due to perceived physician lack of knowledge, no apparent benefit, the time commitment,
and fear of judgment. Alarmingly, as 36.7% reported taking prescribed medication, a lack of disclosure
may pose a risk to patients who may be unaware of the potential for interactions with concurrent
CAM use. An open, patient-centered, non-judgmental approach is recommended for physicians
when discussing supplement therapies [34]. This study highlights that patients would like to receive
information about CAM from their conventional health care team, underscoring the importance of
clinician knowledge about CAM and emerging research findings.
4.3. Limitations
There are a couple areas to consider when examining the limitations of this study. While the study
provides novel information about the use of supplement therapies and special diet use in children
with ASD, the study is limited as the majority of its participants are from Canada, therefore, may
not be generalizable to other geographic regions. Further, as this is a descriptive study, it does not
provide causal information regarding the effect of individual supplement therapies (e.g., omega 3 fatty
acids causing relief of gastroenteritis symptoms). Finally, social desirability, a common bias where
respondents answer in a way viewed favorably by others, may have influenced the data.
5. Conclusions
Supplement use continues to be a prevalent form of CAM used in ASD. While a variety of
supplements and dietary interventions are utilized, the scientific consensus remains that there is
currently little evidence to support the use of any nutritional supplement or dietary therapy for
children with ASD. Future investigation into the effects of individual supplements on physiological
and psychological functioning to determine optimal supplementation strategies in ASD is required.
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Abstract: Probiotics intervention has been proposed as a feasible preventative approach against
adverse health-related complications in infants. Nevertheless, the umbrella concept of probiotics
has led to a massive application of probiotics in a range of products for promoting infant health,
for which the strain-specificity, safety and efficacy findings associated with a specific probiotics
strain are not clearly defined. Bifidobacterium breve M-16V is a commonly used probiotic strain in
infants. M-16V has been demonstrated to offer potential in protecting infants from developing the
devastating necrotising enterocolitis (NEC) and allergic diseases. This review comprehends the
potential beneficial effects of M-16V on infant health particularly in the prevention and treatment
of premature birth complications and immune-mediated disorders in infants. Mechanistic studies
supporting the use of M-16V implicated that M-16V is capable of promoting early gut microbial
colonisation and may be involved in the regulation of immune balance and inflammatory response to
protect high-risk infants from NEC and allergies. Summarised information on M-16V has provided
conceptual proof of the use of M-16V as a potential probiotics candidate aimed at promoting infant
health, particularly in the vulnerable preterm population.
Keywords: Bifidobacterium breve M-16V; infant health; clinical efficacy; probiotics; gut microbiota
1. Introduction
Gut microbiota has become an important aspect of human health. Gut microbes regulate host
intestinal, immunological and metabolic activities through their wide array of modulatory capabilities
and enzymatic armoury [1]. Recent advances in microbial research have revealed the importance
of early gut microbiome for neonatal health development and disease pathologies [2]. Aberrations
of infant gut microbiota—a state of altered microbial composition and functionality—are associated
with adverse health-related consequences including asthma [3], necrotising enterocolitis (NEC) [4],
eczema [5] and inflammatory bowel disease [6] in neonatal stage or later in life.
Microbial ecosystem is established during the first three years of life for which a host–microbe
symbiotic interaction that mutually benefits both is initiated [7]. It has been implicated that a number
of extrinsic factors, such as gestational age, delivery mode and feeding types, are affecting the process
of microbial colonisation in newborns [7,8]. Initial neonatal gut microbial colonisation represents a
crucial window of opportunity for shaping a healthy gastrointestinal tract and immune system [9],
and positive modulation of gut microbiota during this critical period could be an effective preventative
approach against immune-mediated and microbiome-related disease pathologies. Consequently,
probiotics intervention is receiving significant attention as a non-invasive attempt to optimize the
infant microbiota as a means to improve health or prevent disease.
Probiotics are defined as “live microorganisms, which when administered in adequate amounts,
confer a health benefit on the host” [10]. Studies over the last decade have demonstrated that
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probiotics supplementation could promote gut microbial colonisation and prevent or treat diseases
in infants [11,12]. These reports have led to a massive application of probiotics in a range of
products including foods, infant formula, dietary supplements, and pharmaceutical products for
promoting infant health. Nevertheless, many of the marketed probiotic products encompass limited
well-consolidated regulatory oversight and a lack of human substantiation of efficacy [13]. Moreover,
the safety and effects of probiotics in the vulnerable preterm population remain relatively limited and
inconsistent [14,15]. Therefore, a detailed review of the scientific basis of a specific probiotic strain has
emerged as an important aspect for an optimised selection of suitable probiotic candidates for use
in infants.
Bifidobacterium breve M-16V (designated as M-16V) is a commonly used probiotic strain in infants
for modulation of gut microbiota as a means to support healthy growth and promote health. Some
evidence suggests that M-16V can stimulate bifidobacterial colonisation, alleviate allergic disorders
and protect premature infants against NEC. Nevertheless, despite its nutritional and medicinal benefits,
a comprehensive review of its specific clinical effects for infant health is still lacking. In this review, we
discuss the effects of probiotic administration on infant health, with specific attention to the probiotic
strain M-16V. We conducted a systematic survey for publications related to M-16V using the databases
including MEDLINE [16], EMBase [17], medical journal web [18] and JDreamIII [19] from inception to
12 May 2019. Search terms were: M-16V OR M16V and the languages used were English and Japanese.
A total of 60 articles including in vitro, preclinical and clinical studies were extracted (two review and
58 original articles). Among them, 31 were on the single strain of M-16V, five were on the probiotics
mixture with other strains, and 24 were on synbiotics (Supplementary Tables S1 and S2). Herein, we
summarise the significant effects of M-16V on premature birth complications and allergic disorders
from the most relevant in vitro, animal and clinical studies. We believed that improved understanding
of the role of M-16V in governing development of healthy gut microbiota during early life would
inform rational therapeutic application of probiotics aimed at promoting infant health, especially in
the vulnerable preterm population, and ultimately preventing chronic diseases later in life.
2. Probiotics for Infant Health
Probiotics intervention has gained overwhelming popularity over the last two decades as a
potential nutritional supplementation approach to promote and maintain a healthy gut milieu and
protect against dysbiosis in early life [20]. Accumulating evidence suggests that manipulation of
the microbiota with the use of probiotics at an early stage may lead to an appropriate microbial
colonisation and could have long-lasting impacts on child and adult health [21]. Probiotics that have
been commonly given to neonates and infants include species of Bifidobacterium and Lactobacillus.
Among them, Bifidobacterium is thought to be a keystone taxon in infant gut microbiota that plays a
vital role in regulating immunological and physiological functions [22].
Bifidobacterial species have been isolated from the gastrointestinal tract of humans and animals
as well as a few that have been isolated from human vagina, oral cavity, breast milk, sewage and
foods, and could be categorised into two major groups; bifidobacterial species of human origins as
human-residential bifidobacteria (HRB), whereas other species which are the natural inhabitants of
animals or environment as non-HRB [23]. It has been demonstrated that bifidobacterial species of
different residential origins display different levels of adaptability and functionality in the infant
gut [23]. Of note, B. longum subsp. infantis (B. infantis), B. longum subsp. longum (B. longum), B. bifidum,
and B. breve, which are frequently isolated from infant intestines and are referred to as infant-type
HRB [23,24], have a large repertoire of genes for the utilisation of human milk oligosaccharides
(HMOs) [25,26]. Studies have reported that infant-type HRB are capable of utilising HMOs with
different metabolic pathways and degrees of degradation, highly compatible with human breast
milk and tolerant to lysozyme [25,27], demonstrating how well adapted they are to the transmission
routes and growth conditions in the infant gut. In fact, infant-type HRB have been shown to be the
exclusive members of healthy breastfed infants [28,29], while formula-fed infants are also colonised
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with species that are commonly isolated from adult intestines (adult-type HRB) such as B. adolescentis
and B. pseudocatenulatum [30], implying the strains of infant-type HRB could be better probiotic
candidates for infant use.
Several studies have demonstrated the use of infant-type HRB, including the strains of B. breve [31],
B. longum [32], B. infantis [33] and B. bifidum [34], as probiotics for therapeutic purposes in neonates and
infants. Administration of infant-type HRB probiotic strains in the first stage of life may result in the
prevention of NEC and reduction in the risk as well as treatment of infectious and atopic disease [11,12].
Despite the promise, questions and concerns have been raised about the safety and clinical efficacy
of probiotics administration, especially if the product is destined for use in infants. It is increasingly
apparent that not all probiotics are equally safe, and the effects demonstrated with one strain cannot
be extrapolated to another strain, even if they belong to the same species [35]. Of note, among many
infant-type HRB probiotic strains that have been studied, M-16V possesses a proven track record of
safety and a number of beneficial attributes that make it an attractive probiotic candidate for infant use.
The following paragraphs will review the safety and specific health benefits of M-16V in infants within
the field that seek to provide rigorous preclinical characterisation and substantial clinical evidence of
M-16V for successful probiotics selection.
3. Bifidobacterium breve M-16V as Infant Probiotic
3.1. Origin and Characteristics
M-16V was originated from the gut of an infant in 1963 and was first commercially available
in Japan in 1976 with the launch of Vinelac dietary supplement. In 1982, M-16V was added to a
growing-up powdered formula called Yochien-Jidai in Japan and has since been incorporated in several
other products including term and preterm infant formula.
M-16V is a non-motile, non-spore forming, rod-shaped anaerobic Gram-positive bacterium. It
was identified as B. breve based on morphological, physiological and genetic characteristics. M-16V
is highly accessible to human gastrointestinal tract with strong adherence activity [36]. In addition,
lyophilised powder of M-16V manufactured by Morinaga Milk Industry Co., Ltd. possesses excellent
stability during storage and high survivability in finished products such as powdered formula until
consumption [37].
3.2. Safety
M-16V is well-evaluated for safety and has met the safety standards regulated by the Food and
Agriculture Organization of the United Nations/World Health Organization (FAO/WHO) guidelines
for the evaluation of microbes for probiotics use in foods [38]. In 2013, M-16V attained not only
FDA-Notified Generally Recognized as Safe (GRAS) status for food uses (GRN No., 453) [39], but also
GRAS status for infants (GRN No., 454) [40]. In addition, in 2016, M-16V has been included in the list
of authorised probiotic strains for infant’s food in China, in which M-16V is the only infant-type HRB
strain among the nine strains in the list [41]. To date, there has been broad use of M-16V in low birth
weight infants to reduce the risk of preterm birth complications in more than 120 neonatal intensive
care units (NICU) in affiliated hospitals in Japan, Australia, New Zealand and Singapore [42–44].
Comprehensive safety evaluation of M-16V, which includes functional, genomic, and in vivo
analyses, demonstrated that M-16V is a non-pathogenic, non-toxigenic, non-haemolytic and
non-antibiotic resistant probiotic bacterium that does not contain any plasmids and does not display
harmful metabolic activities [36,40,45,46]. M-16V produces L-lactic acid but no D-lactic acid. In addition,
M-16V was reported to possess conjugated bile salt hydrolytic activity [36]. M-16V was able to
hydrolyse conjugated bile acids taurocholic and glycocholic acid to the primary bile acid (cholic acid)
and glycochenodeoxycholic and taurochenodeoxycholic acid to chenodeoxycholic acid, while the
production of hepatotoxic and carcinogenic secondary bile acids (deoxycholic and lithocholic acid)
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was not detected upon complete biotransformation of bile salts [47]. These results resolve the concern
about the safety of administering a secondary bile acids-producing bacterium.
Studies on acute and chronic toxicological features of M-16V revealed that both single and repeated
oral administration of M-16V did not cause death and any toxic symptoms in a rat model [45]. For
instance, groups of 10 male and 10 female three-week-old Crj:CD (SD) rats were orally administered
with a single dose of M-16V at 6000 mg/kg (1.4 × 1012 CFU/kg) or 3000 mg/kg (6.9 × 1011 CFU/kg) and
examined for acute toxic symptoms for 14 days. There were no gross abnormalities or histopathological
findings attributable to the treatment in all organs throughout the test period, although slightly lower
body weight was observed in male rats administered a high dose of M-16V as compared to the
control on days 8 and 10. Furthermore, oral administration of M-16V with a 90-day repeated dose
(2.3 × 1011 CFU/kg/day) to five-week-old Crj:CD (SD) IGS rats revealed no adverse effects attributed to
M-16V during the study period. M-16V induced no significant histopathological changes in all organs
examined. These findings demonstrate the absence of acute and chronic toxicity by consumption of
M-16V. Additional in vitro tests showed that M-16V did not possess mucin degradation ability [48].
Taken together, these studies support that M-16V is safe for use as a probiotic in humans.
4. Effects of M-16V on Premature Birth Complications
Prematurity, prolonged hospitalisation, immunodeficiency, antibiotics use and delayed enteral
feeding are challenging ways to begin life for preterm infants [49]. Premature infants are at elevated
risk to develop multiple health comorbidities; one of which is the devastating necrotising enterocolitis
(NEC) [50]. It is a major cause of morbidity and mortality in extremely preterm infants that is associated
with severe sepsis and intestinal perforation [51]. Although the exact aetiology and pathogenesis of
NEC remain elusive, perturbation of the gut microbiota, leading to a hyperinflammatory response,
appears to be a key factor that predisposes neonates to NEC [52]. Premature infants often present
with an immature gut and exhibit delayed gut colonisation with beneficial commensal bacteria
such as Bifidobacterium and Bacteroides, where instead they are more susceptible to colonisation by
Enterobacteriaceae and Enterococcus [53,54]. Moreover, the use of antibiotics in premature and low
birth weight infants disturbs the colonisation patterns of Bifidobacterium and shifts the gut microbial
composition toward a high abundance of Proteobacteria, with a decreased in the overall diversity of
the infant’s gut microbiota [55–57]. To this end, the neonatal period has; therefore, emerged as an
opportune time for preventive M-16V probiotics intervention to promote bifidobacterial colonisation,
facilitate the development of gut mucosal immune system and improve infant health.
4.1. Preclinical Studies
Several animal studies have demonstrated the potential role of M-16V in improving the maturation
of intestinal immune system and promoting bifidobacterial colonisation during early infancy. In a
neonatal Lewis rat model, oral supplementation with M-16V (4.5 × 108 CFU/100 g of body weight/day;
n = 8) during suckling period (days 6 to 18) showed potential in enhancing the homing process of naïve
T cells to the mesenteric lymph nodes (MLN) and the retention of activated T cells in the intraepithelial
(IEL) compartment [58]. The control group (n = 8) was administered with a matched volume of
mineral water. Administration of M-16V increased the proportion of cells bearing toll-like receptor 4
(TLR4) in the MLN and IEL compartments, and enhanced the percentage of the integrin αEβ7+ and
CD62L+ cells in the MLN and that of the integrin αEβ7+ cells in the IEL, as compared to the control.
However, M-16V did not exert a systemic immune-enhancing effect in which the proportions of the
main lymphocyte subset in spleen were not significantly affected by M-16V. In addition, M-16V induced
no harmful effects on the rats wherein no significant differences were observed in the growth curve of
the control and M-16V groups. Administration of M-16V significantly increased the levels of intestinal
immunoglobulin A (IgA) as compared to the control, indicating M-16V could also strengthen the
humoral intestinal immune response.
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Furthermore, M-16V has also been reported to be able to regulate immune responses and appear to
exert anti-inflammatory effects in rats at different developmental periods [59,60]. Oral administration
of M-16V (5 × 108 CFU/day) to F344/Du rats significantly reduced the expression of inflammatory
molecules during the newborn period (days 1 to 14) and regulated the expression of co-stimulatory
molecules during the weaning period (days 21 to 34) [60]. In addition, the numbers of Bifidobacterium
were also significantly increased in both the caecum and colon during the newborn period but not
during weaning, as compared to the control groups [60].
Similarly, significant improvements in inflammatory conditions were also observed in DSS-induced
colitis F344/N rats administered with M-16V (2.5 × 109 CFU/day) during weaning period (from
postnatal days 21 to 34), as compared to the control rats. M-16V showed potential in altering systemic
T-cell immune functions and suppressing inflammatory responses in colitis rats during the weaning
period [59]. Taken together, these preclinical studies imply that supplementation with M-16V may
aid in the development of intestinal immunity and prevention of intestinal inflammation during
early infancy.
4.2. Clinical Studies
Multiple implementation cohort studies have demonstrated the potential effect of early
administration of M-16V in improving bifidobacterial colonisation in preterm infants (gestation
< 33 weeks) [42,61] and low birth weight infants (<2250 g) [32,42,62,63]. Earlier detection and longer
maintenance of a bifidobacteria-dominant gut microbiome were observed in M-16V-supplemented
infants. For instance, in a randomised, double-blind, placebo-controlled trial involving 159 preterm
neonates (gestation < 33 weeks) ready to commence or on feeds for <12 h, supplementation of M-16V
(3 × 109 CFU/day) for three weeks significantly increased the levels of faecal B. breve as compared to
placebo control where the B. breve counts were below detection level [42]. M-16V supplement was
well-tolerated by all enrolled preterm neonates with no adverse effects including probiotic sepsis and
deaths. These findings suggest that M-16V is a suitable probiotic strain for routine use in preterm
neonates to promote the acquisition of beneficial commensal bacteria.
Another randomised, placebo-controlled trial involving 30 preterm low birth weight infants, with
mean gestation 32.8 weeks and birth weight 1486 g, also revealed a positive effect of M-16V on early
gut colonisation with commensal Bifidobacterium spp. [63]. The subjects were randomly divided into
three groups; (A) subjects received M-16V supplementation within several hours (mean: 7.2 h) of birth,
(B) subjects received M-16V supplementation >24 h (mean: 36.5 h) after birth, and (C) subjects who
were fed normally without M-16V supplementation as control group. Intragastrical administration of
M-16V (1.6 × 108 CFU in 0.5 mL of 5% glucose sterile distilled water, twice daily) until the subjects were
discharged from the hospital remedied the delayed bifidobacterial colonisation in both groups A and
B, while no Bifidobacterium was detected in eight out of ten infants in group C during the observation
period of seven weeks [63]. Notably, a significant earlier detection of bifidobacteria and a significant
decrease in the cell numbers of Enterobacteriaceae were observed at two weeks after birth in infants
administered with M-16V within several hours of birth (group A), indicating timing of administration
of M-16V is highly important for which the earlier the administration of M-16V to preterm low birth
weight infants, the better the effects of M-16V in promoting the colonisation of bifidobacteria and
reducing the susceptibility to colonisation by potentially harmful bacteria.
A comparative, non-randomised controlled, prospective trial involving 44 low birth weight infants
(body weight 1000–2000 g), who were ready for feeds within seven days of birth, administered with
either single strain of M-16V (5 × 108 CFU/day) or probiotics mixture containing three bifidobacterial
strains, M-16V, B. infantis M-63, and B. longum BB536 (5 × 108 CFU/day of each strain), for six weeks
has also revealed a significant increase in the detection rates and cell numbers of bifidobacteria in
the faeces [32]. Notably, administration of the three-species probiotics mixture resulted in an earlier
formation of a bifidobacteria-dominant microbiota and a significantly lower level of Enterobacteriaceae
than those administered with M-16V alone [32]. It was noted that not only the total cell numbers
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of bifidobacteria but also the cell numbers of M-16V was higher in infants administered with the
three-strain probiotics mixture than those administered with M-16V alone. This study suggests that
M-16V may act synergistically and cooperatively with other Bifidobacterium strains to confer a more
remarkable beneficial effect in premature infants. Nevertheless, the comparison between probiotics
and control groups from the different timeline in this trial may introduce bias that tends to compromise
the efficacy of M-16V and is likely to result in unfair comparisons. Additionally, two comparable pilot
studies involving ten very low birth weight premature infants (<1250 g) administered with either
M-16V or B. longum at a dose of 5 × 108 CFU/day for eight weeks have also suggested a potential
capability of M-16V to colonise in the premature gut [62,64]. Supplementation with M-16V had a
longer colonisation rate than those with B. longum, for which, while M-16V was found to colonise
the premature gut as early as week two after birth and remain dominant, the administered strain of
B. longum was not detected from week six after birth [62,64]. Collectively, these data have exemplified
that M-16V is potentially beneficial at promoting early colonisation of bifidobacteria and may; therefore,
support healthy growth in premature infants.
Furthermore, M-16V has also been evaluated for the preventive effects on NEC, death and
late-onset sepsis in premature infants; however, the clinical findings are not conclusive [43,44,65]. The
first evidence of the potential preventive effects of M-16V on NEC came from a non-randomised clinical
trial involving 338 infants (220 extremely low birth weight (ELBW) and 118 very low birth weight
(VLBW) infants) receiving M-16V supplementation (1 × 109 CFU/day in raw breast milk or formula
milk) started within several hours (mean 7.2 h) after birth and continued until discharged from NICU,
and 226 infants (101 ELBW and 125 VLBW infants) as a historical control [44]. The study revealed
that administration of M-16V was potentially effective at reducing the incidence of NEC in ELBW and
VLBW infants as compared to that in the historical control group. A significant reduction in morbidity
and mortality rate, as well as the mortality due to infection, was also observed in ELBW and VLBW
infants receiving M-16V supplementation [44]. These encouraging results have suggested a potential
role of M-16V in protecting premature infants from NEC and infection. However, the use of historical
control from another timeline in this trial may introduce bias that tends to compromise the efficacy of
M-16V and is likely to result in unfair comparisons.
More recently, M-16V was reported to be associated with decreased incidence of “NEC ≥ Stage
II” and “NEC ≥ Stage II or all-cause mortality” in preterm neonates <34 weeks [43]. The study was
a retrospective cohort study involving 835 preterm neonates as historical control and 920 preterm
neonates receiving M-16V routine probiotics supplementation (3 × 109 CFU/day in 1.5 mL breast
milk or sterile water) started when the infants were ready for enteral feeds and continued until the
corrected age of 37 weeks. The initial daily dose for neonates <28 weeks was 1.5 × 109 CFU/day until
reaching feeds of 50 mL/kg/day. It was noted that M-16V significantly lowered the incidence of NEC in
preterm VLBW neonates born <34 weeks, while the incidence of NEC was lower but not statistically
significant in those born <28 weeks, although the small sample size used [43]. Despite the encouraging
results, the trial may introduce potential bias in comparisons with the historical control drawn from
another timeline.
In addition, a recent strain-specific systematic review revealed that the significant efficacy of
M-16V to reduce the risk of NEC remains controversial [65]. It was concluded that current evidence is
limited regarding the potential of M-16V as a probiotic for preterm neonates, albeit the meta-analysis
of non-randomised controlled trials showed a significant effect of M-16V intervention in NEC [65]. No
significant benefits on stage ≥2 NEC, late-onset sepsis, mortality and postnatal age at full feeds were
reported in the meta-analysis of randomised controlled trials. Well-designed and adequately-powered
randomised controlled trials are needed for definite confirmation. Nonetheless, all clinical studies
included in the systematic review have concluded that M-16V supplementation was not associated
with probiotic-associated sepsis in this vulnerable population [65], suggesting the risk of developing
sepsis related to M-16V administration in the setting of severe illness to be relatively low. In fact,
issues on B. breve sepsis in immunocompromised infants [66,67] and meningitis caused by other strain
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of B. breve in preterm infants [68] have been reported. Another systematic review using a network
meta-analysis approach showed that only few probiotic strains have statistically significant effects in
reducing mortality, NEC, late-onset sepsis, and time until full enteral feeding [69]. M-16V was one of
the many studied probiotic strains that did not show significant efficacy in preterm birth complications,
reflecting a lack of adequately-powered randomised controlled trials to precisely define the clinical
efficacy [69]. Further large and well-powered trials are needed to evaluate the effectiveness of M-16V
in preventing NEC.
Taken together, these clinical studies underscore the potential roles of M-16V as a promising infant
probiotic that could potentially impact the incidence, morbidity and mortality associated with NEC
(Table 1).
Table 1. Summary from clinical studies of the effects of M-16V on premature birth complications.
Reference Study Design Study Characteristics
Effect of M-16V on bifidobacterial colonisation




Study population: Preterm infants (<33 weeks; BW < 1500 g)
Country: Australia
Sample size: n = 159 (Probiotics: 79; Placebo: 80)
Intervention and dose: 3 × 109 CFU/day in 1.5 mL of sterile water or breast milk.
Duration of supplementation: Supplementation started when infants were on
enteral feeds for <12 h, continued till 37 weeks of corrected gestational age.
Main outcomes: (1) Significant increase in B. breve faecal counts three weeks
after M-16V supplementation. (2) No probiotic sepsis and death in
M-16V-supplemented infants.
Study limitations: Nil
Patole et al., 2016 [61]
Non-RCT comparative
analytical study
Study population: Preterm infants (<33 weeks; BW < 1500 g)
Country: Australia
Sample size: n = 159; subjects were divided into two groups based on their
gestational age: (1) SGA due to IUGR (Probiotics: 22; Placebo: 20). (2) Non-SGA
(Probiotics: 55; Placebo: 56)
Intervention and dose: 3 × 109 CFU/day in 1.5 mL of sterile water or breast milk.
Duration of supplementation: Supplementation started when infants were on
enteral feeds for <12 h, continued till 37 weeks of gestational age.
Main outcomes: (1) B. breve faecal counts did not differ between SGA and
non-SGA infants. (2) M-16V-treated SGA infants reached full feeds earlier than
SGA controls, after adjustment for age at starting feeds and gestation <28
weeks.
Study limitations: (1) This was a comparative analytical study that relies on the
results obtained from the previous study [42]. (2) Assessment of outcome could
not be blinded; however, that was not expected to introduce a major bias
because of the objectivity of the outcome.
Li et al., 2004 [63] Randomised controlled trial
Study population: Preterm VLBW infants (BW < 1250 g)
Country: Japan
Sample size: n = 30
(A) M-16V given several hours (mean: 7.2 h) after birth; n = 10
(B) M-16V given >24 h (mean: 36.5 h) after birth; n = 10
(C) Control fed normally without probiotic supplement; n = 10
Intervention and dose: 1.6 × 108 CFU twice daily in 0.5 mL of 5% glucose sterile
water.
Duration of supplementation: Continued until discharged.
Main outcomes: (1) Significant increase in bifidobacterial colonisation in both
groups A and B. (2) Significant earlier detection of bifidobacteria and a
significant decrease in the cell numbers of Enterobacteriaceae were observed in
group A.
Study limitations: (1) This was a non-double-blinded randomised controlled
trial which may introduce potential bias. (2) The sample size was relatively
small. (3) Assessment of outcome could not be blinded; however, that was not
expected to introduce a major bias because of the objectivity of some of the
outcomes.
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Table 1. Cont.
Reference Study Design Study Characteristics
Ishizeki et al., 2013 [32] Non-RCT prospective study
Study population: Low birth weight infants (<33 weeks; BW 1000–2000 g) who
were ready for feeds within seven days of birth in three cohorts:
(1) Control group: October 1999 to June 2000; n = 16
(2) Single-strain M-16V group: December 2000 to June 2001; n = 15




(1) Control group: No probiotics
(2) Single strain M-16V group: 5 × 108 CFU/day in 1.5 mL sterile water
(3) Three-strain probiotics mixture group: B. longum BB536, B. breve M-16V and
B. infantis M-63; 5 × 108 CFU/day of each strain in 1.5 mL sterile water
Duration of supplementation: Six weeks.
Main outcomes: (1) Both single-strain M-16V and three-strain probiotics
mixture groups significantly increased the detection rates and cell numbers of
Bifidobacterium in the faeces as compared to the control group. (2) Bifidobacteria
proportion was significantly higher in the single-strain M-16V group at weeks
one to four and in the three-strain probiotics mixture group at weeks one to six
as compared to the control group. (3) The proportion of bifidobacteria in the
three-strain probiotics mixture group was significantly higher than that in the
single-strain M-16V group at weeks one and six. (4) The detection rates of
Clostridium and proportions of Enterobacteriaceae were significantly lower in
both probiotic groups.
Study limitations: (1) This was a retrospective study that relies on the quality of
record keeping. (2) The study was conducted at three different timelines which
may introduce potential bias. (3) Outcome evaluation could not be blinded;
however, that was not expected to introduce a major bias because of the
objective of some of the outcomes.
Akiyama et al., 1994
[62] Non-RCT
Study population: Preterm LBW infants with mean gestation (range) 32.8
weeks (27.8–37.6 weeks) and BW 1486 g (780–2250 g)
Country: Japan
Sample size: n = 10 (Probiotics: 5; Control: 5)
Intervention and dose: 5 × 108 CFU/day of M-16V in 1.0 mL of sterile water
Duration of supplementation: Continued until eight weeks of age
Main outcomes: (1) Significant increase in bifidobacterial colonisation in
M-16V-supplemented infants.
Study limitations: (1) This was a non-randomised controlled trial which may
introduce potential bias. (2) The sample size was very small. (3) Assessment of
outcome could not be blinded; however, that was not expected to introduce a
major bias because of the objectivity of the outcome.
Akiyama et al., 1994
[64] Non-RCT
Study population: Preterm LBW infants with mean gestation (range) 32.8
weeks (27.8–37.6 weeks) and BW 1486 g (780–2250 g)
Country: Japan
Sample size: n = 10 (Probiotics: 5; Control: 5)
Intervention and dose: 5 × 108 CFU/day of B. longum BB536 in 1.0 mL of sterile
water
Duration of supplementation: Continued until eight weeks of age
Main outcomes: (1) Significant increase in bifidobacterial colonisation in B.
longum BB536-supplemented infants. (2) This study compared the results
obtained in the previous study using M-16V and revealed that while M-16V
colonised the premature gut as early as week two after birth and remain
dominant, the administered strain of B. longum was not detected from week six
after birth.
Study limitations: (1) This was a non-randomised controlled trial comparing
the results from the previous study which may introduce potential bias. (2) The
sample size was very small. (3) Assessment of outcome could not be blinded;
however, that was not expected to introduce a major bias because of the
objectivity of the outcome.
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Table 1. Cont.
Reference Study Design Study Characteristics
Effect of M-16V on prevention of NEC
Satoh et al., 2007 [44]
Non-RCT
retrospective study
Study population: Preterm VLBW and ELBW infants in two cohorts:
(1) Control group: January 1994 to December 1998; n = 226 (ELBW: 101, VLBW:
125)
(2) M-16V group: January 1999 to December 2003; n = 338 (ELBW: 220, VLBW:
118)
Country: Japan
Sample size: n = 564
Intervention and dose: 1 × 109 CFU/day in milk or mixed with formula
Duration of supplementation: Commenced within several hours after birth
(mean: 7.2 h) and continued till discharge at 37 weeks
Main outcomes: (1) Significant reduction in the incidence of Stage 1 NEC and
infection. (2) Significant reduction in mortality due to infection. (3) Increased
survival to discharge: 64.2% (301–600 g), 94% (601–1000 g), and 97.8%
(1001–1500 g)
Study limitations: (1) This was a retrospective study that relies on the quality of
record keeping. (2) The study was conducted at two different timelines which
may introduce potential bias. (3) Outcome evaluation could not be blinded;
however, that was not expected to introduce a major bias because of the
objective of some of the outcomes.
Patole et al., 2016 [43] Non-RCT retrospective study
Study population: Preterm neonates <34 weeks over two epochs:
(1) Before probiotic supplementation: December 2008 to November 2010
(2) After probiotic supplementation: June 2012 to May 2014
Country: Australia
Sample size: n = 1755 (Epoch 1: 835; Epoch 2: 920)
Intervention and dose: 3 × 109 CFU/day in 1.5 mL of sterile water or breast milk
Duration of supplementation: Started when the infant was ready for feeds and
continued till 37 weeks corrected gestational age
Main outcomes: (1) Significant reduction in the incidence of NEC ≥ Stage II in
infants supplemented with M-16V. (2) Significant reduction in “NEC ≥ Stage II
or all-cause mortality”, late-onset sepsis, and age at full feeds in M-16V group.
(3) For the subgroup of neonates <28 weeks, the beneficial effects of M-16V did
not reach statistical significance.
Study limitations: (1) This was a retrospective study that relies on the quality of
record keeping. (2) The study was conducted at two different timelines which
may introduce potential bias.
Clinical studies related to the potential mechanisms of action of M-16V
Fuji et al., 2006 [70] Randomised controlled trial
Study population: Preterm infants with mean gestation and mean BW of
(1) Probiotics group: 31.3 ± 3.16 weeks and 1378 ± 365 g
(2) Control group: 31.2 ± 1.98 weeks and 1496 ± 245 g
Country: Japan
Sample size: n = 19 (Probiotics: 11; Control: 8)
Intervention and dose: 1 × 109 CFU/day twice daily in 0.5 mL of 5% glucose
solution
Duration of supplementation: Commenced within several hours after birth and
continued till discharge.
Main outcomes: (1) Significant increase in the expression of serum TGF-β1 level
and expression of TGF-β signalling molecule (Smad3) on day 28 in M-16V
group. (2) Serum cytokine levels were not different in the two groups.
Study limitations: (1) The sample size was small. (2) Assessment of outcome
could not be blinded; however, that was not expected to introduce a major bias
because of the objectivity of the outcome.
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Table 1. Cont.
Reference Study Design Study Characteristics
Wang et al., 2007 [71] Randomised controlled trial
Study population: Preterm LBW, VLBW, and ELBW infants (gestation:
23–36 weeks, BW: 414–2124 g)
Country: Japan
Sample size: n = 66 (ELBW, <1000 g: n =22; VLBW, <1500 g: n = 22; LBW,
<2500 g: n = 22). The infants were divided into two groups: Probiotics and
Control, 11 each).
Intervention and dose: 1.6 × 108 CFU/day twice daily in 0.5 mL of 5% glucose
sterile distilled water.
Duration of supplementation: From birth till discharge
Main outcomes: (1) Significant increase in the ratio of acetate to total SCFAs in
all M-16V-supplemented infants. (2) Significant reduction in faecal butyrate
levels in ELBW and VLBW infants supplemented with M-16V.
Study limitations: (1) The sample size was small. (2) Assessment of outcome
could not be blinded; however, that was not expected to introduce a major bias
because of the objectivity of the outcome.
BW, birth weight; CFU, colony-forming units; Non-RCT, non-randomised controlled trial; B. breve, Bifidobacterium
breve; B. infantis, Bifidobacterium infantis; B. longum, Bifidobacterium longum; SGA, small for gestational age; IUGR,
intrauterine growth retardation; LBW, low birth weight; VLBW, very low birth weight; ELBW, extremely low birth
weight; NEC, necrotising enterocolitis; SCFAs, short-chain fatty acids; TGF-β, transforming growth factor-beta.
4.3. Potential Mechanisms of Action
Colonisation by commensal bifidobacteria during early life is indispensable for the normal
development and growth of the gastrointestinal tract, particularly for epithelial barrier function and
mucosal immunity [72,73]. A high abundance of bifidobacteria may contribute to improved health
status and protect premature infants from diseases [74]. In fact, instability of the microbiome and a lack
of bifidobacteria have been reported to be associated with NEC [74]. Towards this end, it seems likely
that M-16V may potentially reduce the risk of developing NEC in premature infants by promoting the
colonisation of bifidobacteria. Additional studies have been deployed to understand the mechanisms
by which M-16V potentially reduces the risk of developing NEC [60,75]. In an experimental rat model
of NEC, oral administration of M-16V was found to be effective at reducing the pathological scores of
NEC and promoting survivability via modulation of TLR expressions and suppression of inflammatory
responses [75]. Multiple reports have suggested that functional expression of TLRs is critical in the
dynamic interaction between the host epithelium and the microbiota that enables normal intestinal
epithelial development and immune homeostasis [76–78]. Differences in the expression of TLRs may;
therefore, alter a host’s response to a commensal or pathogenic microorganism [79]. Specifically, TLR4,
which recognises the lipopolysaccharides of Gram-negative bacteria, was demonstrated as the key
mediator in NEC development [76]. Increasing evidence suggests that NEC develops in response to an
exaggerated pro-inflammatory signalling upon activation of TLR4 in the mucosa of the premature
gut, leading to increased enterocyte apoptosis, mucosal injury, intestinal ischemia, and bacterial
translocation [76,77,79,80]. It has indeed been demonstrated that TLR4 is expressed at higher levels in
the premature infant gut than the full-term intestine [76,81]. Importantly, oral administration of M-16V
to the experimental NEC rats significantly normalised the expression of TLR4, enhanced the expression
of TLR2, and rectified the increased expression of pro-inflammatory cytokines, including interleukin-1β
(IL-1β), IL-6 and tumour necrosis factor alpha (TNF-α) that resulted from NEC induction [75]. The
superior anti-inflammatory effects of M-16V in colonic inflammation have also been demonstrated in
an in vivo study using F344/Du rat pups models, wherein the expression of inflammation-related genes,
including lipoprotein lipase (Lpl), glutathione peroxidase 2 (Gpx2) and lipopolysaccharide-binding
protein (Lbp), was significantly reduced in the colon during the newborn period [60].
Furthermore, M-16V was also able to restore the tight junction barrier function by stimulating TLR2
expression and consequently protect the host against the development of NEC [75]. It has been reported
that enhanced TLR2 expression by probiotics treatment could contribute to the down-regulation of
TLR4 signalling that is activated by NEC [82,83]. Of note, aberrant TLR4 signalling was found to have
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a direct role in the breakdown of the gut barrier in NEC. Enhanced TLR4 signalling impairs mucosal
repair and weakens the integrity of the gut, allowing for bacterial translocation and the downstream
inflammatory response, which in aggregate lead to NEC [77]. Remarkably, M-16V showed potential
in protecting the experimental NEC rats from intestinal barrier dysfunction via suppression of the
NEC-induced elevated expressions of tight junction-related proteins, including ZO-1, claudin-1 and
occludin [75].
Studies have also shown that daily M-16V supplementation may potentially facilitate the
development of gut immune function and attenuate inflammation in preterm infants [58,59,70].
Administration of M-16V (1 × 109 CFU in 0.5 mL of 5% glucose solution), starting several hours after
birth, twice daily, was shown to be capable of significantly elevating the levels of serum transforming
growth factor beta-1 (TGF-β1) and enhancing the expression of TGF-β signalling molecule Smad3,
while suppressing the levels of Smad antagonist, Smad7 in 19 preterm infants (mean birth weight of
1,378 ± 365 g and mean gestational age of 31.3 ± 3.16 weeks) as compared to the control on day 28 [70].
TGF-β1 is an important immune regulatory cytokine that prevents adverse immunologic reactions in
infants. It exerts potent anti-proliferative and anti-inflammatory effects by activating Smad signalling
pathway that mediates cell cycle arrest and induction of apoptosis [84]. Deficiency in TGF-β1 or its
receptor has been implicated in fulminant inflammatory disease that proves lethal in the first week of
life [85]. The encouraging result obtained in the clinical study has; therefore, implied that M-16V may
assist the development of mucosal immunity and attenuate inflammatory reactions in preterm infants
through upregulation of TGF-β signalling.
In addition to interacting with the immune system, M-16V may also potentially protect premature
infants against gut mucosal injury and NEC through the production of short chain fatty acids (SCFAs)
that can affect the health and integrity of the intestinal epithelial and immune cells [71]. In a randomised
controlled trial involving 66 premature infants (birth weight ranged from 414 to 2124 g and gestation
age ranged from 23 to 36 weeks), the effects of oral administration of M-16V on faecal SCFAs were
evaluated. Based on birth weight, the infants were divided into three groups: 22 extremely low birth
weight infants (ELBW; <1000 g), 22 very low birth weight infants (VLBW; <1500 g), and 22 low birth
weight infants (LBW; <2500 g) and within each group, the subjects were further randomly divided into
M-16V-supplemented or control groups. Administration of M-16V (1.6 × 108 CFU in 0.5 mL of 5%
glucose sterile distilled water) at time of normal feeding, twice daily for four weeks led to an intestinal
environment where the levels of butyrate was significantly decreased in ELBW and VLBW infants,
while the ratio of acetate to total SCFAs was significantly increased in ELBW, VLBW, and LBW infants
as compared with those of the control groups [71]. The exact significant contribution of such changes in
the levels of SCFAs to premature infant health upon M-16V administration remains unclear. Although
evidence is limited, higher acetate level in infants, which is often associated with a high abundance of
bifidobacteria, has been reported to potentially improve intestinal immunity and promote epithelial
cell barrier function [86,87]. Nevertheless, the healthy composition of an infant faecal metabolome
remains understudied.
The premature gut is known to have structural and biochemical deficiencies which predispose
infants to NEC. Although bacterial production of SCFAs plays an important role in the intestinal
maturation and functions, it has been reported that overproduction of certain SCFA could be associated
with an increased risk of NEC in premature infants [88]. Study has suggested that Clostridium spp., for
which the abundance was higher in premature infants, may be implicated in NEC through excessive
production of butyrate as a result of colonic lactose fermentation [89]. Overproduction of butyrate may
cause gut mucosal injury and lead to intestinal inflammation in premature infants [90,91]. However,
numerous studies have also demonstrated the importance of butyrate for colon health and its beneficial
effects on intestinal inflammation and barrier integrity [92–94]. Further studies are warranted to resolve
the contradictory roles of butyrate and to investigate the association between reduction of butyrate
production by M-16V and protection against NEC.
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Taken together, the findings from both animal and clinical studies have shed lights into the
potential protective mechanisms of M-16V against NEC in premature infants. It is evident that M-16V
may potentially reduce the risk of developing NEC in premature infants by promoting bifidobacterial
colonisation, modulating the expressions of TLRs and inflammatory responses, and aiding in the
development of mucosal immunity (Figure 1).
 
Figure 1. Administration of Bifidobacterium breve M-16V showed potential in reducing the risk of
developing necrotising enterocolitis (NEC) in premature infants. M-16V stimulates the colonisation
of bifidobacteria and could potentially improve the intestinal environment and gut barrier function.
Additional mechanistic studies revealed that M-16V may assist the development of mucosal immunity
through up-regulation of transforming growth factor-beta (TGF-β) signalling in premature infants
and attenuate inflammatory reactions by modulating the expressions of toll-like receptor 2 (TLR2) and
TLR4. IL-1β, interleukin-1β; IL-6, interleukin-6; TNF- α, tumour necrosis factor alpha; ↑, increased;
↓, decreased.
5. Effects of M-16V on Allergic Disorders
The prevalence of allergic diseases in infants has increased strikingly worldwide in the past few
decades [95]. While the pathogenesis of allergic diseases is likely to be multifactorial, deviations in
gut colonisation during early life are possible major factors promoting abnormal postnatal immune
maturation [96]. The hygiene hypothesis suggests that insufficient or aberrant microbial stimulation
during the critical neonatal period may lead to an exaggerated adaptive immune response and reduced
tolerance [97]. Although compelling evidence for microbiota associations with allergic disease and
related conditions is emerging, a causal relation between specific bacterial taxa and the development
of allergy remains unclear. Several studies have reported differences in gut microbiota composition
and lower abundance of bifidobacteria and lactobacilli in the infant’s gut precede the onset of allergic
manifestations [98,99]. In addition, multiple cohort studies suggested that high abundance of Escherichia
coli or Clostridium difficile was associated with the development of eczema or atopy [100,101], while a
low gut microbial diversity and an elevated Enterobacteriaceae to Bacteroidaceae (E/B ratio) in early infancy
may contribute to the development of food allergy [102]. In this instance, a notable higher abundance
of Firmicutes particularly Clostridium spp., Blautia spp., and a lower abundance of Actinobacteria in
the early gut microbiota has also been described to contribute to the development of allergic diseases
such as food allergy in infants [103], and type 1 diabetes in children [104]. On this basis, modulation of
gut microbiota during early life through M-16V intervention has emerged as a potential measure to
prevent allergic disorders in infants.
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5.1. Preclinical Studies
The anti-allergic capability of M-16V in allergic airways disease, food allergy, and chronic asthma
has been consolidated in a number of in vitro and animal studies [105–110]. In a bacterial strains
comparative study assessing the capability of a panel of six bacterial strains (M-16V, B. infantis
NumRes251, B. animalis NumRes252 and NumREs253, Lactobacillus plantarum NumRes8 and L.
rhamnosus NumRes6) to alleviate allergic symptoms in ovalbumin (OVA)-sensitized BALB/c mice, M-16V
was identified as the most effective strain in reducing allergic response [105]. Remarkably, in contrast
to the other tested bifidobacteria, only the oral treatment with M-16V significantly inhibited the airway
reactivity to methacholine and reduced acute allergic skin reactions to OVA. These discrepancies
emphasise that the immuno-modulatory activity of probiotic strains is highly strain-specific.
Numerous studies have also shown that a synbiotic intervention, comprising M-16V and
a galacto–fructooligosaccharide (GOS/FOS) mixture, was protective against the development of
symptoms of oral sensitization with whey in mice model [110]. The promising effect was confirmed
in an in vivo study demonstrating the partial prevention of skin reaction due to cow’s milk allergy,
following the probiotic administration in combination with specific β-lactoglobulin-derived peptides
and a specific blend of short and long-chain fructo-oligosaccharides in mice [106]. Particularly, besides
increasing the caecal content of propionic and butyric acid, the treatment with M-16V synbiotic
formulation increased the expression of IL-22, which plays an antimicrobial role in the innate immune
response and on the anti-inflammatory cytokine IL-10 in the Peyer’s patches [106].
Additional preclinical studies revealed that administration of M-16V alone (109 CFU) [108],
or in combination with non-digestible oligosaccharides (scFOS, lcFOS and pectin-derived
acidic-oligosaccharides (AOS)) [109], could suppress pulmonary airway inflammation in murine
OVA-induced chronic asthma model. M-16V treatments (both single-strain and synbiotic interventions)
reduced T cell activation and mast cell degranulation, modulated expression of pattern recognition
receptors, cytokines and transcription factors, and reduced airway remodelling [108,109]. More
specifically, the treatments induced regulatory T cell responses in the airways by increasing IL-10 and
Foxp3 transcription in lung tissue and systemically. These studies suggest that M-16V intervention,
either as a single organism or as synbiotic, could be beneficial in the treatment of chronic inflammation
in allergic asthma. Altogether, these findings laid the ground for the preventive and therapeutic effects
of M-16V on allergic disorders.
5.2. Clinical Studies
Several interventional studies suggest that M-16V could promote bifidobacterial colonisation
and prevent or reduce the severity of allergic diseases, including atopic dermatitis (eczema), food
allergy, allergic rhinitis and asthma [111–113]. In a randomised controlled trial, oral administration
of M-16V significantly improved the symptoms of atopic dermatitis in infants as compared to the
control group [112]. The study randomly allocated 15 infants (aged 8.6 ± 4.5 months) with atopic
dermatitis who had a Bifidobacterium-deficit gut microbiota to receive either lyophilised powder of
M-16V (n = 8; 5 × 109 CFU/day) for one month or no M-16V supplementation as a control. It was noted
that administration of M-16V was not only effective at alleviating the severity of allergic symptoms
but also significantly increased the proportion of Bifidobacterium and decreased the levels of total
aerobes in the gut microbiota of infants with atopic dermatitis [112]. Nevertheless, a significant
correlation between alleviation of allergic symptoms and changes of the gut microbiota was not
detected; suggesting M-16V may possess a direct immuno-modulatory effect on intestinal epithelial
cells and not necessarily through the interaction with the gut microbiota.
Another clinical study involving 17 infants with cow’s milk hypersensitivity with atopic dermatitis
(aged 3.1–18.5 months) has also revealed the capability of M-16V supplementation (5 × 109 CFU/day
for three months) to ameliorate allergic symptoms and improve gut microbiota composition [113].
The preventive effects of M-16V on allergic disorders have further been exemplified in a remarkable
placebo-controlled, double-blinded and randomised trial involving 40 Italian children (mean age
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9 ± 2.2 years) treated with a probiotics mixture containing M-16V (1 × 109 CFU), B. longum BB536
(3 × 109 CFU) and B. infantis M-63 (1 × 109 CFU), for four weeks [111]. Administration of probiotics
mixture protected the children against pollen-induced IgE-mediated allergic rhinitis and intermittent
asthma and improved their quality of life, for which these parameters were worsened in the placebo
group. This study implies that, in addition to its effectiveness as a single organism, as aforementioned,
M-16V could also dampen allergic disorders when combined with other Bifidobacterium strains.
More interestingly, in an open trial, administration of a probiotics mixture including M-16V during
pregnancy as well as in postnatal period tied to lower the risk of developing allergic disorders in
infants [114]. The study involved 130 mothers who were provided with a daily powder formulation
(two sachets daily, 1 g/sachet) containing M-16V and B. longum BB536 (5 × 109 CFU/g of each strain)
one month before the expected date of delivery and postnatally to their infants (one sachet daily) for
six months. Another 36 mother–infant pairs who did not receive the bifidobacterial supplementation
were served as the control. Prenatal and postnatal supplementation with the bifidobacteria mixture
significantly reduced the risk of developing eczema and atopic dermatitis in infants during the first
18 months of life as compared to the control group [114]. Additionally, the probiotics intervention
(M-16V and B. longum BB536) resulted in slight changes in the gut microbial composition, wherein a
significantly higher proportion of Bacteroidetes was observed in the microbiota of infants receiving the
bifidobacteria mixture than in that of the control group at four months of age. The relative abundance
of Proteobacteria was also significantly lower in mothers receiving the bifidobacteria mixture at the
time of delivery than those in the control group, and was positively correlated with that of infants
at four months of age. These findings implicate that supplementation with bifidobacteria mixture
of M-16V and B. longum BB536 during pregnancy may modulate both the maternal and neonatal
gut microbiota for prevention of allergies upset in infants later in life. Further studies are needed to
elucidate the association between the probiotics-modulated gut microbiota and allergy development in
infants. Collectively, these findings are cautiously promising with respect to the use of probiotics for the
primary prevention of eczema in pregnant mothers of infants at high risk for developing allergy and in
high-risk infants, as recommended in recent guidelines from the World Allergy Organization [115].
Furthermore, synbiotic intervention of M-16V has also been reported to be effective in preventing
asthma-like symptoms in infants with atopic dermatitis [116]. The study was a double-blind,
placebo-controlled, multicentre trial involving 90 infants with atopic dermatitis (aged <7 months) who
received either an extensively hydrolysed formula containing M-16V (1.3 × 109 CFU/100 mL and a
GOS/FOS mixture (90%/10%; 0.8 g/100 mL) or the same formula without synbiotics for 12 weeks. The
follow-up period for this trial was one year. It was noted that the synbiotic intervention significantly
reduced the prevalence of frequent wheezing and/or noisy breathing apart from colds as well as
the usage of asthma medication as compared to the placebo group [116]. As a result, it seems to
be likely that combining M-16V with prebiotics—synbiotic intervention—could result in stronger
immunomodulatory effects for prevention against allergic disorders. Collectively, these findings serve
as a basis to incorporate M-16V in prebiotics-supplemented infant formula as a means to promote
infant health.
Taken together, these clinical findings support the notion that administration of M-16V can be a
potential prophylaxis approach to improve immune tolerance and consequently protect high-risk infants
from allergic diseases (Table 2), although larger clinical trials are needed for definite confirmation.
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Table 2. Summary from clinical studies of the effects of M-16V on allergic disorders.
Reference Type of Allergy Study Design Study Characteristics




Study population: Infants aged 8.6 ± 4.5 months
Country: Japan
Sample size: n = 15 (Probiotics: 8; Control: 7)
Intervention and dose: 5 × 109 CFU/day
Duration of supplementation: One month
Main outcomes: (1) Significant increase in the
proportion of Bifidobacterium in the faecal microflora
in M-16V group. (2) Significant reduction in the
proportion of total aerobes in M-16V group.
(3) Significant improvement in the allergic symptoms
(cutaneous symptom score and total allergic score) in
M-16V group. (4) No significant correlation between
the changes in allergic symptoms and changes in
intestinal microflora.
Study limitations: (1) The sample size was small.
(2) Assessment of outcome could not be blinded;
however, that was not expected to introduce a major
bias because of the objectivity of some of the
outcomes.
Taniuchi et al., 2005 [113] Food allergy Randomised
controlled trial
Study population: Infants aged 3.1–18.5 months with
cow’s milk hypersensitivity and atopic dermatitis
Country: Japan
Sample size: n = 17 (Probiotics: 10; Control: 7)
Intervention and dose: 5 × 109 CFU/day
Duration of supplementation: Three months
Main outcomes: (1) Significant increase in the
proportion of Bifidobacterium in the faecal microflora
in M-16V group. (2) Significant reduction in the
proportion of total aerobic bacteria in M-16V group.
(3) Significant improvement in the allergic symptoms
in M-16V group as compared to the beginning of the
study. (4) In the control group, no changes to the
overall faecal microflora and total allergic score
during the entire study period.
Study limitations: (1) The sample size was small.
(2) Assessment of outcome could not be blinded;
however, that was not expected to introduce a major
bias because of the objectivity of some of the
outcomes. (3) Outcomes were compared with the
baseline but not the control group.






Study population: Children aged 9 ± 2.2 years with
pollen-induced IgE-mediated allergic rhinitis and
intermittent asthma
Country: Italy
Sample size: n = 40 (Probiotics: 20; Placebo: 20)
Intervention and dose: one sachet/day
B. breve M-16V: 1 × 109 CFU
B. longum BB536: 3 × 109 CFU
B. infantis M-63: 1 × 109 CFU
Duration of supplementation: Four weeks
Main outcomes: (1) Significant improvement of
allergic symptoms and quality of life in children
treated with the probiotics mixture. (2) The
intergroup analysis showed that probiotics mixture
was significantly more superior to the placebo for all
parameters.
Study limitations: The sample size was relatively
small.
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Table 2. Cont.
Reference Type of Allergy Study Design Study Characteristics
Enomoto et al., 2014 [114] Atopic dermatitis
(eczema)
Non-RCT open trial
Study population: Mother–infant pairs; maternal
age: (1) Probiotics group: 22–41 years; (2) Control
group: 21–38 years.
Country: Japan
Sample size: n = 166 (Probiotics: 130; Control: 36)
Intervention and dose: Pregnant women: 2
sachets/day; infants: 1 sachet/day
B. breve M-16V: 5 × 109 CFU
B. longum BB536: 5 × 109 CFU
Duration of supplementation: One month before the
expected date of delivery and postnatally to the
infants for six months.
Main outcomes: (1) Significant reduction in the risk
of developing eczema/atopic dermatitis during the
first 18 months of life in the probiotics group. (2) The
proportion of Proteobacteria was significantly lower
in mothers at the time of delivery who received
probiotics supplementation when compared with the
control group and was positively correlated with that
of infants at four months of age. (3) No adverse
effects were related to the use of probiotics.
Study limitations: (1) This was a non-randomised
trial which may introduce potential bias. (2)
Assessment of outcome could not be blinded;
however, that was not expected to introduce a major
bias because of the objectivity of some of the
outcomes.







Study population: Full-term infants aged <7 months
with atopic dermatitis.
Country: Netherlands
Sample size: n = 90 (Synbiotics: 46; Placebo: 44)
Intervention and dose: Synbiotics consisted of B.
breve M-16V at a dose of 1.3 × 109 CFU/100 mL and a
mixture of 90% scGOS and 10% lcFOS
(Immunofortis®), 0.8 g/100 mL.
Duration of supplementation: 12 weeks
Main outcomes: (1) Of the 75 children (mean age 17.3
months) completed the one-year follow-up
evaluation, the prevalence of “frequent wheezing”
and “wheezing and/or noisy breathing apart from
colds” was significantly lower in the synbiotic than
in the placebo. (2) Significantly fewer children in the
synbiotic than in the placebo group had started to
use asthma medication after baseline. (3) Total IgE
levels did not differ between the two groups.
Study limitations: The study tested the effect of
M-16V in a synbiotic formulation.
CFU, colony-forming units; IgE, immunoglobulin E; Non-RCT, non-randomised controlled trial; B. breve,
Bifidobacterium breve; B. infantis, Bifidobacterium infantis; B. longum, Bifidobacterium longum; scGOS, short-chain
galactooligosaccharides; lcFOS, long-chain fructooligosacharides.
5.3. Potential Mechanisms of Action
The mechanisms through which M-16V acts to protect infants against allergic disorders are
not fully understood but clearly involve the contributions from M-16V to promote bifidobacterial
colonisation, modulate Th2-skewed immune response and attenuate inflammatory reactions (Figure 2).
M-16V has been shown to exert immuno-regulatory effect and anti-inflammatory capability in vitro,
albeit the effect on allergic reaction has not been specifically demonstrated. M-16V was reported to
interact with TLR2, upregulate the expression of ubiquitin-editing enzyme A20 in porcine intestinal
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epithelial cells challenged with heat-killed enterotoxigenic Escherichia coli, and beneficially modulate
the subsequent TLR4 activation by reducing the activation of MAPK and NF-κB pathways and
the production of pro-inflammatory cytokines (IL-8, monocyte chemotactic protein (MCP)-1, and
IL-6) [83]. Furthermore, in an experimental OVA-immunised mice model, oral administration of
M-16V (5 × 108 CFU/0.5 mL/day/animal) for 21 days significantly reduced the serum levels of total
IgE, OVA-specific IgE and OVA-specific IgG1 and ex vivo production of IL-4 by the splenocytes, as
compared to control [117]. In addition, M-16V could potentially modulate the systemic Th1/Th2
balance in vitro wherein the production of OVA-induced total IgE and IL-4 was suppressed and the
secretion of IFN-γ and IL-10 was induced by M-16V in a dose-dependent manner. Nonetheless, M-16V
did not induce IL-12 production. It is; therefore, suggested that M-16V may have the potential to
restore Th2 skewed immune response, which was at least partially independent of the Th1 cytokine
induction [117].
Figure 2. Bifidobacterium breve M-16V could potentially promote bifidobacterial colonisation and may
prevent or reduce the severity of allergic diseases in infants. Specifically, M-16V may suppress the
differentiation naïve T-helper cells (Th0) into T-helper (Th) 2 cells and the production of Th2 cytokines
such as interleukin-4 (IL-4) and IL-5, and subsequently attenuate allergic inflammation by reducing
the production of immunoglobulin E (IgE) and IgG1 in B cells and the release of pro-inflammatory
mediators including IL-6 and IL-8. In addition, M-16V could also potentially assist immune tolerance
and attenuate allergic reactions in infants through modulation of TGF-β signalling. ↓, decreased;
↑, increased.
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It has been suggested that the pathology of allergic disease is driven by the allergen-specific
Th2 cytokines such as IL-4 and IL-5, which play a triggering role in the activation/recruitment of IgE
antibody-producing B cells, mast cells and eosinophils [118–120]. Notably, in an OVA-allergic asthma
mouse model, oral administration of M-16V (109 CFU/0.4 mL/day/animal) for 17 days prevalently
reduced the number of eosinophils in the bronchoalveolar lavage fluid and reduced the levels of
OVA-specific IgE and IgG1 and Th2 cytokines (IL-4 and IL-5) [105]. In addition, M-16V has also
been shown to potentially assist immune tolerance and attenuate allergic reactions in premature
infants through modulation of TGF-β signalling [70]. Altogether, these findings provide proof of the
potential of M-16V in modulating Th2 skewed allergic immune response. Further in-depth studies
are required to elucidate the exact mechanisms by which M-16V prevents and ameliorates allergic
disorders in infants.
6. Conclusions
Bifidobacterium breve M-16V has emerged as a probiotic strain that exerts positive effects on infant
health. With the data from in vitro animal and clinical studies, M-16V holds promise to treat adverse
health-related conditions in infants, particularly the vulnerable premature populations, and possesses
a proven track record of safety. Mounting evidence favours the use of M-16V as a worthy and suitable
infant probiotic in early life for promoting a healthy gut microbial colonisation and maturation in
premature infants and preventing the development of NEC and allergic diseases. Although the
mechanistic insights supporting the use of M-16V are not robust, it has become clear that M-16V may
modulate the gut microbiota, interact with TLRs and regulate inflammatory responses to reduce the risk
of developing life-threatening diseases and immune-mediated disorders. Despite the promising results,
many studies summarised here have multiple limitations such as potential bias in non-randomised
controlled trials and small sample size. Therefore, additional well-designed randomised controlled
trials with larger sample size are needed to serve as the basis for developing conclusive evidence
on M-16V intervention in vulnerable preterm populations. In addition, further investigations are
required for an increased understanding of the protective mechanisms of M-16V and to releasing the
full potential of M-16V as a human probiotic in paediatrics.
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Abstract: Carica papaya L. is a well-known fruit worldwide, and its highest production occurs in
tropical and subtropical regions. The pulp contains vitamins A, C, and E, B complex vitamins, such
as pantothenic acid and folate, and minerals, such as magnesium and potassium, as well as food
fibers. Phenolic compounds, such as benzyl isothiocyanate, glucosinolates, tocopherols (α and δ),
β-cryptoxanthin, β-carotene and carotenoids, are found in the seeds. The oil extracted from the
seed principally presents oleic fatty acid followed by palmitic, linoleic and stearic acids, whereas
the leaves have high contents of food fibers and polyphenolic compounds, flavonoids, saponins,
pro-anthocyanins, tocopherol, and benzyl isothiocyanate. Studies demonstrated that the nutrients
present in its composition have beneficial effects on the cardiovascular system, protecting it against
cardiovascular illnesses and preventing harm caused by free radicals. It has also been reported that
it aids in the treatment of diabetes mellitus and in the reduction of cholesterol levels. Thus, both
the pulp and the other parts of the plant (leaves and seeds) present antioxidant, anti-hypertensive,
hypoglycemic, and hypolipidemic actions, which, in turn, can contribute to the prevention and
treatment of obesity and associated metabolic disorders.
Keywords: blood glucose; food composition; metabolic syndrome; natural products; Carica papaya
1. Introduction
Plants with healing properties are utilized in folk medicine and, since remote times, have been
considered traditional therapeutic approaches that have effects on health. They are also advantageous
from a cost–benefit point of view [1]. Synthetic drugs used to be the first option for the treatment
of several diseases. However, because of the adverse effects shown by long- or even short-term
consumption, studies aiming at the use of alternative therapies in the treatment and prevention of
diseases have increased considerably [2].
One alternative therapy includes the use of nutraceuticals, which, in turn, according to the existing
regulations, cannot be categorized or defined either as food or a drug, but can be understood in the
category of food supplements, with beneficial properties for health maintenance, in particular for some
pathologic conditions. Therefore, a therapeutic approach, based on nutraceuticals for maintenance of
health, resulted in a worldwide “nutraceutical revolution” [3].
Among plants with beneficial properties on health is Carica papaya, the well-known papaya. This
fruit contains considerable concentrations of vitamins, bioactive compounds and a lipidic composition
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that reduces inflammatory markers and anti-platelet aggregation, protects against thrombogenesis and
oxidative stress, and prevents hypercholesterolemia—factors that can be triggered by obesity [4,5].
Carica papaya is a popular fruit, and its largest production occurs in tropical and subtropical
regions. According to the Food and Agriculture Organization of the United Nations (FAO) [6], over
6.8 million tons of the fruit are produced in the world annually, ca. 440 thousand ha. Central and South
America, especially Brazil, are responsible for 47% of the fruit yield, produced year round, being an
important source of nutrients with a low cost and great availability in the market.
Carica papaya is consumed worldwide, either in natura or processed as jam, sweets and pulp,
and to aggregate the nutritional value, other parts of the plant (leaves and seeds) are added to some
products in the form of teas and flours [7]. The pulp composition presents three important sources of
vitamins with potential antioxidant action, A, C and E [8], besides minerals, such as magnesium and
potassium, and B complex vitamins, such as pantothenic acid and folate [9], as well as the presence of
food fibers [10]. Besides these nutrients, papaya contains the enzyme papain, effective in increasing
intestinal motility and transit time, and is also utilized in the treatment of traumas, allergies and sport
lesions [5]. Some studies observed the presence of proteolytic enzymes, such as chymopapain, with
anti-viral, antifungal and antibacterial properties [5,11].
The seed contains phenolic compounds, such as benzyl isothiocyanate, glucosinolates, tocopherols
(α and δ), β-cryptoxanthin, β-carotene and carotenoids [12,13], while the seed oil principally presents
oleic fatty acid, followed by palmitic, linoleic and stearic acids [14]. The leaves have a high content of
food fibers and polyphenolic compounds, such as flavonoids, saponins, pro-anthocyanins, tocopherol
and benzyl isothiocyanate [15].
Considering the nutrients present in its composition, beneficial effects have been observed, with
a significant improvement in the cardiovascular system, protecting against cardiovascular illnesses,
heart attack and strokes [16]. Other studies have pointed out that this fruit is an excellent source of
beta-carotene (888 IU/100 g), preventing harms caused by free radicals [17], besides exerting a role in
the prevention of cardiovascular illnesses, diabetes mellitus (types 1 and 2) and in the reduction of
cholesterol levels through its high content of fibers, which diminish fat absorption [5,18].
Carica papaya is a plant that is easily accessed and widely available. Furthermore, scientific
studies have demonstrated the biological activities and medicinal applications of different parts of the
plant. However, few studies have demonstrated the therapeutic potential in metabolic dysfunctions in
experimental models specific to obesity. Therefore, the present study will investigate the nutritional
value and bioactive compounds of the plant, as well as the existing medicinal uses and possible
application in the metabolic syndrome.
2. Nutritional Properties: C. papaya L.
2.1. Chemical Composition
The tree C. papaya is native to Central and South America and is one of the most cultivated fruit
plants in the world, especially in tropical and subtropical areas [6]. It is a herbaceous perennial plant,
with a milky latex that can reach 12 m in height. It has a year-round fruit production, and each fruit
weighs between 1000 and 3000 g [18] (Figure 1).
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Figure 1. Images of Carica papaya L. (papaya CV Formosa): (a) Tree with leaves and green fruits,
(b) female flower, and (c) ripe fruit with seeds and pulp. Photos: L. F. Santana.
The fruit of C. papaya is considered one of the most common fruits in relation to human consumption
and provides a favorable cost benefit in consideration of its nutritional value, with a low caloric content
(Table 1) and rich concentration of vitamins and minerals (Table 2) [19].
Table 1. Nutritional value of the macronutrients and fibers of Carica papaya L. (papaya) per 100 g of
pulp of ripe fruit, seeds and leaves [5,18].
Component Pulp Seeds Leaves
Proteins 0.6 g 2.6 g 5.8 g
Lipids 0.1 g 3.1 g 1.4 g
Carbohydrates 7.2 g 43.6 g 78.2 g
Fiber 0.8 g 2.1 g 13.1 g
Energy 32.1 kcal 212.7 kcal 348.6 kcal
Table 2. Value of the minerals and vitamins of Carica papaya L. (papaya) per 100 g of ripe fruit pulp,
seeds and leaves [7,19].
Component Pulp Seeds Leaves
Sodium 3 mg ND ND
Potassium 257 mg 344 mg 534 mg
Phosphorous 5 mg 241.5 mg 221.1 mg
Magnesium 10 mg 10.4 mg 32.4 mg
Iron 0.1 mg 0.2 mg 6.4 mg
Calcium 24 mg 54.4 mg 366.1 mg
Vitamin C 61.8 mg 11.7 mg 31.1 mg
Vitamin B9 (Folate) 38 mg ND ND
Vitamin B6 0.1 mg ND ND
Vitamin B3 (Niacin) 0.34 mg 0.26 mg 0.38 mg
Vitamin B2
(Riboflavin) 0.05 mg 0.05 mg 0.14 mg
Vitamin B1
(Thiamin) 0.04 mg 0.05 mg 0.43 mg
Vitamin A 328 mg ND ND
Betacarotene 888 IU 65.64 IU 659.5 IU
ND: not determined.
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Among the most commercialized fruits, such as apple, banana, water melon, and orange, papaya
has the highest concentrations of vitamin C (61.8 mg·100 g−1), vitamin A (328 mg·100 g−1), riboflavin
(0.05 mg·100 g−1), folate (38 mg·100 g−1), thiamine (0.04 mg·100 g−1), niacin (0.34 mg·100 g−1), calcium
(24 mg·100 g−1), iron (0.1 g·100 g−1), potassium (257 mg·100 g−1), and fiber (0.8 g·100 g−1), as well
as presenting a low caloric value (32 kcal·100 g−1 ripe fruit) and being one of the preferred fruits for
weight loss. In addition, it has a high carotene content when compared with other fruits [5,20].
The green fruit is used in preparations, such as salads, cakes, ice creams and juice, without
carotene [20], but with all of the other nutrients listed in Tables 1 and 2. Besides the ripe papaya pulp,
the consumption of other parts, such as the seeds and leaves, is appropriate, since they have a higher
nutritional value and more fibers [7]. The leaves and seeds present a higher carbohydrate content,
compared with the fruit pulp, presenting 78.2 g and 436 g·100 g−1, respectively (Table 1), and the same
is observed for the values of proteins (5.8 g and 2.63 g·100 g−1), lipids (1.4 g and 3.1 g·100 g−1) and
fibers (13.1 g and 2.13 g·100 g−1). Consequently, they have a higher caloric value (seeds with 212.7 kcal
and leaves with 348.6 kcal) [18].
Compared with the seeds and pulp, the concentrations of vitamins and minerals are different in
the leaves, because they play an important role in fruit development [21]. For example, in relation to
minerals, the contents of magnesium, iron, potassium and calcium are higher in the leaves (the leaves
have 366.1 mg and the seeds 54.4 mg·100 g−1). Regarding vitamins, except for C, the leaves present a
higher content, with the highest concentration in the pulp, as shown in Table 2 [7,22].
2.2. Phytochemical Composition
Different parts of the C. papaya plant, such as the fruits, seeds, roots, leaves, stem and latex were
found to have important bioactive compounds, which, in turn, may exert medicinal effects. The
methanolic extract of unripe fruits exerted antioxidant activity in vivo, for the presence of compounds,
such as quercetin and β−sitosterol [20]. Other studies detected considerable quantities of total phenols
(203 mg·100 g−1 extract) [22] in the methanolic extract of the papaya pulp, while terpenoids, alkaloids,
flavonoids and saponins were identified in the water extract [9] (Table 3). Besides, in papaya seed
extracts, the presence of benzyl isothiocyanate [13] and expressive quantities of glucosinolates were
observed [12].
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Evaluating the oil extracted from the seeds, the main quantified fatty acid was oleic acid (71.30%),
followed by palmitic (16.16%), linoleic (6.06%), and stearic acids (4.73%) (Table 3) [25]. The predominant
tocopherols were α and δ-tocopherol, with 51.85 and 18.9 mg·kg–1, respectively. The β-cryptoxanthin
(4.29 mg·kg–1) and β-carotene (2.76 mg·kg–1) were the quantified carotenoids, and the content of total
phenolic compounds was 957.60 mg·kg–1 [26].
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Studies showed that C. papaya leaves present tocopherol [24], lycopene [14], flavonoids [25] and
benzyl isothiocyanate [23]. Another important study demonstrated that the phytochemical composition
of ethanolic, methanolic, acetate and water extracts of C. papaya leaves is independent of the type of
extract, detecting polyphenols, flavonoids, saponins and pro-anthocyanins, besides the antioxidant
activity, evaluated by the method 1,1-diphenyl-2-picrylhydrazyl (DPPH). However, the water extract
had superior values of polyphenols (23.1 mgGAE/g) and antioxidant activity (166 μgTE/g), while the
ethanolic extract had the highest concentrations of flavonoids (17.1 mgCE/g), saponins (82.8 mgAes/g)
and pro-anthocyanins (7.91 mgCE/g) [15].
3. Medicinal Properties of C. papaya
Carica papaya contains important nutrients (Tables 1 and 2) and bioactive compounds, such
as antioxidants, vitamins, and minerals (Table 3), with nutraceutical characteristics and potential
beneficial effects on health [5]. Studies evaluated the actions of C. papaya in recovery from drug-induced
hepatoxicity in rodents [27–30], e.g., by carbon tetrachloride (CCl4), considered a potent inducer of
toxic effects in the liver for being highly metabolized in bodily tissues because of the high reactivity of
halogenated metabolites (CCl3 and Cl), and such activation of metabolites liberate the active oxygen
species (ROS). Another drug in question was acetaminophen (600 mg·100 g−1), an analgesic and
anti-pyretic, which causes acute hepatocellular damage that can be lethal if not treated [27].
Among the main effects that extracts of different parts of C. papaya demonstrated, in recovery from
toxic effects on the liver, are the decrease in hepatic damage with the increase in antioxidant enzymes
such as superoxide dismutase (SOD), glutathione (GSH), and catalase in the liver and decreases in the
enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase
(ALP) [27–31]. Similar data were observed in nephrotoxicity induced by CCl4 in rats treated with
C. papaya seed water extract, depending on the dose and time of treatment. The results showed a drop
in biochemical parameters, such as the serum levels of uric acid, urea, and creatinine, besides the renal
protecting ion, constated by histological evaluation after recovery from renal lesions [32].
Besides the effects on hepatic and renal toxicity, C. papaya displayed antimicrobial [33],
anti-amoebic [34], anti-parasitic [12,13], and anti-malaria actions [11]. The use of C. papaya leaf water
extract at different concentrations (25, 50, 100, 200 mg·mL−1) had antimicrobial activity on the inhibition
of some human pathogens, such as Escherichia coli, Pseudomonas aeruginosa, Kleibseilla pneumoniae,
Staphylococcus aureus, and Proteus mirabilis [33]. Another study, utilizing the same type of extract at
the dose of 100 mg·mL−1 found anti-amebic activity against Entamoeba histolytica [34]. Furthermore,
C. papaya seeds had an activity on human intestinal parasites (Caernorhabditis elegans), without
considerable side effects, owing to the presence of B-benzylisothiocyanate, a potent anti-helminthic [12].
Studies have shown the inhibitory effects on Plasmodium falciparum (malaria) in vitro, while the extract
from the green fruit pulp of C. papaya demonstrated the highest anti-malaria activity, in comparison
with different extracts of other tested plants [11].
Other studies showed the action of the water extract of C. papaya leaves (20 mg·mL−1) on
proliferation inhibition in strains of solid tumor cells in trials in vitro, e.g., cervical carcinoma (Hela),
breast adenocarcinoma (MCF-7), hepatocellular carcinoma (HepG2), lung adenocarcinoma (PC14),
pancreatic carcinoma (Panc-1) and mesothelioma (H2452) in a dose-dependent manner, suggesting the
anti-tumoral action of the extract. To determine whether the proliferation inhibition was associated
with decreased cell viability, the water extract of C. papaya leaves was shown to inhibit proliferation
responses of hematopoietic cell strains, including T-cell lymphoma (Jurkat), plasma cell leukemia
(ARH77), Burkitt’s lymphoma (Raji), and large-cell anaplastic lymphoma (Karpas-299). In addition, the
C. papaya leaf extract showed immunomodulatory activity on peripheral human blood mononuclear
cells [17].
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Antiulcerogenic actions were verified with the use of C. papaya seed water extract (50–100 mg/kg),
the same action being observed using the methanolic extract, showing gastro-protective activity in
animals, in both prevention and treatment models of gastric ulcer [35]. In addition, the C. papaya
seed extract was able to reduce the contractility of rabbit jejunum smooth muscle—the responsible
compound being benzyl isothiocyanate [36].
Effective anti-inflammatory actions were verified by applying C. papaya leaf ethanolic extract
(25–250 mg·kg−1) on carrageenan-induced paw edema in rats. However, after the ulcerogenic activity
tests, the extract with the highest concentration produced a mild irritation of the gastric mucosa [37].
Besides the effects on inflammation, C. papaya showed wound healing properties. It is known that
diabetic patients often have persistent difficulty in healing and require the delicate handling of wounds,
demanding appropriate care. The topical use of the water extract of green fruits of C. papaya on
wounds in diabetic rats, induced by streptozotocin (STPZ, 50 mg·kg−1), exhibited a 77% reduction
of the wound, induced by excision, with faster epithelization, compared with the control group,
which received Vaseline [10]. Similar results in the healing of wounds induced by excision were
observed on alloxan-induced diabetic rats (150 mg·kg−1), which received a water extract of green
fruits of C. papaya, the healing actions being attributed to the active component, papain, which led to
the enzymatic debridement of wounds, and the fruit vitamin C content, since it is essential for the
conversion of proline to hydroxyproline, a specific marker and component of the granulation tissue
of the extracellular matrix in wounds [38,39]. In this way, besides possessing edible and tasty fruits,
different parts of C. papaya are characterized by the quality of nutrients and bioactive compounds with
medicinal properties that may be used in traditional medicine as an alternative or adjuvant in the
treatment of some pathological conditions.
4. Effects of C. papaya L. on Metabolic Syndrome
Obesity consists of an excessive accumulation of body fat, which can represent a serious health
risk and involves several ethological factors, including social, behavioral, environmental, cultural,
psychological, metabolic, and genetic factors [40]. It is known that excessive fat accumulation, mostly
visceral, can be an important condition in the development of metabolic dysfunctions, such as arterial
hypertension, dyslipidemia and insulin resistance, and alterations conducive to the development
of diabetes mellitus type 2, cardiovascular illnesses [41] and cancer [42], such as prostate [43] and
colon rectal cancer [44]. Thus, the metabolic syndrome can be defined as the set of these risk factors,
i.e., a cluster of metabolic disorders associated with obesity, including insulin resistance, atherogenic
dyslipidemia and hypertension, which can lead to cardiovascular illnesses [45].
Since adipose tissue is a source of a great number of adipokines, such as the tumor necrosis factor
(TNF-α), interleukin 6 (IL-6), monocyte chemoattractant protein, also known as chemokine ligand
2 (MCP-1/CCL-2), leptin, adiponectin, and resistin, among others [46], the larger the accumulation
of adipose tissue, the higher the production of these adipokines. This leads to an imbalance in their
secretion, with increased pro-inflammatory and decreased anti-inflammatory adipokines, stimulating
the systemic and local inflammatory process, contributing to the development of insulin resistance [46].
Furthermore, the metabolic syndrome, besides being associated with the inflammatory process, is
also related with the high production of reactive oxygen species (ROS) and, consequently, can induce
insulin resistance [47,48], which is increasingly recognized as a key factor linking metabolic syndrome
and liver steatosis; the last is associated with excessive fat accumulation in ectopic tissues, such as
the liver, and increased circulating free fatty acids, which can further promote inflammation and
endoplasmic reticulum stress [49].
For the treatment of obesity and its metabolic disorders which characterize the metabolic syndrome,
there are various therapeutic approaches, either pharmacological or non-pharmacological treatments,
and other methods, used as healing adjuvants. As such, the use of plants or fruits, reported since
remote times as alternatives for the treatment and prevention of diseases, stand out in view of their
high concentrations of vitamins, bioactive compounds and also lipidic composition, which reduces
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inflammatory markers, aggregates platelet, protects against thrombogenesis and oxidative stress, and
prevents hypercholesterolemia, hypertriglyceridemia and hyperglycemia, which can be triggered by
obesity [5].
Considering the presence of vitamins, bioactive compounds and lipids of biological and nutritional
importance in C. papaya, several studies (summarized in Table 4) evinced relevant effects of this plant
in the treatment of metabolic dysfunctions, associated or not associated with obesity, which can be
considered an alternative therapeutic approach in the treatment of the metabolic syndrome.
A preliminary study [50] demonstrated that the water extract of C. papaya seeds showed
hypoglycemic and hypolipidemic activity in adult healthy male Wistar rats, without signs of acute
toxicity. The groups received the water extract of C. papaya seeds, at concentrations of 100 mg, 200 mg
and 400 mg/kg, and glibenclamide at 0.1 mg·kg−1 by gavage for 30 days. The treatments at all doses of
the extract led to decreased serum levels of fasting glycemia, triglycerides, total cholesterol, LDL-c, and
VLDL-c, with increased HDL-c levels, depending on the dose, and responses similar to the effects of
the positive control group (glibenclamide). Such a relation with the extract concentration was observed
in the lowered atherogenic index, compared with the group receiving distilled water (10 mL/kg/day)
and glibenclamide (0.1 mg/kg/day). The phytochemical analyses of the extract revealed the presence
of alkaloids, flavonoids, saponins, tannins, anthraquinones and anthocyanosides, and the monitored
animals showed a decrease insugars, related to the metabolic effects.
Another study [51] evaluated the effects of the water extract of C. papaya leaves (200 mg/kg to body
mass), given by gavage in adult healthy male New Zealand rabbits, treated for 24 weeks, resulting in
reduced body weight, concomitant with lowered levels of fasting glycemia during the trial. Moreover,
over the supplementation period, the extract had a hepatotoxic effect, manifesting an increase in
serum values of aspartate transaminase (AST), aspartate aminotransferase (ALT), gamma-glutamine
transferase (γ-GT) and total bilirubin. Therefore, further investigations will be necessary to evaluate
toxicological effects of the extract, especially on the liver, in order to, standardize doses time of
administration and side effects for a safety administration.
While such metabolic effects were observed in healthy animals, other studies elucidated the
hypoglycemic action in an alloxan-induced diabetes model [52–54]. Adenowo et al. (2014) [52]
investigated alloxan-induced (150 mg/kg/body mass) diabetic Wistar rats, treated with an ethanolic
extract of C. papaya leaves (250 and 500 mg·kg−1) by gavage for 21 days, and verified reduced levels of
glycemia, total cholesterol, triglycerides and LDL-c, together with increased HDL-c levels, resulting
mainly from the dose of 250 mg/kg to body mass. Furthermore, they verified that the extract diminished
the serum concentrations of urea, creatinine, ALT and AST, as well as the parameters of diabetic animals
receiving metformin. The data corroborate the study of Maniyar (2011) [54], where the water extract of
C. papaya leaf (400 mg/kg/body mass), given by gavage for 21 days, showed a reduction in the levels of
glycemia, triglycerides and total cholesterol in alloxan-induced diabetic rats (120 mg/kg/body mass),
confirmed by Johnson et al. (2015) [53], who tested the water extract of seeds and leaves of C. papaya
(400 mg/kg/body mass), by gavage for 28 days in an experimental model of diabetes (alloxan 150 mg/kg
to body mass), having observed diminished levels of glycemia total cholesterol, hepatic enzymes, ALT,
AST, urea, and creatinine. Nevertheless, regarding glycemic metabolism and hypoglycemic action, the
seed extract was superior to the leaf extract.
Ezekwe et al. (2014) [55] applied the experimental model of alloxan-induced diabetes (120 mg/kg
to body mass) in albino rats receiving a ration added to grated green C. papaya pulp, splitting the
animals into three groups: control non-diabetic, diabetic and diabetic fed with added grated green
C. papaya pulp for 28 days. The third group presented relevant effects on their metabolism, such as
a reduction of weight, in the levels of glycosylated hemoglobin and in the lipidic profile, including
low-density lipoprotein cholesterol (LDL-c), very low-density lipoprotein (VLDL-c), triglycerides and
total cholesterol, and increased serum values of High-density lipoprotein cholesterol (HDL-c).
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Metabolic effects were also observed in alloxan-induced (90 mg/kg/body mass) albino rats receiving
the water extract of C. papaya root (500 mg/kg/body mass) and glibenclamide (5 mg/kg/body mass) by
gavage for 21 days. The treatment with the extract showed improved parameters of glycemia already
after 7 days of the trial, an improvement in the dyslipidemic parameters and recovery of hepatic
tissues and renal dysfunction. The compounds identified include hexadecanoicacid, methylester,
10-octadecanoic acid, methyl ester, ergosta-5,22-dien-3-olacetate (3β, 22E), dianhydromannitol,
1,1,3,3,5,5,7,7,9,9,11,11-dodecamethylhexasiloxane, methyl-11-hexadecanoate, and octadecanoic acid.
The compounds 10-octadecenoic acid, methylester, hexadecanoic acid, and methyl ester, were the
phytochemicals most present in the root extract. Thus, they may have contributed to the cited metabolic
effects [56].
Hypoglycemic effects were observed not only with the isolated administration of the leaf
extract of C. papaya in alloxan-induced diabetic rats (180 mg/kg/body mass), but also combined with
co-administrated reference antidiabetic drugs, such as metformin and glimepiride. The extract, the
drug, or the combination drug + extract was administered daily by gavage in periods of a short and
long duration, corresponding to 3 and 7 days, respectively. The concentrations of each product given
to the animals were divided based on low and high doses, established in previous studies, as follows:
extract low dose: 5 mg/kg and high dose: 10 mg/kg; glimepiride low dose: 0.2 mg/kg and high dose:
0.4 mg/kg; and metformin low dose: 50 mg/kg and high dose: 100 mg/kg, for 3 and 7 days. The same
period of treatment was utilized for the combinations, glimepiride + extract and metformin + extract,
and the dose combinations corresponded to high-high, high-low, low-high and low-low. The lowest
concentration extract (5 mg/kg) reduced the glycemic level, but the highest concentration (10 mg/kg)
accelerated the starting of the glimepiride activity, while the combination of all extracts with metformin
diminished the glycemic levels after 24 h. Thus, the data demonstrated that the hypoglycemic activity
of the C. papaya leaf extract was as effective as the hypoglycemic agents, metformin and glimepiride.
However, the latter had a faster action onset, as the effect of the duration of application was dependent
on the nature, i.e., on the activity strength, and on the dose. Besides, the interaction between the
combination drug-extract was different for each group, since the action mechanisms of glimepiride
differ from those of metformin [57].
In studies [58] on C. papaya on streptozotocin (STPZ)-induced diabetes, the crude ethanolic
extract of C. papaya leaf (100 mg/kg/day), in comparison with the ethanolic extract of the leaves of
Pandanusam aryllifolius (100 mg/kg/day) and the drug glyburide (10 mg/kg) by gavage for 6 days
in albino mice with induced diabetes by STPZ (60 mg/kg/body mass), did not alter body weight.
However, there was a reduction of glycemia, and the histology showed spleen cell regeneration,
reduced the number of liver pyknotic nuclei and vacuoles, and recovered kidney cuboidal tissue.
The phytochemical analyses indicated the presence of alkaloids, tannins, flavonoids and saponins,
suggesting that these bioactive compounds are responsible for such effects.
A possible hypothesis for the metabolic actions of C. papaya extracts can be seen in the study by
Juárez-Rojop et al. (2012) [59], utilizing the water extract of C. papaya leaves at three doses (0.75, 1.5
and 3 g·100 mL−1) in the drinking water of animals with induced diabetes by STPZ (60 mg/kg to body
mass) and non-diabetic animals for a 4-week period. The results demonstrated that the extracts at 0.75
and 1.5 g·100 mL−1 diminished the levels of glycemia, as well as the serum levels of total cholesterol
and triglycerides. The regeneration of pancreatic islets, with a preserved cell size, was demonstrated,
and yet, a rupture of hepatocytes and accumulation of glycogen and lipids was prevented. Besides, it
was verified that the metabolites of nitric oxide (NO) were reduced in diabetic rats. However, with the
application of the extracts, the NO levels rose. It is known that hyperglycemia and hyperlipidemia are
characterized by the inhibition of endothelial NO Synthase (eNOS) and, consequently, can result in the
formation of reactive oxygen species (ROS) in relaxation, depending on the damaged endothelium,
with a high formation of free radicals, concomitant with a low effectiveness of antioxidant enzymes,
leading to an imbalance between the formation and the protection against free radicals in the organism.
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Thus, the metabolic actions in that study could be related to the increased antioxidant activity of the
extract, exerted in diabetic animals.
Previous studies [60] evaluated the phytochemical composition of C. papaya leaf extracts on the
basis of chloroform, n-hexane and ethanol and verified that the chloroform extract presented steroids
and quinones among its main components, which led to the choosing of this extract for the screening
of biological activity in STPZ-induced diabetic rats (60 mg/kg/body mass).
Different doses of a chloroform extract (0, 31, 62, 125 mg/kg/body mass) of C. papaya leaf were
given by gavage to diabetic and non-diabetic rats, and as the positive control group, diabetic rats were
treated with insulin (5 U/kg, intraperitoneal) for 20 days. The data proved that the extract reduced
the glycemic levels, the serum concentrations of triglycerides and total cholesterol and maintained
the HDL-c at levels similar to those observed in non-diabetic rats. Furthermore, the concentrations of
31 and 62 mg/kg/body mass of the extract reduced the body weight and the levels of AST and ALT,
without differences for the extract with the highest concentration (125/mg/kg/body mass).
Considering not just the systemic and biochemical actions, the extract was able to act on specific
tissues, such as the pancreatic islets, either in diabetic rats induced by STPZ (60 mg/kg/body mass) and
in vitro in cell cultures of pancreatic islets, which were found to be the actions of the chloroform extract
of C. papaya leaves (31, 62, 125 mg/kg/body mass), applied by gavage for 20 days. The animals receiving
the extract at concentrations of 31 and 62 mg/kg/body mass showed a reduction in fastening glycemia.
On the other hand, the serum levels of insulin increased in non-diabetic rats receiving 62 mg/kg/body
mass, compared with the non-diabetic group, without the extract. In cell cultures of pancreatic islets
treated with STPZ (6 mg in 30 μL polyethylene glycol), a decrease in the liberation of the basal insulin
culture with glucose (2 g/L) occurred. Besides, when added to the extract (6 mg in 30 μL polyethylene
glycol) applied to cells with STPZ, more insulin liberation occurred. However, when STPZ was added
simultaneously with the extracts (3, or 6, or 12 mg in 30 μL), insulin liberation was diminished in the
three conditions, independently of the dose. However, when STPZ was added after 5 days of using the
extracts, the insulin liberated from the pancreatic islets was superior to the cells of the control group,
normal and similar to cells with the 6 mg extract, suggesting that the extracts have a protective action
on pancreatic islets. The results are confirmed by an immune histochemical trial of the spleen, in which
it was verified that the diameters and areas were larger in the groups treated with C. papaya extract,
compared with the diabetic group [61].
Among the bioactive compounds of the major proportion in the chloroform extract are the steroids.
In diabetes, changes occur in the structure and function of the absorption of intestinal glucose, e.g.,
an increase in glucose uptake that could cause postprandial hyperglycemia. Thus, the hypothesis is
that the steroids hinder the hydrolysis of carbohydrates and the absorption of intestinal glucose by
hydrolyzing enzymes limiting the levels of post prandial glucose [61–63].
It is known that diabetes mellitus is characterized by a deficiency in insulin secretion and by a low
response of the organs in the action of insulin [64]. The compounds present in the C. papaya extract
may be related to effects similar to those of insulin in glycemic metabolism, promoting glucose uptake
in peripherical tissues or in the skeletal muscle and adipose tissues by a process of regeneration and
revitalization of their main β-cells [60,65].
Another mechanism, which may be related to the effects of C. papaya on glycemic metabolism, may
be the inhibition of important enzymes involved in the digestion of carbohydrates, such as α-amylase
and α-glycosidase. Oboh et al. (2013) [66] demonstrated that the water extract of different parts of
the green fruit of C. papaya was able to promote the inhibition of α-amylase and α-glycosidase in
a dose-dependent way (0 to 2.0 mg/mL), and the combination of different parts of the green fruit,
such as seeds, pulp and peel, in equal proportions had the best inhibitory effects on both enzymes.
The α-amylase degrades complex carbohydrates in the diet into oligosaccharides and disaccharides,
which are converted into monosaccharides by α-glycosidase. The liberated glucose is absorbed
by the intestine, resulting in post prandial hyperglycemia. A higher inhibition of these enzymes
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thereby occurs, and the rise of post prandial glucose from a carbohydrate-rich diet will be significantly
diminished, slowing the process of hydrolysis and uptake of carbohydrates [67,68].
Oxidative stress is also one of the mechanisms conducive to the development and progression of
diabetes mellitus, since an exacerbated increase in the production of free radicals occurs simultaneously
with the decreased mechanisms of antioxidant defenses, which can result in the cell damage of
organelles and enzymes, increased lipidic peroxidation and, consequently, the development of insulin
resistance [69,70]. In this way, C. papaya was also able to present antioxidant activity [68]. Different
parts of the green fruits of C. papaya inhibited the lipidic peroxidation induced by sodium nitroprusside
in rat pancreatic cells in vitro [66]. Sodium nitroprusside is an anti-hypertensive drug, which causes
cytotoxicity by the liberation of cyanide and/or NO. Under conditions of oxidative stress, NO, together
with other ROSs, such as the radical superoxide, lead to the formation of the radical peroxynitrite
(ONOO-), which is a potent oxidant agent that can harm most cell components, such as proteins,
DNA and membrane phospholipids [71,72]. Thus, the study showed that the extract of the pulp with
the peel of green fruits can have a strong inhibitory effect on the production of malondialdehyde
(MDA) and a greater ability of NO radical scavenging than seeds. Such effects are attributed to the
phenolic compounds and alkaloids present in the pulp, seed and peel extracts of C. papaya, which are
biocomponents with a high antioxidant action in removing free radicals, catalyzing chelating metals,
activating antioxidant enzymes, reducing the radicals of α-tocopherol and inhibiting oxidases [64,73].
Corroborating the antioxidant actions of C. papaya, Salla et al. (2016) [74] reported on the
antioxidant activity of the methanolic and hexanic extracts at concentrations of 50, 100 and 250 μg/mL
of C. papaya seed on HepG2 cells, the cell strain of the human hepatoma, which incurred an induction of
oxidative stress by the application of hydrogen peroxide (H2O2) (500μM). The activity of the antioxidant
enzyme superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and levels
of glutathione (GSH) were lower after the induction of oxidative stress by H2O2, and after the use
of methanolic and hexanic extracts, the activity of SOD was restored, except with 50 μg/mL. The
GSH levels increased with the concentration of 250 μg/mL methanolic extract and 100 and 250 μg/mL
hexanic extract, and the CAT activity rose with the concentrations of 250 and 500 μg/mL, with GPx only
at 250 μg/mL of methanolic extract. Besides, the highest concentrations of both extracts diminished
cell viability, but this could be verified in higher proportion with the hexanic extract. The levels
of flavonoids in the extracts were superior in the methanolic extract, compared with the hexanic,
confirming that the antioxidant activity is related to the presence of these polyphenols.
Like glycemic metabolism, the bioactive compounds present in the C. papaya extracts can exert
effects similar to insulin in the lipidic metabolism, as under normal conditions the insulin activates the
lipoprotein lipase, hydrolyses triglycerides and inhibits the lipolysis process. Insulin deficiency, in turn,
stimulates lipolysis in the adipose tissue, leading to hyperlipidemia and an accumulation of hepatic fat,
decreasing the content of the enzyme lipoprotein lipase, which hydrolyses lipids, resulting in increased
concentrations of serum triglycerides. Increased LDL-c levels occur because of the inhibition of the
insulin action in the activity of the enzyme, β-hydroxy-β-methyl glutaryl CoA reductase (HMG-CoA
reductase), which exerts an important role in cholesterol metabolism [53,66].
The action of the C. papaya extract on the enzyme, HMG-CoA reductase, is reported by Hasimun et al.
(2018) [75], assessing specifically the actions in the lipidic metabolism of the ethanolic extract of C. papaya
leaves (50, 100, 200 mg/kg/body mass) by gavage in Wistar rats, receiving 25% of D-fructose in drinking
water for 21 days. The results showed an anti-hyperlipidemic activity of the extract at a dose of
200 mg/kg/body mass, leading to decreased total levels of cholesterol, triglycerides, and LDL-c
and an increase in HDL-c. The mechanism involved is related to the inhibition of the enzyme,
HMG-CoA reductase, activity in the liver, an enzyme with an important role in the synthesis of
endogenous cholesterol, the inhibition of which is similar to the effects of drugs of the class of
statins, such as simvastatin, used as a positive control. Besides, the phytochemical analyses revealed
secondary metabolites, such as alkaloids, flavonoids, tannin, saponins, steroids/triterpenoids and
quinones, suggesting that the flavonoids contained in the leaf extract, especially quercetin, could
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be the responsible for exerting the same mechanism as that of the statins in inhibiting HMG CoA
reductase [75–77].
Similar data in the lipidic metabolism of C. papaya extract were observed in albino Wistar rats, fed
with hyperlipidic diet. The effects on dyslipidemia were observed, testing the water extract of papaya
seed (200 and 300 mg/body mass/day) by gavage for 5 weeks, which led to a significant reduction of
total cholesterol, triglycerides, and LDL-c and an increase in HDL-c in hypercholesterolemic animals.
However, the antilipidemic effects of different extract concentrations were not superior to the group
receiving the reference drug, simvastatin (1.8 mg/bodymass/day) [78].
Besides the effects on glycemia and lipidic series, C. papaya showed actions on the systemic arterial
hypertension (SAH) in animal models. After evaluating the inhibitory action of the extracts on the
activity of the angiotensin-converting enzyme (ACE) in vitro, the methanolic extract of C. papaya leaves
was chosen for the study by Brasil et al. (2014) [79]. The methanolic extract (100 mg/body mass/twice a
day) was given by gavage in spontaneously hypertense Wistar rats (SHR) for 30 days. Like the reference
drug (enalapril 10 mg/body mass/day), an ACE inhibitor, the methanolic extract inhibited plasmatic
ACE activity, enhanced cardiac hypertrophy and normalized baroreflex sensibility, suggesting the
efficiency of this extract as an anti-hypertensive [79]. The systemic arterial pressure is controlled
by both the renin-angiotensin system (RAS) and baroreflex. The latter is an important short-term
reflex, which controls the responses of the heart beats [80]. The uncontrolled activation of RAS has
an important role in the development of cardiac hypertrophy, the ACE inhibitors being important
treatment options, since ACE is an important component of RAS, which leads to the formation of
angiotensin II, the main vasoconstrictor of RAS, and to the reduction of baroreflex sensibility for rising
blood pressure and sympathetic regulation [81,82]. In that study, the extract effects on arterial pressure
could result from the presence of different bioactive compounds, especially flavonoids, e.g., ferulic
acid, caffeic acid, gallic acid and quercetin, with a suggested action on ACE inhibition [79]. Previous
studies demonstrated the presence of quercetin, luteolin and kaempferol in apple peel extract, which
acted as inhibitors of ACE activity in vitro [83,84].
In a model of arterial hypertension induced by deoxycorticosterone acetate (DOCA, 15 mg·100 g−1)
in Wistar rats, the crude extract of C. papaya fruit (20 mg/kg), besides not presenting toxic effects, was
able to generate a fast drop of arterial blood pressure and heart rate, compared with normotensive
rats, and had a more potent anti-hypertensive action than hydralazine (200 mg/100 g, intravenous),
a vasodilator and anti-hypertensive agent [85]. Earlier studies revealed a higher activity in the
synthesis of catecholamines, e.g., a higher activity of tyrosine hydroxylase in the adrenal glands of
DOCA-induced hypertense rats and in rats with renal hypertension [86,87]. Therefore, the capacity of
the extract to depress the arterial pressure and the heart rate may be caused by the reduction of levels
of catecholamines, liberated in response to the extract [88].
While the reviewed studies hitherto were not performed in specific models of metabolic syndrome
or obesity, the achieved results demonstrated that C. papaya has a therapeutic potential for various types
of metabolic dysfunctions, such as diabetes mellitus type 1, leading to alterations in both glycemic and
lipidic metabolism, oxidative stress and in models of arterial hypertension. After those studies on
the actions of C. papaya in metabolism, further investigations on this plant in models of obesity and
metabolic syndrome are needed, which would facilitate the search for new therapeutic approaches
and a better understanding of the mechanisms of action in the metabolic dysfunctions associated
with obesity.
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5. Conclusions
This review evaluated the nutritional and phytochemical composition of C. papaya as well as
the effects of the use of several types of extract from different parts of the plant. C papaya exhibits
curative properties, such as improvements in hepatotoxicity and nephrotoxicity induced by drugs,
antimicrobial, antimalarial, anti-parasitic, antitumor, anti-inflammatory actions and wound healing
effects. In relation to the metabolic dysfunctions, C. papaya displays hypoglycemic, hypolipidemic and
antihypertensive potential and demonstrates increased antioxidant activity in experimental models
in vivo and in vitro. Therefore, further studies including researches on diet-induced and genetic
obesity models in addition to the isolation of specific substances from different parts of C. papaya will
be important for the development of novel natural products on the treatment and prevention of obesity
and metabolic disturbances.
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Abstract: Annona muricata Linn, commonly known as graviola, is one of the most popular plants used
in Brazil for weight loss. The aim of this study is to evaluate the therapeutic effects of three different
doses (50 mg/kg, 100 mg/kg, and 150 mg/kg) of aqueous graviola leaf extract (AGE) supplemented by
oral gavage, on obese C57BL/6 mice. Food intake, body weight, an oral glucose tolerance test (OGTT),
an insulin sensitivity test, quantification of adipose tissue cytokines, weight of fat pads, and serum
biochemical and histological analyses of the liver, pancreas, and epididymal adipose tissue were
measured. AGE had an anti-inflammatory effect by increasing IL-10 at doses of 50 and 100 mg/kg.
Regarding the cholesterol profile, there was a significant decrease in LDL-cholesterol levels in the
AGE 150 group, and VLDL-cholesterol and triglycerides in the AGE 100 and 150 groups. There was
an increase in HDL cholesterol in the AGE 150 group. The extract was able to reduce the adipocyte
area of the epididymal adipose tissue in the AGE 100 and 150 groups. According to the histological
analysis of the liver and pancreas, no significant difference was found among the groups. There were
no significant effects of AGE on OGTT and serum fasting glucose concentration. However, the extract
was effective in improving glucose tolerance in the AGE 150 group.
Keywords: graviola; weight loss; obesity
1. Introduction
Obesity is a worldwide public health problem. It increases the risk of metabolic diseases such
as hypercholesterolemia, hypertriglyceridemia, insulin resistance, heart disease, type 2 diabetes,
atherosclerosis, and cancer [1,2].
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The etiology of obesity is complex and multifactorial. Obesity results from the interaction of
genetic/epigenetic, environmental, emotional, lifestyle factors and that technically obesity results from
a positive energy balance: More energy intake than energy expenditure [3]. Although genetic factors
are determinant in the development of obesity, metabolic factors, an unhealthy diet, and a sedentary
lifestyle provide conditions for the development of this disorder [4].
Obesity is an increased deposition of white adipose tissue and phenotypic changes in this
tissue. It is associated with metabolic changes such as increased production of pro-inflammatory
mediators. This leads to organs dysfunction and chronic low-grade inflammation with high levels
of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and
chemokines, such as monocyte chemotactic protein 1 (MCP1), which in turn promotes migration of
macrophages into the adipose tissue and increases the release of cytokines. In parallel, low levels of
interleukin 10 (IL-10) are observed in obese individuals, and worsens their metabolic profile, since
IL-10 inhibits the synthesis of pro-inflammatory cytokines [2,5–8].
To control such abnormalities, several methods have been suggested to regulate obesity and
weight gain, including agents that could inhibit fat absorption, control biochemical parameters, such
as, serum glucose, serum triglyceride, total cholesterol, high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and very low-density lipoprotein (VLDL) levels, reduce systemic inflammation, and
induce weight loss [9]. Medicinal plants, popularly indicated for the treatment of obesity, have been
used in many countries to control weight gain and obesity [10].
For these reasons, anti-obesity agents, including infusions and extracts, are widely used for weight
control in obese individuals, in addition to reducing biochemical parameters [11].
Tropical countries have a wide variety of flora and a high number of food and medicinal plants.
There is information available on the potential functional properties of several of these plants [12].
The investigation of such properties may be of interest for both the pharmaceutical and the food
industry [13].
Among the species of pharmaceutical interest, the leaf of Annona muricata Linn (Annonaceae),
commonly known as soursop or graviola, is used routinely for weight control. It is used in traditional
medicine as an antihypertensive, vasodilator, antidiabetic, and hypolipidemic agent due to the presence
of several bioactive compounds, such as acetogenins, flavonoids, tannins, alkaloids, coumarins, and
terpenoids [14,15]. Therefore, considering the popular use of tea from graviola leaves to prevent
obesity and its complications, it is important to verify whether treatment using an aqueous extract of
Annona muricata Linn could also be beneficial for the treatment of obesity. Thus, the objective of this
study is to verify the effects of three different doses of aqueous extract of Annona muricata on obese
C57BL/6 mice induced by a high-fat diet.
2. Materials and Methods
2.1. Extraction of Plant Material
Leaves of Annona muricata Linn were collected in June 2015 from an adult specimen that produces
flowers and fruits, in the municipality of Campo Grande, Mato Grosso do Sul state, Brazil. The tree
was properly identified. The geographical coordinates defined by manual GPS were 22◦29′42.6” S and
054◦37′1.6” W. A voucher specimen (number 53,928) was deposited at the Herbarium CGMS of the
Federal University of Mato Grosso do Sul, Brazil. The extract of leaves of Annona muricata Linn was
prepared by immersing 1 kg of leaf powder into 3 L of distilled water for 48 h, then lyophilizing this
until a dry powder was obtained. Then, the extract was stored at room temperature and protected
from light until use [14].
2.2. Quantification of Total Phenols and Flavonoids
The total phenols of aqueous graviola leaf extract (AGE) were determined by the Folin-Ciocalteu
reagent method [16]. Samples and a standard curve of gallic acid were read at 760 nm. The result was
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expressed as mg of gallic acid per g of extract. For the quantification of the flavonoids, the colorimetric
method of aluminum chloride was used [17]. The absorbances were read at 415 nm with a UV-Vis
spectrophotometer. To calculate the concentration of flavonoids, an analytical curve was prepared
using quercetin as standard. The results are expressed as mg quercetin per g of extract.
2.3. Quantification of Condensed Tannins
The extract was dissolved in water at a concentration of 50 μg·mL−1 using the valinine reaction [18].
The absorbance reading was performed using a spectrophotometer at 510 nm. The quantification was
performed using an external calibration curve with catechin as standard. The results are expressed as
mg equivalent of catechin per g of extract.
2.4. Assay of Antioxidant Activity Using the 2,2-Diphenyl-1-Picrylhydrazyl Free Radical (DPPH)
The sequestering capacity was measured using DPPH solution. The absorbances were read at 517
nm with a spectrophotometer. The percentage of DPPH radical sequestration inhibition was calculated
according to the equation:
Percent inhibition activity (%) = [(A0 − A1)/A0] 100 (1)
where A0 is the absorbance of the control, and A1 is the absorbance in the presence of the compound.
Subsequently, the mean inhibitory concentration (IC 50) was calculated. It represents the concentration
of the sample required to capture 50% of the DPPH [19].
2.5. Isolation and Identification of Compounds
The extract was fractionated by XAD-2 (Supelco, Bellefonte, PA, USA) on column chromatography
(30 cm × 3 cm). The extract (3.16 g) was eluted with 0.5 L of water, followed by 0.5 L of methanol,
and again eluted with 0.2 L of ethyl acetate. An aliquot of 0.89 g of the methanolic fraction was
dissolved into 50 mL of methanol and fractionated by chromatography using a Sephadex LH-20
(Amersham Pharmacia Biotech, Uppsala, Sweden) on column chromatography (70 cm × 3 cm) at a
rate of 0.2 mL·min−1. Twenty-five fractions of 2 mL were collected. The fractions were combined
according to their chemical behavior on thin layer chromatography (silica gel plates) using ethyl
acetate:n-propanol:water (123:7:70 v/v/v) as the eluent. The fractions 2–4, 6–8 and 11–14 were
purified using polyvinylpolypyrrolidone (Sigma, St. Louis, MO, USA) on column chromatography
(10 cm × 2 cm) by eluting them with methanol. The result is the identification of compounds. An
aliquot of 0.54 g of the ethyl acetate fraction was dissolved into 10 mL of methanol and fractionated by
chromatography using a Sephadex LH-20 (Amersham Pharmacia Biotech, Uppsala, Sweden) on column
chromatography (80 cm × 2 cm) by eluting it with methanol at a rate of 0.3 mL·min−1. Twenty-eight
fractions of 5 mL were collected. The fractions were combined according to their chemical behavior on
thin layer chromatography (silica gel plates) using ethyl acetate:methanol (60:40 v/v) as the eluent. The
fractions 10–13, 18–19 and 22–25 resulted in the isolation of the other compounds. The identification
of the compounds was carried out using 1H and 13C nuclear resonance (Advance 300 MHz, Brucher,
Ettlingen, Germany) and mass spectrometry (Shimadzu Corp. Shimadzu, Kyoto). Their chemical
structures were confirmed by comparison with literature data [20–22].
2.6. Ethics Statement
All animal experiments were submitted and approved by the Ethics Committee on Animal Use,
Federal University of Mato Grosso do Sul (Protocol no. 682/2015).
2.7. Acute Oral Toxicity
The acute toxicity test of the AGE was performed in female Wistar rats (Rattus norvegicus) based
on the OECD Guidelines 425 (Organization for Economic Co-operation and Development) [23]. For the
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test, the animals were divided into two groups (n = 5): A control group that received saline solution,
and the treatment group that received the aqueous extract of Annona muricata Linn orally (gavage) at a
dose of 2000 mg/kg. After treatment, the animals were observed at 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 12 h,
24 h, and then daily for 14 days.
At the same time, the hippocratic screening test was carried out to quantify the effects of abnormal
morphological and behavioral signs of toxicity. Furthermore, changes in body weight, water and food
intake, as well as excreta production, were also evaluated [24].
At the end of 14 days, the animals were euthanized (ketamine and xylazine). The organs (heart,
lung, liver, spleen, pancreas, and kidneys) were removed, weighed, and analyzed macroscopically to
investigate possible changes [25].
2.8. Animals and Experimental Design
C57BL/6 adult male mice (n = 55, 12 weeks of age) were divided into two groups based on
body weight, as follows: SHAM group (n = 11), treated with standard diet AIN-93M [26], and HFD
group (n = 44), treated with a hyperlipidic diet. After 12 weeks, the animals of the HFD group were
divided into four homogenous groups according to weight and value of fasting blood glucose and
concomitantly supplemented (oral gavage) with aqueous graviola leaf extract in different doses: HFD
SALINE group (HFD + saline), AGE 50 mg/kg group (HFD + aqueous graviola leaf extract of 50 mg/kg)
(n = 11), AGE 100 mg/kg group (HFD + aqueous graviola leaf extract of 100 mg/kg) (n = 11), and AGE
150 mg/kg group (HFD + aqueous graviola leaf extract of 150 mg/kg) (n = 11). The SHAM group
also received saline solution at this stage of the study. Each group had ad libitum access to water
and food during the experimental period. The composition of the experimental diets is show in the
Table 1 below.
Table 1. Composition of experimental diets (g/kg diet).






Soybean oil 40.00 20.00
Fiber 50.00 50.00
Mineral mix 35.00 35.00
Vitamin mix 10.00 10.00
L-cystine 1.80 1.80
Choline bitartrate 2.50 2.50
Tert-butylhydroquinone 0.008 0.008
Energy (kcal/kg) 3802.8 5302.8
Carbohydrates (%) 75.81 31.73
Protein (%) 14.73 10.56
Lipids (%) 9.47 57.71
Calories/g of diet 3.80 5.30
The mice were anesthetized (Ketamine and xylazine, 75 and 10 mg/kg, respectively),
and euthanized by cardiac puncture when they reached 35 weeks of age. The blood and the
organs were collected for subsequent analyses.
2.9. Body Weight and Diet Intake
The mice were weighed weekly to observe weight changes until the end of the study. Food intake
was measured three times per week.
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The energy intake was calculated by multiplying the amount of diet ingested (g/day/animal) by
the energy density of each diet, expressed in kcal/day per animal. In addition, the calculation of the
feed efficiency index (FEI) was performed using the following equation:




where FW is the final body weight in grams, IW is the initial body weight in grams, and TF is the total
amount of food ingested in grams [27].
2.10. Biochemical Analysis
Serum glucose, serum triglyceride, total cholesterol, high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and very low-density lipoprotein (VLDL) levels were analyzed by the enzymatic
colorimetric test, according to the manufacturer’s instructions (Labtest®, Lagoa Santa, Minas Gerais,
Brazil). The atherogenic index was determined by the ratio between total cholesterol and HDL
cholesterol [14].
2.11. Oral Glucose Tolerance Test
The oral glucose tolerance test (OGTT) was performed one day prior to initiating treatment with
the AGE or saline solution, and three days prior to the euthanasia of animals after six hours of fasting.
Fasting glucose was verified via flow rate (time 0) using a G-Tech® glucometer (G-TECH Free, Infopia
Co., Ltd. South Korea). Then, the animals received a D-glucose solution (Sigma Aldrich, Duque de
Caxias, Rio de Janeiro, Brazil), at 2 g/kg of body weight, by gavage. A blood glucose reading was
performed 15, 30, 60 and 120 min after glucose application. The area under the curve (AUC) was
calculated for each mouse, and the mean was calculated for each experimental group [28].
2.12. Insulin Sensitivity Test
The insulin sensitivity test was performed five days before euthanasia. Glycemia was verified
with the animals in a fed state (time 0). Then, 0.75 units of insulin (NovoRapid®, 100 U/mL, Novo
Nordisk, Bagsvaerd, Denmark) per kg of animal weight was injected intraperitoneally. The blood
glucose reading was performed at 15, 30 and 60 min using a G-Tech® glucometer (G-TECH Free,
Korea). The area under the curve (AUC) was calculated for each animal, and the mean was calculated
for each experimental group [28].
2.13. Quantification of Cytokines in the Adipose Tissue
Epididymal adipose tissue was collected, weighed (100 mg) and stored at –80 ◦C. For protein
extraction, the epididymal adipose tissue was thawed on ice and homogenized in 1 mL of RIPA (RIPA
Lysis Buffer, 10×, Cat. no. 20–188, MERCK, Darmstadt, Germany). A cocktail of protease inhibitors was
added (Protease Inhibitor Cocktail Set Calbiochem, Cat. no. 539131, MERCK, Darmstadt, Germany).
The supernatant was collected after centrifugation at 4 ◦C and stored again at –80 ◦C until
cytokine analysis, according to the recommendations of the manufacturer (MILLIPLEX MAP/Mouse
Cytokine/Chemokine and Adipocyte Magnetic Bead panel) (Millipore, Billerica, MA, USA). The
concentrations of the following cytokines were analyzed: IL-10, IL-6, MCP-1, and TNF-α using the
MCYTOMAG-70K kit, and adiponectin using the MADCYMAG-72K kit. The concentration of the
cytokines IL-10, IL-6, MCP-1, and TNF-α in the adipose tissue was expressed as cytokine picograms in
relation to protein content (mg of protein). For adiponectin, the values were expressed as nanograms
of cytokines in relation to protein content (mg of protein). Protein quantification was based on the
bicinchoninic acid assay (BCA) following the manufacturer’s recommendations (BCA Protein Assay
kit) (MERCK, Darmstadt, Germany) [29,30].
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2.14. Assessment of Body Fat and Liver Weight
After euthanasia, the liver and fat pads of white adipose tissue (omental, epididymal, perirenal,
retroperitoneal, and mesenteric) were dissected and weighed. The adiposity index was calculated as
the total sum of visceral white adipose tissue (g) divided by the final body weight of the animal × 100
and expressed as percentage of adiposity [31].
2.15. Histopathological Analysis
Samples of the liver, pancreas, and epididymal adipose tissue were fixed with 10% formalin
solution. After fixation, the specimens were dehydrated, embedded in paraffin, cut in a microtome to a
thickness of 5 mm each, and stained with hematoxylin-eosin. An expert pathologist performed the
histological analysis of the liver and pancreas. For the analysis of treatment effects on the hepatocytes, a
scoring system was used [32]. In the evaluation of the architecture of the pancreas, there were changes
in the Islets of Langerhans and pancreatic acini, and inflammation was observed [33,34]. For the
analysis of the adipocyte area of the epididymal adipose tissue, the images were initially taken using a
LEICA DFC 495 digital camera system (Leica Microsystems, Wetzlar, Germany) integrated into a LEICA
DM 5500B microscope (Leica Microsystems, Wetzlar, Germany), with a magnification of 20X. The
images were analyzed using the LEICA Application Suite software, version 4.0 (Leica Microsystems,
Wetzlar, Germany), and the mean area of 100 adipocytes per sample was determined [35].
2.16. Statistical Analyses
The results were expressed as mean ±MSE (mean standard error). For multiple comparisons of
parametric results, an ANOVA followed by a Tukey post-test were performed. The Student t-test was
performed for comparison between two groups. The chi-square test was used to evaluate associations
in histological analyses. A significance level of p < 0.05 was adopted. Statistical analysis was performed
using the software Jandel Sigma Stat, version 3.5 (Systat software, Incs., San Jose, CA, USA), and Sigma
Plot, version 12.5 (Systat Software Inc., San Jose, CA, USA).
3. Results
3.1. Chemical Composition
The content of phenols, flavonoids, and tannins in AGE was 156.37 ± 1.2 mg/g, 92.07 ± 1.8 mg/g
and 42.99 ± 0.6 mg/g, respectively. The antioxidant activity of IC50 was 12 ± 0.1 μg·mL−1. In addition, six
compounds were isolated and identified in the extract: kaempferol-3-O-a-l-rhamnopyranoside, quercetin
3-O-rutinoside, kaempferol 3-O-rutinoside, luteolin, quercetin, and sitosterol-3-O-β-d-glucopyranoside.
3.2. Acute Oral Toxicity
The results showed no signs of systemic toxicity. There are no changes in body weight, water
consumption, food intake, and excretion of urine and feces. In addition, no changes in the Hippocratic
screening test were observed, such as motor and/or sensory and neurological changes, as no animals
died. The weight of the liver, spleen, pancreas, lungs, heart, and kidneys did not show significant
differences among groups. Macroscopic changes in the organs of the animals were not visualized
(Supplementary Material Figure S1).
3.3. Effects of AGE on Body Weight and Food Intake
At the beginning of the experiment, the animals in the HFD group did not present significant
differences in body weight when compared to animals in the SHAM group (p = 0.971) (Table 2).
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Table 2. Initial and final weight, weight gain and food intake assessment during obesity induction







Initial weight (g) 26.55 ± 0.55 26.52 ± 0.28
Final weight (g) 32.91 ± 0.99 37.87 ± 0.60 ***
Weight gain (g) 6.36 ± 0.95 11.34 ± 0.68 **
Food intake (g/day) 3.47 ± 0.05 2.73 ± 0.03 ***
Food intake (kcal/day) 13.18 ± 0.19 14.54 ± 0.16 ***
Feed efficiency index 0.0216 ± 0.0031 0.0501 ± 0.0033 ***
SHAM: Standard diet. HFD: Hyperlipidic diet. Values represent the mean ± mean standard error;, ** p ≤ 0.01,
*** p ≤ 0.001 vs. SHAM SALINE. Student t test.
However, with the HFD, the weight evolution evidenced a greater gain of body weight in the
HFD group, with maintenance of a significant difference from the fourth week up to the 12th week
(p = 0.005) compared to the control group (p ≤ 0.001) (Figure 1A).
Then, the animals of groups receiving a hyperlipidic diet began treatments with different doses of
the extract or saline solution. At the 12th week, there was a significant difference in body weight in
relation to the SHAM SALINE group (Table 3). However, this difference was not stable throughout the
treatment. At the end of the 24th week, this group had a statistically similar body weight compared to
the other groups (Figure 1B).
Table 3. Initial and final weight, weight gain, and food intake of control animals and animals treated
with AGE between the 13th and the 24th week.
Parameter
Experimental Group
SHAM SALINE HFD SALINE AGE 50 AGE 100 AGE 150
Initial weight (g) 32.89 ± 0.94 38.09 ± 1.42 * 37.91 ± 1.09 * 37.82 ± 0.91 * 37.64 ± 1.43 *
Final weight (g) 35.91 ± 1.26 40.27 ± 1.42 37.82 ± 1.05 36.82 ± 1.33 38.27 ± 1.94
Weight gain (g) 3.09 ± 0.60 2.18 ± 0.26 −0.09 ± 0.53 * −1.00 ± 1.14 **,§ 0.64 ± 0.92
Food intake (g/day) 3.40 ± 0.43 2.62 ± 0.62 *** 2.76 ± 0.05 *** 2.70 ± 0.98 *** 2.83 ± 0.07 ***
Food intake (kcal/day) 12.89 ± 0.16 13.89 ± 0.33 14.65 ± 0.25 ** 14.30 ± 0.52 * 14.99 ± 0.37 ***
Feed efficiency index 0.0109 ± 0.0021 0.010 ± 0.00128 −0.0006 ± 0.0023 −0.0036 ± 0.0050 *,§ 0.0031 ± 0.0040
SHAM SALINE: standard diet + saline solution. HFD SALINE: hyperlipidic diet + saline solution. AGE 50:
hyperlipidic diet + 50 mg/kg of aqueous graviola leaf extract. AGE 100: hyperlipidic diet + 100 mg/kg of aqueous
graviola leaf extract. AGE 150: hyperlipidic diet + 150 mg/kg of aqueous graviola leaf extract. Values represent the
mean ±mean standard error. In the same line, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs. SHAM SALINE; § p ≤ 0.05 vs.
HFD SALINE; ANOVA followed by post Tukey test.
At the end of the treatment with the extract, the groups AGE 50 mg/kg and AGE 100 mg/kg
presented a lower weight gain in comparison to the other groups (Table 3). The group AGE 50 mg/kg
presented a statistical difference in relation to the SHAM SALINE group (p = 0.034). The group AGE
100 mg/kg had a significant body weight loss compared to the SHAM SALINE (p = 0.003) and HFD
SALINE (p = 0.034) groups.
Food intake during the induction period was significantly higher in the SHAM group than in
the HFD group (p ≤ 0.001). However, the caloric intake and the FEI were significantly higher in the
HFD group than in the SHAM group (p ≤ 0.001) (Table 2). During the treatment period with the
extract, similar results were observed for food intake, but daily caloric intake was significantly higher
in the groups AGE 50 mg/kg (p = 0.007), AGE 100 mg/kg (p = 0.048) and AGE 150 mg/kg (p ≤ 0.001),
compared to the SHAM SALINE group. However, the FEI was significantly lower in the group AGE
100 mg/kg when compared to the SHAM SALINE group (p = 0.021) and the HFD SALINE (p = 0.035)
group (Table 3). That is, there was a lower feed conversion capacity into body mass in the group AGE
100 mg/kg.
203






































































































































































































































































































































































































Nutrients 2019, 11, 1509
3.4. Effects of AGE on Serum Biochemical Parameters
In this experimental model, the AGE was not able to decrease serum fasting glucose concentrations
at the end of the study (p = 0.242) (Figure 2A).
Figure 2. Evaluation of serum parameters. (A) Blood glucose (mg/dL), (B) total cholesterol
(mg/dL), (C) LDL-cholesterol (mg/dL), (D) HDL-cholesterol (mg/dL), (E) VLDL-cholesterol (mg/dL), (F)
triglycerides (mg/dL), and (G) atherogenic index of control animals (SHAM SALINE: standard diet +
saline solution, HFD SALINE: hyperlipidic diet + saline solution), and of animals treated with aqueous
graviola leaf extract (AGE) at 50, 100, and 150 mg/kg + hyperlipidic diet between the 13th and the 24th
week of study. Values represent mean ±mean standard error. * p < 0.05, ** p < 0.01 vs. SHAM SALINE;
§ p < 0.05 vs. HFD SALINE. ANOVA followed by post Tukey test.
The AGE was also not able to significantly change the total serum cholesterol and HDL
concentration (Figure 2B,D). However, serum HDL-cholesterol levels showed a 30.35% increase
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in concentration in the group treated with AGE 150 mg/kg (61.57 ± 6.47 mg/dL), compared to the HFD
SALINE group (42.88 ± 5.40 mg/dL) (Figure 2D). For total serum cholesterol, the percentage decrease
in AGE-treated groups was 4.92% for AGE 50 mg/kg (200.84 ± 8.30 mg/dL), 20.54% for AGE 100 mg/kg
(167.85 ± 8.22 mg/dL), and 17.49% for AGE 150 mg/kg (174.30 ± 13.10 mg/dL) compared to the HFD
SALINE group (211.24 ± 16.33 mg/dL) (Figure 2B).
In this study, the decrease in LDL-cholesterol concentration in the AGE-treated groups seems to
be directly associated with the dose given. That is, the higher the AGE dose, the greater the decrease.
There was a significant difference (p = 0.038) between AGE 150 mg/kg in relation to the HFD SALINE
group (Figure 2C). In addition, AGE was able to significantly decrease triglyceride concentrations in
the treated groups at doses of 100 mg/kg (p = 0.026) and 150 mg/kg (p = 0.025) compared to the SHAM
SALINE group (Figure 2F). There was also a decrease in VLDL cholesterol using AGE 100 mg/kg and
150 mg/kg (p = 0.030) compared to the SHAM SALINE group (Figure 2E). Regarding the atherogenic
index, which evaluates the risk of developing cardiovascular diseases, the group AGE 150 mg/kg presented
a significantly lower mean value (p = 0.025) than the HFD SALINE group. In addition, the HFD SALINE
group presented a significantly higher value in relation to the SHAM SALINE group (Figure 2G).
3.5. Effects of AGE on Insulin Sensitivity and Glucose Tolerance
The OGTT was performed prior to the beginning of the AGE treatment. No significant increases in
fasting glycemia were observed between the hyperlipidic and the normolipidic diet groups. However,
there was a significant increase (p ≤ 0.05) in the glycemia of animals at 15 min in the groups HFD
SALINE and AGE 150 mg/kg, in relation to the group fed on a normolipidic diet (SHAM SALINE).
At 30 min, all groups fed on a hyperlipidic diet had a significant increase in glycemia in relation to the
SHAM SALINE group (Figure 3A).
Figure 3. Evaluation of the glycemic profile before and at the end of the treatment with AGE. (A) Oral
glucose tolerance test prior to the beginning of treatment (12th week). (B) Area under the curve (AUC)
of blood glucose of animals evaluated prior to the beginning of treatment (12th week). (C) Oral glucose
tolerance test at the end of treatment (24th week). (D) Area under the curve (AUC) of glycemia of
animals evaluated at the end of treatment (24th week). SHAM SALINE: standard diet + saline solution.
HFD SALINE: hyperlipidic diet + saline solution. AGE 50: hyperlipidic diet + 50 mg/kg of aqueous
graviola leaf extract. AGE 100: hyperlipidic diet + 100 mg/kg of aqueous graviola leaf extract. AGE 150:
hyperlipidic diet + 150 mg/kg of aqueous graviola leaf extract. Values represent mean ±mean standard
error. * p < 0.05 vs. SHAM SALINE, § p < 0.05 vs. HFD SALINE, # p < 0.05 vs. AGE 150. ANOVA
followed by post Tukey test.
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The OGTT performed at the end of the experiment indicated that the AGE 150 mg/kg dose
was able to significantly reduce blood glucose (p ≤ 0.05) at 15 min, in relation to the groups SHAM
SALINE, HFD SALINE and AGE 50 mg/kg. However, there was no significant difference between
AGE 100 mg/kg and AGE 150 mg/kg. The area under the curve did not indicate a significant difference
for the comparison among groups (Figure 3B).
The insulin sensitivity test performed at the end of the treatment with AGE or saline solution did
not present a statistical difference in glycemia at the times analyzed after administration of insulin.
This result is confirmed by observing the total area under the curve among the groups that received
AGE or SALINE during the experimental period (Figure 4A,B).
Figure 4. Evaluation of the glycemic profile at the end of the treatment with AGE. (A) Insulin sensitivity
test performed at the end of treatment. (B) Area under the curve (AUC) of the insulin sensitivity test at
the end of treatment. SHAM SALINE: standard diet + saline solution. HFD SALINE: hyperlipidic diet
+ saline solution. AGE 50: hyperlipidic diet + 50 mg/kg of aqueous graviola leaf extract. AGE 100:
hyperlipidic diet + 100 mg/kg of aqueous graviola leaf extract. AGE 150: hyperlipidic diet + 150 mg/kg
of aqueous graviola leaf extract. Each column represents the mean, and the bar represents the mean
standard error. ANOVA.
3.6. Effects of AGE on Anti- and Pro-inflammatory Cytokines, Chemokines and Adiponectin
The animals treated with AGE showed an increase in IL-10 concentration, with a significant
difference for the groups AGE 100 mg/kg (p= 0.021) and AGE 50 mg/kg (p= 0.042) when compared to the
HFD SALINE group (Figure 5A). In analyzing MCP-1, no significant changes were observed between
the groups studied (p = 0.840) (Figure 5B). As shown in Figure 5C,D, the levels of proinflammatory
cytokines TNF-α (p = 0.640) and IL-6 (p = 0.768) also did not differ between study groups. Furthermore,
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there was no significant difference (p = 0.244) in the levels of adiponectin in the adipose tissue of mice
(Figure 5D).
Figure 5. Effects of AGE on anti- and pro-inflammatory cytokines, chemokines and adiponectin.
(A) Interleukin-10 (pg/mg protein). (B) Interleukin-6 (pg/mg protein). (C) Monocyte-1 chemotactic
protein (pg/mg protein). (D) Tumor necrosis factor alpha (pg/mg protein). (E) Adiponectin (ng/mg
protein) of control animals (SHAM SALINE: standard diet + saline solution. HFD SALINE: hyperlipidic
diet + saline solution) and of animals treated with aqueous graviola leaf extract (AGE) at 50, 100 and
150 mg/kg + hyperlipidic diet between the 13th and the 24th week of study. The cytokines are measured
in adipose tissue. Values represent mean ± mean standard error. § p < 0.05 vs. HFD SALINE.
ANOVA/Tukey. Kruskal-Wallis test.
3.7. Effects of AGE on Fat Pads, Adiposity Index and Liver Weight
The AGE at the doses studied was not able to reduce the rate of adiposity of the animals. However,
there was a decrease, although not significant, in the weight of fat pads of groups treated with aqueous
graviola leaf extract: AGE 50 mg/kg: omental (22.22%), mesenteric (6.79%), retroperitoneal (8.79%),
perirenal (9.41%); AGE 100 mg/kg: omental (11.11%), epididymal (14.34%), mesenteric (21.36%),
retroperitoneal (31.04%); and AGE 150 mg/kg: omental (33.33%), epididymal (6.17%), mesenteric
(6.08%), retroperitoneal (3.16%), and perirenal (2.35%), all compared to the HFD SALINE group
(Table 4).
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Table 4. Effects of AGE on fat pads, adiposity index, and liver weight.
Parameter
Experimental Group
SHAM SALINE HFD SALINE AGE 50 AGE 100 AGE 150
Omental weight (g) 0.028 ± 0.009 0.018 ± 0.005 0.014 ± 0.004 0.016 ± 0.004 0.012 ± 0.004
Epididymal weight (g) 1.068 ± 0.127 1.506 ± 0.112 1.543 ± 0.783 1.290 ± 0.149 1.413 ± 0.169
Mesenteric weight (g) 0.496 ± 0.634 0.707 ± 0.092 0.659 ± 0.049 0.556 ± 0.122 0.664 ± 0.136
Retroperitoneal weight (g) 0.360 ± 0.053 0.728 ± 0.087 * 0.664 ± 0.053 0.502 ± 0.090 0.705 ± 0.125
Perirenal weight (g) 0.198 ± 0.039 0.255 ± 0.039 0.231 ± 0.026 0.275 ± 0.061 0.198 ± 0.036
Adiposity index (%) 6.080 ± 0.514 10.893 ± 0.481 *** 11.620 ± 0.387 *** 10.212 ± 0.797 *** 10.713 ± 0.779 ***
Liver (g) 1.225 ± 0.066 1.236 ± 0.056 1.213 ± 0.030 1.200 ± 0.058 1.185 ± 0.047
Values represent mean ±mean standard error. * p ≤ 0.05, *** p ≤ 0.001 vs. SHAM SALINE; ANOVA followed by
post Tukey test.
3.8. Effects of AGE on Liver, Pancreas, and Epididymal Adipose Tissue
The histological analysis of the pancreas showed no statistical differences among groups regarding
pancreatic acini (p = 0.400), Islet of Langerhans (p = 0.291), and inflammation (p = 0.458) (Table 5,
Figure 6). However, the atrophy/necrosis was less frequent in the pancreas of animals treated with
AGE, especially in the AGE 100 mg/kg group (Table 5).
Table 5. Results for changes observed in the pancreas of the animals in each experimental group.
Variable
Experimental Group
SHAM SALINE HFD SALINE AGE 50 AGE 100 AGE 150
Changes in the pancreas
Islet of Langerhans (p = 0.291)
No change 36.4 (4) 45.5 (5) 72.7 (8) 80.0 (8) 54.5 (6)
Discrete atrophy 9.1 (1) 0.0 (0) 0.0 (0) 0.0 (0) 9.1 (1)
Atrophy 18.2 (2) 36.4 (4) 9.1 (1) 0.0 (0) 0.0 (0)
Discrete hypertrophy 18.2 (2) 9.1 (1) 0.0 (0) 20.0 (2) 27.3 (3)
Hypertrophy 18.2 (2) 9.1 (1) 18.2 (2) 0.0 (0) 9.1 (1)
Pancreatic acini (p = 0.400)
No change 81.8 (9) 72.7 (8) 90.9 (10) 100.0 (10) 90.9 (10)
Necrosis/Atrophy 18.2 (2) 27.3 (3) 9.1 (1) 0.0 (0) 9.1 (1)
Inflammatory cells (p = 0.458)
No change 90.9 (10) 81.8 (9) 90.9 (10) 100.0 (10) 100.0 (11)
Insulitis 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Perinsulitis 9.1 (1) 18.2 (2) 9.1 (1) 0.0 (0) 0.0 (0)
Data presented as relative frequency (absolute frequency). Value of p in the chi-square test.
Similarly, the liver histological analysis also showed that the treatment with AGE did not change
the quantification of steatosis (p = 0.881), microvesicular steatosis (p = 0.501), lobular inflammation
(p= 0.501), balloonization (p= 0.192), Mallory’s Hyaline (p= 0.408), apoptosis (p= 1.00), and glycogenate
nucleus (p = 0.408) (Table 5, Figure 6). However, ballooning was more frequent in the HFD SALINE
group compared to the groups that received AGE at different concentrations when fed on a hyperlipidic
diet. Furthermore, hepatic steatosis was also frequent in the experimental groups that received a
hyperlipidic diet or a normolipidic diet. However, the carbohydrate content in normolipidic diet was
high, which may have contributed to this result (Table 6).
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Figure 6. Histological analysis of the liver (Black arrows indicate hepatic steatosis, arrow head
lobular inflammation and red arrows indicate ballooning) and pancreas of each experimental group.
20×magnification. Bar scale: 100 μm.
Table 6. Results for changes observed in the liver of animals in each experimental group.
Variable
Experimental Group
SHAM SALINE HFD SALINE AGE 50 AGE 100 AGE 150
Liver Changes
Steatosis (p = 0.881)
< 5% 54.5 (5) 36.4 (4) 54.5 (6) 60.0 (6) 54.5 (6)
5 to 33% 36.4 (4) 36.4 (4) 36.4 (4) 10.0 (1) 36.4 (4)
34 to 66% 9.1 (1) 18.2 (2) 9.1 (1) 20.0 (2) 9.1 (1)
>66% 0.0 (0) 9.1 (1) 0.0 (0) 10.0 (1) 0.0 (0)
Microvesicular steatosis (p = 0.501)
Absent 45.5 (5) 18.2 (2) 54.5 (6) 40.0 (4) 36.4 (4)
Present 54.5 (6) 81.8 (9) 45.5 (5) 60.0 (6) 63.6 (7)
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SHAM SALINE HFD SALINE AGE 50 AGE 100 AGE 150
Liver Changes
Lobular inflammation (p = 0.919)
Absent 63.6 (7) 72.7 (8) 81.8 (9) 70.7 (7) 72.7 (8)
<1 focus/field 36.4 (4) 27.3 (3) 18.2 (2) 30.0 (3) 27.3 (3)
2–4 focuses/field 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
> 4 focuses/field 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Ballooning (p = 0.91)
Absent 72.7 (8) 36.4 (4) 81.8 (9) 70.7 (7) 72.7 (8)
Few cells 27.3 (3) 63.6 (7) 18.2 (2) 30.0 (3) 27.3 (3)
Many cells 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Mallory’s hyaline (p = 0.91)
Absent 100.0 (11) 100.0 (11) 100.0 (11) 100.0 (10) 90.9 (10)
Present 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 9.1 (1)
Apoptosis
Absent 100.0 (11) 100.0 (11) 100.0 (11) 100.0 (10) 100.0 (11)
Present 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Glycogenate nucleus (p = 0.408)
None/rare 100.0 (11) 100.0 (11) 100.0 (11) 100.0 (10) 90.9 (10)
Some 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 9.1 (1)
Data presented as relative frequency (absolute frequency). Value of p in the chi-square test.
Regarding adipocytes, AGE at the dose of 100 mg/kg (4682.52 ± 476.91 μm2) and at the dose of
150 mg/kg (4410.54 ± 426.73 μm2) was able to significantly reduce the adipocyte area of the epididymal
adipose tissue compared to the HFD SALINE group (6675.10 ± 736.87 μm2) (Figure 7).
Figure 7. Histological analysis of the epididymal adipose tissue of each experimental group. (A) SHAM
SALINE group. (B) HFD SALINE group. (C) AGE 50 mg/kg group. (D) AGE 100 mg/kg group.
(E) AGE 150 mg/kg group. 20× magnification. Bar scale: 100 μm. (F) Adipocyte area (μm2) of the
groups studied. Values represent mean ±mean standard error. § p < 0.05 vs. HFD SALINE. ANOVA
followed by post Tukey test.
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4. Discussion
The choice of Annona muricata Linn for this study is because this plant is used for the treatment of
obesity and its comorbidities. However, more scientific evidence is needed to support the notion that
this plant extract can be used for treating obese patients [36].
Plants interact with the environment to survive and are influenced by many factors, such
as pathogen attacks, temperature, circadian rhythm, water availability, nutrients, pollutants, and
pesticides, all of which can cause stress. In response, plants produce secondary metabolites such as
flavonoids, coumarins, saponins, alkaloids, tannins, and glucosinolates, among others. Thus, plants of
the same species grown in different environments may present different concentrations of a certain
secondary metabolic compound [37]. In a previous study, a high concentration of tannins and a
medium concentration of flavonoids and saponins were identified in the methanolic and aqueous
leaf extracts of A. muricata [38]. These substances were absent from the aqueous graviola leaf extract
produced in this study. However, another study identified a low concentration of flavonoids and
a high concentration of tannins, alkaloids, phenols, saponins, and phytosterols in AGE [39]. Thus,
the different concentrations of the chemical composition of Annona muricata Linn leaves found in the
literature and in our study may be related to the mentioned factors.
Studies have indicated that two hundred and twelve bioactive compounds have already been
identified in Annona muricata Linn. Phenolic compounds are the major phytochemicals responsible for
the antioxidant activity of Annona muricata Linn [36,40–42].
Acute toxicity tests using AGE found in the literature corroborate the results presented here. In
the literature, the administration of a single dose of 2000 mg/kg and 5000 mg/kg of AGE to mice was
not able to induce changes in animal behavior or mortality, or visible macroscopic changes in organs
after euthanasia on the 14th day of the experiment [14].
Experimental models with modified diets can simulate pathophysiological changes in rodents
that are similar to what occurs in humans. Such experiments allow understanding of the specific
mechanisms of obesity and its metabolic changes. However, the feed composition and duration of
experimental period have not been consistently established in the literature. In general, high-fat diets
and physical inactivity are used in these models and are also the main risk factors for humans [40,43].
In experimental models with a high-fat diet, the increase in body weight is significant after two
weeks of treatment, and after four weeks of induction this model shows different obesity phenotypes.
However, long-term induction leads to obesity-related comorbidities such as moderate hyperglycemia
and glucose intolerance [43]. Furthermore, in another model using C57BL/6J mice fed on a high-fat
diet and 10% fructose after 16 weeks of treatment, the animals developed central obesity, dyslipidemia,
arterial hypertension, insulin resistance, systemic oxidative stress, inflammation, and steatohepatitis.
These are the main characteristics of metabolic syndrome [44].
In our study, we exposed mice to a 58% lipid diet for 12 weeks to induce obesity. After this period,
our results indicated a significant increase in the weight of the HFD group compared to the SHAM
group. The weight gain in the HFD group is consistent with the higher caloric intake evidenced by
the FEI. Furthermore, at the end of the experimental period, we verified a significant increase in total
and LDL cholesterol, and in the atherogenic index, of the HFD group in relation to the control group,
which indicates that the model allowed the desired changes.
Among the various medicinal plants used for weight reduction, Annona muricata Linn is the second
most used by the Brazilian population [16]. In our study, AGE at the doses 50 mg/kg and 100 mg/kg
represented the popularly understood relationship between graviola and weight loss. Despite an
observed decrease in body weight, no reduction in caloric intake was observed in the groups treated
with AGE during the experimental period. Thus, weight reduction in this study is probably not related
to a lower caloric intake.
Effective medicinal plants for weight loss have phenolic compounds among their chemical
constituents, such as flavonoids, which modulate lipid metabolism and increase the rate of basal
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metabolism [45]. Quercetin and kaempferol stand out among flavonoids with an antiobesity effect.
These were identified in AGE in the literature. We also found them in our study [42,46].
In the current study, regarding the cholesterol profile, no significant effects of the aqueous extract
were observed on total cholesterol and HDL in two of the groups that received AGE. However, a
significant increase in HDL cholesterol was observed in the group treated with AGE 150 mg/kg
compared to the HFD SALINE group. We also observed a significant (p = 0.038) decrease in
LDL-cholesterol, VLDL-cholesterol (p = 0.030), and triglyceride (p = 0.026) concentrations. In a
study with streptozotocin-induced diabetic rats, AGE was able to significantly reduce plasma lipid
concentrations. However, no difference was observed in relation to the diabetic group treated with
10 IU/kg of insulin [14].
The mechanisms of action of the aqueous extract of graviola on metabolism are not fully
understood. However, several studies have reported isolated chemical compounds such as
tannins, flavonoids, saponins, and coumarins, among other constituents, as being responsible for
hypoglycemic, hypolipidemic, hypotensive, anti-inflammatory, and hepatic tissue changes, among
other properties [47].
In our study, we observed a decrease in the atherogenic index after treatment with AGE,
mainly in the group treated with 150 mg/kg. This decrease is directly related to the decrease in the
development of cardiovascular diseases. This was associated with a decrease in triglycerides and
LDL-cholesterol, and an increase in HDL-cholesterol, mainly in the 150 mg/kg group. Previous studies
have shown that the antioxidant capacity of some substances can modify lipid metabolism and reduce
inflammation, suggesting positive effects on cardiovascular diseases mainly by modulating oxidative
stress. Furthermore, the high plasma level of the atherogenic index is related to small LDL-cholesterol
particles. This is a predictor of conditions such as obesity, insulin resistance and inflammation, and
consequently coronary artery disease, diabetes mellitus, and metabolic syndrome [48,49].
In our study, there were no significant effects of aqueous graviola leaf extract on capillary fasting
glycemia evaluated in the oral glucose tolerance test performed at the end of treatment, and in the
serum concentration of fasting glucose. When we calculated the area under the curve at the end of
the experiment, we did not observe a significant difference in the comparison between the groups.
However, there was a reduction in blood glucose levels at 15 min according to the oral glucose tolerance
test in group 150 mg/kg. Some studies have demonstrated a significant decrease in plasma glucose
concentrations after treatment with graviola extract in diabetic animals induced by streptozotocin or
monohydrate aloxane [14,47,50,51].
Thus, the results found in our study do not indicate the effectiveness of aqueous graviola leaf
extract on insulin resistance and diabetes mellitus type 2, in relation to the intake of a high calorie diet,
high in saturated fat and simple carbohydrates and low in dietary fiber associated with sedentary
lifestyle. However, further studies with AGE concentrations above 150 mg/kg may prove effective in
reducing blood glucose, and therefore should be conducted.
Evidence shows that a greater fluctuation of glycemia induces endothelial dysfunction in diabetic
or non-diabetic individuals, through oxidative stress resulting from an increase in free radicals [52,53].
Pro-inflammatory cytokines and chemokines, such as TNF-α, IL-6 and MCP-1, are required to
initiate an inflammatory response. TNF-α is a cytokine that initiates the inflammatory response since
it triggers the production of other cytokines, such as IL-6. On the other hand, anti-inflammatory
cytokines, such as IL-10, are required to inhibit the synthesis of proinflammatory cytokines [54].
Previous studies have demonstrated that secondary metabolites present in plants, such as
triterpenes, flavonoids and steroids, can modulate the inflammation and metabolic dysfunctions
associated with obesity [55]. In our study, AGE did not change the levels of the inflammatory markers
TNF-α, IL-6 and MCP-1 in adipose tissue. On the other hand, the AGE showed an anti-inflammatory
effect due to a significant increase in IL-10 levels at the AGE doses of 50 and 100 mg/kg. In this
study, the increased doses of AGE did not significantly interfere with TNF-α, IL-6 and MCP-1 levels.
However, recent studies have demonstrated that IL-10 can exert anti-inflammatory effects via Janus
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kinase (JAK) signal transducer of activation 3 (JAK-STAT3), by binding IL-10 to the receptor on the
target of the cell membrane—tyrosine kinase 2—leading to activation of the signal transducer and
activator of transcription 3 (STAT3). However, further studies are needed to evaluate the possible
effects of AGE on this pathway [56].
Adiponectin is a protein secreted by adipocytes. It exerts anti-diabetic, anti-atherogenic and
anti-inflammatory effects directly. An increased expression may prevent and/or assist in the treatment
of metabolic diseases related to obesity [57]. In our study, no significant effects of AGE were observed
on adiponectin in adipose tissue. However, an increase of this protein was noticed in the group treated
with AGE 50 mg/kg in relation to the other groups treated with AGE. Furthermore, the HFD SALINE
group presented the lowest levels of adiponectin among the groups in our study.
Although the aqueous graviola leaf extract is able to induce a significant reduction in body
weight according to the experimental model studied, and although there was a decrease in the weight
percentage of all fat pads evaluated without significant differences in the comparison among groups, no
decrease of visceral adiposity was observed at the end of the experiment when analyzing the weight of
fat pads and the adiposity index. It is also possible to observe a significant decrease in the epididymal
adipocyte area in the animals treated with AGE. Therefore, AGE attenuates the accumulation of lipids
in mice, as was reported by another study after administration of blueberry and mulberry juice to
C57BL/6 mice fed on a hyperlipidic diet for 12 weeks [58]. It should be noted that epididymal adipose
tissue in mice is one of the major deposit areas of visceral fat [44].
In our experimental model, aqueous graviola leaf extract at the doses studied is not sufficient
to prevent accumulation of liver fat and lesions to hepatocytes, as well as lesions to the pancreas.
However, the ballooning of hepatocytes is less frequent in animals receiving treatment with the extract,
as well as necrosis/atrophy of pancreatic acini. Thus, treatment with AGE is not able to avoid hepatic
changes. However, it seems to protect the hepatocytes from morphological changes.
This may be related to a decrease in oxidative stress. In yet another study, the aqueous graviola
leaf extract of Annona muricata Linn was able to protect pancreatic β-cells, and hence improve glucose
metabolism, which was not visualized in our results [14].
5. Conclusions
In conclusion, no neurotoxic, behavioral, or mortality effects are produced by AGE in the acute
toxicity test immediately after or during the post-treatment period. In addition, this study confirms the
popular knowledge that graviola leaf tea reduces body weight and may also reduce cardiovascular risks,
due to its beneficial effects in reducing plasma concentrations of LDL-cholesterol, VLDL-cholesterol,
triglycerides, and the atherogenic index, while also attenuating the accumulation of body fat. In
addition, in our experimental model, the results found do not indicate the effectiveness of aqueous
graviola leaf extract on insulin resistance and diabetes mellitus type 2. However, the extract was
effective in improving glucose tolerance in the higher concentration of the AGE. Furthermore, AGE
has anti-inflammatory activity due to the increase in IL-10. However, it does not inhibit the expression
of TNF-α, IL-6 and MCP-1. These data support the utility of conducting further studies aimed at
identifying the active compounds of the aqueous extract of the aqueous graviola leaf extract, and at
clarifying its mechanism of action.
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Abstract: Preventing muscle wasting in certain chronic diseases including cancer is an ongoing
challenge. Studies have shown that polyphenols derived from fruits and vegetables shows promise
in reducing muscle loss in cellular and animal models of muscle wasting. We hypothesized that
polyphenols derived from plums (Prunus domestica) could have anabolic and anti-catabolic benefits on
skeletal muscle. The effects of a polyphenol-enriched plum extract (PE60) were evaluated in vitro on
C2C12 and Colon-26 cancer cells. Data were analyzed using a one-way ANOVA and we found that
treatment of myocytes with plum extract increased the cell size by ~3-fold (p < 0.05) and stimulated
myoblast differentiation by ~2-fold (p < 0.05). Plum extract induced total protein synthesis by ~50%
(p < 0.05), reduced serum deprivation-induced total protein degradation by ~30% (p < 0.05), and
increased expression of Insulin-Like Growth Factor-1 (IGF-1) by ~2-fold (p < 0.05). Plum extract also
reduced tumor necrosis factor α (TNFα)-induced nuclear factor κB (NFκB) activation by 80% (p < 0.05)
in A549/NF-κB-luc cells. In addition, plum extract inhibited the growth of Colon-26 cancer cells, and
attenuated cytotoxicity in C2C12 myoblasts induced by soluble factors released from Colon-26 cells.
In conclusion, our data suggests that plum extract may have pluripotent health benefits on muscle,
due to its demonstrated ability to promote myogenesis, stimulate muscle protein synthesis, and
inhibit protein degradation. It also appears to protect muscle cell from tumor-induced cytotoxicity.
Keywords: cachexia; plum; cancer; muscle wasting; myoblasts; protein synthesis
1. Introduction
Skeletal muscle weakness and wasting, which is also referred as cachexia, is a major clinical
problem for advanced cancer patients [1]. In 1932, Warren described cachexia as the most common
cause of death across a variety of cancers in a post mortem study of 500 patients [2]. The term “Cachexia”
is derived from the Greek words “kakos” and “hexis,” meaning “bad condition.” It is a multi-organ
syndrome associated with and characterized by at least 5% body weight loss due to muscle and
adipose tissue wasting [3]. Cancer cachexia is a multifactorial syndrome that is common in advanced
malignancy occurring in 80% of patients, which cannot be reversed by nutritional support and leads
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to significant function deficits [4], and which is responsible for an estimated 20% of cancer-related
deaths [5].
Colorectal cancer (CRC) patients are often presented with cachexia syndrome, which is a major
contributor to colorectal cancer-related morbidity and mortality [4–8]. About 35 to 60% of CRC patients
show some degree of muscle wasting and 28% lose >5% of their body weight in the six months
preceding diagnosis [9]. Blocking muscle wasting can prolong life even in the absence of effects on
tumor growth [10].
Oxidative stress through activating initial steps in protein degradation via the ubiquitin-proteasome
pathway and the activation of caspases contributes to muscular atrophy [11–13]. In addition,
inflammation also leads to muscle atrophy and this is mediated through cytokine (e.g., tumor necrosis
factor α (TNFα), interleukin-6 (IL-6), and interferon γ (IFNγ)) induced activation of the nuclear factor
κB (NF-κB) pathway [14].
Recent studies have shown that polyphenol-rich plant extracts prevent oxidative stress,
reduce inflammation, and help reduce muscle atrophy. We have previously shown that curcumin
treatment attenuated muscle wasting in cancer cachectic mice [15]. Supplementation with red grape
polyphenols mitigated muscular atrophy in transforming growth factor (TGF) mice, a model of chronic
inflammation, by reducing mitochondrial oxidative stress and by inhibiting caspase activation [16].
Grape seed extract supplementation effectively prevented muscle wasting in IL10-knock out mice [17].
Green tea polyphenol, catechins, protected normal and dystrophic muscle cells from oxidative
damage [18]. Epigallocatechin-3-gallate (EGCG) supplementation preserved muscle in sarcopenic
rats [19] and attenuated skeletal muscle atrophy caused by experimentally induced cancer cachexia in
in mice [20]. More recently, ursolic acid—a polyphenol present in apple peels, basil leaves, prunes,
and cranberries [21]—has been shown to increase muscle mass in mice exhibiting fasting-induced
muscle atrophy [22]; it has also increased muscle mass, fast and slow fiber size, grip strength, and
exercise capacity in mice with diet-induced obesity [23]. These observations clearly suggest that intake
of polyphenols can be beneficial in preserving muscle mass.
The common plum (Prunus domestica) is well known to be rich in polyphenols and contains unique
phytonutrients called neochlorogenic and chlorogenic acid which have high antioxidant activities.
Among functional foods, plums are also considered “super foods” since their consumption has been
associated with the decrease in chronic degenerative diseases and circulatory and digestive issues [24].
Dried plums have been shown to reduce symptoms of arthritis in an inflammation model [25].
These effects are attributed to their high polyphenolic composition and related high antioxidant
activity [26]. Plums have several health benefits and studies have found that plums also initiate
anti-cancer mechanisms that may help prevent the growth of cancerous cells and tumors [27–29].
In addition, plums have been extensively studied for their effects on bone health [30,31].
Plums contain caffeic acid (the polyphenol component of neochlorogenic and chlorogenic acids)
and rutin, which have been shown to inhibit the deterioration of bone tissues and prevent diseases such
as osteoporosis in postmenopausal women [32]. Research has also shown that regular consumption of
dried plums helps in the restoration of bone density lost to aging [33].
Formation of bone and much of the skeletal tissues is derived from the proliferation and
differentiation of skeletal stem cells. As dried plum was found to be a potent regulator of bone health,
it is possible that plum and its associated polyphenols may have benefits on other cells of musculoskeletal
system. Thus, in the present study, we sought to investigate the effect of a polyphenol-enriched plum
extract on muscle cell growth and differentiation, and on muscle protein synthesis and degradation
in vitro. In addition, we explored the effect of plum extract on inflammation as well as studied its effect
on colon cancer cells.
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2. Materials and Methods
2.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), horse serum, and
Penicillin-Streptomycin solution were purchased from Gibco-Thermo-Fisher Scientific (Grand Island,
NY, USA). L-[2,3,4,5,6-3H] Phenylalanine and L-[Ring-3, 5-3H]-Tyrosine was purchased from
Perkin-Elmer (Waltham, MA, USA), Prune extract-60% enriched polyphenol extract (PE60) was
purchased from PL Thomas (Morristown, NJ, USA). All other chemicals were of reagent grade, and
were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
2.2. Composition of the PE60-Plum Extract
Free gallic acid, 3-cholorogenic acid, rutin, free quercetin, and proanthocyanidins were determined
with an Agilent Technologies (Wilmington, DE, USA) Model 1200 HPLC System equipped with a
Model G1311A quaternary pump, Model G1322A vacuum degasser, Model G1329A autosampler,
Model G1316A thermostatted column compartment, a Model G1315B diode array detector, and a Chem
Station data processor. The separations were performed with a YMC-Pack ODS-AQ analytical column
(4.6 × 250 mm, 5 μm, P/N AQ12S05-2546WT, Waters Corporation, Milford, MA, USA), using mobile
phase A= 1000/100 (v/v) 0.05 M KH2PO4, pH 2.9/acetonitrile, and mobile phase B = 200/800 (v/v) Milli-Q
Plus water/acetonitrile, a column temperature of 40 ◦C, an injection volume of 5 μL, and the analytes
were quantified at signals of 280 nm/590 nm (for gallic acid and the proanthocyanidins), 330 nm/590 nm
(for 3-chlorogenic acid), and 375 nm/590 nm (for rutin and quercetin). The elution program was 0%
mobile phase B from 0 to 5 min, 0 to 60% (linear gradient) mobile phase B from 5 to 35 min, 100% mobile
phase B from 35 to 40 min, and 0% mobile phase B from 40 to 55 min (end). The PE60 extract was prepared
for analysis by stirring (at room temperature for 15 min) 0.250 g in 100 mL of 50/50 (v/v) 0.05 M citric
acid/methanol. The determinations were calibrated with standard solutions of gallic acid, 3-chlorogenic
acid, rutin hydrate, and quercetin dihydrate (all obtained from Sigma-Aldrich, St. Louis, MO, USA),
also prepared in the citric acid/methanol medium. The proanthocyanidin content was estimated by
peak area proportionation vs. the corresponding peak areas (at 280 nm/590 nm) of grapeseed extracts
(from Kikkoman, Polyphenolics, and Seppic) of known (i.e., label claim) proanthocyanidin content,
included in the analysis. The anthocyanin concentration was estimated by a published colorimetric
method [34]. During present investigation, minor isomers of chlorogenic acid (4-chlorogenic acid,
5-chlorogenic acid) were not determined.
2.3. Characterization of Anti-Oxidation Capacity of the Plum Extract
The PE60 (Lot PE6009-1601) extract was dissolved in water (10 mg/mL) and then centrifuged at
1500 × g for 10 min to remove any insoluble material. The dissolved material was sterile filtered and
the filtrate was assayed for total polyphenols by the Folin Ciocalteu method [35], for total flavonoids by
the AlCl3 complexation method [36], for anti-oxidant activity by the DPPH assay [37], and for oxygen
scavenging activity by the ABTS assay [38], as described.
2.4. Cell Culture
C2C12 cell line (mouse myoblasts) were obtained from American Type Culture Collection
(Manassas, VA, USA). The undifferentiated cells were grown in complete media consisting of Dulbecco’s
modified Eagle’s medium (DMEM, 4.5 mg/mL glucose) supplemented with heat-inactivated fetal
calf serum (10%), penicillin (100 units/mL), and streptomycin (100 μg/mL) at 37 ◦C in the presence
of 5% CO2. The myoblasts were differentiated into myotubes by culturing them into differentiation
medium, consisting of DMEM supplemented with heat-inactivated horse serum (5%), penicillin
(100 units/mL), and streptomycin (100 μg/mL) for five days.
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2.5. Determination of C2C12 Myoblast Cell Size
Muscles cells were grown in a 96-well plate for 24 h in 100 μL complete media. Cells were
then treated with 0, 50, 100, 150, and 200 μg/mL of extract for 48 h to evaluate a dose-response
effect of plum extract. After incubations, the cells were observed under a microscope and pictures
(100 ×magnification) were taken using a Nikon microscope with calibrated objectives. The size of cells
was determined using Element-BR software (Nikon Instruments Inc, Melville, NY, USA).
2.6. Assaying C2C12 Myoblast Differentiation
Muscle cells were initially cultured in a 96-well plate for 24 h in 100 μL complete media. Cells were
then incubated with 0, 50, 100, and 200 μg/mL plum extract for five days and the medium containing
corresponding concentration of plum extract was changed every 24 h. After treatment, the cells were
washed once with PBS, and then fixed with cold 4% paraformaldehyde for 10 min on ice. The cells
were washed three times with PBS and the monolayer was treated with blocking solution containing
2% albumin. The cells were then incubated with anti-myosin antibody at room temperature for 2 h.
Cell were washed again and then incubated with anti-mouse Alexa-488 antibody (Abcam, Cambridge,
MA) for two hours. Cells were washed again three times with PBS and the nuclei were stained briefly
with Hoechst 33342 dye (1:2000 dilution). Pictures were taken at 200 ×magnification using a Nikon
Fluorescent Microscope (Nikon Instruments Inc, Melville, NY 11747, USA). Myotubes were defined as
myosin positive cells with 2 or more fused nuclei.
2.7. Protein Synthesis in Cultured C2C12 Myotubules
C2C12 cells (375,000) were initially plated on a 12-well tissue culture plate that was initially coated
with 2% gelatin. Cells were differentiated for five days in 5% horse serum (media was changed every
two days) and then starved for 30 min by replacing the media with 1 ml PBS. The cells were then treated
with 0, 50, 100, and 200 μg/mL of plum extract in PBS, spiked with [3H] phenylalanine (1μCi/well),
and incubated for 2 h at 37 ◦C. The reaction was stopped by placing the plates on ice. Wells were
washed two times with DPBS-media containing 2 mM cold phenylalanine. Further, 1 mL of 20% cold
trichloroacetic acid (TCA) solution was added to each well and plates were incubated on ice for 1 h for
protein precipitation. Wells were washed two times with cold TCA and then the precipitated proteins
were dissolved in 0.5 mL of 0.5N NaOH containing 0.2% Triton X-100 overnight in a refrigerator.
An aliquot (5 μL) of the NaOH solubilized material was used for protein determination and the rest of
the dissolved proteins were mixed with scintillation fluid and counted. Data is computed as cpm/mg
of proteins and then % change over control is calculated.
2.8. Protein Degradation in C1C12 Myotubules
C2C12 myoblasts were cultured and differentiated as described above. Cells were then labelled
with [3H] Tyrosine 1 μCi/1 mL in serum free-DMEM (SF-DMEM) for 24 h. The unincorporated [3H]
Tyrosine was removed by washing the cell monolayer three times with SF-DMEM containing 50 μM
cycloheximide (protein synthesis inhibitor) and 2 mM non-labelled Tyrosine. Proteolysis was induced
by serum deprivation for 48 h in the presence or absence of 50, 100, 200 μg/mL of plum extract in
serum-free DMEM containing 50 μM cycloheximide. The extent of protein degradation was assayed
by monitoring release of radioactive tyrosine in the media after 48 h of incubation and was expressed
as protein degradation in comparison to control (normalized to 100%).
2.9. Determination of Insulin-Like Growth Factor-1 (IGF-1) Expression
Total RNA was extracted from C2C12 myotubules with RNeasy Plus Universal Mini Kit (Qiagen,
Hilden, Germany), according to the manufacturer’s instructions. The concentration and purity of RNA
was determined by measuring the absorbance in a Nano drop spectrophotometer. RT2 First Strand Kit
from Qiagen (Qiagen, Hilden, Germany) was used to synthesize first strand complementary DNA
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(cDNA). The gene expression levels were analyzed by Quantitative real-time RT-PCR conducted on
the Bio-Rad CFX-96 Real-Time PCR System using RT2 SYBR Green Master mix (Bio-Rad Laboratories,
Hercules, CA). The primers (IGF: forward primer GGACCAGAGACCCTTTGCGGGG and reverse
primer, AGCTCAGTAACAGTCCGCCTAGA; GAPDH: forward primer ATCCCATCACCATCTTCCAG
and reverse primer CCATCACGCCACAGTTTCC) were designed. Hot-Start DNA Taq Polymerase
was activated by heating at 95 ◦C for 10 min and real time PCR was conducted for 40 cycles (15 s for
95 ◦C, 1 min for 60 ◦C). All results were obtained from at least three independent biological repeats.
Data were analyzed using the ΔΔCT method. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes were used as house-keeping genes for expression calculation.
2.10. Determination of NFkB Activation
A549/NFkB-luc cells (Panomics Catalog No. RC0002) at 3 × 105/well were seeded in 1 mL of Initial
Growth Media (Dulbecco’s Modified Eagle’s medium containing 10% FBS and 1% Pen-Strep) in a
12-well plate. The cells were incubated in a humidified incubator at 37 ◦C and 5% CO2 for 24 h to allow
cells to recover and attach. After washing the cells once with serum-free media containing penicillin
(100 units/mL), and streptomycin (100 mg/mL), 1 mL of this media was added to each well. Cells were
pretreated with varying concentrations of plum extracts for 1 h at 37 ◦C and 5% CO2, and then TNFαwas
added to achieve a final concentration of 2 ng/mL to all wells except control untreated cells. The cells
were incubated in a humidified incubator at 37 ◦C and 5% CO2 for 6 h. After treatment, the media
was carefully removed. Cells were washed with PBS once and then lysed by 100 μL of 1× lysis buffer.
Assay for luciferase activity was performed according to assay manufacturer’s (Promega P/N E1500)
recommendations. The average relative luminescence units (RLU) were calculated and corrected for
baseline quenching for each set of triplicate wells, using WinGlow software (PerkinElmer, Waltham,
MA 02451, USA and Microsoft Excel (Microsoft Corporation, Redmond, WA 98073, USA). The data is
reported as the relative percent inhibition of TNFα mediated NFκB activation on A549 cells.
2.11. Effect of Plum Extract on Colon-26 Proliferation and its’ Soluble Factor Induced Cytotoxicity on
C2C12 Myotubules
Colon 26 cells, a mouse colon carcinoma cell line, was obtained from American Type Culture
Collection (Manassas, VA, USA). Effect of plum extract on Colon-26 cell proliferation was assayed
using a Water-Soluble Tetrazolium-1 (WST-1) (Talkara, Shiga, Japan) assay as described previously [39].
To determine the effects of soluble factors released from Colon-26 on C2C12 myotubules, conditioned
media from Colon-26 culture was collected after 24 h. of cultivation. The media was centrifuged at
2500 × g for 20 min to remove cellular material. The clear supernatant (conditioned media) was diluted
1:10 with normal complete media. The C2C12 differentiated myoblasts were then treated with normal
complete medium or with Colon-26 conditioned medium with or without 50 μg/mL plum extract.
A lower dose of plum extract (50 μg/mL) was used to avoid a direct effect of higher dose of plum
extract (100 μg/mL or 200 μg/mL) on protein synthesis and degradation. The cell viability was assayed
using a WST-1 assay. Control cells were subjected to equal amounts of non-conditioned media.
2.12. Data Analysis
The data is expressed as mean ± SD for at least three replicates. All comparisons were made by
one-way ANOVA with Tukey’s -HSD-post-hoc test using SPSS Statistics 20 software. All significant
differences are reported at p < 0.05 and indicated by “*”.
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3. Results
3.1. Characterization of PE60 Plum Extract Composition and Anti-Oxidation Properties
As shown in Table 1, the major components identified in the polyphenol-enriched PE60 plum
extract are proanthocyanidins, along with minor components such as anthocyanidins, 3-chlorogenic
acid, rutin, quercetin (free), and gallic acid (free).
The PE60 was also characterized by determining total phenolic content (TPC), total flavonoid
content (TFC), anti-oxidant activity (DPPH assay), and oxygen scavenging activity (ABTS). The data in
Table 2 shows that the content of TPC was in the same range as reported by the commercial vendor
(60%). The data indicate that the PE60 contained TPC in range 525–575 mg/g of dry extract. The TFC
was in 480–560 mg/g dry weight range. The anti-oxidation effects as determined by inhibition of DPPH
oxidation and ABTS assay ranged from 3280–3460 and 4000–4500 μM Trolox equivalents/g, respectively.
Table 1. Characterization of composition of polyphenol-enriched plum extract (PE60).
Component
Concentration
(g per 100 g) n = 3 Flavonoid Type (USDA) Analytical Method
Anthocyanins 0.391 ± 0.020(rsd = 5.1%) Anthocyanidin Colorimetric
3-chlorogenic acid 1.76 ± 0.01(rsd = 0.6%) Hydroxycinnamic acid LC/UV *
Rutin 1.12 ± 0.01(rsd = 0.6%) Flavanol LC/UV *
Quercetin (free) 0.718 ± 0.005(rsd = 0.7%) Flavanol LC/UV *
Gallic acid (free) 0.381 ± 0.004(rsd = 1.1%) Hydroxybenzoic LC/UV *
Proanthocyanidins 60 ± 10(rsd < 2%) Flavan-3-ol LC/UV *
Contents in PE60 plum extract were determined either using an Agilent Technologies Model 1200 HPLC System
(Wilmington, DE, USA) or a colorimetric method as described in Section 2.2 in the text. Values are mean ± SD of
three experiments. * LC/UV = liquid chromatography/ultraviolet light detection
Table 2. Characterization of anti-oxidation properties of PE60.
Assays Units Mean ± SD
Total Phenolic Content (TPC) mg/g 542.44 ± 24.75
Total Flavonoid Content (TFC) mg/g 520.00 ± 40.10
Anti-oxidant activity (DPPH) μM Trolox Equivalent/g 3375 ± 90
Oxygen Scavenging Activity (ABTS) μM Trolox Equivalent/g 4250 ± 250
The anti-oxidation properties of PE60 plum extract were determined using specific assays (TPC: total phenolic content,
TFC: total flavonoid content, DPPH: 2,2-diphenyl-1-picrylhydrazyl, ABTS: 2,2’-azino-bis{3-ethylbenzothiazoline-
6-sulfonic acid}) as described in Section 2.3 in the text. Values are mean ± SD of three experiments.
3.2. Effect of PE60 Plum Extract on C2C12 Myoblast Size and Differentiation
Plum extract had no cytotoxic effect on myoblast when used even at a high dose of 250 μg/mL
(data not shown). It is evident from images that plum extract has some effect on cell proliferation;
however, it was interesting to note that the plum extract increased the size of undifferentiated myoblasts
cells in a dose-dependent manner (Figure 1a). The size of myoblast increased ~two-fold (p < 0.05)
after treating cells with 50 μg/mL of plum extract when compared to that of untreated-control cells.
Increase in myoblast size plateaued to a maximum increase of three-fold at 200 μg/mL concentration
(Figure 1b). The effect of plum extract was also assessed on myoblast differentiation. Figure 2a
indicates that the plum extract stimulated differentiation of myoblast in a dose-dependent manner
using expression of myosin heavy chain as a marker for differentiation. The number of myotubes
formed resulting from fusion of differentiated cells was increased by two-fold in cells treated with
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100 μg/mL plum extract (p < 0.05) and by three-fold at 200 μg/mL (p < 0.05) compared to that of control
cells (Figure 2b).
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Figure 1. The effect of plum extract on C2C12 myoblast cell size. (a) The representative pictures of
myoblast after treatment with varying concentration of plum extract (100 ×magnified images) taken by
a Nikon Microscope. The bar represents a length of 500 μm. (b) The size of myoblast was determined
using Element-BR software as described in “Materials and Methods”. The data are expressed as
mean ± SD for at least three experiments. All comparisons were made to control (untreated cells) using





                        0 g/mL                             50 g/mL 
  








Figure 2. The effect of plum extract on C2C12 myoblast differentiation. (a) Images of differentiated
cells after treatment with varying concentration of plum extract showing nuclei stained in blue
(Hoechst 33342) and myofibers stained in green (Alexa 488). Pictures were taken at 200×magnification
using a Nikon Fluorescent Microscope. The bar represents a length of 300 μm. (b) Fused cells from five
random fields were counted manually under 200× as described in “Materials and Methods”. The data
are expressed as mean ± SD for at least three experiments. All comparisons were made to control
(untreated cells) using one-way ANOVA; significant differences are reported at * p < 0.05.
3.3. Effect of PE60 Plum Extract on Myotubule Protein Synthesis
Plum extract showed almost a linear increase in [3H] phenylalanine incorporation into proteins in
a dose dependent manner in C2C12 myotubules (Figure 3). Doses of 100 μg/mL and 200 μg/mL of
plum extract caused a significant increase in protein synthesis by 30% and 50%, respectively (p < 0.05).
3.4. Effect of PE60 Plum Extract on Myotubules Protein Degradation
We also examined if plum extract could reduce myotubule protein degradation induced by serum
starvation. Figure 4 revealed that plum extract did inhibit protein degradation in a dose-dependent
manner. Doses of 100 μg/mL and 200 μg/mL significantly inhibited protein degradation by 20% and
30%, respectively (p < 0.05).
μ
μ
Figure 3. The effect of plum extract on myotubule protein synthesis. Protein synthesis was measure by
the incorporation of labeled phenylalanine into total myotubule proteins in response to various levels
of plum extract. Data were computed as cpm/mg of proteins followed by calculation of % change over
control. The data were expressed as mean ± SD for at least three experiments. All comparisons were
made to control (untreated cells) using one-way ANOVA; significant differences are reported at * p < 0.05.
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μ
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Figure 4. The effect of plum extract on myotubule protein degradation. Proteolysis was induced
by 48 h-serum starvation in the presence or absence of plum extract, and monitored by release of
radioactive tyrosine from pre-labelled cells. Data were computed as cpm/mg of proteins and then %
change over control was calculated. The data were expressed as mean± SD for at least three experiments.
All comparisons were made to control (untreated cells) using one-way ANOVA; significant differences
are reported at * p < 0.05.
3.5. Effect of PE60 Plum Extract on IGF-1 Expression in Myotubules
Expression of IGF-1 mRNA in C2C12 myotubules upon treatment with plum extract is shown in
Figure 5. Compared to that of untreated cells, low concentration of plum extract (50 μg/mL) has no
significant effect on IGF-1 mRNA expression; however, it significantly stimulated IGF-1 expression
when cells were treated at a higher dose (100 or 200 μg/mL) plum extract.
μ
μ
Figure 5. The effect of plum extract of IGF-1 gene expression. Total RNA was extracted from C2C12
myotubules treated with various concentrations of plum extract and compared to untreated control.
All results were obtained from at least three independent biological repeats. Data were analyzed
using the ΔΔCT method. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were used as
house-keeping genes for expression calculation. All comparisons were made to control (untreated cells)
using one-way ANOVA; significant differences are reported at * p < 0.05.
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3.6. Anti-Inflammatory Effect of PE60 plum Extract in Vitro
We evaluated the anti-inflammatory activity of plum extract by assessing its effect on
TNF-α-induced NFkB activation where the activity was measured in terms of luciferase activity
of NFkB reporter system assay. Plum extract inhibited NFkB activation in a dose dependent manner
(Figure 6). A dose response assay indicated that ~40% inhibition (p < 0.05) of TNF-α-mediated NFkB
activation was achieved at 25 μg/mL plum extract, and >80% inhibition (p < 0.05) of TNF-α-mediated
NFkB activation was achieved at 50 μg/mL plum extract.
μ
κ
Figure 6. Effects of plum extract on NFkB activation. The effect of plum extract on TNFα-mediated
NFkB activation was measured in the A549/NFκB-luc reporter stable cell line. Activity was measured in
terms of luciferase activity. The data are reported as the relative percent inhibition of TNFα-mediated
NFkB activation. The data are expressed as mean ± SD for at least three experiments. All comparisons
were made to control (untreated cells) using one-way ANOVA; significant differences are reported at
* p < 0.05.
3.7. Effect of PE60 Plum Extract on Colon-26 Mouse Adenocarcinoma Cell Line
When Colon-26 cells were treated with plum extract, the cells viability was reduced in a
dose-dependent manner reaching ~80% reduction (p < 0.05) at 150 μg/mL. Upon further increasing
the concentration of plum extract, the cell viability was further reduced 90% (p < 0.05) at 200 μg/mL
(Figure 7).
μ
Figure 7. Effect of plum extract on Colon-26 adenocarcinoma cells. Data were calculated as % inhibition
of cell growth in response to various concentrations of plum extract. The data are expressed as
mean ± SD for at least three replicates. All comparisons were made to control (untreated cells) using
one-way ANOVA; the significant differences are reported at * p < 0.05.
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3.8. Effect of PE60 Plum Extract on C2C12 Cell Viability in Response to Colon-26 Cells Cytotoxicity-Inducing Factors
Mouse derived Colon-26 adenomacarcinoma cells are known to induce muscle wasting in
rodents [40]. The effect of these circulating soluble factors released by Colon-26 was examined on
growth of C2C12 myotubules in vitro in presence or absence of plum extract. Figure 8a,b shows that in
the absence of plum extract, soluble factors released in media derived from Colon-26 cells caused a
significant reduction of C2C12 cell viability by ~25% (p < 0.05). However, in the presence of plum
extract, the negative effects of Colon-26-derived media on C2C12 viability was prevented and the cell
viability was maintained to a similar level that was seen in the untreated cells.
μ
(i) Normal Medium (ii) Normal Medium + Plum Extract
(iii) Colon-26 Conditioned medium (iv) Colon-26 Conditioned medium + Plum Extract
Figure 8. The effect of plum extract on C2C12 viability in response to Colon-26-induced cytotoxicity.
(a) Differentiated C2C12 myotubes were treated with normal medium (i & ii) or Colon-26-conditioned
medium (iii & iv) in the absence (i & iii) or presence (ii & iv) of plum extract (50 μg/mL). (b) The viability
of C2C12 myotubules were determined using WST-1 assay. The data is expressed as mean ± SD for
at least three experiments. All comparisons were made to control (untreated cells) using one-way
ANOVA; significant differences are reported at * p < 0.05.
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4. Discussion
In our study, we sought to investigate if plums had benefits on skeletal muscle. Specifically,
we selected to use a plum extract that was enriched in polyphenols (~60% polyphenols) because the
health benefits of plum have been partly attributed to its high polyphenol content [41–43]. Our data
indicates that about 95% of total phenolic content in the plum extract used was present in the form of
flavonoids. This data is not surprising as fruits are often reported to have phenolic compounds which
are high in flavonoids with a range of 90–100% [44]. The anti-oxidant activity in the plum extract was
found to be in range of 3–4 mM of Trolox equivalent/g, which is higher than that of turmeric (0.27–0.35
mM Trolox eq/g) and mulberry (1–2 mM Tolox eq/g), but lower than green tea (13–17 mM Trolox eq/g)
and pomegranate (20–25 mM Trolox eq/g) [45–49].
Dried plum has previously been reported to have health benefits on bone. In rat models of
osteoporosis, dried plum intake resulted in prevention and reversal of bone loss [50,51]. A three-month
clinical intervention study showed that dried plum intake improved biomarkers of bone formation
in postmenopausal women, whereas longer-term intake of dried plum resulted in mitigating loss of
bone mineral density [31]. The present study was designed to analyze the effects of plum extract
on muscle metabolism in C2C12 myotubules. In our initial experiments, the effect of plum extract
was tested on myoblast viability. The data show that this plum extract has no toxicity on the muscle
cells, even at very high doses. These results are consistent with prior literature on plum effects on
non-diseased cells [52]. The maintenance of muscle mass is dependent on synthesis of new proteins
and breakdown of old or damaged proteins. If these processes are balanced, the muscle mass is
maintained; however, with aging and under certain catabolic condition including cancer, renal failure
or trauma, muscle protein degradation exceeds the synthesis of new proteins, and results in muscle
atrophy [53]. One interesting observation was that that plum extract increased the size of growing
myoblast under un-differentiated conditions, suggestive of inducing increase in cytoplasmic volumes
by stimulating protein synthesis. We also measured effect of plum extract on protein synthesis and
degradation in differentiated myotubules. Our data clearly demonstrated that plum extract not only
increased protein synthesis but also inhibited myotubules protein degradation in response to serum
starvation, demonstrating both an anabolic and anti-catabolic effect.
The activity of the plum extract appears to be at least partly mediated through IGF-1 stimulation.
Several studies have shown that IGFs stimulated both proliferation and differentiation of myoblasts,
and also play a role in regenerating damaged skeletal muscle [54–58]. In line with our results, prior
studies have also demonstrated that plums can increase IGF-1 levels in both humans [58] and animal
models [51,59]. One of the manifestations of muscle loss is associated with decreased production of
IGF-1 [60]. The signaling pathway IGF-1/PI3K/Akt (Insulin like growth factor -1/phosphatidyl inositol
3-kinase/protein kinase) is considered the main mediator of normal muscle development and one of the
most studied signaling molecular systems involved in muscle metabolism [61]. Akt activation leads to
activation of mTOR (mammalian target of rapamycin), which is responsible for promoting protein
synthesis. The Akt-mTOR signaling pathway and its downstream components (p70s6k and 4E-BPI) are
attenuated with muscle wasting [62]. Further studies need to be performed to confirm the if plum extract
is indeed regulating Akt activity. The identification of compound or compounds in plum responsible
for stimulating IGF-1 levels in myoblast was beyond the scope of the present study. As discussed
earlier, ursolic acid has been shown to increase muscle mass in mice exhibiting fasting-induced muscle
atrophy [22] or diet-induced obesity [23]. Interestingly, ursolic acid has also been shown to induce
IGF-1 levels in the skeletal muscle of these mice with an increased Akt phosphorylation [22,23].
During present investigation, we were not able to detetect ursolic acid in PE60 extracts due to technical
limitation for detecting all polyphenols; however, other studies have reported presence of ursolic
acid in plums [21]. Therefore, it is possible that ursolic to some extent may have contributed in IGF-1
mediated muscle growth in our studies.
Studies have demonstrated the anti-inflammatory effect of dried-plum or plum juice in
several cellular system including lipopolysaccharide-induced macrophages [63,64], splenocytes from
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ovariectomized mice [65], colorectal cells in azoxymethane-treated rats [66], heart tissues in obese
rats [67] and joints of TNF-over expressing mice [25]. The antioxidation activities of plum appeared to
be mediated through the inhibition of NFκB activation [25,66,67]. Based on these reported studies, we
decided to test the effect of plum extract on NFκB activation, since oxidative stress and inflammatory
responses through activation of NFκB play an important part in muscle atrophy. Activation of NFkB
plays a central role in muscle atrophy in several catabolic situations including cancer cachexia [68,69].
We found that even a small dose of plum extract was able to almost completely inhibit (>80% inhibition)
TNF-α-induced NFκB activity in vitro. It is likely that the proanthocyanidins, which comprise over
70% of the polyphenols, may be involved in suppressing the inflammatory cytokine (TNF)-induced
activation of NFκB, although this has not been systematically tested with the individual components
of the extract.
Cancer cachexia-related morbidity and mortality are often accompanied by whole body and muscle
loss [4,7,8] and it is suggested that blocking muscle wasting can prolong life despite tumor growth [10].
The effect of plum extract on colon cancer cell viability, as well as its ability to protect muscle cells
from colon-cancer cell induced cytotoxicity, were, therefore, also investigated. We used Colon-26
adenocarcinoma cells, which is a widely used preclinical model because it induces clinical cachexia,
including its development as well as the resultant physiological and metabolic impairment [40,69,70].
Treating the Colon-26 colon cancer cells with plum extract caused a significant decrease in the Colon-26
cell’s viability, indicating potential anti-tumor activity.
It is known that muscle wasting in cancer patients is mediated through factors released from
tumor in circulation [71–74]. Studies have shown that elevated circulating levels of IL-6 mediated
skeletal muscle cell death in severely cachectic mice with colon cancer [75]. Our studies found that
plum extract can protect C2C12 myotubules from cytotoxicity induced by soluble factors released by
the Colon-26 cells. The exact pathways leading to reduced cell viability in response to tumor induced
soluble factors are not known, but it is possible that both atrophy and apoptosis may be attenuated by
the plum extract. It is also possible that compound(s) in plum extract may directly affect colon cells
to inhibit secretion of inflammatory cytokines. Future studies need to be conducted to elucidate the
molecular mechanism involved in the anti-cytotoxic activity of the plum extract.
Our current studies have several limitations. The study was performed using an in vitro system
that may not represent the complexities of an in vivo system. Furthermore, polyphenols in the plum
extract can undergo biotransformation in vivo, which could either enhance or diminish the anabolic of
plum extract on muscle as well as its anti-inflammatory benefit. However, previous human studies
with dried plum still demonstrated its ability to activate IGF-1 as well as its anti-inflammatory benefits,
indicating that biotransformation may not result in loss of these effects observed in our study.
5. Conclusions
In conclusion, the polyphenol-enriched plum extract has both anti-catabolic and anabolic effects
on muscle cells, as well as myogenic potential. In addition, this plum extract exhibited anti-cytotoxic
properties in response to soluble factors released from cancer cells. Thus, plum extract may be a
useful intervention to be considered for cancer cachexia or other chronic disease-induced cachexia
involving inflammation. These results need to be confirmed in an animal model of cachexia, followed
by clinical translation.
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Abstract: Streptococcus agalactiae (Group B Streptococci, GBS) can cause severe neonatal sepsis. The
recto-vaginal GBS screening of pregnant women and intrapartum antibiotic prophylaxis (IAP) to
positive ones is one of the main preventive options. However, such a strategy has some limitations
and there is a need for alternative approaches. Initially, the vaginal microbiota of 30 non-pregnant
and 24 pregnant women, including the assessment of GBS colonization, was studied. Among the
Lactobacillus isolates, 10 Lactobacillus salivarius strains were selected for further characterization.
In vitro characterization revealed that L. salivarius CECT 9145 was the best candidate for GBS
eradication. Its efficacy to eradicate GBS from the intestinal and vaginal tracts of pregnant women
was evaluated in a pilot trial involving 57 healthy pregnant women. All the volunteers in the probiotic
group (n = 25) were GBS-positive and consumed ~9 log10 cfu of L. salivarius CECT 9145 daily from
week 26 to week 38. At the end of the trial (week 38), 72% and 68% of the women in this group were
GBS-negative in the rectal and vaginal samples, respectively. L. salivarius CECT 9145 seems to be an
efficient method to reduce the number of GBS-positive women during pregnancy, decreasing the
number of women receiving IAP during delivery.
Keywords: Lactobacillus salivarius; Streptococcus agalactiae; GBS; probiotic; pregnancy
1. Introduction
Neonatal sepsis contributes substantially to neonatal morbidity and mortality and is a major
global public health challenge worldwide. According to the age of onset, neonatal sepsis is divided
into early-onset sepsis (EOS) and late-onset sepsis (LOS). EOS has been variably defined based on
the age at onset, with bacteremia or bacterial meningitis occurring at ≤72 h in infants hospitalized in
the neonatal intensive care unit versus <7 days in term infants, and usually reflects transplacental or
ascending infections from the maternal genitourinary tract [1].
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Streptococcus agalactiae (Group B Streptococci, GBS) is one of the microorganisms most frequently
involved in severe neonatal EOS cases [2–4]. Women, men and children of all ages can be
asymptomatically colonized with GBS, acting the gastrointestinal tract, vagina and urethra as reservoirs.
A recent systematic review and meta-analyses found that adjusted estimate for maternal GBS
colonization worldwide was 18% (95% confidence interval [CI], 17%–19%), with regional variations
(11%–35%) [5]. GBS vaginal and/or intestinal colonization is considered as a risk factor for ascending
infection during pregnancy [6].
The relevance of GBS as an agent of neonatal infections soon prompted the finding of strategies
for its eradication from the intestinal and genitourinary mucosal surfaces of pregnant women [7],
including the use of chlorhexidine, which showed no effect [8] and, particularly, the development of
vaccines. Unfortunately, no GBS vaccine is available at present despite the strong research efforts made
in the last decades [9]. At present, two main approaches have been recommended for the prevention
of neonatal GBS infections in Western countries: (a) a risk-based strategy; and (b) a screening-based
strategy [10]. The second approach, involving recto-vaginal GBS screening at week 35–38 of pregnancy
and subsequent intrapartum antibiotic prophylaxis (IAP) to positive mothers, is the preventive option
followed in the USA and some European countries.
However, such a strategy also faces some limitations: (a) it does not guarantee GBS eradication [11];
(b) it does not prevent GBS-related abortions, stillbirths and preterm births [4]; (c) it may lead to
increasing rates of antibiotic resistance among GBS and other clinically relevant microorganisms [12–14];
and (d), it has a very negative impact on the acquisition, composition and development of the infant
microbiota. Perinatal antibiotic use affects the gut microbiota development during the critical first
weeks of life [15,16]. The composition of the gut microbiota of neonates whose mothers received
IAP has been described as aberrant in comparison with that of non-treated neonates [17,18]. The
detrimental impact of perinatal antibiotics, mainly IAP, on early life microbiota may have a lasting
effect on the host’s health [19]. Therefore, there is a need for alternative strategies to avoid GBS
colonization during pregnancy.
In this context, the objective of this work was, first, the assessment of the presence of GBS in
the vaginal exudate of healthy pregnant and non-pregnant women; and, second, the selection of a
safe probiotic strain with the ability to eradicate GBS from the intestinal and genitourinary tracts of
pregnant women.
2. Material and Methods
2.1. Microbiological Analysis of Vaginal Swabs Obtained from Pregnant and Non-pregnant Women
A total of 54 women (30 non-pregnant women and 24 pregnant women), aged 25–35, participated
in this part of the study. In accordance with the Declaration of Helsinki, all volunteers gave written
informed consent to the protocol, which had been approved (protocol 10/017-E) by the Ethical
Committee of Clinical Research of the Hospital Clínico San Carlos Madrid (Spain). In relation to
non-pregnant women, 4 vaginal exudates samples were collected within a menstrual cycle (days 0,
7, 14 and 21). Pregnant women provided a single sample in week 35–37 of pregnancy. All women
claimed to be completely healthy.
Samples were diluted in peptone water and spread onto Columbia Nalidixic Acid (CNA), Mac
Conkey (MCK), Sabouraud Dextrose Chloramphenicol (SDC), Gardnerella (GAR) and Mycoplasma
agar plates (BioMerieux, Marcy l’Etoile, France) for selective isolation and quantification of the
main agents involved in vaginal infections. They were also spread onto agar plates of MRS (Oxoid,
Basingstoke, UK) supplemented with either L-cysteine (2.5 g/L) (MRS-C) or horse blood (5%) (MRS-B)
for isolation of lactobacilli. All the plates were incubated for 48 h at 37 ◦C in aerobic conditions, with
the exception of the MRS-C and MRS-B ones, which were incubated anaerobically (85% nitrogen, 10%
hydrogen, 5% carbon dioxide) in an anaerobic workstation (DW Scientific, Shipley, UK). Parallel, all the
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samples were submitted to an enrichment step in Todd Hewitt broth (Oxoid) to facilitate the isolation
of S. agalactiae in CNA plates.
Initially, identification of the bacterial strains (at least one isolate of each colony morphology
per medium and per sample) was performed by 16S rDNA sequencing using the primers and
PCR conditions described by Kullen et al. [20]. Sequencing reactions were prepared using the ABI
PRISM® BigDye™ Terminator Cycle Sequencing kit with AmpliTaq DNA polymerase according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA) and were run on an ABI 377A
automated sequencer (Applied Biosystems). The resulting sequences were used to search sequences
deposited in the EMBL database using the BLAST algorithm. The identity of the strain was determined
on the basis of the highest (>98%) scores.
Identification of yeasts and confirmation of the initial 16S rDNA-based bacterial identifications
was performed by MALDI-TOF (VITEK MS, BioMerieux, Marcy-L’Étoile, France) [21]. Identification of
S. agalactiae isolates was also confirmed by using a latex agglutination test (Streptococcal grouping kit,
Oxoid, Basingstoke, UK), following the instructions of the manufacturer.
Those isolates identified as belonging to the genus Lactobacillus were preserved for further studies.
For such a purpose, an MRS-C broth culture of each isolate was mixed with glycerol (30%, v/v)
and kept at −80 ◦C until required. A total of 89 different Lactobacillus strains were isolated from the
vaginal swabs and submitted to the Random Amplification of Polymorphic DNA (RAPD) genotyping
as described [22] in order to avoid duplication of isolates. Among them, 10 Lactobacillus salivarius
strains were selected for further characterization on the basis of the following criteria: (1) absence
of S. agalactiae, Gardnella vaginalis, Candida spp., Ureaplasma spp. and Mycoplasma spp in the vaginal
samples from which the lactobacilli were originally isolated; (2) Qualified Presumption of Safety (QPS)
status conceded by EFSA; and (3) the ability of the strain to grow rapidly in MRS broth under aerobic
conditions (≥1 ×106 cfu/mL after 16 h at 37 ◦C).
2.2. Antimicrobial Activity of the Lactobacilli Strains against GBS
Initially, an overlay method [23] was used to determine the ability of the lactobacilli strains to
inhibit the growth of 12 different S. agalactiae strains. Among them, 6 strains had been isolated from
blood or cerebrospinal fluid in clinical cases of neonatal sepsis (Hospital Universitario Ramón y Cajal,
Madrid, Spain) while the remaining 6 had been isolated from vaginal samples of pregnant women
(our own collection). It was performed using MRS agar plates, on which the lactobacilli strains were
inoculated as approximately 2 cm-long lines and incubated at 37 ◦C for 48 h. The plates were then
overlaid with the indicator S. agalactiae strains vehiculated in 10 mL of Brain Heart Infusion (BHI,
Oxoid) broth supplemented with soft agar (0.7%), at a concentration of ~104 colony-forming units
(cfu)/mL. The overlaid plates were incubated at 37 ◦C for 48 h and, then, examined for clear zones of
inhibition (>2 mm) around the lactobacilli streaks. All experiments assaying inhibitory activity were
performed in triplicate.
2.3. Production of Specific Antimicrobials (Bacteriocins, Lactic Acid, Hydrogen Peroxide) by the Lactobacilli
Strains
Bacteriocin production was assayed using an agar diffusion method as described by
Dodd et al. [24] and modified by Martín et al. [25], using the S. agalactiae strains as the indicator
bacteria employed for the overlay method. The lactobacilli strains were screened for hydrogen
peroxide production following the procedure described by Song et al. [26]. In the case of positive
strains, hydrogen peroxide production was also measured by the quantitative method of Yap and
Gilliland [27]. The concentration of L- and D-lactic acid in the supernatants of MRS cultures of the
lactobacilli strains was quantified using an enzymatic kit (Roche Diagnostics, Mannheim, Germany),
following the manufacturer’s instructions. The pH values of the supernatants were also measured. All
these assays were performed in triplicate and the values were expressed as the mean ± SD.
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2.4. Coaggregation and Co-culture Assays
The ability of the lactobacilli strains to aggregate with cells of the S. agalactiae strains was
investigated following the procedure of Younes et al. [28]. The suspensions were observed under a
phase-contrast microscope after Gram staining.
To test the anti-S. agalactiae activity of the lactobacilli in a broth assay format, tubes containing
20 mL of MRS broth were co-inoculated with 1 mL of a Lactobacillus strain culture (7 log10cfu/mL) and
1 mL of an S. agalactiae strain (7 log10 cfu/mL). Subsequently, the cultures were incubated for 6 h at 37 ◦C
in aerobic conditions. Immediately after the co-inoculation and after the incubation period, aliquots
were collected, serially diluted and plated on MRS-C plates and CHROMagar StrepB agar plates
(CHROMagar, París, France) for the selective enumeration of lactobacilli and streptococci, respectively.
Correct taxonomic assignment was confirmed by the MALDI-TOF analysis as described previously.
2.5. Survival After In Vitro Exposure to Saliva and Gastrointestinal-Like Conditions
The survival of the strain to conditions resembling those found in the human digestive tract (saliva,
human stomach and small intestine) was assessed in the in vitro system described by Marteau et al. [29],
with the modifications reported by Martín et al. [25]. For this purpose, the strain was vehiculated
in UHT-treated milk (25 mL) at a concentration of 109 CFU/mL. The values of the pH curve in the
stomach-like compartment were those recommended by Conway et al. [30]. Different fractions were
taken at 20, 40, 60, and 80 min from this compartment, and exposed for 120 minutes to a solution
with a composition similar to that of human duodenal juice [30]. The survival rate of the strain was
determined by culturing the samples on MRS agar plates, which were incubated at 37 ◦C for 48 h.
2.6. Adhesion to Caco-2, HT-29 and Vaginal Cells and to Mucin
The ability of the strains to adhere to HT-29 and Caco-2 cells was evaluated as described by
Coconnier et al. [31] with the modifications reported by Martín et al. [25]. HT-29 and Caco-2 were
cultured to confluence in 2 mL of DMEM medium (PAA, Linz, Austria) containing 25 mM of glucose,
1 mM of sodium pyruvate and supplemented with 10% heat-inactivated fetal calf serum, 2 mM of
L-glutamine and 1% non-essential amino acid preparation. At day 10 after confluence, 1 mL of the
medium was replaced with 1 mL of DMEM containing 108 CFU/mL of the strains. Adherence was
measured as the number of lactobacilli adhered to the cells in 20 random microscopic fields. The assay
was performed by triplicate.
Adherence to vaginal epithelial cells collected from healthy premenopausal women was
performed as described previously [32].
The adhesion of the lactobacilli strains to mucin was determined according to the method
described by Cohen and Laux [33].
2.7. Sensitivity to Antibiotics
The sensitivity of the strains to antibiotics was tested using the lactic acid bacteria susceptibility
test medium (LSM) [34] and the microtiter VetMIC plates for lactic acid bacteria (National Veterinary
Institute of Sweden, Uppsala, Sweden), as described previously [35]. Parallel, minimum inhibitory
concentrations (MICs) were also determined by the E-test [AB BIODISK, Solna, Sweden) following
the instructions of the manufacturer. Results were compared to the cut-off levels proposed by the
European Food Safety Authority [36].
2.8. Hemolysis, Formation of Biogenic Amines and Degradation of Mucin
For investigation of hemolysis, strains were streaked onto layered fresh horse blood agar plates
and grown for 24 h at 37 ◦C. Zones of clearing around colonies indicated hemolysin production. The
capacity of the strains to synthesize biogenic amines (tyramine, histamine, putrescine and cadaverine)
from their respective precursor amino acids (tyrosine, histidine, ornithine and lysine; Sigma-Aldrich)
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was evaluated using the method described by Bover-Cid and Holzapfel [37]. The potential of the
strains to degrade gastric mucine (HGM; Sigma) was evaluated in vitro as indicated by Zhou et al. [38].
2.9. Acute and Repeated Dose (4-Weeks) Oral Toxicity Studies in a Rat Model
Wistar male and female rats (Charles River Inc., Marget, Kent, UK) were used to study the acute
and repeated dose (4-weeks) oral toxicity of L. salivarius CECT 9145 in a rat model. Acclimation,
housing and management (including feeding) of the rats was performed as previously described [39].
The rats were 56-days old at the initiation of treatment. Acute (limit test) and repeated dose (4 weeks)
studies were conducted in accordance with the European Union guidelines (EC Council Regulation
No. 440), and authorized by the Ethical Committee on Animal Research of the Complutense University
of Madrid (protocol 240111).
In the acute (limit test) study, 24 rats (12 males, 12 females) were distributed into two groups
of 6 males and 6 females each. After an overnight of fasting, each rat received skim milk (500 μL)
orally (control group or Group 1), or a single oral dose of 1 × 1010 CFU of L. salivarius CECT 9145
dissolved in 500 μL of skim milk (treated group or Group 2). Doses of the test and control products
were administered by gavage. At the end of a 14 days observation period, the rats were weighed,
euthanized by CO2 inhalation, exsanguinated, and necropsied.
The repeated dose (4 weeks) (limit test) study was conducted in 48 rats (24 males, 24 females)
divided in four groups of 6 males and 6 females each (control group or Group 3; treated group or
Group 4; satellite control group or Group 5; and satellite treated group or Group 6). Rats received a
daily oral dose of either skim milk (Groups 3 and 5) or 1 × 109 CFU of L. salivarius CECT 9145 dissolved
in 500 μL of skim milk (Groups 4 and 6) for 4 weeks. All rats of Groups 3 and 4 were deprived of
food for 18 h, weighed, euthanized by CO2 inhalation, exsanguinated, and necropsied on Day 29. All
animals of the satellite groups (Groups 5 and 6) were kept a further 14 days without treatment to detect
the delayed occurrence, persistence or recovery from potential toxic effects. All rats of the Groups 5
and 6 were deprived of food for 18 h, weighed, euthanized by CO2 inhalation, exsanguinated, and
necropsied on day 42.
Behavior and clinical observations, blood biochemistry and hematology analysis, organ weight
ratios and histopathological analysis were carried as described previously [39]. Bacterial translocation
to blood, liver or spleen, and total liver glutathione (GSH) concentration was evaluated following the
methods described by Lara-Villoslada et al. [40].
2.10. Efficacy of L. salivarius CECT 9145 to Eradicate GBS from the Intestinal and Vaginal Tracts of Pregnant
Women: A Pilot Clinical Trial
In this prospective pilot clinical assay, 57 pregnant women (39 rectal and vaginal GBS-positive
women; 18 rectal and vaginal GBS-negative women at the start of the intervention), aged 25–36,
participated in this study. All met the following criteria: a normal pregnancy and a healthy status.
Women ingesting probiotic supplements or receiving antibiotic treatment in the previous 30 days were
excluded. Women with lactose intolerance or a cow’s milk protein allergy were also excluded because
of the excipient used to administer the strain. All volunteers gave written informed consent to the
protocol (10/017-E), which had been approved by the Ethical Committee of Clinical Research of the
Hospital Clínico San Carlos Madrid (Spain).
Volunteers were distributed into 3 groups (1 probiotic group and 2 placebo groups). All the
volunteers in the probiotic group (n = 25) were GBS-positive and consumed a daily sachet with ~50 mg
of freeze-dried probiotic (~9 log10 cfu of L. salivarius CECT 9145) from week 26 to week 38 of the
pregnancy. Placebo subgroup 1 (n = 14) included GBS-positive women (pregnancy week ranging from
19 to 30) that were going to receive IAP because they had a previous baby that suffered a GBS sepsis.
Placebo subgroup 2 (n = 18) included GBS-negative women (pregnancy week ranging from 14 to 26).
Women in both placebo subgroups received a daily sachet containing 50 mg of the excipient used to
carry the probiotic strain. In all cases, the intervention lasted from the start of the intervention to week
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38. Probiotic- and excipient-containing sachets were kept at 4 ◦C throughout the study. All volunteers
were provided with diaries to record compliance with the study product intake. Minimum compliance
rate (% of the total treatment doses) was set at 86%.
Recto-vaginal GBS screening was performed at 28, 32 and 38 weeks. Rectal and vaginal exudates
samples collected during the trial were serially diluted and plated on Granada (Biomerieux; isolation
of hemolytic GBS, which appear as orange colonies), and CHROMagar StrepB (CHROMagar; for
isolation of hemolytic and non- hemolytic GBS, which appear as purple colonies) agar plates. To avoid
sensitivity-related problems, samples were submitted to a GBS enrichment step in Todd-Hewitt broth
(Oxoid). After 24 h at 37 ◦C, the broth cultures were spread on CHROMagar agar plates. Correct
taxonomic assignment was confirmed by MALDI-TOF and latex agglutination analyses, as described
previously. At the last sampling time (week 38), recto-vaginal GBS screening was performed not only
in our laboratory but also in those of the hospitals in which the respective women were going to deliver
their babies.
Microbiological data were recorded as CFU/mL and transformed to logarithmic values before
statistical analysis. Two-way ANOVA was used to investigate the effect of the individual (woman)
and sampling time on the semiquantitative S. agalactiae counts in vaginal swabs. Statistical significance
was set at P < 0.05. Statgraphics Centurion XVI version 17.0.16 (Statpoint Technologies Inc, Warrenton,
Virginia) was used to carry out statistical analyses.
3. Results
3.1. Microbiological Analysis of Vaginal Swabs Obtained from Pregnant and Non-Pregnant Women
Bacterial growth was detected in all the samples when they were inoculated on MRS (2.70–8.08
log10 colony-forming units (cfu); mean 5.36 log10 cfu); CNA (3.00–7.92 log10 cfu; mean 5.13 log10 cfu)
and GAR (2.70–8.10 log10 cfu; mean 5.24 log10 cfu) agar plates. Similar bacterial groups grew in these
three media. Growth on MCK, SDC or Mycoplasma plates was only detected in a few percentages of
samples (from 0% in Mycoplasma plates to ~40% in SDC plates).
S. agalactiae could be isolated from both non-pregnant (~25%) and pregnant (~19%) women.
Candida albicans and other yeasts were isolated from approximately 7 and 36% of the non-pregnant and
pregnant women, respectively. Gardnerella vaginalis was isolated in ~7% of the pregnant women. In both
groups, Lactobacillus was the dominant genus since it was detected in ~93% of the participating women.
In relation to the samples provided by non-pregnant women, a total of 433 isolates (including at
least one representative of each colony and cell morphology) were submitted to taxonomical analyses.
The highest number of isolates corresponded to the genus Lactobacillus (28% of the total isolates),
followed by Staphylococcus (17%), Enterococcus (11%), Corynebacterium (7%), and Streptococcus (4%).
Among the Lactobacillus isolates, the main species were L. gasseri (24%), L. crispatus (23%), L. salivarius
(21%), L. vaginalis (12%), L. plantarum (13%), L. coleohominis (5%), and L. jensenii (2%). Isolates belonging
to the species L. crispatus, L. gasseri, L. salivarius, L. vaginalis, and L. plantarum could be isolated from
the 4 phases of the menstrual cycle sampled in this study.
From the samples provided by pregnant women, 120 isolates were submitted to taxonomical
analyses. Again, the genus Lactobacillus was associated to the highest number of isolates (17%),
followed by Staphylococcus (15%), Streptococcus (8%), yeasts (8%), Enterococcus (5%), Bifidobacterium (3%)
and Corynebacterium (1%). Among the Lactobacillus isolates, the main species were L. gasseri (41%), L.
casei (19%), L. salivarius (16%), L. fermentum (8%), L. vaginalis (6%), L. reuteri (5%) and L. jensenii (5%).
Among the Lactobacillus isolates obtained in this study, a few were selected to evaluate their
potential as probiotics to control GBS populations on the basis of the following criteria: (1) absence
of S. agalactiae, Gardnella vaginalis, Candida spp., Ureaplasma spp., and Mycoplasma spp. in the vaginal
samples from which the lactobacilli were originally isolated; (2) Qualified Presumption of Safety (QPS)
status (European Authority of Food Safety, EFSA); and (3) ability of the strain to grow rapidly in MRS
broth under aerobic conditions (≥1 ×106 cfu/mL after 16 h at 37 ◦C). In fact, only 10 strains (V3III-1,
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V4II-90, V7II-1, V7II-62, V7IV-1, V7IV 60, V8III-62, V11I-60, V11III-60 y, V11IV-60) met all the criteria
and all of them belonged to the same species (Lactobacillus salivarius). These strains were then selected
for further characterization. Later, L. salivarius V4II-90 was deposited in the Spanish Collection of
Type Cultures (CECT) as L. salivarius CECT 9145 and, therefore, this is the name used for this strain in
this article.
3.2. Antimicrobial Activity of the Lactobacilli Strains Against GBS and the Production of Potential
Antimicrobial Compounds
Initially, the antimicrobial activity of the 10 selected lactobacilli against the S. agalactiae strains was
determined by an overlay method. Clear inhibition zones (ranging from 2 to 20 mm) were observed
around the lactobacilli streaks.
In relation to the antimicrobial compounds that may be responsible for such activity, the
concentration of L- and D-lactic acid and the pH of the supernatants obtained from MRS cultures of
the lactobacilli are shown in Table 1. The global concentration of L-lactic acid was similar (~10 mg/mL)
in all the supernatants. In contrast, D-lactic acid was not detected in the supernatants of the tested
strains. In addition, all the strains acidified the MRS-broth medium to a final pH of ~4 after 16 h of
incubation; among them, L. salivarius V7IV-1 showed the highest acidifying capacity (final pH of 3.8).
No bacteriocin-like activity could be detected against the tested S. agalactiae strains. Two strains (L.
salivarius CECT 9145 and V7IV-1) were able to produce hydrogen peroxide (7.29 μg/mL ± 0.69 and
7.46 μg/mL ± 0.58, respectively) (Table 1).
Table 1. The pH and concentrations of L- and D-lactic acid (mg/mL; mean ± SD), and hydrogen
peroxide (μg/mL; mean ± SD) in the supernatants obtained from the MRS cultures of the lactobacilli
(n = 4).
Strain pH L –lactic Acid D-lactic Acid Hydrogen Peroxide
L. salivarius V3III-1 4.00 9.66 ± 0.57 Nd Nd
L. salivarius CECT 9145 4.01 10.03 ± 0.60 Nd 7.29 ± 0.69
L. salivarius V7II-1 4.02 9.82 ± 0.69 Nd Nd
L. salivarius V7II-62 4.01 9.76 ± 0.54 Nd Nd
L. salivarius V7IV-1 3.85 10.47 ± 0.58 Nd 7.46 ± 0.58
L. salivarius V7IV-60 4.02 9.72 ± 0.63 Nd Nd
L. salivarius V8III-62 4.04 9.91 ± 0.55 Nd Nd
L. salivarius V11I-60 4.03 9.84 ± 0.43 Nd Nd
L. salivarius V11III-60 4.07 9.61 ± 0.47 Nd Nd
L. salivarius V11IV-60 4.03 10.02 ± 0.62 Nd Nd
L. salivarius CECT 5713 3.93 10.26 ± 0.62 Nd -
The initial pH value of MRS broth was 6.2. Nd: not detectable.
The capacity of the lactobacilli strains to form large well-defined co-aggregates with S. agalactiae
was strain-dependent. Strains V3III-1, V7IV-60 and V11IV-60 coaggregated with 5 S. agalactiae strains;
strains V8III-62, V11I-60 and V11III-60 with 7; strain V7II-62 with 9 S. agalactiae strains; and strains
CECT 9145, V7II-1 and V7IV-1 with 10 S. agalactiae strains (Figure 1). The ability of the lactobacilli
strains to interfere or inhibit the growth of four S. agalactiae strains was evaluated using MRS broth
co-cultures. Co-cultures with S. agalactiae seemed not to affect the growth of any of the L. salivarius
strains (Table 2). In contrast, most of the L. salivarius strains were able to interfere at a higher or lower
degree with the growth of the different S. agalactiae strains included in this assay. Among them, L.
salivarius CECT 9145 showed the highest ability to inhibit the growth of S. agalactiae since the presence
of two of the four S. agalactiae strains was not detectable in the co-cultures and the concentration of
the other two showed a ~2.5 log10 decrease after an incubation period of only 6 h at 37 ºC (Table 2).
Interestingly, no viable streptococci could be detected when the co-cultures were incubated for 24 h
(Table 2).
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Table 2. The bacterial counts (log10 cfu/mL) of the S. agalactiae strains when co-cultured with the L.
salivarius strains in MRS broth for 0, 6 and 24 h at 37 ◦C.
L. salivarius (Strain) S. agalactiae (Strain) 0 h 6 h 24 h
V3III-1
RC5 7.10 6.44 Nd
RC6 7.24 7.04 Nd
V2I-80 7.10 7.04 Nd
V14I-63 7.27 7.10 Nd
CECT 9145
RC5 7.04 4.48 Nd
RC6 7.23 Nd Nd
V2I-80 7.10 4.70 Nd
V14I-63 7.34 Nd Nd
V7II-1
RC5 7.15 7.27 Nd
RC6 7.15 6.70 Nd
V2I-80 7.04 7.10 Nd
V14I-63 7.35 5.65 Nd
V7II-62
RC5 7.24 7.04 Nd
RC6 6.98 7.49 Nd
V2I-80 7.35 7.92 Nd
V14I-63 7.10 6.93 Nd
V7IV-1
RC5 7.32 7.58 Nd
RC6 7.34 6.90 Nd
V2I-80 7.15 7.38 Nd
V14I-63 7.23 6.04 Nd
V7IV-60
RC5 7.24 7.32 Nd
RC6 7.32 8.06 Nd
V2I-80 7.04 7.15 Nd
V14I-63 7.35 8.34 Nd
V8III-62
RC5 7.15 7.90 Nd
RC6 7.34 7.23 Nd
V2I-80 7.24 6.90 Nd
V14I-63 7.20 8.77 Nd
V11I-60
RC5 7.31 7.44 Nd
RC6 7.01 6.94 Nd
V2I-80 7.23 7.07 Nd
V14I-63 6.93 6.60 Nd
V11 III-60
RC5 7.27 6.44 Nd
RC6 6.95 6.88 Nd
V2I-80 7.28 6.52 Nd
V14I-63 7.37 6.85 Nd
RC5 7.26 6.74 Nd
V11IV-60
RC6 7.42 6.60 Nd
V2I-80 7.10 6.60 Nd
V14I-63 7.06 5.32 Nd
RC5 7.20 9.32 9.34
Control cultures
(no L. salivarius strain)
RC6 7.31 9.20 9.27
V2I-80 7.04 9.15 9.23
V14I-63 7.10 9.02 9.15
Nd: S. agalactiae was not detected.
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Figure 1. The strong co-aggregation between L. salivarius CECT 9145 (rods) and an S. agalactiae strain
(cocci chains).
3.3. Survival After In Vitro Exposure to Saliva and Gastrointestinal-Like Conditions
The viability of the strains after exposition to conditions simulating those found in the
gastrointestinal tract varied from ~64% (L. reuteri CR20, L. salivarius CECT 9145) to 30% (L. salivarius
V3III-1) (Table 3).
Table 3. The percentage (%) of initial lactobacilli (9 log10 cfu/mL) that survived to conditions simulating
those of the gastrointestinal tract.
Strain % Total *
L. salivarius V3III-1 30.2 a
L. salivarius CECT 9145 64.3 b
L. salivarius V7II-1 59.8 b
L. salivarius V7II-62 50.5 b
L. salivarius V7IV-1 48.1 b
L. salivarius V7IV-60 53.3 b
L. salivarius V8III-62 41.3 c
L. salivarius V11I-60 40.8 c
L. salivarius V11III-60 41.1 c
L. salivarius V11IV-60 42.3 c
L. salivarius CELA2 64.4 b
*, different letters mean statistically different values.
3.4. Adhesion to Caco-2, HT-29 and Vaginal Cells and to Mucin
In this study, the lactobacilli strains tested were strongly adhesive to both Caco-2 and HT-29
cells, with the exception of the negative control strain (L. casei imunitas) which showed a low adhesive
potential (Table 4). In addition, all showed adhesion to vaginal epithelial cells. Among the L. salivarius
strains, L. salivarius CECT 9145 globally displayed the highest ability to adhere to both intestinal and
vaginal epithelial cells (Table 4). The lactobacilli strains tested showed a variable ability to adhere to
porcine mucin (Table 4). L. salivarius CECT 9145 and L. salivarius V7IV-1 were the strains that showed
the highest adherence ability.
3.5. Sensitivity to Antibiotics
The MIC values of the lactobacilli strains for 16 antibiotics assayed are shown in Table 5. All the
strains were sensitive to most of the antibiotics tested, including those considered clinically relevant
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antibiotics such as gentamycin, tetracycline, clindamycin, chloramphenicol, and ampicillin, showing
MICs equal to or lower than the breakpoints defined by EFSA (EFSA, 2018). All the strains were
resistant to vancomycin and kanamycin, which is an intrinsic property of the L. salivarius at the
species level.
Table 4. The ability of the lactobacilli to adhere to HT-29, Caco-2 and vaginal epithelial cells, and to
porcine mucin.
Strain HT-29 a Caco-2 a Vaginal Cells b Adhesion c
L. salivarius V3III-1 877.3 ± 303.2 259.1 ± 67.1 + 9.3 ± 2.0
L. salivarius CECT 9145 905.2 ± 297.0 345.1 ± 72.8 +++ 10.9 ± 1.8
L. salivarius V7II-1 900.5 ± 336.2 297.8 ± 84.5 ++ 8.9 ± 1.9
L. salivarius V7II-62 911.7 ± 250.9 321.5 ± 80.2 ++ 9.0 ± 1.6
L. salivarius V7IV-1 884.0 ± 226.3 252.3 ± 67.1 ++ 8.5 ± 1.2
L. salivarius V7IV-60 799.7 ± 210.1 255.9 ± 60.3 ++ 9.6 ± 1.7
L. salivarius V8III-62 623.4 ± 200.2 108.7 ± 24.3 + 3.3 ± 0.7
L. salivarius V11I-60 593.2 ± 191.5 121.6 ± 22.0 + 2.9 ± 0.8
L. salivarius V11III-60 612.4 ± 188.2 153.2 ± 26.7 + 2.4 ± 1.0
L. salivarius V11IV-60 601.6 ± 172.0 159.5 ± 23.4 + 3.4 ± 0.8
a The adherent lactobacilli in 20 random microscopic fields were counted for each test (n = 4). b Semiquantitative
scale: 0, no adhesion; +, low adhesion; ++, middle adhesion; +++, high adhesion. c Values are expressed as the
percentage of the fluorescence retained in the wells after the washing steps of the assay.
3.6. Hemolysis, the Formation of Biogenic Amines and the Degradation of Mucin
The strains did not show the ability to produce biogenic amines, and they were neither hemolytic
nor able to degrade gastric mucin in vitro.
3.7. Acute and Repeated Dose (4 Weeks) Oral Toxicity Studies in a Rat Model
All animals survived both oral toxicity trials. The development of the treated animals during the
experimental periods corresponded to their species and age. There were no significant differences in
body weight or body weight gain among groups treated with L. salivarius CECT 9145 (including the
satellite ones) in comparison to the control groups at any time point of the experimental period. No
abnormal clinical signs, behavioral changes, body weight changes, hematological and clinical chemistry
parameters, macroscopic or histological findings, or organ weight changes were observed. There
were no statistical differences in body weights among groups. Similarly, no statistically significant
differences in body weight gain, food and water consumption were observed between the groups.
No significant differences in liver GSH concentration were observed between the control and treated
groups (9.54 ± 1.21 vs. 9.37 ± 1.39 mmol/g, P > 0.1). L. salivarius CECT 9145 could be isolated from
colonic material and vaginal swabs samples of all the treated animals (probiotic groups) at the end of
the treatment. The concentration oscillated between 5.39 and 8.85 log10 cfu/g of the colonic material,
and between 3.34 and 6.14 log10 cfu/swab in the vaginal samples. The strain could not be detected in
any sample from the placebo group.
3.8. The Efficacy of L. salivarius CECT 9145 to Eradicate GBS from the Intestinal and Vaginal Tracts of
Pregnant Women: A Pilot Clinical Trial
At the inclusion in the study, GBS was detected in both rectal and vaginal swabs obtained from
39 women, out of a total of 57 participating women, while the rest of the women (n = 18) were
GBS-negative (Table 6). This last group of GBS-negative women, who did not ingest the L. salivarius
strain also had negative GBS cultures from rectal and vaginal swabs taken regularly at 28, 32 and 36–38
weeks (Table 6). A group of GBS-positive women at the start of the study (n = 14) did not receive the
probiotic and the routine screening results for vaginal and rectal GBS at 28, 32 and 36–38 weeks were
found to be all positive (Table 6).
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Significantly, the group of GBS-positive women that started using the probiotic (9 log10 cfu/daily)
since they were enrolled in this study (from 26 weeks) also tested positive for GBS at 28 weeks, but an
increasing number of GBS-negative results appeared in the successive swabs collected until delivery
(Table 6). At 30 weeks, the culture of rectal swabs taken from four women of this group rendered a
negative result and the number of these samples increased to 18 (72% of the participants) at 38 weeks.
Similar results were obtained by culturing vaginal swabs obtained from this group, although the
proportion of women testing negative for GBS were always slightly higher when analyzing the rectal
swabs than in vaginal swabs (Table 6).
The estimation of the concentration of GBS in vaginal swabs taken regularly up to the delivery
from all participants is shown in Figure 2. There were no significant changes in both GBS-negative
women (n = 18) and GBS-positive women (n = 14) without oral administration of L. salivarius CECT
9145 regarding the semiquantitative estimation of GBS. However, the number of vaginal swabs where
GBS could not be detected increased in successive sampling times in the group that initially tested
positive for GBS taking 9 log10cfu of L. salivarius CECT 9145 (n = 25). The mean value for S. agalactiae
counts decreased significantly with the administration time of L. salivarius CECT 9145 (Figure 2) from a
mean value of 5.14 cfu/mL at 26 weeks (n = 25) to 3.80 cfu/mL at 38 weeks (n = 9) (Figure 2).
 Week 






















a a c c c b
n=25 n=25 n=15 n=10 n=8 
Figure 2. The mean concentrations (CFU/mL) of S. agalactiae (GBS) in vaginal swabs sampled regularly
up to the delivery from Group B Streptococci (GBS)-positive women taking 9 log10 cfu of L. salivarius
CECT 9145 daily. Statistically significant differences between samples taking at different sampling
times are indicated by letters (Bonferroni post-hoc test).
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No adverse effects arising from the intake of L. salivarius CECT 9145 were reported by any of the
women who participated in this study. The results of the GBS status obtained in our laboratory at week
38 were identical to those obtained in the hospitals were the recruited women were screened for GBS
and, as a result, none of the women who became GBS-negative in this study received IAP.
4. Discussion
In this work, the GBS colonization rates were 25% and 20% among non-pregnant and pregnant
women, respectively. In pregnant women, GBS colonization is found in up to 30% of rectovaginal
samples [2,41] and stable colonization with the same clone for several years has been demonstrated [41].
Previous studies have shown that the presence of GBS is not linked to an abnormal microbiome or a
reduction of the predominant Lactobacillus genus in the vaginal tract of the mother [42–44].
In contrast, a study involving a low number of participants found significant taxonomic differences
in stools of 6-month infants, when mothers were GBS carriers, as compared to non-carriers [45].
Anyway, there is no epidemiological evidence for a correlation between neonatal colonization with
GBS and specific shifts in the maternal intestinal or vaginal microbiome.
In the USA and many other countries (including Spain), women are routinely screened in the late
third trimester (between 35 and 37 weeks’ gestation) for GBS colonization by rectovaginal swabs and
subsequent cultures. If the rectovaginal swab is culture-positive, or if the patient has GBS in the urine,
or has a prior history of GBS perinatal infection, intrapartum prophylactic antibiotics are administered
to prevent vertical transmission of GBS to the neonate during labor and delivery. Some European
countries (e.g., UK) have not adopted the GBS screening program but, instead, administer antibiotics
upon the development of a risk factor for GBS neonatal disease (e.g., prolonged rupture of membranes).
However, none of these approaches has eliminated neonatal GBS infections. This is because these
prevention strategies do not address the risk of ascending infection, which can potentially occur
anytime during pregnancy, leading to preterm birth or stillbirth.
Overall, the prevention of GBS infection in pregnancy is still a complex question, with risk likely
associated to several factors, including the pathogenicity of the GBS strain, host factors, influence of
the vaginal/rectal microbiome, false-negative screening results, and/or changes in GBS antibiotic
resistance [6,46]. Currently, strategies are mainly focused on the prevention of GBS transmission during
labor and delivery through the use of antibiotics. This strategy does not fully capture the biology
of the GBS infection, nor does it completely address the full burden of the GBS disease. Moreover,
antibiotic resistance is increasing and the use of antibiotics during pregnancy has consequential effects
for neonatal health that are only now being appreciated [47]. To successfully eradicate the burden of
disease, interventions need to be specifically targeted while having minimal detrimental effects on the
microbiome. Therefore, there is a need for alternatives that are respectful with the neonatal and infant
microbiota, and that do not compromise the health of future generations. In this context, the final
objective of this work was the selection of safe probiotic strains with the in vitro and in vivo ability to
eradicate GBS from the intestinal and genitourinary tracts of pregnant women and/or their infants.
The genus Lactobacillus constitutes the dominant bacterial group of the vaginal tract in most
healthy women, playing a key role in the genitourinary homeostasis [48–52]. In this study, all the
vaginal isolates (from either pregnant or non-pregnant healthy women) that fulfilled the initial selection
criteria belonged to the species L. salivarius. This species is part of the indigenous microbiota of
the human gastrointestinal tract, oral cavity, genitourinary tract and milk, and some strains have
been studied as probiotics because of their in vitro and in vivo antimicrobial, anti-inflammatory and
immunomodulatory properties [53–64]. Previous studies have shown the ability of L. salivarius strains
to inhibit the growth of vaginal pathogens, including Gardnerella vaginalis and Candida albicans and,
therefore, we have suggested their potential to be used as probiotics for the treatment or prevention of
vaginal infections [65,66].
Administration of probiotic bacteria benefits the host through a wide array of mechanisms that are
increasingly recognized as being either species- and/or strain-specific [67]. A comparative genomics
249
Nutrients 2019, 11, 810
study that included 33 L. salivarius strains isolated from humans, animals or food revealed that this
species displays a high level of genomic diversity [68]. Therefore, the selection of L. salivarius strains
for probiotic use requires the experimental validation of target-tailored phenotypic traits. Some L.
salivarius strains have shown to be efficient in preventing infectious diseases such as mastitis caused
by staphylococci and streptococci, when administered during late pregnancy [69]. Moreover, the oral
administration of L. salivarius strains is also a valid strategy for the treatment of such a condition
during lactation and, in fact, one of the strains was more efficient than antibiotics for this target [70].
In this work, the target was the antagonism towards GBS and, as a consequence, properties such as
antimicrobial activity against S. agalactiae strains or coaggregation with this species were considered
particularly relevant.
The production of antagonistic substances such as bacteriocins, hydrogen peroxide or organic
acids represents an important contribution to the defense mechanisms exerted by intestinal and vaginal
lactobacilli [59,71]. Some L. salivarius strains produce bacteriocins or display bacteriocin-like activity
against a variable spectrum of Gram-positive bacteria, including S. agalactiae strains [72]. However,
none of the L. salivarius strains selected in our study displayed bacteriocin-like activity against S.
agalactiae strains. Therefore, the antimicrobial activity that the selected L. salivarius strains exhibited
against S. agalactiae must be related to the production of other antimicrobial compounds, such as
organic acids. The ability of lactobacilli to acidify the vaginal milieu contributes to the displacement
and inhibition of pathogens proliferation [73] and, more specifically, the acid production by lactobacilli
has been directly correlated with the inhibition of GBS growth [74]. Another antimicrobial defense
mechanism attributed to some intestinal or vaginal lactobacilli is the production of peroxide hydrogen,
a compound that is toxic for catalase-negative bacteria, such as streptococci [75]. The production of
this compound by L. salivarius has already been reported [59,76,77]. In our study, L. salivarius CECT
9145 (the strain that showed the highest anti-GBS activity) produced high amounts of lactic acid and,
in addition, was able to produce peroxide hydrogen.
The ability to adhere to intestinal or vaginal epithelial cells or to mucin, and to co-aggregate
with potential pathogens constitutes one of the main mechanisms for preventing their adhesion and
colonization of mucosal surfaces. Therefore, it is not strange that such properties are considered
relevant to the selection of probiotic strains [28]. The high adherence of L. salivarius strains to Caco-2
and HT-29 cells or to mucin has been previously observed [53,59,78]. Globally, L. salivarius CECT
9145 showed the best combination of adherence to epithelial cells, co-aggregation with S. agalactiae
and the inhibition of S. agalactiae strains in broth co-cultures. This strain showed a high survival rate
during transit through an in vitro gastrointestinal model and survival of lactobacilli when exposed to
conditions found in the gastrointestinal tract seems to be a critical pre-requisite for a probiotic strain
when its use as a food supplement is pursued, as it was the case.
Some vaginal strains of L. gasseri and L reuteri have also been reported to co-aggregate with
GBS [78]. In contrast, no co-aggregation activity between S. agalactiae and other vaginal lactobacilli
belonging to the species L. acidophilus, L. gasseri and L. jensenii was observed in another study [32],
a fact suggesting that such property is a highly strain-specific trait. In relation to broth co-cultures, the
capacity to antagonize the growth of S. agalactiae by lactobacilli strains belonging to different species,
including L. salivarius, has been previously reported [79,80]. Similar to our results, this activity was
strain-dependent [79].
One of the most important criteria for the selection of probiotic strains is the assessment of their
safety, particularly to the target population. In this work, no adverse effect was reported by any of
the women who participated in the clinical trial and ascribed to the probiotic group [thus, receiving L.
salivarius CECT 9145 at 9 log10 cfu daily for several weeks). Previously, other L. salivarius strains have
been shown to be well-tolerated and safe in animal models [40] and in human clinical assays [70,81–83],
including one involving pregnant women [69].
The L. salivarius strains included in this study were very susceptible to most of the antimicrobials
tested. In fact, their MICs were lower than the cut-offs established for lactobacilli to seven out of
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the eight antibiotics required for this species by the European Food Safety Authority [36]. The
only exception was kanamycin. The intrinsic resistance of lactobacilli to kanamycin and other
aminoglycosides (such as neomycin or streptomycin) has been repeatedly reported [84,85], and
this is thought to be an L. salivarius species-specific trait due to the lack of cytochrome-mediated
transport of this class of antibiotics [86]. The L. salivarius strains were also resistant to vancomycin but
the assessment of vancomycin sensitivity is not required by EFSA in the case of homofermentative
lactobacilli (including L. salivarius) since they are intrinsically resistant to this antibiotic probably due
to the presence of D-Ala-D-lactate in their peptidoglycan structure [87]. Therefore, L. salivarius CECT
9145 and the other strains evaluated in this study can be considered as safe from this point of view.
Lactobacilli are among the Gram-positive bacteria with the potential to produce biogenic amines
and these substances can cause several toxicological problems and/or may act as potential precursors
of carcinogenic nitrosamines [37]. The screened L. salivarius strains neither produced histamine,
tyramine, putrescine or cadaverine nor harbored the gene determinants required for their biosynthesis.
Additionally, they were unable to degrade gastric mucin in vitro.
Some studies have been focused on the potential of different lactic acid bacteria strains or their
metabolites to inhibit the growth of S. agalactiae in vitro or in murine models [74,80,88–95]. However,
few studies have evaluated the efficacy of probiotic strains for the rectal and vaginal eradication
of GBS in pregnant women. Ho et al. [96] examined the effect of Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14 taken orally on GBS-positive pregnant women at 35–37 weeks of gestation,
and found that GBS colonization changed from positive to negative in 42.9% of the women in the
probiotic group. The rate of women that became GBS-negative was lower than in our study and this
might be due to the fact that, in the cited study, the recruited women started the probiotic intake
many weeks later. A second study using the same two strains (L. rhamnosus GR-1 and L. reuteri RC-14)
provided non-conclusive results due to the low adherence to the probiotic treatment since only seven
of 21 women in the intervention group completed the entire 21 days of probiotics [97].
It is important to highlight that nutrition may also play a key role in creating mucosal conditions
favoring the action of bacterial strains that are able to improve the rectal and vaginal environments, as it
is the case of L. salivarius CECT 9145. Such conditions may include the selective fermentation of dietary
fiber, the production of relevant bioactive compounds, such as short-chain fatty acids [98], or the use of
hyaluronic acid, which has been shown to be useful in the treatment of female recurrent genitourinary
infections [99]. The impact of diet on the outcomes of clinical assays involving probiotic-interventions
is often underrated and should be taken into account in future studies.
Our study includes the whole process from strain isolation to a pilot clinical study specifically
targeting GBS eradication in pregnant women. The criteria followed for the selection of the best
candidate for such a target (L. salivarius CECT 9145) allowed a notable reduction in the rate of
GBS-colonized women and led to a reduction in the use of antibiotics during the peripartum period.
As a conclusion, the administration of L. salivarius CECT 9145 to GBS-positive pregnant women is a
safe and successful strategy to significantly decrease the rates of GBS colonization during pregnancy
and, therefore, to reduce the exposure of pregnant women and their infants to intrapartum prophylaxis.
Work is in progress to study the mechanisms involving GBS antagonism, including the study of the
strain genome and to initiate a multicenter well-designed clinical trial involving a higher number
of women.
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Abstract: The main purpose of this study was to investigate the hepatotoxic potential and effects on
the gut microbiome of decaffeinated green tea extract (dGTE) in lean B6C3F1 mice. Gavaging dGTE
over a range of 1X–10X mouse equivalent doses (MED) for up to two weeks did not elicit significant
histomorphological, physiological, biochemical or molecular alterations in mouse livers. At the same
time, administration of dGTE at MED comparable to those consumed by humans resulted in significant
modulation of gut microflora, with increases in Akkermansia sp. being most pronounced. Results
of this study demonstrate that administration of relevant-to-human-consumption MED of dGTE to
non-fasting mice does not lead to hepatotoxicity. Furthermore, dGTE administered to lean mice,
caused changes in gut microflora comparable to those observed in obese mice. This study provides
further insight into the previously reported weight management properties of dGTE; however, future
studies are needed to fully evaluate and understand this effect.
Keywords: catechins; green tea extract; herbal dietary supplements; hepatotoxicity; microbiome
1. Introduction
The importance of dietary polyphenols for systemic health benefits is becoming increasingly
recognized. Green tea, a major source of catechin polyphenols, is the second most popular beverage
in the world and extracts of green tea are common ingredients in many dietary supplements. Major
green tea extract (GTE) catechins include epicatechin (EC), epicatechin gallate (ECG), epigallocatechin
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(EGC) and epigallocatechine gallate (EGCG), where the latter constitutes 50-80% of total catechins [1,2].
Catechins are reported to exert a number of positive effects on human health, including antioxidant,
antibacterial and anti-inflammatory activities as well as reduced risks for cancer and cardiovascular
disease [3–6]. Furthermore, the association of green tea or GTE consumption with weight loss and
weight management, has further attracted interest to studies on catechins [7,8]. While these claims
are based mostly upon the results of animal studies or equivocal clinical trial findings, the popularity
of GTE and GTE-containing herbal dietary supplements (HDS) continues to grow. At the same time,
GTE and its various catechin components (mainly–EGCG) are linked to a number of hepatotoxicity
cases [9–15]. This hepatotoxicity has been confirmed experimentally and was shown to be further
exacerbated by fasting conditions [16–19]. Therefore, the first aim of this study was to investigate
potential hepatotoxicity and associated mechanisms of decaffeinated GTE (dGTE) in non-fasting mice.
The potentially beneficial effects associated with GTE and their mechanisms remain poorly
understood. It has been demonstrated that short-term ingestion of GTE increases energy expenditure
and promotes weight loss among lean and overweight volunteers but the long-term effects of GTE on
energy expenditure were less conclusive [20–25]. Other hypotheses include GTE-mediated effects on
sympathetic nervous system activity and promotion of fat oxidation [8]. Furthermore, a number of
in vitro studies have indicated that EGCG inhibits adipocyte differentiation and proliferation while
inducing adipocyte apoptosis [26–28]. However, it must be recognized that most in vitro studies have
utilized EGCG concentrations (50–400 μM) much greater than that typically observed in humans (up to
1 μM) following GTE ingestion [29]. Furthermore, it is become increasingly recognized that intestinal
absorption of catechins is at best nominal with less than 30% of ingested green tea polyphenols reaching
the systemic circulation [30–34]. Poor absorption coupled with extensive first-pass metabolism likely
explains the poor tissue accumulation of catechins following oral ingestion [35,36]. Therefore, the
purported health benefits of GTE are not readily attributable to circulating levels of catechins.
Substantial levels of unabsorbed catechins, mainly EGCG, have been shown to reach the proximal
and distal colon [37,38]. To what extent gut microbial metabolism plays a role in mediating GTE’s health
benefits remains to be determined. However, accumulating evidence indicates that GTE can modulate
the gut microbiome in both experimental models and in humans [39–42]. Therefore, it has been
proposed that GTE’s health benefits may be linked to the effects catechins exert on particular bacterial
species in the gut. Recent studies report similar patterns in the effects GTE causes on the gut microbiome
in both experimental models and in human subjects. Those patterns are characterized by higher
Shannon and Simpson microbiome diversities, increases in abundance of Bacteroidetes concomitant with
deceases in Firmicutes at the phyla level and increases in Prevotellaceae and Bacteroidaceae paralleled by
decreases in Eubacteriaceae, Lachnospiraceae, Ruminococcaceae and Clostridiaceae at the family level [39–41].
These studies, however, were performed on obese individuals or obese/fed high-fat diet mice; however,
the effects of GTE on the gut microbiome associated with the lean phenotype remain unknown.
Therefore, the second aim of this study was to investigate the effects of dGTE on the gut microbiome as
a result of short-term ingestion in lean B6C3F1 mice.
2. Materials and Methods
2.1. Decaffeinated Green Tea Extract (dGTE)
The studied product was a standardized dGTE manufactured by Nature’s Way (Green Bay, WI,
USA; lot # 20055697, expiration 11/30/18). The gavage solution was prepared by extracting the contents
of 10 capsules with 10 mL of distilled water (pH = 5.3) in 20 mL round bottom, glass screw cap tubes
via rotation (12 revolutions per minute) for 24 h. Tubes were then centrifuged at 10,000 rpm for 1 h, the
supernatant was collected and two 1 mL aliquots were analyzed by the University of Mississippi’s
National Center for Natural Products Research for analysis (NCNPR).
dGTE was characterized for phytochemical content using validated analytical methods
incorporating ultra-high performance liquid chromatography (UPLC) coupled with photodiode
260
Nutrients 2019, 11, 776
array (PDA) and mass spectrometry (MS) detection previously developed for the quantitative analysis
of caffeine, theobromine and individual catechins (i.e., catechin, epicatechin, epicatechin gallate,
epigallocatechin gallate) in Camellia sinensis leaves and GTE-containing products. Quantitative analysis
was performed using a Waters Acquity UPLCTM H-class system (Waters Corp., Milford, MA, USA)
including a quaternary solvent manager, sample manager, column compartment and PDA (Waters
Acquity model code UPD) connected to a Waters Empower 2 data station. Separations were achieved
within 15 min using a Waters C18 column. The injection volume was 2 μL and the PDA wavelength
was 230 nm. The effluent from the LC column was directed into an electrospray ionization (ESI) probe.
Compounds were confirmed under both positive and negative ionization modes.
2.2. Animals
Male B6C3F1/J mice, 8 weeks of age, were purchased from Jackson Laboratories (Bar Harbor, ME)
and were housed at the UAMS Division of Laboratory Animal Medicine facility. B6C3F1/J mice are
characterized by an average sensitivity to hepatotoxicants and are widely used by both the U.S. Food
and Drug Administration (FDA) and industry to investigate the potential for xenobiotics to produce
hepatotoxicity. Male mice were used on account of previous reports indicating a higher sensitivity
to GTE-induced toxicity in male animals [17]. Animals were given one week to acclimate before the
initiation of studies. Animal experiments were conducted in two stages. In the first stage, mice were
gavaged with a single dose of either 1X, 3X or 10X mouse equivalent doses (MED) of dGTE with
the subsequent tissue harvest at 24 h. This stage was performed in order to address the potential
for acute toxicity of dGTE. During the second stage, mice were gavaged with dGTE for two weeks
(Mon-Fri). The duration of this stage was chosen to investigate dGTE’s sub-acute toxicity. To avoid
potential fasting-exacerbated toxicity, food and water were provided ad libitum. Animal body weights
were measured and recorded twice a week. All procedures were approved by the UAMS Institutional
Animal Care and Use Committee at UAMS (protocol number: AUP #3701).
2.3. Dosage Information/Dosage Regimen
Allometric scaling for mouse equivalent doses for dGTE was determined per the recommendation
of Wojcikowski and Gobe [43] which, in turn, is based upon the FDA Industry Guidance for Estimating
the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Volunteers [44].
According to the label, each capsule 250 mg of dGTE was standardized to 95% polyphenols
(75% catechins). Label recommended dose was “2 capsules daily, preferably with food.” The human
dose of catechins was calculated to be 375 mg catechins/70 kg = 5.36 mg/kg. MED of dGTE was
calculated as 5.36 mg/kg × 12.3 = 65.9 mg/kg, where 12.3 is the scaling factor commonly used for mice
weighing between 11–34 g. Concentration of total catechins per mL for the Nature’s Way extraction
solution as determined by NCNPR was 723.5 mg/mL. Therefore, for the 1X MED, the quantity of
catechins administered was 65.9 mg/kg × 0.0235 kg (average mouse weight in our study) = 1.5 mg total
catechins delivered in 300 μL of gavage solution. Consequently, 3X MED = 4.5 mg total catechins and
10X MED = 15 mg total catechins.
All extract supernatants were kept in the refrigerator and gavage doses were prepared fresh each
day. After 40 days, a reanalysis of the catechin content of the supernatants was performed and the
total catechin concentration was 92% of the original quantity.
2.4. Blood Sampling and Clinical Biochemistry
To measure the effects of dGTE on the panel of enzymes characteristic for liver injury, blood was
collected at the end of each experimental stage. Blood was collected under isoflurane anesthesia from
the retroorbital plexus. Tubes were kept on ice and centrifuged at 10,000 rpm for 20 min; serum samples
were then immediately aliquoted and delivered to Arkansas Livestock and Poultry Commission
Veterinary Diagnostic Laboratory (Little Rock, AR, USA) where the samples were processed same day.
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2.5. Histopathological Assessment
Livers were excised, and a 1 mm section was obtained from the left lateral lobe and another from
the right medial lobe. The sections were fixed in 4% formalin for 24 h, then briefly rinsed in PBS and
stored in 70% ethanol for 24 h. Livers were then processed at the UAMS Pathology Core Facility,
stained with hematoxylin eosin and shipped to the Heartland Veterinary Pathology Services, PLLC
(Edmond, OK) where they were assessed by a board-certified veterinary pathologist in a blind fashion.
For histologic evaluation purposes, each liver was represented by two sections obtained from
different lobes. Each section was initially evaluated at magnifications of 4 × 0 and 100X. The sections
were then evaluated at 200X and 400X to better determine if significant changes were present and to
check for the presence of mitotic figures and apoptotic bodies.
2.6. Glutathione Analysis
Glutathione was measured using a modified Tietze assay [45]. Briefly, liver tissue was homogenized
in 3% sulfosalicylic acid. One aliquot was diluted in N-ethylmaleimide (NEM) to mask reduced
glutathione (GSH) to facilitate measurement of oxidized glutathione (GSSG), while another was diluted
in 0.1 M HCl for measurement of total (GSH+GSSG) glutathione. After removal of NEM by solid
phase extraction with a C18 column, glutathione was measured in both aliquots using a colorimetric
glutathione reductase cycling detection method [45].
2.7. Gene Expression Array
Total RNA was extracted from flash frozen liver tissue using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). Following purification, 1000 ng were reverse transcribed with the High
Capacity cDNA Reverse Transcription Kit (ThermoFisher, Waltham, MA, USA). The cDNA was diluted
to 5 ng/μL and 105 μL was mixed with an equal volume of 2X TaqMan® Fast Advanced Master
Mix. For real-time PCR, 100 μL of the mix was applied to each of two channels on a TaqMan Low
Density Hepatotoxicity Array (TLDA) (Supporting Information Table S1) (ThermoFisher, Waltham,
MA, USA). Four biological samples were loaded on each array with five samples per each group
analyzed. Analysis was performed using the ExpressionSuite Software v1.1 (ThermoFisher, Waltham,
MA, USA).
2.8. Analysis of the Gut Microbiome
Fecal samples from individual mice were placed into collection tubes containing a nucleic
acid stabilizer (Zymo Research, Irvine, CA, USA). Bacterial DNA extraction was performed using
ZymoBIOMICS DNA Kits (Zymo Research). In total, 400 ng of each sample was used for tagmentation
and library preparation, as directed by manufacturer’s protocol of KAPA HyperPlus Kit (Roche,
Madison, WI, USA). Then, each library was purified using AMPure XP bead (Beckman Coulter,
Indianapolis, IN, USA). Normalized libraries were pooled and pair-end sequencing using the Illumina
NextSeq 500 platform to obtain 150 bp paired-end reads was performed.
Raw Illumina fastq files were preprocessed to ensure that only the high-quality reads would be
used for further bioinformatics analysis; adapter trimming and quality filtering were performed using
Trimmomatic software version 0.36 with default parameters [46]. High quality fastqs were further used
as the inputs for reference taxonomic classification and quantification using Centrigue version 1.0.4
with default parameters to generate species profile [47]. Profiles were then visualized on a taxonomic
hierarchy using Pavian package for comparison purposes. The high quality reads were used for
de novo assembly binning to construct high quality metagenomic gene profiling using the metaWRAP
pipeline—a flexible pipeline for genome-resolved metagenomic data analysis with default parameters
except using the mouse genome (mm10) to account for host contamination. Non-redundance gene
sets were constructed as per Foong et al. from the obtained ORFs of the samples using Usearch fast
clustering with identity cutoff of 95% and overlap length of 90% [48]. The constructed non-redundance
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gene sets were then translated into amino acid sequences for KEGG pathway annotation using
ghostKOALA pipeline [48,49]. Differential abundance analysis of taxonomic and gene profiles were
performed from the count data using DESeq2 package [50]. The adjusted p-values were then used for
KEGG pathway enrichment analysis using piano package [51]. Pathways that had enrichment p-value
of < 0.001 were selected to plot heatmaps. Raw sequence reads have been uploaded to NCBI, accession
ID: PRJNA523806.
2.9. Statistical Analysis
All statistical analyses were performed with the GraphPad Prism 6 software (GraphPad Software.
San Diego, CA, USA). Treatment groups were compared with their respective untreated group using
ANOVA followed by Tukey’s multiple comparison test. In cases where the data was not normally
distributed, a Kruskal-Wallis test followed by a Dunn’s multiple comparisons test was used instead.
3. Results
3.1. Phytochemical Characterization of Dgte Utilized in the Study
Phytochemical characterization of utilized dGTE is presented in Table 1. The catechin composition
of the characterized product was comparable to the catechin composition in the product used in other
animal studies with no more than 10% difference for each particular catechin ingredient.












Sum of catechins 255.3
Sum of E-catechins 243.0
3.2. Studies on Acute dGTE Toxicity
Acute toxicity was investigated 24 h after a single gavage of mice with either 1X, 3X or 10X MED of
dGTE to determine if dGTE can cause hepatotoxicity in a fed state. Significant decreases in body weight
were observed in mice gavaged with 10X MED (12%, p < 0.001) (Figure 1A). The liver-to-body weight
ratio was slightly but significantly decreased in all experimental groups (Figure 1B). Moderate changes
in the organ-to-body weight ratios were also observed in the heart but not in the kidney (Supporting
Information Figure S1A,B). No appreciable differences in cytoplasmic vacuolation, apoptotic or mitotic
events, nor steatosis were observed in the livers of control versus experimental animals (Figure 1C).
Analysis of clinical biochemistry did not reveal any substantial changes in any of the evaluated
parameters, besides the insignificant nearly two-fold increase in ALT and ~20% increase in AST after
gavage with 1X MED (Table 2). To determine if dGTE had any effect on glutathione concentration or
generation of reactive oxygen species (ROS) in the liver, we measured both total (GSH+GSSG) and
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oxidized (GSSG) glutathione. dGTE dose-dependently decreased hepatic GSH+GSSG content at 24 h,
with ~40% (p < 0.05) depletion at 10X MED (Figure 1D). On the molecular level, only two genes out of
84 investigated were significantly deregulated—Lss and Chrebp. The expression of both genes was
decreased; however, the extent of the changes was low (below 2-fold) (Figure 1E).
Figure 1. Analysis of dGTE acute toxicity. Body weights (A) and liver-to-body weight ratio (B).
Photomicrograph of intact mouse liver after a single gavage with 10X mouse equivalent dose (MED)
of dGTE (C). Total glutathione (D). mRNA levels of Lss and Chrebp genes (E). * p < 0.05, ** p < 0.01,
*** p < 0.001; mean +/- SEM (n = 5 per group).
Table 2. Clinical chemistry parameters after dosing with dGTE for 24 h and 2 weeks.
24 h Units Vehicle 1X 3X 10X
Total Bilirubin mg/dL <0.2 <0.2 <0.2 <0.2
ALT U/L 28.8 (±8.8) 52.6 (±20.2) 34.4 (±14.8) 32.2 (±11.9)
AST U/L 66.2 (±5.7) 84.2 (±8.2) 65.2 (±9.8) 68.2 (±10.3)
GGT U/L <3.0 <3.0 <3.0 <3.0
Alkaline Phosphatase IU/L 197 (±3.8) 196.2 (±7.3) 163.8 (±13.5) * 189.8 (±6.4)
2 weeks Units Vehicle 1X 3X 10X
Total Bilirubin mg/dL <0.2 <0.2 0.2 <0.2
ALT U/L 28.8 (±8.8) 24.8 (±2.3) 34.2 (±14.4) 33.5 (±11.6)
AST U/L 66.2 (±5.7) 49.2 (±12.9) 70.8 (±13.9) 67.6 (±10.4)
GGT U/L <3.0 4.8 (±1.3) <3.0 <3.0
Alkaline Phosphatase IU/L 148 (±4.5) 91.6 (±12.9) ** 131.2 (±18.1) 140.2 (±6.7)
Data presented as mean +/- SEM (n = 5 per group) * p < 0.05, ** p < 0.01 compared to vehicle.
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3.3. Studies on Sub-Acute dGTE Toxicity
Sub-acute toxicity was investigated after 2 weeks (Mon-Fri) of daily gavage with either 1X, 3X or
10X MED dGTE. A statistically significant decrease in body weight (8%, p = 0.012) was observed after
gavaging mice with 1X MED dGTE compared to control mice at the end of the study (Figure 2A). No
differences in body weight were observed after 3X and 10X MED dGTE. Gavaging with dGTE did
not cause any changes in liver-to-body weight ratio (Figure 2B) as well as heart-to-body weight ratios
(Supporting Information Figure S2A). A small increase in kidney-to-body weight ratio was observed in
mice gavaged with 1X MED dGTE (Supporting Information Figure S2B).
Similar to the acute toxicity study, there were no histomorphological changes in the livers of
experimental animals (Figure 2C). Furthermore, no changes were observed in the evaluated serum
parameters except for the ~30% decrease in ALP in mice gavaged with 1X MED dGTE (Table 2).
GSH+GSSG did not differ between groups after 2 weeks (Figure 2D), indicating compensatory GSH
synthesis with prolonged exposure. Although the ratio of GSSG to GSH was significantly increased
after GTE treatment at 24 h (data not shown), the absolute amount of GSSG was unchanged at both
24 h and 2 weeks (Figure 2E).
Gene expression analysis revealed only one (1) out of 84 genes significantly deregulated, Mcm10,
increased expression of which was observed after administration of 10X MED dGTE (1.9-fold, p < 0.01)
(Figure 2F).
Figure 2. Analysis of dGTE sub-acute toxicity. Body weights ((A) # significant compared to
vehicle, *significantly different from Day 1 within a dose group) and liver-to-body weight ratio
(B). Photomicrograph of intact liver after gavaging mouse with 10X MED dGTE for 2 weeks (C).
GSSH/GSH ratio (D), total glutathione (E) and mRNA levels of Mcm10 gene (F). * p < 0.05, ** p < 0.01;
# p < 0.05 compared to vehicle (F); mean +/- SEM (n = 5 per group).
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3.4. Studies on the Gut Microbiome
Next, we sought to investigate whether or not orally administered dGTE affected the gut
microbiome of lean mice. We selected 3X MED (equivalent of ~200 mg/kg/bw) since this is a dGTE
dose analogous to that commonly consumed by humans [52].
We report that gavaging lean B6C3F1 mice with 3X MED dGTE for the period of two weeks,
caused substantial perturbations in the mouse gut ecology. Taxonomic profiling using Centrifuge
software identified a clear discrimination between the control and dGTE mice (Figure 3A). At the
cut-off of 0.5% relative abundance, B. thetaiotaomicron, a common resident bacteria in a mouse gut,
was the most abundant species, followed by L. johnsonii, Akkermansia muciniphila, Lachnoclostridium
sp. YL32, Parabacteroides sp. YL27 and Ruminoclostridium sp KB18 (Figure 3B). Administration of dGTE
caused an increase in the Bacteroidetes to Firmicutes ratio (Figure 3C,D). Interestingly, only A. muciniphila
abundance was dramatically increased in the dGTE group compared to control in the high abundance
taxa (Figure 3C,D) with the most statistically significant adjusted p-value of 1.75e-7 (Supporting
Information Figure S3, Table S2). Based on KEGG pathway analysis, increased abundance of genes
associated with glycan degradation-related pathway in dGTE group compared to control was found
(Figure 3E). As mucin is composed of different types of glycans, this correlates with the increased
abundance of A. muciniphila, which is the main consumer of mucin in both human and animal gut [53].
On the other hand, decreased abundance of genes related with Salmonella infection, bacterial chemotaxis
and bacterial mobility proteins in dGTE group was noted.
Figure 3. Shot gun metagenome analysis of dGTE (green) compare with control (blue). PCA plot of gut
microbiome species abundance (A). Bag plots of high abundance gut bacteria (>5% relative abundance)
in the study (B) * p < 0.05 compared to vehicle; mean +/- SEM (n = 5 per group). Sankey diagram for
visualization of species abundance in a taxonomic tree of a sample control group (C) and dGTE (D).
Heat map of directional enrichment score (−log10 enrichment p-value) for selected KEGG pathway (E).
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4. Discussion
To assess the hepatotoxic potential of dGTE, we utilized an integrative approach similar to
our other recent studies for the safety assessment of multi-ingredient botanical dietary supplement
formulations [54,55]. This approach considers analyses based upon: (1) the number of end-points
characteristic for liver injury; (2) a dose range of 1X to 10X MED (65.9 to 659 mg/kg bw/day of
dGTE for this study); and (3) single and repeated dosing studies. This allows for a fast and
comprehensive investigation of phytochemical hepatotoxicity as well as provide insight into potential
toxicological mechanisms.
Our findings are in agreement with previous pre-clinical and clinical studies on dGTE
hepatotoxicity that reported a lack of liver injury at doses below ~750 mg/kg bw/day [13,16,52].
Despite administering dGTE at doses as high as 10X MED, no appreciable toxicological responses were
observed in experimental mice. Specifically, gavaging mice with dGTE produced no histopathological
abnormalities in the livers and no significant alterations were observed in clinical biochemistry
parameters indicative of liver injury. Small decreases in total glutathione were observed in mice livers
24 h after a single administration of dGTE; however, these effects were short-lived and had disappeared
by day 14. The fact that dGTE had no effect on GSSG at 1X and 3X MED argues against the idea that
orally administered dGTE is an antioxidant and the observed depletion of GSH+GSSG after a bolus
dose of dGTE may even increase the risk of oxidative stress. This finding underscores the necessity of
validating in vitro data using in vivo models and warrants further in vivo studies to investigate the
potential anti- and pro-oxidant effects of GTE [56,57].
Only very modest, dose-independent changes in gene expression were detected in the livers
of dGTE-gavaged mice. Analysis of expression panels for genes involved in xenobiotic metabolism
or hepatocellular responses to toxicants revealed only a small subset (<5%) that was significantly
dysregulated. Importantly, the magnitude of responses in those genes was minimal, with only one
gene, Mcm10, exceeding a 1.5-fold increase from control. Furthermore, reduced expression of Lss
and Chrebp genes that are associated with cholesterol and glycogen metabolism in mice may suggest
potentially beneficial health effects and warrant future studies. No dGTE-induced weight-loss was
observed; however, this can be explained by the lean nature of the mice and the study’s short duration.
It must be noted that our study was performed under conditions that purposefully omitted
other potential contributors to liver injury, such as genetics, fasting and caffeine [16,19,58]. GTE-
or EGCG-induced liver injury is considered idiosyncratic by nature. While the mechanisms of this
idiosyncrasy remain unknown, genetic components seem to play a significant, if not key, role [10,59].
Furthermore, in their elegant study using diversity outbred (DO) mice, Church and colleagues
demonstrated that variations in select genomic loci may predispose to higher sensitivity to EGCG [19].
Therefore, our observed lack of dGTE-induced hepatotoxicity among inbred B6C3F1 mice, a strain
characterized by average sensitivity to hepatotoxicants, is not surprising.
Previous research hints at a contribution of fasting in GTE/catechins-induced liver injury.
For instance, in two classical studies with beagle dogs, fasted animals exhibited high sensitivity
to orally administered EGCG, including mortality at doses of 400 mg/kg bw with No-Observed-
Adverse-Effect-Level (NOAEL) observed at 40 mg EGCG/kg bw/day [16]. At the same time, the
NOAEL in dogs that received food ad libitum was 460 mg/kg bw/day and could potentially have been
higher, as this dose of EGCG was the highest used in the study [16]. In our study, the mice received
food ad libitum, with a NOAEL of 659 mg/kg bw/day.
Furthermore, our study utilized dGTE, thereby precluding any contributory effects from
caffeine [58]. Importantly, in many GTE-associated cases of hepatotoxicity, GTE was one but not
the only, constituent of the formulation. For example, GTE was present in both Hydroxycut™ and
X-elles™, two dietary supplement formulations linked to multiple cases of hepatotoxicity that were
voluntarily withdrawn from the market [14]. Besides GTE, both of those formulations contained
caffeine and a host of other botanical ingredients. Caffeine’s propensity to exacerbate the toxicity of
267
Nutrients 2019, 11, 776
other phytochemicals was recently recognized by the FDA, which banned the sale of pure caffeine
powder and dietary supplements containing high caffeine content [60].
Finally, product adulteration with prescription medications (e.g., acetaminophen, amphetamines,
etc.) or contamination with heavy metals, pesticides/herbicides or bacteria cannot be ruled
as contributors to the hepatotoxicity of multi-ingredient, GTE-containing supplements [10,11].
Phytochemical characterization of the dGTE used in the present study revealed no evidence of
adulteration, heavy metal or bacterial contamination.
Accumulating evidence indicates that catechin oral bioavailability is relatively low [13,15–18,34,35].
Our findings, together with a wealth of previously published data, suggest that any dGTE-derived
health effects from catechins, likely stem from dGTE-mediated alterations in the distal gut microbiome
and potential active metabolites generated therein, rather than from catechin absorption in the proximal
intestine. Indeed, even minimal dietary interventions can substantially affect the gut microbiome and
metabolome [61].
It has been proposed that GTE’s health benefits may be linked to the effects catechins exert on
particular bacterial species in the gut. For instance, catechins have been shown to affect the growth
of Bacteroidetes and Firmicutes [62]. It is especially important to note that the relative proportion of
Bacteroidetes to Firmicutes and bacterial alpha diversity are markedly decreased in both obese humans
and obese mice [25,63–65]. Further studies have confirmed EGCG-induced changes to gut ecology [66].
Additionally, administration of green tea polyphenols appears to modulate gut microbiota diversity,
including restoration of the Bacteroidetes to Firmicutes ratio resulting in body weight loss in mice fed
a high fat diet [65]. Interestingly, another recent study that used liquid green tea reported opposite
results with a decrease observed in the Bacteroidetes to Firmicutes ratio [42]. In our study, coincident
with an increased Bacteroides to Firmicutes ratio, we also found an increase in A. muciniphila, a mucin
degrading bacteria, which has been reported as a beneficial gut microbe associated with body fat
reduction, correction of dyslipidemia and reduced insulin resistance [67].
In conclusion, we demonstrate that dGTE, when administered to non-fasting and genetically
uncompromised mice, does not elicit hepatotoxic effects even when administered at doses as high
as 659 mg/kg bw/day. Additional studies, however, will be needed to delineate the role of other
confounding factors like caffeine, which may decrease tolerance to GTE. We further demonstrate that
dGTE doses ~200 mg/kg bw can substantially modulate the gut microbiome, leading to increases in the
health-beneficial bacteria Akkermansia sp. These findings may give insight into the potential weight
management properties of GTE; however, future studies are needed to fully delineate this effect.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/4/776/s1,
Figure S1: Analysis of dGTE acute toxicity. Heart-to-body weight ratio (A) and kidney-to-body weight ratio (B).
* p < 0.05, Figure S2: Analysis of dGTE sub-acute toxicity. Heart-to-body weight ratio (A) and kidney-to-body
weight ratio (B). * p < 0.05, Figure S3: High abundance taxa in individual gut microbiome samples, Table S1:
Taqman Custom Array targets, Table S2: Listing of taxa abundance.
Author Contributions: B.J.G. and I.K. designed the study; I.R.M., I.N., L.E.E., S.K.-M., C.M.S. and B.A. performed
the experiments; B.J.G., I.R.M., I.N., P.J., T.W., S.K.-M., B.A., J.-Y.B., M.R.M., D.U., I.A.K. and I.K. analyzed the data;
B.J.G., I.N. and I.K. wrote the manuscript.
Funding: This work was supported by the National Institute of General Medical Sciences (P20 GM109005 and
P20GM125503) and Arkansas Biosciences Institute. DWU, IN, PJ and TW are supported by the Helen Adams &
Arkansas Research Alliance Endowment.
Acknowledgments: The authors are thankful to Robin Mulkey for excellent animal care at the UAMS
Animal Facility.
Conflicts of Interest: The authors declare no conflict of interests and did not receive any financial or other
compensation from Nature’s Way for this study.
References
1. Graham, H.N. Green tea composition, consumption and polyphenol chemistry. Prev. Med. 1992, 21, 334–350.
[CrossRef]
268
Nutrients 2019, 11, 776
2. Khan, N.; Mukhtar, H. Tea polyphenols for health promotion. Life Sci. 2007, 81, 519–533. [CrossRef]
3. Higdon, J.V.; Frei, B. Tea catechins and polyphenols: Health effects, metabolism and antioxidant functions.
Crit. Rev. Food Sci. Nutr. 2003, 43, 89–143. [CrossRef]
4. Cooper, R.; Morre, D.J.; Morre, D.M. Medicinal benefits of green tea: Part i. Review of noncancer health
benefits. J. Altern. Complement. Med. 2005, 11, 521–528. [CrossRef]
5. Lambert, J.D.; Hong, J.; Yang, G.Y.; Liao, J.; Yang, C.S. Inhibition of carcinogenesis by polyphenols: Evidence
from laboratory investigations. Am. J. Clin. Nutr 2005, 81, 284S–291S. [CrossRef]
6. Hodgson, J.M.; Croft, K.D. Tea flavonoids and cardiovascular health. Mol. Aspects Med. 2010, 31, 495–502.
[CrossRef]
7. Thielecke, F.; Boschmann, M. The potential role of green tea catechins in the prevention of the metabolic
syndrome—A review. Phytochemistry 2009, 70, 11–24. [CrossRef]
8. Rains, T.M.; Agarwal, S.; Maki, K.C. Antiobesity effects of green tea catechins: A mechanistic review.
J. Nutr. Biochem. 2011, 22, 1–7. [CrossRef]
9. Roytman, M.M.; Poerzgen, P.; Navarro, V. Botanicals and hepatotoxicity. Clin. Pharmacol. Ther. 2018,
104, 458–469. [CrossRef]
10. Navarro, V.J.; Khan, I.; Bjornsson, E.; Seeff, L.B.; Serrano, J.; Hoofnagle, J.H. Liver injury from herbal and
dietary supplements. Hepatology 2017, 65, 363–373. [CrossRef]
11. Surapaneni, B.K.; Le, M.; Jakobovits, J.; Vinayek, R.; Dutta, S. A case of acute severe hepatotoxicity and
mild constriction of common bile duct associated with ingestion of green tea extract: A clinical challenge.
Clin. Med. Insights Gastroenterol. 2018, 11, 1179552218779970. [CrossRef]
12. Brown, A.C. Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of
5 series. Food Chem. Toxicol. 2017, 107, 472–501. [CrossRef]
13. Isomura, T.; Suzuki, S.; Origasa, H.; Hosono, A.; Suzuki, M.; Sawada, T.; Terao, S.; Muto, Y.; Koga, T.
Liver-related safety assessment of green tea extracts in humans: A systematic review of randomized
controlled trials. Eur. J. Clin. Nutr. 2016, 70, 1340. [CrossRef]
14. Garcia-Cortes, M.; Robles-Diaz, M.; Ortega-Alonso, A.; Medina-Caliz, I.; Andrade, R.J. Hepatotoxicity by
dietary supplements: A tabular listing and clinical characteristics. Int. J. Mol. Sci. 2016, 17, 537. [CrossRef]
15. Mazzanti, G.; Di Sotto, A.; Vitalone, A. Hepatotoxicity of green tea: An update. Arch. Toxicol. 2015,
89, 1175–1191. [CrossRef]
16. Isbrucker, R.A.; Edwards, J.A.; Wolz, E.; Davidovich, A.; Bausch, J. Safety studies on epigallocatechin
gallate (egcg) preparations. Part 2: Dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 2006,
44, 636–650. [CrossRef]
17. Kapetanovic, I.M.; Crowell, J.A.; Krishnaraj, R.; Zakharov, A.; Lindeblad, M.; Lyubimov, A. Exposure and
toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology 2009, 260, 28–36. [CrossRef]
18. Wu, K.M.; Yao, J.; Boring, D. Green tea extract-induced lethal toxicity in fasted but not in nonfasted dogs.
Int. J. Toxicol. 2011, 30, 19–20. [CrossRef]
19. Church, R.J.; Gatti, D.M.; Urban, T.J.; Long, N.; Yang, X.; Shi, Q.; Eaddy, J.S.; Mosedale, M.; Ballard, S.;
Churchill, G.A.; et al. Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic
background in diversity outbred mice. Food Chem. Toxicol. 2015, 76, 19–26. [CrossRef]
20. Berube-Parent, S.; Pelletier, C.; Dore, J.; Tremblay, A. Effects of encapsulated green tea and guarana extracts
containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation
in men. Br. J. Nutr. 2005, 94, 432–436. [CrossRef]
21. Dulloo, A.G.; Duret, C.; Rohrer, D.; Girardier, L.; Mensi, N.; Fathi, M.; Chantre, P.; Vandermander, J. Efficacy
of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat
oxidation in humans. Am. J. Clin. Nutr. 1999, 70, 1040–1045. [CrossRef]
22. Rudelle, S.; Ferruzzi, M.G.; Cristiani, I.; Moulin, J.; Mace, K.; Acheson, K.J.; Tappy, L. Effect of a thermogenic
beverage on 24-hour energy metabolism in humans. Obesity 2007, 15, 349–355. [CrossRef]
23. Most, J.; Goossens, G.H.; Jocken, J.W.; Blaak, E.E. Short-term supplementation with a specific combination of
dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects.
Int. J. Obes. 2014, 38, 698–706. [CrossRef]
24. Janssens, P.L.; Hursel, R.; Westerterp-Plantenga, M.S. Long-term green tea extract supplementation does not
affect fat absorption, resting energy expenditure and body composition in adults. J. Nutr. 2015, 145, 864–870.
[CrossRef]
269
Nutrients 2019, 11, 776
25. Janssens, P.L.; Penders, J.; Hursel, R.; Budding, A.E.; Savelkoul, P.H.; Westerterp-Plantenga, M.S. Long-term
green tea supplementation does not change the human gut microbiota. PLoS ONE 2016, 11, e0153134.
[CrossRef]
26. Furuyashiki, T.; Nagayasu, H.; Aoki, Y.; Bessho, H.; Hashimoto, T.; Kanazawa, K.; Ashida, H. Tea catechin
suppresses adipocyte differentiation accompanied by down-regulation of ppargamma2 and c/ebpalpha in
3t3-l1 cells. Biosci. Biotechnol. Biochem. 2004, 68, 2353–2359. [CrossRef]
27. Hung, P.F.; Wu, B.T.; Chen, H.C.; Chen, Y.H.; Chen, C.L.; Wu, M.H.; Liu, H.C.; Lee, M.J.; Kao, Y.H.
Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3t3-l1 preadipocytes depends on the erk and
cdk2 pathways. Am. J. Physiol. Cell Physiol 2005, 288, C1094–C1108. [CrossRef]
28. Huang, J.; Wang, Y.; Xie, Z.; Zhou, Y.; Zhang, Y.; Wan, X. The anti-obesity effects of green tea in human
intervention and basic molecular studies. Eur. J. Clin. Nutr. 2014, 68, 1075–1087. [CrossRef]
29. Yang, C.S.; Chen, L.; Lee, M.J.; Balentine, D.; Kuo, M.C.; Schantz, S.P. Blood and urine levels of tea catechins
after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev. 1998,
7, 351–354.
30. Chen, L.; Lee, M.J.; Li, H.; Yang, C.S. Absorption, distribution, elimination of tea polyphenols in rats.
Drug Metab. Dispos. 1997, 25, 1045–1050.
31. Kohri, T.; Matsumoto, N.; Yamakawa, M.; Suzuki, M.; Nanjo, F.; Hara, Y.; Oku, N. Metabolic fate of
(-)-[4-(3)h]epigallocatechin gallate in rats after oral administration. J. Agric. Food Chem. 2001, 49, 4102–4112.
[CrossRef]
32. Kohri, T.; Suzuki, M.; Nanjo, F. Identification of metabolites of (-)-epicatechin gallate and their metabolic fate
in the rat. J. Agric. Food Chem. 2003, 51, 5561–5566. [CrossRef] [PubMed]
33. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols
in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S–242S. [CrossRef]
34. Stalmach, A.; Troufflard, S.; Serafini, M.; Crozier, A. Absorption, metabolism and excretion of choladi green
tea flavan-3-ols by humans. Mol. Nutr. Food Res. 2009, 53 (Suppl. 1), S44–S53. [CrossRef]
35. Okushio, K.; Suzuki, M.; Matsumoto, N.; Nanjo, F.; Hara, Y. Identification of (-)-epicatechin metabolites and
their metabolic fate in the rat. Drug Metab. Dispos. 1999, 27, 309–316. [PubMed]
36. Donovan, J.L.; Manach, C.; Rios, L.; Morand, C.; Scalbert, A.; Remesy, C. Procyanidins are not bioavailable
in rats fed a single meal containing a grapeseed extract or the procyanidin dimer b3. Br. J. Nutr. 2002,
87, 299–306. [CrossRef]
37. Jenner, A.M.; Rafter, J.; Halliwell, B. Human fecal water content of phenolics: The extent of colonic exposure
to aromatic compounds. Free Radic. Biol. Med. 2005, 38, 763–772. [CrossRef] [PubMed]
38. Auger, C.; Mullen, W.; Hara, Y.; Crozier, A. Bioavailability of polyphenon e flavan-3-ols in humans with an
ileostomy. J. Nutr. 2008, 138, 1535S–1542S. [CrossRef] [PubMed]
39. Zhang, X.; Chen, Y.; Zhu, J.; Zhang, M.; Ho, C.T.; Huang, Q.; Cao, J. Metagenomics analysis of gut microbiota
in a high fat diet-induced obesity mouse model fed with (-)-epigallocatechin 3-o-(3-o-methyl) gallate
(egcg3”me). Mol. Nutr. Food Res. 2018, 62, e1800274. [CrossRef] [PubMed]
40. Cheng, M.; Zhang, X.; Miao, Y.; Cao, J.; Wu, Z.; Weng, P. The modulatory effect of (-)-epigallocatechin
3-o-(3-o-methyl) gallate (egcg3”me) on intestinal microbiota of high fat diet-induced obesity mice model.
Food Res. Int 2017, 92, 9–16. [CrossRef]
41. Henning, S.M.; Yang, J.; Hsu, M.; Lee, R.P.; Grojean, E.M.; Ly, A.; Tseng, C.H.; Heber, D.; Li, Z. Decaffeinated
green and black tea polyphenols decrease weight gain and alter microbiome populations and function in
diet-induced obese mice. Eur. J. Nutr. 2018, 57, 2759–2769. [CrossRef]
42. Yuan, X.; Long, Y.; Ji, Z.; Gao, J.; Fu, T.; Yan, M.; Zhang, L.; Su, H.; Zhang, W.; Wen, X.; et al. Green tea liquid
consumption alters the human intestinal and oral microbiome. Mol. Nutr. Food Res. 2018, 62, e1800178.
[CrossRef]
43. Wojcikowski, K.; Gobe, G. Animal studies on medicinal herbs: Predictability, dose conversion and potential
value. Phytother. Res. 2014, 28, 22–27. [CrossRef]
44. Nair, A.B.; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic
Clin. Pharm. 2016, 7, 27–31. [CrossRef]
45. McGill, M.R.; Jaeschke, H. A direct comparison of methods used to measure oxidized glutathione in biological
samples: 2-vinylpyridine and n-ethylmaleimide. Toxicol. Mech. Methods 2015, 25, 589–595. [CrossRef]
270
Nutrients 2019, 11, 776
46. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for illumina sequence data. Bioinformatics
2014, 30, 2114–2120. [CrossRef]
47. Kim, D.; Song, L.; Breitwieser, F.P.; Salzberg, S.L. Centrifuge: Rapid and sensitive classification of metagenomic
sequences. Genome Res. 2016, 26, 1721–1729. [CrossRef]
48. Foong, J.; Girdea, M.; Stavropoulos, J.; Brudno, M. Prioritizing clinically relevant copy number variation
from genetic interactions and gene function data. PLoS ONE 2015, 10, e0139656. [CrossRef]
49. Kanehisa, M.; Sato, Y.; Morishima, K. Blastkoala and ghostkoala: Kegg tools for functional characterization
of genome and metagenome sequences. J. Mol. Biol. 2016, 428, 726–731. [CrossRef]
50. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for rna-seq data with
deseq2. Genome Biol. 2014, 15, 550. [CrossRef]
51. Varemo, L.; Nielsen, J.; Nookaew, I. Enriching the gene set analysis of genome-wide data by incorporating
directionality of gene expression and combining statistical hypotheses and methods. Nucleic Acids Res. 2013,
41, 4378–4391. [CrossRef] [PubMed]
52. Dekant, W.; Fujii, K.; Shibata, E.; Morita, O.; Shimotoyodome, A. Safety assessment of green tea based
beverages and dried green tea extracts as nutritional supplements. Toxicol. Lett. 2017, 277, 104–108. [CrossRef]
[PubMed]
53. Derrien, M.; Vaughan, E.E.; Plugge, C.M.; de Vos, W.M. Akkermansia muciniphila gen. Nov., sp. Nov.,
a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469–1476. [CrossRef]
54. Skinner, C.M.; Miousse, I.R.; Ewing, L.E.; Sridharan, V.; Cao, M.; Lin, H.; Williams, D.K.; Avula, B.; Haider, S.;
Chittiboyina, A.G.; et al. Impact of obesity on the toxicity of a multi-ingredient dietary supplement, oxyelite
pro (new formula), using the novel nzo/hiltj obese mouse model: Physiological and mechanistic assessments.
Food Chem. Toxicol. 2018, 122, 21–32. [CrossRef]
55. Miousse, I.R.; Skinner, C.M.; Lin, H.; Ewing, L.E.; Kosanke, S.D.; Williams, D.K.; Avula, B.; Khan, I.A.;
ElSohly, M.A.; Gurley, B.J.; et al. Safety assessment of the dietary supplement oxyelite pro (new formula) in
inbred and outbred mouse strains. Food Chem. Toxicol. 2017, 109, 194–209. [CrossRef]
56. Tan, X.L.; Shi, M.; Tang, H.; Han, W.; Spivack, S.D. Candidate dietary phytochemicals modulate expression
of phase ii enzymes gstp1 and nqo1 in human lung cells. J. Nutr. 2010, 140, 1404–1410. [CrossRef]
57. Coyle, C.H.; Philips, B.J.; Morrisroe, S.N.; Chancellor, M.B.; Yoshimura, N. Antioxidant effects of green tea
and its polyphenols on bladder cells. Life Sci. 2008, 83, 12–18. [CrossRef] [PubMed]
58. Gurley, B.J.; Steelman, S.C.; Thomas, S.L. Multi-ingredient, caffeine-containing dietary supplements: History,
safety and efficacy. Clin. Ther. 2015, 37, 275–301. [CrossRef] [PubMed]
59. de Boer, Y.S.; Sherker, A.H. Herbal and dietary supplement-induced liver injury. Clin. Liver Dis. 2017,
21, 135–149. [CrossRef] [PubMed]
60. Gurley, B.J.; Yates, C.R.; Markowitz, J.S. “ . . . Not intended to diagnose, treat, cure or prevent any disease.”
25 years of botanical dietary supplement research and the lessons learned. Clin. Pharmacol. Ther. 2018,
104, 470–483. [CrossRef] [PubMed]
61. Miousse, I.R.; Pathak, R.; Garg, S.; Skinner, C.M.; Melnyk, S.; Pavliv, O.; Hendrickson, H.; Landes, R.D.;
Lumen, A.; Tackett, A.J.; et al. Short-term dietary methionine supplementation affects one-carbon metabolism
and DNA methylation in the mouse gut and leads to altered microbiome profiles, barrier function, gene
expression and histomorphology. Genes Nutr. 2017, 12, 22. [CrossRef] [PubMed]
62. Xue, B.; Xie, J.; Huang, J.; Chen, L.; Gao, L.; Ou, S.; Wang, Y.; Peng, X. Plant polyphenols alter a pathway of
energy metabolism by inhibiting fecal bacteroidetes and firmicutes in vitro. Food Funct. 2016, 7, 1501–1507.
[CrossRef] [PubMed]
63. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with
obesity. Nature 2006, 444, 1022–1023. [CrossRef] [PubMed]
64. Bajzer, M.; Seeley, R.J. Physiology: Obesity and gut flora. Nature 2006, 444, 1009–1010. [CrossRef] [PubMed]
65. Wang, L.; Zeng, B.; Zhang, X.; Liao, Z.; Gu, L.; Liu, Z.; Zhong, Q.; Wei, H.; Fang, X. The effect of green tea
polyphenols on gut microbial diversity and fat deposition in c57bl/6j hfa mice. Food Funct. 2016, 7, 4956–4966.
[CrossRef] [PubMed]
271
Nutrients 2019, 11, 776
66. Ikarashi, N.; Ogawa, S.; Hirobe, R.; Kon, R.; Kusunoki, Y.; Yamashita, M.; Mizukami, N.; Kaneko, M.;
Wakui, N.; Machida, Y.; et al. Epigallocatechin gallate induces a hepatospecific decrease in the cyp3a
expression level by altering intestinal flora. Eur. J. Pharm. Sci. 2017, 100, 211–218. [CrossRef] [PubMed]
67. Plovier, H.; Everard, A.; Druart, C.; Depommier, C.; Van Hul, M.; Geurts, L.; Chilloux, J.; Ottman, N.;
Duparc, T.; Lichtenstein, L.; et al. A purified membrane protein from akkermansia muciniphila or the
pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 2017, 23, 107–113.
[CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Protein Hydrolysates from Fenugreek
(Trigonella foenum graecum) as Nutraceutical
Molecules in Colon Cancer Treatment
Amine Allaoui 1 , Sonia Gascón 2, Souhila Benomar 1, Javier Quero 2, Jesús Osada 3 ,
Moncef Nasri 4, María Jesús Rodríguez-Yoldi 2,* and Ahmed Boualga 1,*
1 Laboratoire de Nutrition Clinique et Métabolique, Faculté des Sciences de la Nature et de la Vie,
Université Oran1, 31000 Oran, Algeria; amn.allaoui@gmail.com (A.A.); souhila-13@hotmail.fr (S.B.)
2 Departamento de Farmacología y Fisiología, Unidad de Fisiología, Facultad de Veterinaria,
Universidad de Zaragoza, CIBERobn (ISCIII), IIS Aragón, IA2, 50013 Zaragoza, Spain;
gasconmsonia@hotmail.com (S.G.); javierquero94@gmail.com (J.Q.)
3 Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Veterinaria,
Universidad de Zaragoza, CIBERobn (ISCIII), IIS Aragón, IA2, 50013 Zaragoza, Spain; josada@unizar.es
4 Laboratoire de Génie Enzymatique et de Microbiologie—Ecole Nationale d’Ingénieurs de Sfax, 3038 Sfax,
Tunisia; mon_nasri@yahoo.fr
* Correspondence: mjrodyol@unizar.es (M.J.R.-Y.); boualga.ahmed@univ-oran1.dz (A.B.);
Tel.: +213-772599943 (A.B.)
Received: 8 March 2019; Accepted: 23 March 2019; Published: 28 March 2019
Abstract: The application of plant extracts for therapeutic purposes has been used in traditional
medicine since the plants are a source of a great variety of chemical compounds that possess biological
activity. Actually, the effect of these extracts on diseases such as cancer is being widely studied.
Colorectal adenocarcinoma is one of the main causes of cancer related to death and the second most
prevalent carcinoma in Western countries. The aim of this work is to study the possible effect of two
fenugreek (Trigonella foenum graecum) protein hydrolysates on treatment and progression of colorectal
cancer. Fenugreek proteins from seeds were hydrolysed by using two enzymes separately, which are
named Purafect and Esperase, and were then tested on differentiated and undifferentiated human
colonic adenocarcinoma Caco2/TC7 cells. Both hydrolysates did not affect the growth of differentiated
cells, while they caused a decrease in undifferentiated cell proliferation by early apoptosis and
cell cycle arrest in phase G1. This was triggered by a mitochondrial membrane permeabilization,
cytochrome C release to cytoplasm, and caspase-3 activation. In addition, the hydrolysates of
fenugreek proteins displayed antioxidant activity since they reduce the intracellular levels of ROS.
These findings suggest that fenugreek protein hydrolysates could be used as nutraceutical molecules
in colorectal cancer treatment.
Keywords: fenugreek; protein hydrolysate; antiproliferative; apoptosis; antioxidant; Caco2 cells
1. Introduction
Fenugreek is one of the oldest plants used in traditional medicine. It has been used for a long time
due to its beneficial properties in the treatment of wounds, abscesses, arthritis, bronchitis, and digestive
disorders [1]. The seeds are the most important and useful part of the fenugreek plant [1]. Many of the
functional and medicinal properties of fenugreek are attributed to its chemical composition (20–25%
protein, 45–50% dietary fiber, 20–25% mucilaginous soluble fiber, 6–8% fatty acids and essential oils,
and 2–5% steroidal saponins) [2].
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Belguith-Hadriche, et al. [3] and Subhashini, et al. [4] demonstrated that seed fenugreek extracts
are effective against free radical mediated diseases. In addition, Madhava Naidu et al. [5] observed
that fenugreek husk, which is more rich in fiber, exhibits an important antioxidant property. However,
the proteins of fenugreek seeds, unlike other plants, have been barely investigated.
Legume proteins have become a topic of many studies on health being and certain disease
treatments. They are associated with a reduction in the incidence of various cancers, cholesterol,
type-2 diabetes, and heart disease [6]. Furthermore, protein hydrolysate has the additional advantage
of having improved functional properties as compared to the original protein isolates from which
they are prepared. This is due to the release of certain bioactive peptides, which are encoded in the
native protein molecule. More recently, potential health-promoting properties of peptides in these
hydrolysates have been discovered [7].
The antiproliferative property is among the numerous biological activities attributed to
hydrolysates. Effectively, several peptides with anticancer activity have been found in food protein
hydrolysates as well as colon antitumor activity of egg yolk proteins or the cytotoxic activity on human
colon carcinomas and mouse lymphoma cell lines of hydrophobic peptides extracted from soy [8].
The same findings have been reported in many other studies on Vicia faba protein hydrolysate [9],
common beans peptides [10], and rice brain peptides [11].
Even if the mechanisms underpinning the antiproliferative effect of the protein hydrolysates is not
well established, some hypotheses are proposed. For example, Ortiz-Martinez et al. [12] suggest that
the antiproliferative effect on HepG2 cells of peptide fractions isolated from maize albumin hydrolysate
is based on the induction of apoptosis due to the decrease of antiapoptotic factors expression. However,
Xue et al. [13] reported that a chickpea-derived peptide inhibits the proliferation of breast cancer cells
by increasing the p53 expression. Yet, Gao et al. [14] found that peptides derived from soy Vglycin
activate the expression levels of pro-apoptotic proteins and caspase-3.
Since colorectal cancer is one of the most commonly diagnosed cancers, and it is strongly influenced
by diet [8], the aim of this work has been to study the functional properties of the hydrolysed proteins
of fenugreek seeds in relation to the treatment of colon cancer. For this, we have measured the possible
antiproliferative and antioxidant effect of these hydrolysates on Caco-2 cells, and determined its
mechanism of action.
2. Materials and Methods
2.1. Fenugreek Protein Hydrolysates Preparation
Fenugreek was purchased from a local spices market in the city of Tiaret (Algeria). Seeds were
cleaned, grounded to a fine powder, and defatted in Soxhlet, (Labotech LT-6, Rosdorf, Germany), using
n-hexane for 12 cycles and their proteins were extracted at an isoelectric point (pH 4.5) according to
Boye et al. [15], as detailed previously [16]. The protein isolate was freeze dried and then hydrolyzed.
2.2. Preparation of FP Hydrolysates (FPHs)
Two hydrolysates were prepared from fenugreek proteins using Esperase® 0.8L (Sigma Chemical,
St. Louis, MO, USA) (pH 9; 50 ◦C) or Purafect® 2000E (Genencor International, Palo Alto, CA, USA)
(pH 10; 50 ◦C). FP were dissolved in distilled water at a proportion of 5% (w/v). Mixture pH and
temperature were adjusted to optimum enzyme activity prior its incorporation. The enzymes were
added to the solution at an enzyme/substrate ratio (E/S) of 5. Once the enzyme added, the mixture pH
was maintained constant by a continuous addition of 2N NaOH solution. The degree of hydrolysis
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where B is the amount (mL) of NaOH consumed to keep the pH constant during the reaction, NB is
the normality of NaOH, MP is the mass of protein (g), and α is the average degree of dissociation of
the α-NH2 groups released during hydrolysis. htot is the total number of peptide bonds, which was
assumed to be 7.6 meq/g.
Hydrolysis was performed for 5 hours. Afterward, the reaction was stopped by heating the
solution at 90 ◦C for 10 min. Then, the digest was cooled at room temperature and centrifuged at
5000× g for 15 min. The obtained hydrolysates: Esperase-fenugreek proteins hydrolysate (EFPH) and
Purafect-fenugreek proteins hydrolysate (PFPH), were collected, freeze dried, and then stored at 4 ◦C.
2.3. Hydrolysates Proximate Composition
The protein, moisture, lipids, and ash contents in the freeze-dried fenugreek proteins and proteins
hydrolysates were determined by using the AOAC methods [18]. A factor of 6.25 was used to convert
the nitrogen value to protein. Minerals were analyzed by using Inductively Coupled Plasma-Optical
Emission Spectroscopy (ICP-OES, Perkin Elmer 4300DV, Shelton, CT, USA), after dissolving samples in
nitric acid (70%).
2.4. Amino Acid Analysis
A total of 50 μL of the sample (1 mg proteins/mL) were first hydrolyzed in a vacuum-sealed glass
tube for 24 h at 110 ◦C in the presence of 6 N HCl and 1% phenol. For tryptophane analysis, samples
were hydrolyzed in 4N NaOH, as described by Yust et al. [19]. At the end of hydrolysis, the samples
pH was adjusted to 7 and filtered through a 0.45 μm cellulose acetate membrane filter.
The samples were then analyzed by the reversed phase HPLC (Agilent 1100 HPLC
system, Wilmington, DE, USA) after automatic precolumn derivatization with a combination of
OPA-3MPA (o-phtaldialdehyde-3-mercaptopropionic acid) for primary amino acids and FMOC
(9-fluorenylmethylchloroformate) for secondary amino acids, following the manufacturer instructions.
The separation was done on a reversed-phase Zorbax Eclipse-AAA column (4.6 × 150 mm, 3.5 μm). The
quantification was determined by using norleucine as internal standard. The amino acid composition
was expressed as the percent of residues.
2.5. Cell Culture
The biological activity of fenugreek protein hydrolysates was evaluated on the human colonic
adenocarcinoma Caco2 cell line TC7 clone, provided by Dr. Edith Brot-Laroche (Université Pierre
et Marie Curie-Paris 6, UMR S 872, Les Cordeliers, France). Caco2/TC7 cells were maintained in a
humidified atmosphere of 5% CO2 at 37 ◦C. Cells (passages 38–41) were grown in Dulbecco’s Modified
Eagles Medium (DMEM) (Gibco Invitrogen, Paisley, UK) supplemented with 20% fetal bovine serum,
1% non-essential amino acids, and 1% amphotericin (250 U/mL). The cells were passaged enzymatically
with 0.25% trypsin-1 mM EDTA and sub-cultured on 25 cm2 plastic flasks at a density of 5 × 105 cells
per flask. Culture medium was replaced every three days. Cell confluence (80%) was confirmed by
the microscopic observance. Experiments were performed in differentiated cells and in cancerous or
undifferentiated cells (24 h post-seeding to prevent cell differentiation).
2.6. Cell Treatment and Antiproliferative Property Analysis
EFPH and PFPH were diluted in DMEM to the final concentration of 1 mg/mL. For an antiproliferative
experiment, 4 × 103 cells were dispensed into each well of a 96-well plate. The culture medium was
then replaced after 24 h with fresh medium (without fetal bovine serum, FBS) containing fenugreek
protein hydrolysates, with an exposure time of 24, 48, or 72 h. Untreated cells were taken as a
control. The anti-proliferative effect was measured with the sulforhodamine B assay, as described by
Sánchez-de-Diego et al. [20]. Cells were fixed with 10% trichloroacetic acid (1 h, 4 ◦C), washed with
distilled water, and stained with 4 g/L of sulforhodamine B (20 min, at room temperature). The plates
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were then washed with 1% acetic acid (v/v) to remove the unbound dye. Protein-bound dye was
extracted with 10 mM Tris base (pH 10.5). Untreated cells were taken as a control (C).
The same experiment was done with the differentiated cells. Lastly, the results were
obtained by measuring absorbance (A) with a scanning multi-well spectrophotometer (SPECTROstar
Nano Microplate Reader—BMG LABTECH, Ortenberg, Germany) at a wavelength of 562 nm.







Undifferentiated Caco2/TC7 cells were exposed for 24 h to 1 mg/mL of EFPH or PFPH, then
collected and stained with AnnexinV-FTIC in combination with propidium iodide (PI), as described by
Sánchez-de-Diego et al. [20]. Untreated cells were used as a negative control. After incubation, cells
were transferred to flow-cytometry tubes and washed twice with temperate phosphate-buffered saline
and re-suspended in 100 μL Annexin V binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2). Afterward, 5 μL of the Annexin V-FITC and 5 μL of PI were added to each 100 μL
of cell suspension. After incubation for 15 min at room temperature in the dark, 400 μL of Annexin
binding buffer were added and analyzed by flow cytometry within one hour. The signal intensity
was measured using a BD FACSAria (BD Biosciences, Piscataway, NJ, USA) and analyzed using BD
FACSDiva (BD Biosciences, San Jose, CA, USA).
2.8. Propidium Iodide Staining of DNA Content and Cell Cycle Analysis
The fenugreek protein hydrolysates treated Caco2/TC7 cells were fixed in 70% ice-cold ethanol
and stored at 4 ◦C for 24 h. After centrifugation (2500 rpm, 5 min), cells were rehydrated in PBS and
stained with propidium iodide (PI) solution (50 μg/mL) containing RNase A (100 μg/mL). PI stained
cells were analysed for DNA content in a BD FACSArray (BD Biosciences, Piscataway, NJ, USA). The
red fluorescence emitted by PI was collected by a 620-nm longer pass filter, as a measure of the amount
of DNA-bound PI and displayed on a linear scale. Cell cycle distribution was determined on a linear
scale. The results were treated with ModFit LT 3.0 (Verity Software House, Topsham, ME, USA) [20].
2.9. Mitochondrial Membrane Potential Assay by Flow Cytometry
Caco2/TC7 cells were plated in 25 cm2 flask at a density of 3 × 105 cells per flask and incubated
for 24 h under standard cell culture conditions. Afterward, cells were treated with 1 mg/mL of
fenugreek hydrolysates and incubated for 24 h. The control cells were incubated with a new
medium without treatment and without FBS. Then, cells were washed twice with temperate PBS and
re-suspended in temperate PBS at a concentration of 1 × 106 cells/mL. Later, 5 μL of 10 μM cationic dye
1,1′,3,3,3′-hexamethylindodicarbo-cyanine iodide (DiIC1) were added to each sample and the cells
were incubated 15 min at 37 ◦C, 5% CO2. After the incubation period, 400 μL of PBS were added to
each tube and fluorescence was analyzed by flow cytometry using a BD FACSArray equipped with an
argon ion laser. Excitation and emission settings were 633 and 658 nm, respectively.
2.10. Determination of Caspase 3 and Cytochrome C
Caco2/TC7 cells were plated in a 25 cm2 flask at a density of 3 × 105 cells per flask and incubated
for 24 h under standard cell culture conditions. Then, 1 mg/mL fenugreek hydrolysate solution was
added to the flask and incubated for 24 h.
The caspase-3 analysis were studied as previously described by Sánchez-de-Diego et al. [20].
The cells were fixed in 0.01% formaldehyde for 15 min and centrifuged for 5 min at 300× g. Then,
the pellet was suspended in 100 μL digitonin lysis buffer (50 mg/mL digitonin, 100 mM KCl, in 1× PBS)
and incubated for 15 min in the dark at room temperature (RT). After incubation, cells were washed
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with 2 mL of PBS containing 0.1% digitonin and centrifuged at 300× g for 5 min. The supernatant was
discarded and the pellet was re-suspended in 200 μL of PBS containing 0.1% digitonin. In addition,
2 μL of diluted caspase-3 antibody (Novus Biologicals, Abingdon, UK) were added to each sample and
the resultant mix was incubated for 1 hour. After incubation, cells were centrifuged at 500× g, for 5 min
at room temperature, and washed twice with PBS. Lastly, the cells were re-suspended in 400 μL of PBS.
Fluorescence was analyzed by flow cytometry (Ex: 494 nm, Em: 520 nm) using a BD FACSArray.
Cells with liberated cytochrome C were analyzed according to Christensen et al. [21] with slight
modifications [20]. Cells were initially resuspended thoroughly in 100 μL digitonin permeabilization
buffer (50 μg/mL digitonin; 100 mM KCl; in 1× PBS) followed by incubation for 5 min at room
temperature. This was followed by fixing the cells with 100 μL of 4% paraformaldehyde (PFA) in PBS
for 30 min. Centrifugation (500× g, 5 min) was carried out to remove PFA and cells were washed once
with 100 μL 1× PBS. Cells were then incubated with 100 μL blocking buffer (3% bovine serum albumin,
0.05% saponin, in 1× PBS) for 15 min at room temperature. Afterward, 2 μL of diluted cytochrome C
antibody 7H8-2C12 (Novus Biologicals, Abingdon, UK) was incubated with cells for 1 h. Cells were
washed twice with 1× PBS, then re-suspended in 400 μL of blocking buffer, and samples were analyzed
by flow cytometry (Ex: 488 nm, Em: 575 nm) in BD FACSArray.
2.11. Intracellular Levels of Reactive Oxygen Species (ROS)
The cells were seeded in 96-wells plate at a density of 4 × 103 cells/well. The intracellular level of
ROS was assessed using the dichlorofluorescein assay [22]. Caco2/TC7 cells were cultured for 24 h
before oxidative stress induction, and then incubated with 100 μL of serum-free culture media with
1 mg/mL of EFPH or PFPH for 24 h. After that, the medium was removed, cells were washed twice
with phosphate buffered saline, and incubated for 1 h with 100 μL of 20 μM 2′,7′-dichlorofluorescein
diacetate (DCFH-DA) in PBS at 37 ◦C. After this period, cells were washed and re-suspended in PBS
supplemented with 20 mM or 500 μM H2O2. The formation of the fluorescence oxidized derivative of
DCF was monitored at an emission wavelength of 535 nm and an excitation wavelength of 485 nm
in a multiplate reader. A measure at time “zero” was performed, cells were then incubated at 37 ◦C
in the multiplate reader, and generation of fluorescence was measured after 20 min. ROS levels
were expressed as a percentage of fluorescence (f ) compared to the control, and reported using the
following formula.





2.12. Thioredoxin Reductase 1 (TrxR1) Activity Assay
Undifferentiated cells were seeded in a 96-well plate with different protein hydrolysates for 24 h.
The cells were then lysed (5 M NaCl, 1 M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0, SDS 10%, miliQ water)
and incubated in a shaking motion for 20 min. After the incubation time, 25 μL of the reaction mixture
(500 μL PBS pH 7.0, 80 μL, 100 mM EDTA pH 7.5, 20 μL 0.05% BSA, 100 μL 20 mM NADPH, 300 μL
H2O) were added to each well. Lastly, the reaction was started by adding 25 μL of 20 mM DTNB in pure
ethanol. The absorbance increase was followed at 405 nm every minute for 6 min. Wells with TrxR1
inhibitor (auranofin) were measured in the same conditions to subtract the unspecific activity [20]. Cell
protein contents were calculated by the Bradford method [23]. The result is expressed as a percentage
of TxrR1 activity of treated cells compared to the TxrR1 activity of C cells.
2.13. Statistical Analysis
Data are presented as mean ±SD. Data were subjected to one-way ANOVA and the LSD-Fisher
post hoc test. Differences were considered significant at p ≤ 0.05.
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3. Results
3.1. Kinetic and Degree of Hydrolysis
The hydrolysis curve of fenugreek proteins, illustrated in Figure 1, showed a first fast reaction
kinetics characterized by an initial rapid phase (during the first 60 min for Esperase and the first
15 min for Purafect). At the end of the hydrolysis reaction, the DHs of the protein isolate were 9% with
















Figure 1. Kinetic of fenugreek proteins hydrolysis. E/S ratio= 5 U/mg proteins. EFPH: Esperase-fenugreek
proteins hydrolysate. PFPH: Purafect-fenugreek proteins hydrolysate.
3.2. Chemical and Amino Acids Composition of FP and FPHs
Since the properties of protein hydrolysates depend strongly on their composition,
the physicochemical composition of fenugreek protein hydrolysates was first analyzed. The proximate
composition of EFPH and PFPH and their amino acid composition are shown in Table 1. Protein and
lipids contents in EFPH were higher when compared to PFPH.
Table 1. Chemical composition of fenugreek protein hydrolysates.
PFPH EFPH
(%) (%)




Lipids 2.8 ± 0.2 3.3 ± 0.4 *
Total fiber 3.0 ± 0.1 2.0 ± 0.1 *
Carbohydrates # 1.5 <1
Moisture 1.0 ± 0.1 1.1 ± 0.1
Ash 1.8 ± 0.2 1.3 ± 0.3
Mineral composition
Potassium (mg/100 g) 986 ± 5 1001 ± 1 *
Phosphorus (μg/g) 1933 ± 7 1927 ± 11
Sulphide (μg/g) 1128 ± 5 1268 ± 48 *
Magnesium (μg/g) 1013 ± 4 985 ± 9 *
Calcium (μg/g) 636 ± 2 502 ± 14 *
Sodium (μg/g) 122 ± 4 110 ± 3 *
Selenium (μg/kg) 53 ± 1 52 ± 1
PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. HAA: hydrophobic
amino acids (Ala, Val, Ile, Leu, Tyr, Phe, Trp, Pro, Met, and Cys). AAA: aromatic amino acids (Phe, Tyr, Trp). PCAA:
positively charged amino acids (Arg, His, Lys). Results are presented as mean ± SD (n = 3). Superscripted (*) means
within a row are significantly different (p ≤ 0.05). #: Calculated by difference.
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The bioactive properties of proteins hydrolysates are tightly related to the nature of their amino
acids (Maestri et al., 2018). Aromatic, hydrophobic, and positively charged amino acids were similar in
both hydrolysates. The detailed amino acids composition of fenugreek protein hydrolysates is reported
in Reference [16].
Potassium, sulphide, and phosphorus were the most abundant minerals in FPHs, while selenium
and sodium concentrations represented the less abundant.
3.3. Antiproliferative Activity
We first examined if the exposition of Caco2 TC7 cells to 1 mg/mL of FPH inhibits their proliferation.
The treatment of undifferentiated Caco2/TC7 cells with fenugreek proteins hydrolysates exhibited
a decrease in their viability. The PFPH anti-proliferative property was time dependent and passed
from 27% after 24 h to 55% after 72 h of the incubation period, compared to the control. With EFPH,
there was also a cells proliferation inhibitory effect, which varied between 39% and 50%. Nevertheless,
it was not significantly time dependent (Figure 2A). In order to demonstrate if the antiproliferative
effect of FPH found on Caco2/TC7 cells was specific for the undifferentiated cells or was a cytotoxic
mechanism, we tested this property on differentiated cells. There was no difference in differentiated















































Figure 2. Relative viability of undifferentiated ((A): 24 h, 48 h, and 72 h) and differentiated Caco2/TC7
cells (B) treated (24 h) or not with fenugreek proteins hydrolysates. Data are presented as mean ± SD.
The experiment was done in triplicate (each performed with six determinations). Superscripted (*)
means are significantly different (p ≤ 0.05) compared to their respective control. Control: Untreated
cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate.
The hydrolysates were used at a final concentration of 1 mg/mL.
3.4. Apoptosis Analysis
Two major mechanisms could lead to cell death: necrosis and apoptosis. Necrosis is characterized
as passive, with uncontrolled release of inflammatory cellular contents. On the opposite side, apoptosis
is considered to be a regulated and controlled process that avoids eliciting inflammation [24]. Thus, we
examined which of the two mechanisms was triggered by FPH. After 24 h of incubation with PFPH and
EFPH (final concentration 1 mg/mL) vs. untreated cells, undifferentiated Caco2 living cells decreased.
Whereas, those with early apoptosis increased by 4.6-fold. There were no significant differences in cells
with late apoptosis or necrosis before and after treatment (Figure 3).
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Figure 3. Effect of treating undifferentiated Caco2/TC7 cells with fenugreek proteins hydrolysates (24 h)
on apoptosis. (a) Representative histogram of cytometry analysis. (b) Cell death process repartition.
Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted (*) means
are significantly different (p ≤ 0.05) when compared to their respective control. Control: Untreated
cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate.
The hydrolysates were used at a final concentration of 1 mg/mL.
3.5. Cell Cycle Analysis
We subsequently analyzed if the treatment with 1 mg/mL of FPH caused a cell-cycle arrest in Caco2
TC7. Cell-cycle analysis (Figure 4) showed that cells stopped in the G0-G1 phase were, respectively,
1.6-fold and 1.5-fold higher in PFPH and EFPH-treated cells compared to non-treated cells. In the S
phase, the cells treated with EFPH, and not those treated with PFPH, decreased by 40% vs. the control
cells. Even if there was a reduction in PFPH-treated cells blocked in the G2-M phase (−33%), this




























Figure 4. Cell cycle repartition of undifferentiated Caco2/TC7 treated (24 h) or not with fenugreek
proteins hydrolysates. (a): a representative cells cycle histogram. (b): G1, S, and G2 phases percentage
distribution. Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted
(*) means are significantly different (p ≤ 0.05) when compared to their respective control. Control:
Untreated cells. PFPH: Purafect fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins
hydrolysate. The hydrolysates were used at a final concentration of 1 mg/mL.
3.6. Analysis of Mitochondrial Membrane Potential Change, Cytochrome C Release, and Caspase-3 Activation
Since FPH treatment (at 1 mg/mL) caused apoptosis in undifferentiated cells, we hypothesized
that it could induce mitochondrial permeabilization and cytochrome C release in Caco-2/TC7 cells.
Compared to non-treated cells, the number of cells exhibiting a changed in the mitochondrial membrane
potential (ΔΨm) increased by 70% in PFPH-treated and EFPH-treated cells. The results also showed
that, in treated cells, mitochondria cytochrome C contents decreased significantly compared to the
untreated cells.
The release of cytochrome C can lead to the activation of caspase 3, which is an executor of the
apoptosis pathway. The activated caspase-3 concentrations were significantly increased by 24-fold and
13-fold, respectively, in PFPH-treated and EFPH-treated cells when compared to the control (Table 2).
Table 2. Percentage of Caco2/CT7 cells with a positive mitochondrial membrane potential. Cells
with mitochondrial cytochrome C and active caspase-3, quantified by flow cytometry in response to
fenugreek proteins hydrolysates treatment (24 h).
Number of Cells (/100 Cells) Control PFPH EFPH
Cells with positive MMP 28.7 ± 10.9 69.2 ± 11.4 * 70.4 ± 4.1 *
Cells with mitochondrial cytochrome C 90.7 ± 1.6 71.3 ± 1.2 * 61.0 ± 9.8 *
Cells with active caspase-3 1.4 ± 0.0 33.3 ± 4.3 * 18.5 ± 3.8 *
Data are presented as mean ± SD. The experiment was done in duplicate. Superscripted (*) means within a row are
significantly different (p ≤ 0.05) when compared to their respective control. Control: untreated cells. PFPH: Purafect
fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates were used at a
final concentration of 1 mg/mL. MMP: mitochondrial membrane potential.
3.7. Antioxidant Activity of FPH in Caco2 Cells
Oxidative stress is a characteristic state of many cancers, and it is implicated in cancer development
and progression. The intracellular ROS levels, in the presence of high concentration of H2O2 (20 mM),
decreased by 35% in cells incubated with 1 mg/mL of EFPH when compared to the control. PFPH cells
did not exhibit any modification. However, in the presence of low concentrations of H2O2 (0.5 mM),
both treated cells exhibited better antioxidant activity vs. untreated cells. The inhibition reached 39%
and 33%, respectively, in EFPH and PFPH treated cells (final concentration 1 mg/mL) (Figure 5).
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Figure 5. Relative reactive oxygen species levels in undifferentiated Caco2/TC7 cells treated (24 h) or
not with fenugreek proteins hydrolysates. Data are presented as mean ± SD. The experiment was
done in triplicate (each performed with six determinations). Superscripted (*) means are significantly
different (p ≤ 0.05) compared to their respective control. Control: Untreated cells. PFPH: Purafect
fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates
were used at a final concentration of 1 mg/mL.
3.8. Thioredoxin Reductase 1 Activity
Since FPH induced a decrease in intracellular ROS levels in Caco2 TC7, we proposed to study
whether this decrease is caused by up-regulated enzyme activities or not. Hence, we proposed to
measure the activity of one of the most important cellular antioxidant enzyme: thioredoxin reductase.















Figure 6. Relative thioredoxin reductase activity in undifferentiated Caco2/TC7 cells treated (24 h) or
not with fenugreek proteins hydrolysates. Data are presented as mean ± SD. The experiment was
done in duplicate (each performed with six determinations). Superscripted (*) means are significantly
different (p ≤ 0.05) compared to their respective control. Control: Untreated cells. PFPH: Purafect
fenugreek proteins hydrolysate. EFPH: Esperase fenugreek proteins hydrolysate. The hydrolysates
were used at a final concentration of 1 mg/mL.
4. Discussion
The anticancer property of natural products became one of the most studied topics. In recent
years, the studies on plant proteins and peptides have increased, which is motivated by their huge
diversity, affordability, and lack of side effects. Legumes are the plant source for which most peptides
with anticancer properties are reported [25]. Fenugreek is a legume-rich protein, which could be a
potential source of biological active peptides.
The hydrolysis curve of fenugreek proteins was typical of many protein hydrolysates obtained
by Sbroggio et al. [26] with okara hydrolysates. The differences in hydrolysis shape and DH values
were probably due to the difference in enzyme specificity. On the other hand, the DH could inform the
peptides’ mean size [17]. Hence, EFPH with DH = 19% could contain smaller peptides than PFPH.
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Our results suggest that protein contents of the hydrolysates are important. These findings were
in line with Pownall et al. [27] and Mundi and Aluko [28]. The high protein content could be a result of
the solubilisation of peptides during hydrolysis. It is speculated that the hydrolysis, especially when
alkaline enzymes are used, enhance the solubilisation of proteins and removes insoluble undigested
non-protein substances [29].
Even if the amino acids profile showed that aromatic and hydrophobic amino acids did not differ
between the hydrolysates, these values are higher than those found by other authors [27,28,30].
After analyzing the FPH composition, we tried to check if FPH possesses an anti-proliferative
property in cells. The treatment of undifferentiated Caco2/TC7 cells with FPH exhibited a decrease in
their viability, especially with PFPH that was correlated with incubation time. These results are in
line with works reporting an anti-proliferative property of peptides and hydrolysates from soy [14],
corn [12,31], chickpeas [13], and rice [11] on different cell models. Vglycin, a peptide isolated from soy,
inhibited the proliferation of three types of colon cancer cells [14]. Ortiz-Martinez et al. [12] also found
that corn peptide fractions decreased HepG2 cells growth by more than 50%. Li et al. [31] noticed
that this antiproliferative property was time-dependent. In addition, a pentapeptide from rice brane
showed 84% of viability inhibition on colon cancer cells [11].
Caco2/TC7 differentiated cell viability was not influenced by the FPH treatment. Same observation,
in normal and cancer oral cells, was also reported by Kumar et al. [32] with a chickpea protein fraction.
Ours findings could indicate a possible selective antiproliferative effect of PFPH and EFPH on cancer
cells without affecting the normal cells.
One of the possible ways by which FPH inhibited the cancerous cells could be the same mechanism
seen with antimicrobial peptides when they act as anticancer agents as well. It is believed that normal
cells exhibit an asymmetric composition between the internal and the external layers of their membrane.
In cancer cells, this asymmetry is affected principally by the externalization of phosphatidylserine
(normally confined to the inner leaflet), and the external layer of cancer cell membranes that will carry
a net negative charge. This permits an electrostatic interaction between cationic anticancer peptides
and anionic cell membrane components [33].
It seemed interesting to investigate if FPH could induce the anti-proliferative effect by apoptosis.
The study with EPFH and PEPH was carried out in undifferentiated cells by flow cytometry analysis after
staining with annexin V/propidium iodide. Since cells in early apoptosis express phosphatidylserine
in their outer side of the cytoplasmic membrane, they will be stained by Annexin-V labelled with
FITC (early apoptosis). However, membranes of dead and damaged cells are permeable to propidium
iodide (necrosis) and are also stained with annexin-V (late apoptosis) [20]. It seemed that PFPH and
EFPH set off an early apoptosis mechanism, rather than necrosis, in undifferentiated cells. In this way,
Ortiz-Martinez et al. [12] showed that HepG2 cells treated with corn peptide fractions have a four-fold
increase of both early and late apoptotic events, compared to the untreated cells. Similarly, Li et al. [31]
remarked that corn peptides generated apoptosis in 11% to 55% of HepG2 cells in a dose-dependent
manner. Moreover, Vglycin treatment for 24 hours caused a significant increase of apoptosis in different
colon cancer cells [14].
With apoptotic and no necrotic property, PFPH and EFPH seem to have a beneficial effect against
cancer cells. Additionally, in this work, it was found that both FPH stimulated the early apoptosis,
which is favored to the late one since it allows early recognition of dead cells [34].
By analyzing the effect of fenugreek proteins hydrolysates on cell cycles, it is suggested that both
hydrolysates caused mainly a cell cycle arrest in the G1 phase, which has also been shown in other
studies. In this way, Gao et al. [14] deduced that soy Vglycin induced a G1-phase arrest of colorectal
cancer cells. Li et al. [31] indicated that corn peptides could induce HepG2 cell cycle arrest in the S
phase. The hemagglutinin caused cell cycle arrest in the G2/M phase, as demonstrated by Lam and
Ng [35].
Many studies have shown associations between some minerals and carcinogenesis. Mg2+ ions are
enzyme cofactors involved in DNA repair mechanisms that maintain genomic stability and fidelity.
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Magnesium deficiency may also be associated with inflammation and increased levels of free radicals
where both inflammatory mediators and free radicals arising could cause oxidative DNA damage
and, therefore, tumor formation [36]. There is also evidence that dietary Ca2+ loading reduces colon
cell proliferation and carcinogenesis [37]. The presence of these two elements in FPH could also
be responsible for their anti-proliferative properties. According to Kasprzak [38], the molecular
mechanisms involved in the effects of such minerals are likely to include binding at chromatin
(e.g., DNA, histones, transcription factors, DNA repair enzymes) and other regulatory molecules in the
target cells.
Apoptosis manifests in two major execution programs downstream of the death signal: the caspase
pathway and organelle dysfunction of which mitochondrial dysfunction is best characterized [39]. To see
if the apoptotic action of FPH was led by these mechanisms, we analyzed, by flow cytometry, the change
in mitochondrial membrane potential, cytochrome C in the mitochondria, and the cytoplasmic level of
the active form of caspase-3.
Mitochondria play a pivotal role in life and death of the cell since it produces the majority of energy
required for survival and regulates the intrinsic pathway of apoptosis. The involvement of mitochondria
in cell death is generally measured by following mitochondrial membrane depolarisation [21].
FPH-treated cells showed a higher change in mitochondrial membrane potential. Disruption of
the mitochondrial outer membrane permeability leads to the release of proteins confined in the
intermembrane space into the cytosol. These proteins include the apoptogenic factors, such as
cytochrome C, which plays a crucial role in activating the mitochondrial-dependent death in the
cytosol [32].
With the aim to discover whether PFPH and EFPH were able to induce mitochondrial
permeabilization and cytochrome C release, we used flow cytometry to analyze the mitochondrial
cytochrome C in treated and untreated cells. The results showed that, in treated cells, there was a
greater cytochrome C release to cytoplasm than in the untreated cells. Once cytochrome C is released to
the cytoplasm, it could activate different proteins of the intrinsic apoptosis pathway such as the effector
caspase-3 [40]. Once caspase-3 is activated, it induces the proteolytic cleavage of a large number of
essential proteins for apoptosis [41]. Moreover, caspase-3 is a prototypical executioner caspase that,
upon activation by extrinsic and intrinsic pathways, cleaves a wide panel of several substrates that are
vital for the cell, which precipitates regulated cell death. It is also responsible for modulating some
enzyme activities like those required for the exposure of phosphatidylserine (PS) on the outer leaflet of
dying cells [42].
Activated caspase-3 concentrations were increased in PFPH and EFPH treated cells. Gao et al. [14]
also confirmed that Vglycin promoted caspase-3 activity in colon cancer cells. The same results were
obtained by Li et al. [31], with corn peptides on HepG2 cells.
Higher levels of ROS are generated through the increased metabolic activity of cancer cells
including enhanced signalling pathways or mitochondrial dysfunction [43]. The ROS levels in Caco2
cells were determined based on the reaction between ROS and DCFH-DA [13].
In our assays, Fenugreek protein hydrolysates showed antioxidant power. EFPH showed a better
ROS inhibitory property even though PFPH was not effective with high levels of ROS. In this way,
when HepG2 cells were incubated with 100 μM of peroxide, the corn peptides fraction could not
decrease the peroxide-ROS generation [12]. In contrast, Xue et al. [13] showed that chickpea peptides
decreased the ROS in MCF-7 and MDA-MB-231 cells. Torres-Fuentes et al. [44] and Zhang et al. [45]
reported an antioxidant property of chickpea and soy proteins hydrolysates in Caco2 cells.
A study undertaken by Chi et al. [46] confirmed that peptides with a smaller molecular size,
the presence of hydrophobic and aromatic amino acid residues, and the amino acid sequences were
the key factors that determine the antioxidant activities of hydrolysates and peptides. Fenugreek
protein hydrolysates are rich in hydrophobic and aromatic amino acids [16]. Moreover, as the cells
incubated with protein hydrolysates were washed, some peptides may be lost since they are not able
to cross the cell membrane due to their big size and polarity. However, small hydrophobic peptides
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are able to cross this membrane and stay in the cytoplasm, where they may exert their antioxidant
property [44]. EFPH in which DH is higher than that of PFPH (19% vs. 9%, respectively) has higher
ROS inhibition activity.
Because of the increase in ROS production in tumor cells, it is concerted that many antioxidants
and redox control systems are up regulated. One of the most important cellular redox systems is the
thioredoxin (Trx) system, comprised of Trx, TrxR1, and NADPH [43]. However, in our study, TrxR1
activity was found to be lower in both FPH-treated cells. Since the antioxidant enzymes activities are
up-regulated following an increase of ROS production in cancer cells, we supposed that the decrease in
TrxR1 could result from the low levels of ROS in treated cells (low stimuli of Trx and TrxR1 expression),
and not a direct inhibition of the enzyme by FPH.
5. Conclusions
This data demonstrated that Purafect and Esperase fenugreek protein hydrolysates possess a
selective antiproliferative property on colorectal cancer cells, by enhancing intrinsic apoptosis rather
than necrosis on Caco2/TC7, and by blocking the cell cycle in the G1 phase. Both hydrolysates induced
alteration in mitochondrial membrane permeability, induced cytochrome C release to the cytoplasm,
and induced caspase-3 activation. Furthermore, these two hydrolysates exerted an antioxidant activity
by inhibiting the reactive oxygen species. In light of these results, fenugreek proteins hydrolysates
could represent a promising nutraceutical in the treatment and progression of colon cancer. Future
studies will be interesting to perform in order to see if these fenugreek protein hydrolysates are also
effective in other types of cancer cells and in vivo animal models.
Author Contributions: A.B. and M.J.R.-Y. were responsible for the overall direction of the research. A.A. performed
the experiments, analysis of data, and wrote the manuscript. S.G. performed and supervised the experiments.
S.B. and J.Q. performed a part of the experiments. J.O. contributed with materials and analysis results. M.N.
supervised the hydrolysis processes. A.A. performed cell culture experiments supervised by M.J.R.-Y. A.B. and
M.J.R.-Y. analyzed the obtained data. All authors have given approval to the final version of the manuscript.
Funding: The Spanish Ministry of Economy and Innovation under Grant (SAF 2016-75441-R); Aragón Regional
Government (A-32 B16-R17), CIBERobn under Grant (CB06/03/1012) of the Instituto de Salud Carlos III,
European Grant Interreg/SUDOE (Redvalue, SOE1/PI/E0123), and the Algerian Ministry of Higher Education,
Scientific Research and the Tunisian Ministry of Higher Education and Scientific Research (Joint Research Project
Algeria/Tunisia 137/2012) supported this research.
Acknowledgments: Authors thank Centro de Investigation Biomédica de Aragón (Spain) for technical assistance
(http://www.iacs.aragon.es). Authors also thank the Regional Laboratory of Quality Control and Fraud Repression
of Oran (Algeria) for their help with amino acid composition analysis of fenugreek protein hydrolysates.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Meghwal, M.; Goswami, T.K. A Review on the functional properties, nutritional content, medicinal utilization
and potential application of fenugreek. J. Food Process. Technol. 2012, 3, 181–190. [CrossRef]
2. Khorshidian, N.; Asli, M.Y.; Arab, M.; Mirzaie, A.A.; Mortazavian, A.M. Fenugreek: Potential applications as
a functional food and nutraceutical. Nutr. Food Sci. Res. 2016, 3, 5–16. [CrossRef]
3. Belguith-Hadriche, O.; Bouaziz, M.; Jamoussia, K.; Simmonds, M.; El Feki, A.; Makni-Ayedi, F. Comparative
study on hypocholesterolemic and antioxidant activities of various extracts of fenugreek seeds. Food Chem.
2013, 138, 1448–1453. [CrossRef] [PubMed]
4. Subhashini, N.; Thangathirupathi, A.; Lavanya, N. Antioxidant activity of Trigonella foenum graecum using
various in vitro and ex vivo models. J. Pharm. Pharm. Sci. 2011, 3, 96–102.
5. Madhava Naidu, M.; Shyamala, B.N.; Pura Naik, J.; Sulochanamma, G.; Srinivas, P. Chemical composition
and antioxidant activity of the husk and endosperm of fenugreek seeds. Food Sci. Technol. 2011, 44, 451–456.
[CrossRef]
6. Roy, F.; Boye, J.I.; Simpson, B.K. Bioactive proteins and peptides in pulse crops: Pea, chickpea and lentil.
Food Res. Int. 2010, 43, 432–442. [CrossRef]
285
Nutrients 2019, 11, 724
7. Girón-Calle, J.; Vioque, J.; Pedroche, J.; Alaiz, M.; Yust, M.M.; Megías, C.; Millán, F. Chickpea protein
hydrolysate as a substitute for serum in cell culture. Cytotechnology 2008, 57, 263–272. [CrossRef] [PubMed]
8. Zambrowicz, A.; Timmer, M.; Polanowski, A.; Lubec, G.; Trziszka, T. Manufacturing of peptides exhibiting
biological activity. Amino Acids 2013, 44, 315–320. [CrossRef] [PubMed]
9. León-Espinosa, E.B.; Sánchez-Chino, X.; Garduño-Siciliano, L.; Álvarez-González, R.I.; Dávila-Ortiz, G.;
Madrigal-Bujaidar, E.; Téllez-Medina, D.I.; Jiménez-Martínez, C. Hypocholesterolemic and anticarcinogenic
effect of Vicia faba protein hydrolyzates. Nutr. Cancer 2016, 68, 856–864. [CrossRef]
10. Luna Vital, D.A.; González de Mejía, E.; Dia, V.P.; Loarca-Piña, G. Peptides in common bean fractions inhibit
human colorectal cancer cells. Food Chem. 2014, 157, 347–355. [CrossRef]
11. Kannan, A.; Hettiarachchy, N.S.; Lay, J.O.; Liyanage, R. Human cancer cell proliferation inhibition by a
pentapeptide isolated and characterized from rice bran. Peptides 2010, 31, 1629–1634. [CrossRef] [PubMed]
12. Ortiz-Martinez, M.; de Mejia, E.G.; García-Lara, S.; Aguilar, O.; Lopez-Castillo, L.M.; Otero-Pappatheodorou, J.T.
Antiproliferative effect of peptide fractions isolated from a quality protein maize, a white hybrid maize, and
their derived peptides on hepatocarcinoma human HepG2 cells. J. Funct. Foods 2017, 34, 36–48. [CrossRef]
13. Xue, Z.; Wen, H.; Zhai, L.; Yu, Y.; Li, Y.; Yu, W.; Cheng, A.; Wang, C.; Kou, X. Antioxidant activity and
anti-proliferative effect of a bioactive peptide from chickpea (Cicer arietinum L.). Food Res. Int. 2015, 77, 75–81.
[CrossRef]
14. Gao, C.; Sun, R.; Xie, Y.R.; Jiang, A.L.; Lin, M.; Li, M.; Chen, Z.W.; Zhang, P.; Jin, H.; Feng, J.P. The soy-derived
peptide Vglycin inhibits the growth of colon cancer cells in vitro and in vivo. Exp. Boil. Med. 2017, 242,
1034–1043. [CrossRef] [PubMed]
15. Boye, J.I.; Aksay, S.; Roufik, S.; Ribéreau, S.; Mondor, M.; Farnworth, E.; Rajamohamed, S.H. Comparison of
the functional properties of pea, chickpea and lentil protein concentrates processed using ultrafiltration and
isoelectric precipitation techniques. Food Res. Int. 2010, 43, 537–546. [CrossRef]
16. Allaoui, A.; Barranquero, C.; Yahia, S.; Herrera-Marcos, L.V.; Benomar, S.; Jridi, M.; Navarro-Ferrando, M.Á.;
Rodriguez-Yoldi, M.J.; Nasri, M.; Osada, J.; et al. Fenugreek proteins and their hydrolysates prevent
hypercholesterolemia and enhance the HDL antioxidant properties in rats. Nutr. Food Sci. 2018, 48, 973–989.
[CrossRef]
17. Adler-Nissen, J. A review of food hydrolysis specific areas. In Enzymic Hydrolysis of Food Proteins;
Adler-Nissen, J., Ed.; Elsevier Applied Science Publishers: Copenhagen, Dermark, 1986; pp. 57–109.
18. Horwitz, W. Food composition; additives; natural contaminants. In Official Methods of Analysis of AOAC
International, 17th ed.; Horwitz, W., AOAC International, Eds.; AOAC International: Gaithersburg, MD, USA,
2000; Volume 2.
19. Yust, M.M.; Pedroche, J.; Girón-Calle, J.; Vioque, J.; Millán, F.; Alaiz, M. Determination of tryptophan
by high-performance liquid chromatography of alkaline hydrolysates with spectrophotometric detection.
Food Chem. 2004, 85, 317–320. [CrossRef]
20. Sánchez-de-Diego, C.; Mármol, I.; Pérez, R.; Gascón, S.; Rodriguez-Yoldi, M.J.; Cerrada, E. The anticancer
effect related to disturbances in redox balance on Caco-2 cells caused by an alkynyl gold(I) complex.
J. Inorg. Biochem. 2017, 166, 108–121. [CrossRef] [PubMed]
21. Christensen, M.E.; Jansen, E.S.; Sanchez, W.; Waterhouse, N.J. Flow cytometry based assays for the
measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release.
Methods 2013, 61, 138–145. [CrossRef] [PubMed]
22. Ruiz-Leal, M.; George, S. An in vitro procedure for evaluation of early stage oxidative stress in an established
fish cell line applied to investigation of PHAH and pesticide toxicity. Mar. Environ. Res. 2004, 58, 631–635.
[CrossRef] [PubMed]
23. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [CrossRef]
24. Fink, S.L.; Cookson, B.T. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying
eukaryotic cells. Infect. Immun. 2005, 73, 1907–1916. [CrossRef]
25. Ortiz-Martinez, M.; Winkler, R.; García-Lara, S. Preventive and therapeutic potential of peptides from cereals
against cancer. J. Proteom. 2014, 111, 165–183. [CrossRef]
26. Sbroggio, M.F.; Montilha, M.S.; de Figueiredo, V.R.G.; Georgetti, S.R.; Kurozawa, L.E. Influence of the degree
of hydrolysis and type of enzyme on antioxidant activity of okara protein hydrolysates. Food Sci. Technol.
2016, 36, 375–381. [CrossRef]
286
Nutrients 2019, 11, 724
27. Pownall, T.L.; Udenigwe, C.C.; Aluko, R.E. Amino acid composition and antioxidant properties of pea
seed (Pisum sativum L.) enzymatic protein hydrolysate fractions. J. Agric. Food Chem. 2010, 58, 4712–4718.
[CrossRef]
28. Mundi, S.; Aluko, R.E. Inhibitory properties of kidney bean protein hydrolysate and its membrane fractions
against renin, angiotensin converting enzyme, and free radicals. Austin J. Nutr. Food Sci. 2014, 2, 1008.
29. Kristinsson, H.G.; Rasco, B.A. Fish protein hydrolysates: Production, biochemical, and functional properties.
Crit. Rev. Food Sci. Nutr. 2000, 40, 43–81. [CrossRef]
30. Yust, M.d.M.; Millán-Linares, M.d.C.; Alcaide-Hidalgo, J.M.; Millán, F.; Pedroche, J. Hypocholesterolaemic
and antioxidant activities of chickpea (Cicer arietinum L.) protein hydrolysates. J. Sci. Food Agric. 2012, 92,
1994–2001. [CrossRef]
31. Li, J.T.; Zhang, J.L.; He, H.; Ma, Z.L.; Nie, Z.K.; Wang, Z.Z.; Xu, X.G. Apoptosis in human hepatoma HepG2
cells induced by corn peptides and its anti-tumor efficacy in H22 tumor bearing mice. Food Chem. Toxicol.
2013, 51, 297–305. [CrossRef]
32. Kumar, S.; Kapoor, V.; Gill, K.; Singh, K.; Xess, I.; Das, S.N.; Dey, S. Antifungal and antiproliferative protein
from Cicer arietinum: A bioactive compound against emerging pathogens. BioMed Res. Int. 2014, 2014, 387203.
[CrossRef]
33. Hoskin, D.W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys.
Acta Biomembr. 2008, 1778, 357–375. [CrossRef]
34. Pistritto, G.; Trisciuoglio, D.; Ceci, C.; Garufi, A.; D’Orazi, G. Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic strategies. Aging 2016, 8, 603–619. [CrossRef]
35. Lam, S.K.; Ng, T.B. Apoptosis of human breast cancer cells induced by hemagglutinin from Phaseolus vulgaris
cv. Legumi secchi. Food Chem. 2011, 126, 595–602. [CrossRef]
36. Blaszczyk, U.; Duda-Chodak, A. Magnesium: Its role in nutrition and carcinogenesis. Roczniki Państwowego
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Abstract: Coenzyme Q10 (CoQ10) is a natural compound with potent antioxidant properties.
Its provision through diet does not always allow adequate levels in the human body, and
supplementation is often necessary. This bioavailability study intended to explore the plasma
concentration levels of a novel CoQ10 oral preparation (COQUN®, Coenzyme Q10 Miniactives
Retard 100 mg capsules) mimicking assumption on a regular basis. Twenty-four healthy adults tested
a single dose of CoQ10 100 mg in one day to assess bioavailability. After a one week wash-out period,
they were randomly assigned (1:1) to continuous administration for four weeks: Group A (n = 12)
100 mg once a day (OD); and Group B (n = 12) 100 mg twice a day (BID). During the single dose
phase, Cmax was observed at 4 h, and the mean values of AUCt and Tmax were 8754 μg/mL·h and
4.29 h, respectively. The multiple dose phase showed increasing plasma levels up to 7 days after
the start of administration, and sustained high concentrations during the all administration period.
No relevant adverse events were reported. These results show that Miniactives® technology can
release CoQ10 to allow high constant blood concentrations without a sharp decrease. This may be the
first step of evidence for a potential new antioxidative treatment in human chronic diseases deserving
high CoQ10 levels.
Keywords: coenzyme Q10 (CoQ10); bioavailability; intestinal absorption; neuroprotection
1. Introduction
Coenzyme Q (CoQ), or ubiquinone, is a lipophilic, vitamin-like compound with exceptional
biochemical properties, synthetized by prokaryotic and eukaryotic cells. CoQ10 is the lipid form
produced by the human body, where Q10 indicates the number of isoprenoid subunits in the lipid
tail attached to the quinone ring of the coenzyme [1]. CoQ10 can also be obtained from diet, mainly
from meat, poultry, and fish, and in much less quantity from fruits, vegetables, cereals, and dairy
products [2].
CoQ10 is a physiological component of the human mitochondrial electron transport chain, but
its half-reduced and fully reduced forms allow CoQ10 to function as an antioxidant [3]. By virtue of
its proven ability to change in a reduced form, CoQ10 has been shown to induce protective effects
against lipid peroxidation in a ubiquitous manner in the human body, with special regard in organs
and systems’ tissues such as cardiovascular, nervous, and metabolic. Over the years, an ever-increasing
number of diseases have been associated with mitochondrial dysfunction and oxidative stress.
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Significant reduction of cardiovascular mortality, decrease of NT-proBNP blood levels, and
improvement of cardiac function has been reported among elderly subjects after five years of combined
supplementation of CoQ10 and selenium [4]. The long-term (two years) beneficial effects of CoQ10
supplementation on symptoms improvement and reduction of major adverse cardiovascular events
(i.e., cardiovascular and all-cause mortality, and incidence of hospital stay) have also been assessed in
patients with chronic heart failure (CHF) [5].
Most of clinical evidence sustains that the glycemic control among individuals with type-2
diabetes mellitus (T2DM) can be improved by CoQ10 supplementation. CoQ10 administration at
different daily doses (ranging 60–200 mg/day) and for different periods (eight weeks–six months)
can determine increased insulin synthesis and secretion by pancreatic β cells, significant decrease of
glycated hemoglobin level, and kidney protection against diabetic nephropathy. However, despite
other studies reported, marginal or not significant clinical benefits of CoQ10 in glycemic control, it is
now clear that mitochondrial dysfunction is secondary to oxidative stress that, most of time, can be
successfully treated by adequate supplementation of CoQ10 in T2DM patients [6].
Promising results have been reported in the treatment of neurodegenerative disorders such as
Parkinson disease (PD) and Huntington’s disease (HD) with CoQ10. As these are chronic, progressive
and non-regressive disorders, the goal of any treatment is to cause a slowing of the disease progression,
since improvement and cure are not currently possible. That is why only the highest dose of CoQ10
slowed the functional decline of PD among the three dosages tested of 300, 600 or 1200 mg/day
in subjects with the early stage of disease, and not yet requiring treatment for their disability [7].
Conversely, a chronic supplementation with 600 mg/day of CoQ10 did not produce any significant
slowing in functional decline in patients with early HD [8].
An interesting field of CoQ10 neuroprotective research against reactive oxygen species focused on
promoting mitochondrial functions and retinal ganglion cell (RGC) survival in ischemic retina under
conditions of intraocular pressure elevation (glaucoma). Glaucoma is a progressive neurodegenerative
disease of RGCs associated with axon degeneration in the optic nerve. During recent years, researchers
became aware that traditional strategies of lowering intraocular pressure were often unsatisfactory
to prevent progressive vision loss. Thus, the current trend of using neuroprotective strategies for the
treatment of glaucoma is sustained by the growing evidence that glaucomatous neurodegeneration
is analogous to other neurodegenerative disorders in the central nervous system [9,10]. Consistently,
CoQ10 showed to significantly block activation of astroglial and microglial cells and apoptosis in
ischemic retina in addition to protecting RGCs in animals [11], and to improving inner retinal function
and visual cortical responses in humans [12].
Combination of appropriate formulations and dosages is a key factor to allow optimal
absorption and achieve adequate blood concentration of CoQ10 to exert the expected clinical benefits.
The importance of achieving an optimal CoQ10 bioavailability is justified by the possible risk of
exposing treated subjects to a lack of efficacy in the case of underdosing. On the other hand, too high
concentrations can induce toxic effects or increase the rate of adverse events. The clinical evidence
suggests that CoQ10 bioavailability can greatly vary not only after different daily doses or dose
strategies, but especially belongs to formulations used [13–17]. For instance, it was shown that an
emulsified CoQ10 preparation can increase the intestinal absorption, being more permeable across
cellular membranes and allowing a relatively low-dose administration [13]. Despite many other factors
can influence plasma CoQ10 concentrations, such as serum lipoproteins levels, i.e., cholesterol, High
Density Lipoprotein (HDL), and Low Density Lipoprotein (LDL)/Very Low Density Lipoprotein
(VLDL) are carriers of CoQ10 in the circulation–diet, daily motion, time of day, human race, age, and
gender, and some authors indicated that dissolution is probably the more important factor rather than
release and absorption rate [14,15]. Lu and coworkers [14] administered the same single daily dose of
CoQ10 (50 mg/day) to a small group of healthy Asian volunteers using two different formulations.
The baseline plasma values, and after day 15 of treatment of CoQ10, were similar to the respective
values observed in European subjects, but CoQ10 bioavailability was higher in subjects treated with
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the sustained release tablets compared to regular tablets. Another colloidal CoQ10 preparation
achieved astonishingly higher plasma levels compared to the same doses (120 mg/day) of other more
conventional formulations [15].
Good intestinal absorption and the achievement of high peak plasma concentrations should not be
the only objectives of an oral formulation of CoQ10. It is important to ensure that plasma concentrations
remain constant over time, avoiding excessive fluctuations in bioavailability, especially if once-daily
dosing is clinically required. The authors of Reference [16] showed that the plasma concentrations
of the five formulations used, following a high peak reached after 2–4 h, returned to the same initial
levels after 12 h from the administration. Moreover, the dosing strategy is another major important
cause to reach adequately high plasma CoQ10 concentrations. A divided dose administration (e.g.,
BID) improves absorption by almost double, as compared with the same amount of active substance
taken in one single dose [16]. The dose fractionation strategy should be carefully considered when
high doses have to be administered or when high bioavailability should be achieved with a relatively
small daily dose.
The aim of this bioavailability study was to determine the single (100 mg) and multidose dose
(100 mg/day vs. 2 × 100 mg/day) pharmacokinetics (i.e., dosage effect and dosage strategy) of a novel
CoQ10 preparation based on neutral micro-particles dissolution technology (i.e., formulation effects),
a prolonged-release capsule administered orally to healthy volunteers. Bioavailability intended to
explore the plasma concentration levels which might assure antioxidant effect if the novel CoQ10
preparation were taken on a regular basis.
2. Materials and Methods
2.1. Study Design
This was a single-center (Consultmed Iasi, IASI, Romania), open-label, single and multi-dose
bioavailability study of an innovative CoQ10 oral formulation in 24 healthy adults. All subjects tested
a single dose of 100 mg of CoQ10 in 1 day to assess bioavailability. Then, the subjects followed a 1 week
wash-out period after which they were randomly assigned (1:1) to a 4 week period of continuous
administration of CoQ10: Group A of 12 subjects with intake of 100 mg OD (after dinner); Group B of
12 subjects with intake of 100 mg BID (after lunch and dinner). The primary objective was to evaluate
the best dosage between 100 mg OD or 100 mg BID of the novel CoQ10 oral formulation in order to
reach a level of plasma concentration which might assure its antioxidant effect if taken on a regular
basis. The secondary objectives were to evaluate the safety and tolerability of both the single 100 mg
oral dose and the multiple doses of 100 mg OD and BID during the 1 month daily dose phase.
In order to participate in the study, each subject had to meet all major inclusion and exclusion
criteria at screening and at check-in visits. Inclusion criteria: informed consent form (ICF) signed,
both gender aged between 25–75 years, body mass index (BMI) between 20–29 kg/m2, fasting the
night before enrolment for at least 10 h, healthy status, abstention from consumption of any food
supplements except vitamin D and calcium at least 2 weeks before and during the study, consumption
of dairy and cereal products, and willing to follow all study procedures. Exclusion criteria: intake of
any prescribed medication within 2 weeks of the beginning of the study, hypotension, any clinically
significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease,
diabetes, gastrointestinal disorders, or other serious acute or chronic diseases, known lactose/gluten
intolerances/food allergies, inadequate veins, or known contraindication to placement of a dedicated
peripheral line for venous blood withdrawal, known drug and/or alcohol abuse, use of any form of
nicotine or tobacco, mental incapacity precluding adequate understanding or cooperation, participation
in another investigational study or blood donation within 3 months prior to or during this study.
During the study the following procedures were performed: Physical examination, vital signs
recording (blood pressure, heart rate, temperature, and respiratory rate), body measurements (height
and weight), 12 lead electrocardiogram (ECG), safety laboratory analysis (Haematology: Red blood
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cells, white blood cells, platelet, haemoglobin, and haematocrit; Biochemistry: hepatic transaminases,
alcalin phosphatase, total cholesterol, LDL, and HDL cholesterol), concomitant medication recording,
and adverse events monitoring. With special regard to the latter, mild insomnia, elevated levels of
liver enzymes, rash, nausea, upper abdominal pain, dizziness, sensitivity to light, irritability, headache,
heartburn, and fatigue were closely monitored.
2.2. Pharmacokinetic Timing and Assessments
When they arrived at the study center, subjects were hospitalized for at least 12 h for the single
dose phase, and they remained at study site for approximately 24 h. At the end of this visit (visit 1),
if no serious adverse event (SAE) occurred, subjects were dismissed and requested to return after
1 week (wash-out period) for the second study visit (visit 2), in order to initiate the multidose phase.
Besides, subjects received a diary and were requested to report any possible adverse event experienced
between V1 and V2, as well as any treatment taken for treating adverse events (AEs), if applicable.
In the wash-out period subjects had to respect the same lifestyle regimen and no medication had to be
taken, if not necessary.
During the single-dose phase plasma CoQ10 levels were measured before dosing (0 h) and
over the next 12 h after intake: at 1, 2, 4, 8, and 12 h. Pharmacokinetic properties were measured
accordingly: Area under the curve until the last observation (AUCt) (μg/mL·h), maximum plasma
concentration (Cmax) (μg/L), time at which the Cmax was observed (Tmax) (hours), and elimination
half-life (T 1
2
) (hours). During the multidose-dose phase, plasma CoQ10 concentrations were measured
once at the following timepoints: V2 (day 0), V3 (day 7), V4 (day 14), and V5 (day 28) (Figure 1).
The pharmacokinetic properties measured were AUCt, Cmax, Tmax. Samples were analyzed for plasma
CoQ10 using an immunosorbent assay (ELISA; enzyme-linked immunosorbent assay) validated at the
analytical laboratory (Consultmed Iasi Laboratory, IASI, Iasi county, Romania).
Figure 1. Flow-chart of blood sampling times ( ) for the bioavailability assessment after a single dose
of 100 mg and after multiple doses of 100 mg once a day (OD) or twice a day (BID) of CoQ10. During
visits, V2, V3, V4, and V5 (multiple dose phase) only had one sample (at one timepoint) was collected.
AUC: area under the curve; PK: pharmacokinetic; Cmax: maximum concentration; Tmax: the time at
which the Cmax is observed; T1/2: half-life.
For pharmacokinetic analyses 4 mL of blood were collected in blood collection tubes. Each blood
sample was allowed to clot for 20–25 min at room temperature. Then, they were centrifuged for
15 min at 1300 g at 4 ◦C. Afterwards the plasma was separated into the secondary sample tubes as
follows: 0.5 mL plasma into two cryotubes, one to be sent to the pharmacokinetic laboratory and one
as back-up. The plasma cryotubes were appropriately labeled (study code, treatment period, subject
number, sampling time) and stored at −20 ◦C to −80 ◦C at the study center until shipment to the
292
Nutrients 2019, 11, 527
specified laboratory. The backup cryotubes were kept at the study center at least until the confirmation
from the pharmacokinetic laboratory that the samples arrived in good conditions.
2.3. Formulation Administered
The CoQ10 formulation administered (COQUN®, Coenzyme Q10 Miniactives Retard 100 mg
capsules, Visufarma S.p.A.) is a novel oral preparation based on an innovative modified release
technology of active principles at certain time intervals. The basis in Miniactives® form is neutral
microparticles of round shape, with dimensions between 400 and 500 microns. Each single particle is
covered with one or more concentric layers of the active ingredients, and subsequently coated with a
polymeric membrane suitable for obtaining a pre-established timed release. This technology leaves the
time of the active ingredients absorption unchanged. This formulation gradually releases the active
ingredients by diffusion, in a pre-determined time, thanks to a polymeric permeable and insoluble
membrane coating each single particle, thus assuring a constant release.
2.4. Ethical Conduct of the Study
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki revised in 2013, and
the protocol was approved by the local Ethics Committee Comisia Locala de Etica Consultmed,
Sos Paracurari n. 70, bl 550, parter, Iasi, Romania (Project identification code: VF-BAQ10/2018) on
May 31st, 2018, and also approved by Romanian Ministry of Health (Ministerul Sanatatii, Str Cristian
Popisteanu, n. 1–3, Bucaresti, Romania) on June 19th, 2018.
The study was registered at ClinicalTrials.gov (Internet). Bethesda (MD): National Library of
Medicine (US) (Identifier NCT03819491).
2.5. Statistical Analysis
Due to the explorative aim of the study no formal power calculation has been attempted, and no
hypotheses were pre-specified. Twenty-four subjects (12 for each arm) have been considered sufficient
to obtain reliable results for the exploratory purposes of the study. Descriptive statistics and confidence
intervals (CI) at 95% level are provided. In particular, continuous variables are presented as arithmetic
mean values ± standard deviation (SD), median values with interquartile range, minimum, maximum,
and coefficient of variation (CV); for categorical variables, the absolute and percentage frequencies
are provided. When normality assumption hold, results of Student t-tests are presented in order to
compare pharmacokinetics parameters in subjects assigned to the two treatment groups. The statistical
software package used was SAS version 9.4.
The following analysis sets were considered in the study: Safety Population (SP), all
randomized subjects who signed the informed consent and took at least one dose of study product;
Intention-To-Treat Population (ITT), all randomized subjects; and Protocol Population (PP), all subjects
who met all inclusion/exclusion criteria and who did not have any major protocol deviation.
3. Results
Twenty-seven subjects were screened in the study but 3 were screening failures. A total of
24 subjects entered the study, half (n = 12) allocated to CoQ10 100 mg OD oral intake and half (n = 12)
to CoQ10 100 mg BID. All randomized subjects completed the study. The SP, ITT- and PP-population
were composed of 24 subjects. The two treatment groups were comparable for baseline characteristics
(Table 1). A complete listing of all demographic variables of each participating subject is reported in
Table S1.
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Table 1. Demographic features of subjects randomized in each CoQ10 treatment group.
Group A Group B
Total
(CoQ10 100 mg OD) (CoQ10 100 mg BID)
Gender
Female n (%) 8 (66.67) 8 (66.67) 16
Male n (%) 4 (33.33) 4 (33.33) 8
Ethnic Group
Caucasian n (%) 12 (100.00) 12 (100.00) 24
Age (years)
Mean (SD) 35 (7.08) 43 (6.61) 39 (7.69)
Median 35 43 39
Range 26–46 30–50 26–50
Height (cm)
Mean (SD) 168.08 (5.85) 165.92 (8.51) 167.00 (7.23)
Median 169.50 162.50 167.00
Range 156.00–178.00 154.00–185.00 154.00–185.00
Weight (kg)
Mean (SD) 70.88 (9.59) 70.24 (13.87) 70.56 (11.67)
Median 71.50 76.20 72.50
Range 58.00–85.00 48.00–87.00 48.00–87.00
BMI (kg/m2)
Mean (SD) 25.05 (2.84) 25.16 (3.37) 25.11 (3.05)
Median 25.02 25.80 25.47
Range 20.79–28.81 20.23–28.86 20.23–28.86
SD: standard deviation.
3.1. Single Dose Phase
The plasma concentration curve of CoQ10 over time is shown in Figure 2. The distribution of
plasma concentrations was wide as well as standard deviations, indicating quite different levels of
plasma concentration among subjects. The mean baseline plasma CoQ10 concentration (0 h) was 649.8
(191.8) μg/L. However, a slightly increasing absorption phase of CoQ10 mean plasma values was
observed until 4 h (772.1 μg/L), followed by a slow terminal decline until 12 h (696.3 μg/L) (Table S2A.
Plasma concentration of CoQ10 by time (0, 1, 2, 4, 8, 12 h) during the single dose phase (V1)—ITT
population; Table S2B. Individual plasma concentrations of CoQ10 (μg/L) in the single dose oral
administration phase—ITT population).
Figure 2. Single dose phase: mean plasma concentrations of CoQ10 by time after 100 mg single dose
oral administration— Intention-To-Treat Population (ITT) population.
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The descriptive statistics for pharmacokinetic parameters in the single dose phase are reported in
Table 2. The mean AUCt was 8754 μg/mL·h. The maximum registered value was almost the double
the mean (15,394.54 μg/mL·h) while the minimum was 5277.62 μg/mL·h. Among other parameters,
Tmax values showed very high fluctuation with a minimum of 0 h (i.e., the maximum concentration
was reached before CoQ10 oral intake) and a maximum of 12 h. The standard deviation was 3.58 h and
the coefficient of variation was 83%, indicating that subjects registered very different time of maximum
concentration (Table S3. Individual pharmacokinetic parameters of CoQ10 in the single dose oral
administration phase—ITT population).
Males showed higher mean plasma concentrations compared to females at each time point (i.e.,
males: 759.79, 894.74, 844.33, 915.58, 840.01, and 772.41 μg/mL; females: 594.79, 628.38, 706.88, 700.34,
657.84, and 658.28 μg/mL, at 0, 1, 2, 4, 8, and 12 h, respectively). In the samples, significantly different
plasma concentrations of CoQ10 between males and females were registered (p < 0.001); on average,
females had a plasma concentration of 182.16 μg/L lower than men.













Mean (SD) 8754.34 (2382.03) 2657.45 (681.74) 3459.05 (1026.66)
CI 95% 7748.41–9760.1 2224.29–3090.6 2806.75–4111.36
Median 8319.91 2490.96 3520.28
Range 5277.62–15,394.54 1671.77–3778.37 2173.31–6068.15
Coefficient of variation (%) 27 26 30
Interquartile range 2920.10 1025.78 1073.09
Cmax (μg/L)
Mean (SD) 828.92 (233.09) 1163.99 (354.95) 1501.89 (474.64)
CI 95% 730.49–927.35 938.46–1389.51 1200.32–1803.47
Median 830.37 1131.38 1495.78
Range 482.54–1438.45 679.81–1826.85 906.43–2441.84
Coefficient of variation (%) 28 30 32
Interquartile range 283.69 542.84 759.72
Tmax (h */day **)
Mean (SD) 4.29 (3.58) 17.5 (10.12) 16.92 (8.68)
CI 95% 2.78–5.80 11.07–23.93 11.4–22.43
Median 4.00 14.00 14.00
Range 0–12 0–28 7–28
Coefficient of variation (%) 83 58 51








Coefficient of variation (%) 27
Interquartile range 0.79
* h: Tmax during single dose phase, ** day: Tmax during multiple dose phase.
3.2. Multiple Dose Phase
The mean plasma concentrations of CoQ10 increased over time in both treatment groups (Figure 3).
At each study visit subjects who were assigned to 100 mg BID (Group B) had higher mean values than
subjects in Group A, indicating that the assumption CoQ10 twice a day gave a higher concentration in
the body.
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Figure 3. Multiple dose phase: plasma concentrations of CoQ10 by visit and by treatment group
(Group A: 100 mg OD; Group B: 100 mg BID)—ITT population.
The two dosages of the same CoQ10 oral formulation followed the same pattern over time.
In both groups, the mean values of plasma concentrations increased considerably from Visit 2 (Day 0)
to Visit 3 (Day 7). At Visit 2 (Day 0), the mean plasma CoQ10 concentrations in Group A and B
(701.95 ± 295.17 μg/L and 756.96 ± 201.17 μg/L, respectively) represent the mean plasma values
after the end of the washout period. After day 7 (Visit 3), constant trends of high plasma levels were
observed, which remained high during the rest of the multidose phase (21 days), with higher values
for the Group taking 100 mg BID.
Additionally, in the multidose phase males showed higher plasma concentration of CoQ10
compared to females at each study visit. As in the single dose phase, the pattern over time was
the same for men and women. The distribution of plasma concentration was very wide: Standard
deviations and coefficients of variation—showing the extent of variability in relation to the mean of
the population—were quite large indicating that levels of plasma concentration were different among
individuals. The high inter-individual variability observed in this study could be probably due to a
series of physiological conditions such as age, gender, and multiple administration time, which makes
a subject very different from another. More likely, by reviewing the pharmacokinetics profile of each
subject randomized in this study, exceptionally high pharmacokinetic values were observed. They
belong to a 36-year-old man randomized to Group B, who registered values of plasma concentration
far above from the mean of the total set of subjects. By considering this individual as an outlier and by
excluding him from the analysis (n = 23), mean plasma concentration values (and SD) were smaller for
Group B, as follows (μg/L): 743.83 (205.53), 1153.86 (290.86), 1118.12 (421.44), and 1155.94 (338.48) at
visit 2, visit 3, visit 4, and visit 5, respectively (Table S4. Individual plasma concentrations of CoQ10
(μg/mL) in the multiple dose oral administration phase—ITT population).
The descriptive statistics for pharmacokinetic parameters by treatment group are reported in
Table 2. The mean CoQ10 bioavailability (AUCt) in Group B (3459.05 μg/mL·h) was statistically
higher than in Group A (2657.45 μg/mL·h) (p = 0.0345). Despite values of the other pharmacokinetics
parameters (Cmax, Tmax) remained higher for subjects treated by CoQ10 100 mg BID compared to ones
with the OD dosing scheme, no statistically significant differences between groups were detected.
As previously described, by excluding the outlier subject from the analysis, the difference between the
AUCt values of the two groups was no more statistically significant (p = 0.0548) (Table S5. Individual
pharmacokinetic parameters of CoQ10 in the multiple dose oral administration phase—ITT population).
In the scenario without this subject, there is evidence of a difference in the CoQ10 bioavailability (AUCt)
between the two dosages of the novel oral formulation of CoQ10, but the low power of the study
296
Nutrients 2019, 11, 527
due to the small sample size did not allow highlighting, albeit slightly, a significant difference when
excluding him.
3.3. Adverse Events
The oral formulation of CoQ10 was well tolerated in all 24 healthy subjects; only 3 non-serious,
moderate intensity AEs were reported during all the study period. The 3 AEs occurred in 2 subjects,
both enrolled in the Group B (100 mg BID): (1) Intermittent dizziness of 5 days duration, possibly
related to the oral preparation, and spontaneously resolved; (2) 1 day respiratory virosis, adequately
treated, but unrelated to the study product; and (3) pultaceous angina of 5 days duration, unrelated to
the CoQ10 oral preparation.
During the multiple dose phase (at visit 2 and visit 5), 21 subjects (9 in Group A and 12 in Group B)
showed some biochemical values out of normal ranges, but none was considered clinically significant.
Only 5 subjects—2 in Group A and 3 in Group B—showed clinically not significant out-of-range liver
biochemical values. The ranges of values considered outside the normal ranges are shown in Table 3.
Table 3. Range of values of liver biochemical parameters outside the normal ranges observed during
the multiple dose phase in both treatment groups—ITT population.
Biochemistry (Normal Ranges)
Group A Group B
(n. of Subjects) * (n. of Subjects) *
AST (<32 U/L) 39–42 (2) 34–40 (2)
ALT (<33 U/L) 43–48 (2) 42–96 (3)
ALP (35–104 U/L) --- 27–237 (2)
TC (<200 mg/dL) 203–235 (3) 200–251 (5)
HDL (≥60 mg/dL) 39 (1) 36–40 (2)
LDL (<100 mg/dL) 100–186 (8) 101–200 (11)
TGs (<100 mg/dL) --- 257 (1)
AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; ALP = Alkaline Phosphatase; TC = Total
Cholesterol; HDL = High-Density Lipoprotein; LDL = Low-Density Lipoprotein; and TGs = Triglycerides. * Some
subjects experienced more than one biochemical value outside the normal range of the reference laboratory.
Subjects randomized to treatment with 100 mg BID of CoQ10 did not show higher out-of-range
liver values compared to subjects treated with the halved dose (100 mg OD). Both doses were safely
tolerated. However, renal function tests were not monitored during the study because they were not
included in the protocol requirements, and no blood samples were taken for the evaluation of basic
plasma biochemistry.
4. Discussion
These results demonstrate that in human plasma high levels of CoQ10 can be achieved by
administrating relatively low oral doses by the use of a novel timed-release oral formulation
determining optimal intestinal absorption and sustained plasma concentrations over time.
The combination of bioavailability and safety results obtained with two oral dosages of CoQ10 (100 mg
OD and BID) contribute to the construction of a rationale for a clinical use of this novel formulation
of CoQ10. The information can help clinicians to protect patients from the negative effects of lipid
peroxidation, on the one hand preventing possible therapeutic failures due to CoQ10 underdosing,
and on the other, the possible development of toxicity following administration of too high doses.
In the experience of Joshi and coll. the pharmacokinetic properties of two new oral CoQ10
formulations (i.e., fast-melting tablet and effervescent tablet) were not statistically different compared
with those of commercial formulations (i.e., soft gelatin capsule and powder-filled hard shell) when
administered at 60 mg in single dose fashion [16]. The mean Cmax values of the four formulations
(around 80 μg/mL) measured over 12 h were essentially similar to the one of CoQ10 Miniactives
Retard capsule we studied (83 μg/mL), but the mean Tmax values were almost halved (1.3 and 2.0 h
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for fast-melting and effervescent tablets, respectively) compared to the one of Miniactives capsule
(4.29 h). It is hard to believe that the more rapid delivery of the two fast melting formulations can
play a significant role in the clinical cure of diseases in which the main feature of long-term treatment
should be to ensure consistently high levels of CoQ10 over time. Furthermore, the bioavailabilities
of the four formulations (ranging 4.9–5.5 μg/mL·h) were far below the bioavailability of the one we
tested (8.754 μg/mL·h). This can be probably explained mainly by the dissolution properties of the
Miniactives® technology that allows more sustained plasma concentrations over time (until 12 h after
dosing), as well as by the higher dose administered (100 mg) in our study.
When supplemented at 100 mg/day by oral formulation consisting of soya oil in soft gelatin
capsule (Myoqinon® 100 mg CoQ10), CoQ10 achieved median plasma concentration of 2.5 mg/L
(2500 μg/L) after a 2 month administration period [18], far above the median plasma level achieved
at day 28 with Miniactives capsule (773.35 μg/L) administered at 100 mg/day in Group A. It is
difficult to draw conclusions when comparing our results with those of Zita and coll. [18] due to
the profound difference between the durations of oral administration of CoQ10 in the two studies
(2 months vs. 1 month). In addition to this, no other pharmacokinetic parameters were reported by
the authors of Reference [18]. Astonishingly, in another study [17], the same 100 mg/day CoQ10 soya
oil in soft gelatin capsule (Myoqinon® 100 mg CoQ10) did not generate comparable pharmacokinetic
results to those reported by Zita. After 20 days CoQ10 plasma concentration was approximately
0.9 mg/L (900 μg/L), a result much below the 2.5 mg/L reported in the study [18]. The mean plasma
concentrations of CoQ10 after administration of oil/soft gel formulation used by Singh [17] are closer
to those observed in our study after 28 days of CoQ10 100 mg/day administration (944.8 μg/L).
Moreover, the author also highlighted the importance of the dosing strategy in addition to the daily
dose. Divided dosages (2 × 100 mg) of oil/soft gel CoQ10 formulation caused a larger increase in
plasma levels of CoQ10 (approximately >1.9 mg/L) than a single dose of 200 mg (approximately
>1.3 mg/L) [17]. Our results show that, after 28 days of supplementation of Miniactives®, formulation
2 × 100 mg the mean plasma concentration was a little higher than 1200 μg/L.
With the aim to overcome the poor intestinal absorption, the bioavailability of a CoQ10 colloidal
oral preparation was determined versus one oil-based formulation and two solubilizates in a single
dose (120 mg) study. The mean Cmax colloidal formulation was the highest among the four formulations
studied (6890 μg/L), as well as its AUC(0-10) (30,620 μg/mL·h). Nevertheless, the oil-based formulation
and the two solubilizates showed rather high bioavailability (i.e., 4900, 6100, 10,700 μg/mL·h,
respectively) [15]. When comparing the pharmacokinetic profiles of the four formulations with
Miniactives® capsule, all achieved the peak of plasma concentration 4 h after the administration and
maintained sustained levels afterwards. Once again, it is difficult to compare the results of different
studies, since several factors may have contributed to the achievement of a particular bioavailability
profile (e.g., study design, selection criteria, diet, analytical procedures, etc.). In the case of colloidal
preparation, it is undoubted that it has favored the intestinal absorption of the conveyed CoQ10.
Very recently, a pharmacokinetic study highlighted the importance of inter-subjects variability in
the plasma level of CoQ10 caused by significant variation of intestinal absorption of CoQ10 between
subjects and irrespective of the oral formulation or molecular form administered [19]. The three
commercial preparations tested (i.e., ubiquinol 150 mg capsule, ubiquinone 150 mg capsule and
liposome ubiquinone 40 mg/2 sprays) showed plasma levels of CoQ10 ranging 5000–6000 μg/L at
the 2 h interval, with ubiquinol preparation having the highest response, but a high inter-individual
variation was observed for each preparation at every time interval. In our experience, this phenomenon
has also been observed in both the single and multiple dose phase. After the single dose phase,
the mean AUCt (8754.34 ± 2382.03 μg/mL·h) showed a very wide range (5277.62–15,394.54 μg/mL·h)
and also mean Tmax had a high fluctuation, indicating different times of maximum concentration
between subjects (coefficient of variation: 83%). During the multidose phase a very wide distribution of
plasma concentration was observed, indicating quite different levels among individuals. Particularly,
the exceptionally high pharmacokinetic values of a single subject (36-year-old man) randomized in the
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group of 2 × 100 mg CoQ10 dose contributed to increase in the overall variability of pharmacokinetic
results of the entire subject population. Despite the bioavailability values of CoQ10 of the two
groups (Group A and Group B), they were not statistically different after exclusion of the outlier
subject (p = 0.0548), however, there is evidence of a difference at limits of the significance threshold
(p < 0.05) between the two groups. Probably, a clear difference did not emerge due to the small sample
size studied.
During both single and multiple dose phases, males showed higher plasma CoQ10
concentration than females at each time point. CoQ10 baseline is naturally higher in men than
in women [14,20], ranging 0.40–1.72 μmol/L (345.34–1484.94 μg/L) for males and 0.43–1.47 μmol/L
(371.24–1269.11 μg/L) for females in European (Finnish) population [20]. Our results on baseline CoQ10
plasma levels (0 h) in both sexes are included in these normal ranges (males 759.79 ± 198.09; females
594.79 ± 168.63). During the multidose phase, the same pattern of plasma CoQ10 concentration
was observed between genders (e.g., males 909.79 ± 241.54 μg/L, females 639.29 ± 203.81 μg/L
at Visit 2; males 1173.32 ± 524.40 μg/L, and females 1061.03 ± 464.98 μg/L at Visit 5). In this
study, the proportion between genders was unbalanced (i.e., 8 males/16 females). However,
this disproportion did not appear to have influenced the plasma concentrations of CoQ10 according
to the expected levels in males and females. In addition, another pharmacokinetic study reported
the same numerical disproportion between the two genders, without any reported influence on the
observed results [15]. Regarding the difference between genders in CoQ10 plasma concentrations, our
results are in line with previous studies. The present experience and others in the literature support
the conclusions that men can have better absorption and/or lower clearance than women [13].
The results presented in our bioavailability study suggest that Miniactives® timed release
formulation of CoQ10 gradually released the active ingredient by diffusion, in a pre-determined
time, thanks to a polymeric permeable and insoluble membrane coating each single particle, thus
assuring a constant release. After having achieved the peak at 4 h, CoQ10 plasma concentrations did
not undergo a sharp decrease and remained constantly high. The development of this technology was
supported with the aim of creating an oral formulation able to ensure consistently high CoQ10 blood
concentrations, useful for supporting a treatment strategy in the neuroprotection of RGC. In glaucoma,
retinal neuroprotection can be significantly improved through maintenance of mitochondrial functions
and survival of RGC by CoQ10, one of the most powerful antioxidant compounds. The potential
clinical significance of this finding should be further evaluated.
In conclusion, based on the obtained results and on data available in literature regarding the
expected average plasma levels of CoQ10, this exploratory study highlighted that both 100 mg OD
or BID are safe and assure a plasma concentration of CoQ10 that remains high for the duration of
the intake and that 100 mg COQUN® Miniactives® BID would be preferred than OD in reaching a
higher plasma concentration of CoQ10. These positive results suggest that further studies are needed
in order to investigate the antioxidative effects of COQUN® OS oral formulation in patients with
specific diseases like glaucoma where the antioxidative effect of the CoQ10 is expected to be seen at
the target organ.
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Abstract: Mulberry plants belonging to the Moraceae family have been grown for the purpose of
being the nutrient source for silk worm and raw materials for the preparation of jams, marmalades,
vinegars, juices, wines, and cosmetics. Morus nigra L. (black mulberry) is native to Southwestern
Asia, and it has been used as a traditional herbal medicine for animals and humans. In this article,
recent research progress on various biological and pharmacological properties of extracts, fractions,
and isolated active constituents from different parts of M. nigra are reviewed. M. nigra exhibited
a wide-spectrum of biological and pharmacological therapeutic effects including antinociceptive,
anti-inflammatory, antimicrobial, anti-melanogenic, antidiabetic, anti-obesity, anti-hyperlipidemic,
and anticancer activities. M. nigra also showed protective effects against various human organs and
systems, mainly based on its antioxidant capacity. These findings strongly suggest that M. nigra can
be used as a promising nutraceutical resource to control and prevent various chronic diseases.
Keywords: Morus nigra L.; black mulberry; nutraceutical; pharmacological properties
1. Introduction
Morus, commonly known as mulberry, is the genus of a flowering plant belonging to the Moraceae
family. They are widely distributed into subtropic regions of Asia (including Korea, Japan, China,
and India), North America, and Africa [1]. In Asian countries, mulberry plants have been grown
for the production of silk worms (Bombyx mori L.), because their leaves are a major and important
nutrient source for silk worms [2]. Meanwhile, most European countries have usually used mulberry
fruits to prepare jams, marmalades, vinegars, juices, wine, and cosmetic products [3]. Various parts of
mulberry plants have also been used as traditional herbal medicines [4]. Diels-Alder-type adducts,
flavonoids, benzofurans, stilbenes, and polyhydroxylated alkaloids are the most representative
bioactive compounds identified from Sang-Bai-Pi (Chinese name for root barks of Morus species) [5].
Some previous review articles on Morus alba L. (M. alba), one of the most valuable plants rich in natural
ingredients, have demonstrated that extracts, fractions and major constituents from M. alba exhibit
numerous pharmacological activities such as antioxidant, anti-inflammatory, anticancer, antimicrobial,
antifungal, skin-whitening, antidiabetic, anti-hyperlipidemic, anti-atherosclerotic, anti-obesity,
cardioprotective, cognitive enhancing, hepatoprotective, anti-platelet, anxiolytic, anti-asthmatic,
anthelmintic, antidepressant, and immunomodulatory activities [6–8].
Morus nigra L. (M. nigra), also called black mulberry, is native to Southwestern Asia. It has been
grown throughout Europe and around the Mediterranean for centuries. Although biological and/or
pharmacological activities of M. nigra have been relatively less studied compared to those of M. alba,
several bioactive compounds isolated from M. nigra have also been used as herbal medicines for
animals and humans due to their analgesic and anti-inflammatory effects [1]. Budiman et al. [9] briefly
summarized chemical compounds isolated from various parts of M. nigra and their pharmacological
activities. In this review article, we extensively covered recent research progress on biological and
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pharmacological properties of M. nigra extracts, fractions, and active constituents, suggesting its
potential and usefulness as a nutraceutical resource. Major biological and pharmacological therapeutic
activities of M. nigra were summarized in Table 1.
2. Antinociceptive Activity
In 2000, de Souza et al. [10] firstly reported on the antinociceptive effect of morusin, the main
prenylflavonoid of M. nigra isolated from acetonic extract of its root barks. Morusin showed a significant
inhibitory effect on acetic acid-induced abdominal constriction responses and formalin-induced pain,
and it also resulted in prolongation of the latency period in a hot plate test in mice. Because morusin
is also purified from other mulberry plants, such as M. alba [11], M. australis [12] and M. lhou [13],
this study result alone is insufficient to fully reflect the analgesic activity of M. nigra. Nine years later,
Padilha et al. [14] investigated the antinociceptive effect of methylene chloride extract of M. nigra leaves
in mice. Similar to the results of de Souza et al. [10], M. nigra leaves extract showed significantly
and dose-dependently reduced acetic acid-induced writhing and formalin-induced pain and increased
response latency period in a tail-immersion test and hot plate test without any acute toxicity when the
dose of the extract was up to 300 mg/kg.
Two studies by Chen et al. [15,16] recently evaluated the antinociceptive properties of total
flavonoid extracts and main active ingredients from fresh fruits of M. nigra. In the first study [15],
total flavonoids from M. nigra showed dose-dependent decreases in the duration of formalin-induced
pain-response behaviors. In the second study, three different mulberry fruits (M. alba, M. nigra and
M. mongolia) were compared [16]. M. nigra fruits had more anthocyanin and flavonol contents than
other species. The duration of the formalin-induced secondary pain phase (inflammatory phase) in the
group treated with total flavonoid extract from M. nigra was significantly shorter than that in the control
group. Reduced development of inflammatory cytokine interleukin-6 (IL-6) and an increased level of
an anti-inflammatory cytokine IL-10 associated with the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) and nitric oxide (NO) pathways were observed after treatment with M. nigra
extract, suggesting the possible mechanism of its antinociceptive effects. Interestingly, the three main
flavonoid ingredients (cyanidin-3-O-glucoside, rutin and isoquercetin) from M. nigra did not reduce the
duration of formalin-induced pain individually, although they significantly decreased such duration
when they were used as a mixture.
3. Anti-Inflammatory Activity
Inflammation is defined as a set of physiological defense mechanisms taking place in the body.
However, inflammation is also considered an initial event of major chronic diseases such as cardiovascular,
autoimmune, eye, age-related, neurodegenerative diseases, and cancers [17]. In this respect, inhibiting
and controlling inflammatory responses in the human body can be one of fundamental approaches for
treating chronic diseases.
As a follow-up research of a previous study on antinociceptive activity, Padilha et al. [18]
evaluated the anti-inflammatory effects of methylene chloride extract of M. nigra leaves in male rats.
M. nigra leaves extract significantly inhibited the volume of paw edema induced by intraplantar
injection of carrageenan at a half-maximal inhibitory concentration (IC50) value of 15.2 mg/kg.
M. nigra leaves also significantly inhibited the formation of granulomatous tissues in the chronic
inflammation status using a cotton pellet-induced granuloma rat model (IC50 of 71.1 mg/kg). In the
same year, Wang et al. [19] isolated three new compounds (mornigrol D, G and H) with six other known
compounds (norartocarpetin, dihydrokaempferol, albanin A, albanin E, moracin M, and albafuran
C) from the stem bark of M. nigra and assessed their anti-inflammatory activities by calculating
the inhibition of releasing β-glucuronidase from rat polymorphonuclear leukocytes induced by
platelet-activating factor. At a concentration of 10−5 M, mornigrol D and norartocarpetin showed
potent anti-inflammatory properties, showing inhibition rates of 65.9% and 67.7%, respectively. In 2014,
Zelová et al. [20] investigated into the anti-inflammatory activities of two Diels-Alder adducts (soroceal
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and sanggenon E) isolated from the root bark of M. nigra, by determining the attenuation of secretion
of pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) and IL-1β, in lipopolysaccharide
(LPS)-stimulated macrophages. Although sanggenon E significantly reduced the production of TNF-α
compared to the vehicle control, both compounds failed to significantly affect the level of IL-1β.
Chen et al. [15] reported that the total flavonoid extract of M. nigra fruits can dose-dependently
inhibit xylene-induced ear edema (edema rate 60.1% at a concentration of 200 mg/20 mL/kg) and
carrageenan-induced paw edema (edema rate 9.5% at a concentration of 100 mg/20 mL/kg; 8.6% at a
concentration of 200 mg/20 mL/kg) in mice. Levels of pro-inflammatory cytokines including IL-1β,
TNF-α, NO, and interferon-gamma (IFN-γ) were also significantly decreased after the treatment of
M. nigra fruit extract in mice with xylene-induced inflammation. In addition, M. nigra fruits extract
significantly reduced levels of NO in LPS-stimulated RAW 264.7 cells without showing the cytotoxicity
effect at the concentration of 50 to 100 μg/mL.
A very recent study [21] has shown that extracts of M. nigra pulps and leaves can improve survival
rate and decrease the number of total leukocytes in bronchoalveloar lavage fluid in LPS-induced septic
mice, indicating the reduction of inflammatory infiltrate in the lung. Although most hepatic and serum
cytokine levels were not changed by the administration of M. nigra extracts, serum levels of TNF,
an important mediator of sepsis, were significantly lower in the M. nigra extract-treated group than
those in the septic animal group.
4. Antimicrobial Activity
Antibacterial activities of M. nigra leaves have been investigated in various organic fractions.
Tahir et al. [22] reported that the ethyl acetate fraction of M. nigra leaves is active against four dental
caries-causing bacterial strains: Streptococcus mutans, Escherichia coli (E. coli), Staphylococcus aureus
(S. aureus), and Bacillus subtilis (B. subtilis). Also, the chloroform fraction showed antibacterial properties
against Pseudomonas aeruginosa (P. aeruginosa) and B. subtilis, while the methanol fraction was only
active against B. subtilis. No activity was observed for n-hexane or aqueous fraction. The inhibition
rate of streptococcal biofilm formation (anti-adherence effect) by M. nigra ethyl acetate fraction was
87%. In another study conducted by Souza et al. [23], crude ethanol extract of M. nigra leaves exhibited
bactericidal activities against Bacillus cereus (B. cereus), Enterococcus faecalis (E. faecalis), and E. coli,
with minimal inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) less than
0.195 mg/mL for all. Potent antibacterial activities against B. cereus and E. faecalis were also observed
for hexane, chloroform and ethyl acetate extracts (MIC values < 0.195 mg/mL for all). However,
their measured MBCs were over 6 mg/mL. It was noted that chloroform extract exclusively showed a
bactericidal effect against Salmonella choleraesuis (MIC and MBC value < 0.195 mg/mL, respectively).
The antibacterial activities of the total flavonoid extract of M. nigra fruits were evaluated against
three inflammatory pain-causing bacteria, E. coli, P. aeruginosa and S. aureus. Its fruit extract strongly
inhibited all three strains, with MBC values of 2 mg/mL or less [16].
The antimicrobial activities of fresh juice of M. nigra fruits against five Gram-positive and three
Gram-negative bacterial strains have been compared with conventional antibiotics [24]. Although
100 μL of M. nigra fruits juice produced generally smaller zones of inhibition (ranging from 9.98
to 19.87 mm) than other antibiotics treated at their standard doses, it showed a broad-spectrum
antimicrobial effect against both Gram-positive and Gram-negative bacteria, having the highest
inhibition against P. aeruginosa. Minhas et al. [25] investigated into the antimicrobial effect of five
M. nigra fruits extracts classified by different solvents against 16 bacterial and 2 fungal strains in
comparison with conventional antibiotics and antifungal agent nystatin. Ethanolic and acetone extracts
of M. nigra fruits showed highly-sensitive inhibition (defined as 20 mm or more longer diameter of
zone of inhibition) against E. coli, S. aureus, and Neisseria spp.; methanolic extract against Klebsiella
pneumoniae and Neisseria spp.; and chloroform extract against Serratia marcesscens, Staphylococcus
epidermidis (S. epidermidis), P. aeruginosa, and S. aureus. Similar to the results of Khalid et al. [24],
M. nigra extracts had smaller zones of inhibition than those observed with conventional drugs.
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In a recent study assessing antibacterial activities against two strains causing acne, S. epidermidis
and Propionibacterium acnes (P. acnes), the ethanolic extract of M. nigra fruits had MIC values of 2.5% for
both strains and MBC values of 2.5% and 5%, respectively [26]. As a follow-up approach, a comparative
study was performed for extracts from three parts (stem barks, fruits and leaves) of M. nigra on their
antibacterial effects against S. epidermidis and P. acnes [27]. M. nigra stem barks possessed the most
potent antibacterial activities against both strains, with an MIC value of 4 mg/mL for S. epidermidis
and 2 mg/mL for P. acnes. In addition, M. nigra stem barks extract induced nucleic acid, protein,
and ion leakages and cellular membrane damages against P. acnes. These results suggest that the
antibacterial effect of M. nigra stem bark is related to reduced cell membrane fluidity and bacterial cell
wall destruction.
Mazzimba et al. [28] reported that six isolated constituents (oxyresveratrol, moracin M, cyclomorusin,
morusin, kuwanon C, and a derivative of kuwanon C) from aerial parts of M. nigra show antibacterial
activities against S. aureus, B. subtilis, Micrococcus flavus, S. faecalis, Salmonella abony, and P. aeruginosa,
with morusin having the most potent activity against B. subtilis (MIC value 3.91 μg/mL).
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis),
is one of the top 10 causes of death in the world. TB is a curable and preventive disease, but resistance
against conventional antibiotic medications for M. tuberculosis has increased the number of cases of
multidrug-resistant or extensively drug-resistant TB [29]. In this respect, demand for new medications
with novel therapeutic targets such as protein tyrosinase phosphatases (PTPs) is growing [30,31].
Mascarello et al. [32] evaluated the anti-tuberculosis activity of Diel–Alder-type adducts from M. nigra
root bark to determine their potential as candidates for M. tuberculosis PTP inhibitor. A total of
eight compounds (Kuwanon L, G, and H; cudraflavanone A; morusin, oxyresveratrol; chalcomoracin;
and norartocarpetin) were isolated from M. nigra. They all significantly inhibited M. tuberculosis
PTP-B (Mtb PtpB) with IC50 values ranging from 0.36 to 8.42 μM. Further enzyme kinetic analyses for
Kuwanon G and H, two of the most potent compounds, showed that both compounds competitively
inhibited Mtb PtpB, with inhibitory constant (Ki) values of 0.39 ± 0.27 μM and 0.20 ± 0.01 μM,
respectively. In addition, Kuwanon G inhibited the growth of M. tuberculosis inside macrophages
by 61.3% at a non-cytotoxic concentration (10 μg/mL, corresponding to 14.4 μM of Kuwanon G),
indicating that it is the most promising anti-tuberculosis constituent isolated from M. nigra.
Antimicrobial activity of M. nigra against Candida spp., the most common cause of fungal infections
around the world [33], was assessed with aqueous and methanol extracts of its fruits, by using a
disc-diffusion assay [34]. Of nine selected Candida spp., both extracts exhibited anticandidal effect against
Candida (C.) albicans, C. parapsilosis, C. tropicalis, and Geotricum candidum, with lower MIC values observed
for the methanol extract (0.625–2.5 mg/mL) than those for the aqueous extract (1.25–5 mg/mL).
5. Anti-Melanogenic (Skin-Whitening) Activity
Although melanin pigmentation in the skin is an important defense mechanism against ultraviolet
radiation, abnormal melanin hyperpigmentation catalyzed by tyrosinase can cause several serious aesthetic
problems [35–37]. As an anti-melanogenic strategy, tyrosinase inhibitors have become increasingly
important for treating skin disorders associated with pigmentation and to improve skin-whitening.
Zhang et al. [38] investigated the inhibitory effect of 2,4,2’,4’-tetrahydroxy-3-(3-methyl-2-butenyl)-
chalcone (TMBC) isolated from the stem of M. nigra on tyrosinase activity and melanin biosynthesis.
TMBC dose-dependently and competitively inhibited mushroom tyrosinase-mediated L-dopa oxidation
(IC50 value 0.95 ± 0.04 μM), which was more potent than kojic acid (IC50 value 24.88 ± 1.13 μM),
a well-known skin depigmenting agent. Furthermore, TMBC significantly reduced the melanin content
and cellular tyrosinase activity in B16 melanoma cells, although it increased mRNA levels of cellular
tyrosinase. Zheng et al. [39] screened tyrosinase inhibitory properties of a total of 29 constituents
isolated from roots of M. nigra. Among them, nine compounds (5’-geranyl-5,7,2’,4’-tetrahydroxyflavone,
steppogenin-7-O-β-D-glucoside, 2,4,2’,4’-tetrahydroxychalcone, moracin N, kuwanon H, mulberrofuran G,
morachalcone A, oxyresveratrol-3’-O-β-D-glucopyranoside and oxyresveratrol-2-O-β-D-glucopyranoside)
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showed better tyrosinase inhibitory activities than kojic acid (IC50 value 46.95 ± 1.72 μM, with
2,4,2’,4’-tetrahydroxychalcone having the highest activity (IC50 value 0.062 ± 0.002 μM, 757-fold lower
IC50 than kojic acid). More recently, de Freitas et al. [40] reported that five different batches of standardized
ethanolic extracts of M. nigra leaves all exhibited tyrosinase inhibitory activities, with IC50 ranging from
5.00 to 8.49 μg/mL.
Koyu et al. [41] tested the microwave-assisted extraction of fresh fruits of M. nigra in variable
conditions for optimizing and maximizing tyrosinase inhibitory activity. Consequently, the highest
tyrosinase inhibitory activity (IC50 value 1.44 mg/mL) was observed in the optimum microwave
extraction system yielding the highest amount of anthocyanin content (13.28 mg/g cyanidin-3-glucoside
equivalent), suggesting the important potential of anthocyanins on tyrosinase inhibition.
6. Antidiabetic and Anti-Obesity Activity
Diabetes mellitus is a chronic endocrine disorder characterized by hyperglycemia related to
metabolic impairment of insulin production, secretion, and/or utilization. It is closely associated
with the development of several important complications in cardiovascular, neurological and renal
systems that can lead to increased morbidity and mortality in diabetic patients [42]. Various classes
of antihyperglycemic agents are now available. However, some undesirable adverse effects such
as hypoglycemia, gastrointestinal symptoms, weight gain and hepato-renal toxicity caused by the
administration of these medications have been arousing interests on the discovery of new effective and
safer naturally-occurring antidiabetic agents with different therapeutic pathophysiological mechanisms
and targets [43–45].
M. nigra has also shown good antidiabetic effects on extracts and active constituents from some
parts of this plant. Abd El-Mawla et al. [46] investigated the hypoglycemic efficacy of M. nigra
leaf extracts and its cell suspension cultures treated with methyl jasmonate to induce accumulation
of flavonoid contents in cell cultures. Extracts from M. nigra leaves dose-dependently decreased
plasma glucose concentrations and increased insulin levels up to 500 mg/kg/day in streptozotocin
(STZ)-treated diabetic rats. In addition, a slightly higher hypoglycemic effect was observed when rats
were treated with extracts from cultured cells, indicating the additive action of flavonoids induced by
methyl jasmonate. Hydroethanolic extracts of M. nigra leaves also significantly decreased serum fasting
and 2-h glucose concentrations (at dose of 50 mg/kg) and increased serum insulin level (at dose of
10 mg/kg) in nicotinamide-STZ-induced type 2 diabetic rats [47]. Diabetes-induced changes in blood
vessels may enhance the pathophysiological activity of metalloproteinases (MMPs). It is known that
the inhibition of MMPs can improve insulin resistance and oxidative stress [48,49]. Araujo et al. [49]
demonstrated the hypoglycemic potential of M. nigra leaves via reduction of expression and activity of
MMP-2 in livers of diabetic rats. In addition, several phenolic compounds and isoprenylated flavonoids
isolated from extracts of M. nigra twigs showed good antidiabetic activities, involving mechanisms
of peroxisome proliferators-activated receptor gamma (PPARγ) activation [50] and α-glucosidase
inhibition [51]. On the other hand, 3-week treatment of aqueous extract of M. nigra leaves failed to
affect serum glucose levels in non-diabetic or diabetic pregnant rats [52].
Although there is no published report on the antidiabetic activity of black mulberry fruit yet,
its effects on obesity, associated with increased risk of many chronic adverse health effects including
cardiovascular diseases, dyslipidemia, non-alcoholic hepatic disease, cancer, and type 2 diabetes [53,54]
have been evaluated by Fabroni et al. [55]. They demonstrated that 80% hydroethanolic freeze-dried
extract of fruits of M. nigra had moderate total anthocyanin and total phenolic contents, with an IC50
value for pancreatic lipase inhibition at 6.32 ± 0.01 mg/mL.
7. Anti-Hyperlipidemic and Anti-Atherosclerotic Activity
Cholesterol is a lipid molecule that acts as a structural component of cell membrane modulating
fluidity and permeability, and as a precursor for steroid hormone and bile acid synthesis [56].
At the same time, hypercholesterolemia, a typical type of hyperlipidemia characterized by excessive
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accumulation of cholesterol in serum, is one of the crucial risk factors for coronary heart disease and
atherosclerotic progression [57]. It has also been reported that reduction of low-density lipoprotein
cholesterol (LDL-C) and improvement in levels of high-density lipoprotein cholesterol (HDL-C) can
contribute to the anti-atherogenic condition [58,59].
Results from biochemical profile studies conducted by Volpato et al. [52] and Mahmoud [60]
demonstrated that M. nigra extracts can decrease total cholesterol, triglyceride, LDL-C, and very
low-density lipoprotein cholesterol (VLDL-C) levels and increase HDL-C in diabetic pregnant rats [52]
and rats fed a high-fat diet [60]. Zeni et al. [61] evaluated the lipid-lowering effect of M. nigra leaf extract
using Triton WR-1339-induced hyperlipidemic rats. The LDL-C level had significantly decreased after
treatment with 100 mg/kg M. nigra infusion extract and HDL-C levels were restored in all groups
treated with M. nigra extract at three different concentrations (100, 200 and 400 mg/kg), compared
to those in the group only treated with Triton WR-1339. Atherogenic index and cardiac risk factor,
indicators of likelihood of cardiovascular diseases associated with hyperlipidemia, were also decreased
by M. nigra leaf extract. In another study by Jiang et al. [62], a high dose (210 mg/kg) of ethanolic
extract of M. nigra fruit (EEBM) resulted in lowering mean body weight in rats fed a 6-week high-fat
diet, which is comparable to the effect observed in the group treated with 5 mg/kg simvastatin. EEBM
also dose-dependently improved serum lipid profiles, atherosclerosis indexes and lipid peroxidation
compared to the control (high-fat diet-induced hyperlipidemic model) group. Histopathological
changes in rat liver and thoracic aorta with reduction in the intima-media thickness of rat aortic arch




Turgut et al. [63] investigated the effect of M. nigra leaves extract on D-galactose-induced cognitive
impairment and oxidative stress in mice. The results from the Morris water maze test showed
significant and dose-dependent decreases in mean escape latency and time required to reach the target
quadrant. Time spent in the target quadrant and number of times crossed the platform location
were increased after the administration of lyophilized M. nigra extract, suggesting its potential
neuroprotective role by preventing D-galactose-induced learning dysfunction and memory loss.
M. nigra extract also showed DNA damage protection, reduced malondialdehyde (MDA) levels
and augmented activities of three anti-oxidant enzymes, superoxide dismutase (SOD), glutathione
peroxidase (GPx), and catalase (CAT) in the serum, brain and liver of D-galactose-treated mice. These
antioxidant and anti-aging properties are considered as one of key mechanisms of M. nigra in delaying
neurodegenerative processes.
Dalmagro et al. [64] performed a forced swimming test (FST) and tail suspension test (TST) to
evaluate antidepressant-like activities of M. nigra and its major phenolic compounds syringic acid in
mice. Acute and subchronic oral administration of aqueous extract of M. nigra leaves significantly
decreased the immobility time in FST and TST except for acute administration at a dose of 100 mg/kg
extract in TST. Acute treatment with 1 mg/kg and 10 mg/kg and subchronic treatment with 1 mg/kg
of syringic acid also significantly decreased immobility time in TST. Nitro-oxidative stress in the
serum and brain was assessed by measuring thiobarbituric acid reactive substances (TBARS), nitrite,
protein carbonyl content (PC) and non-protein thiol groups (NPSH) levels, with some inconsistent
and controversial study results. A significant decrease of TBARS level was observed at acute doses
of 3 mg/kg M. nigra extract. However, TBARS levels were oppositely increased at subchronic doses
of 3, 10, and 100 mg/kg extract in the serum and at a subchronic dose of 3 mg/kg extract in the
brain. Levels of nitrites in the serum were significantly decreased after subchronic administration of
10, 30 and 100 mg/kg extracts of M. nigra leaves, and nitrites in the brain were also decreased after
subchronic treatment with the extract at doses of 30 and 100 mg/kg. In addition, subchronic treatment
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with 1 mg/kg syringic acid resulted in significant changes in TBARS and nitrite levels in the serum
and brain (all decreased, except TBARS level was increased in the brain). PC level was decreased after
treatment with 30 mg/kg M. nigra extract and syringic acid. There was no significant change in NPSH
level at all treatment conditions. Nevertheless, M. nigra leaf extract and syringic acid both exhibited
good cell viabilities in hippocampal and cerebral cortex slices incubated with 100 mM glutamate,
suggesting their proper neuroprotective effect against glutamate-induced toxicity.
8.2. Hepatoprotective Effect
Tag et al. [65] evaluated the hepatoprotective effect of the ethanolic extract of M. nigra leaves.
With an IC50 value at 14.5 μg/mL in in vitro cytotoxicity to HepG2 (a well-differentiated human
hepatocellular carcinoma) cell line, M. nigra leaf extract also significantly decreased levels of liver
enzymes alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), alkaline phosphatase
(ALP), and lactate dehydrogenase (LDH) in male albino rats with methotrexate-induced hepatotoxicity.
Hematosomatic index, defined as the ratio between liver- and body-weight and considered as
an indicator for hepatic damage and liver inflammation, in the group co-treated with M. nigra
extract and methotrexate, was also apparently decreased compared to that in methotrexate-only
treated group. In histopathological studies, M. nigra treatment resulted in moderate enhancement
in the hepatoprotection from methotrexate-related injury. Microscopic damage scores (hepatocyte
degeneration, congestion, leukocyte infiltration, fibrosis, and total histopathology score) were
significantly decreased when M. nigra extract was simultaneously administered compared to those in
the group treated with methotrexate alone. In addition, methotrexate-induced progressive increases in
collagen deposition of liver tissue were normalized by treatment with M. nigra leaf extract. Another
study performed by Hassanalilou et al. [66] also showed that M. nigra leaf extract can lead to less
fatty degeneration in liver tissue and smaller distension of hepatic cytoplasm due to fatty droplets
in STZ-induced diabetic rats along with reduced fasting blood glucose, compared to glibenclamide,
a well-known sulfonylurea antihyperglycemic agent.
Hepatoprotective activity of M. nigra fruits in carbon tetrachloride (CCl4, a well-known potent
hepatotoxin)-treated HepG2 cells [67] and adult male Sprague-Dawley rats [68] have been reported.
Extracts of M. nigra fruits dose-dependently and significantly reduced levels of hepatic enzymes
AST, ALT and gamma-glutamyl transferase (GGT) compared to control (CCl4-treated group). At the
same time, they significantly increased SOD and gluatathione peroxidase (GPx) enzymatic capacities
and decreased expression levels and activities hepatic capsase-3 (a biomarker for cell apoptosis) and
8-oxo-2’-deoxyguanosine (a biomarker for oxidative stress) in rat liver tissues, indicating that the
hepatoprotective effect of M. nigra fruits might be closely associated with its antioxidant activity [67,68].
8.3. Renal-Protective Effect
The effects of hydroalcoholic extract of M. nigra fruits on biochemical and histopathological
changes in serum and kidney tissues have been evaluated in alloxan-induced diabetic rats [69]. Milder
glomerular damage and no mesenchymal tissue expansion into renal glomerular vessels were observed
in the group after 8 weeks of treatment with 800 mg/kg M. nigra fruit extract compared to those in
diabetic and positive control (150 mg/kg metformin) groups. Although an increase in serum creatinine
level was observed in the group treated with 800 mg/kg M. nigra extract, this group had lower
serum glucose and urea levels compared to diabetic and positive control groups. These results
suggest that M. nigra fruits have a protective effect on diabetic nephropathy and related kidney tissue
injury. The extract of M. nigra leaves also significantly improved biochemical parameters reflecting
kidney functions (serum creatinine, urea, and uric acid) and exhibited milder histopathological
glycogen accumulation, fatty degeneration, and lymphocyte infiltration of renal convoluted tubules in
STZ-induced diabetic rats compared to non-treated and glibenclamide-treated groups [66].
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8.4. Gastroprotective Effect
Nesello et al. [70] reported that oral administration of methanolic extract from M. nigra fruits at
a high dose (300 mg/kg) can protect gastric mucosa against acidified ethanol-induced acute gastric
ulcer in female mice. This study result was confirmed by macroscopic and microscopic representative
images, showing that the degree of epithelial damage in gastric tissue was decreased. To further
investigate the underlying mechanisms for the gastroprotective effect, levels of lipid hydroperoxide
(LOOH) and glutathione (GSH) in ulcerated gastric mucosa were quantified. M. nigra fruits extract
prevented GSH depletion and promoted partial reduction of LOOH, suggesting its ability to ameliorate
oxidative stress involved in the development of gastric injury by acidified ethanol. Because M. nigra
fruits did not affect the activity of H+/K+-ATPase in their study, they have pharmacological advantages
of being free from the risk of several side effects such as rebound acid hypersecretion, hypergastrinemia,
gastric polyps, or atrophic gastritis [71] known to be associated with suppressed gastric acid secretion.
9. Activity on Female Reproductive System
De Queiroz et al. [72] investigated the estrogenic effect of M. nigra on the female reproductive
system and embryonic development. Five different concentrations (25, 50, 75, 350, and 700 mg/kg) of
hydroalcoholic extract of dried M. nigra leaves were administered in female Wistar rats for 15 days and
their biological and clinical features were compared with the control group, in which distilled water
instead of M. nigra extract was used as treatment. There were no significant differences in the number
of deaths, clinical signs of toxicity, changes in food consumption, or body weight between groups,
suggesting that M. nigra leaves did not cause maternal reproductive toxicity. Histological changes in
ovarian structures, signs of edema, cystic follicles, retained oocytes, or thickened uterine epithelium
were not observed. The number of corpora lutea, live fetuses, implants, resorptions, implantation,
and pre- or post-implantation loss were not affected by the administration of M. nigra leaf extract either.
Consequently, M. nigra exhibited no estrogenic effect or toxicity on the female reproductive system.
Another study conducted by Cavalcante et al. [73] showed that ethanolic extract of M. nigra
fresh leaves at 0.1 mg/mL can improve percentages of follicular morphology, antrum formation,
and fully grown oocytes, as well as the diameter of follicles compared to control group at 12 days after
treatment. Furthermore, additive effects on follicular growth (described as follicular diameter increase
and higher daily growth rate) were observed when M. nigra extract with supplemented medium
and follicle-stimulating hormone (FSH) were used as co-treatment, indicating its capacity on ovine
secondary follicle development.
10. Anticancer Activity
Cancer is a life-threatening disease state characterized by unregulated and permanent cell growth
and proliferation [74]. Because of its ability to avoid programmed cell death (apoptosis) as one of the
main driving forces for maintaining cancer cell proliferation, induction of apoptosis in cancer has been
considered a reasonable strategy to treat cancer [75,76].
Morniga M, a mannose-specific jacalin-related lectin from the bark of M. nigra, can preferentially
trigger the proliferation and activation of human T- and natural killer- (NK-)lymphocytes and
dose-dependently induce cell death of α-CD3 activated T lymphocytes when compared with
concanavalin A (Con A), a well-known mannose-specific legume leptin from Canavalia ensiformis [77].
Results from flow cytometry analysis have demonstrated that morniga M-induced cell death is
probably associated with the apoptotic mechanism, suggesting the anticancer potential of morniga M
via cell-death induction and immunomodulation as reported in previous studies with Con A [78,79].
Anticancer activities of morniga M were further investigated by Çakıroğlu et al. [80], in which they
demonstrated that both M. nigra fruit extract and morniga M significantly and dose-dependently
decreased cell viability against HT-29 cell line (human colorectal cancer). Another brief research
by Qadir et al. [81] the demonstrated dose-dependent anticancer activity of n-hexane and aqueous
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methanol extract of M. nigra leaves against HeLa cell line (human cervical cancer), with IC50 values of
185.9 ± 8.3 μg/mL and 56.0 ± 1.7 μg/mL, respectively.
Anti-proliferative and apoptotic effects of M. nigra fruits against several human adenocarcinoma
cell lines have been reported [80,82,83]. Ahmed et al. [82] compared the anticancer effects between fresh
and dried fruit extracts of M. nigra on MCF-7 cell line (human breast cancer). Study results have shown
that both ethanolic extracts dose- and time-dependently inhibit cellular growth of MCF-7 cells; exhibit
apoptotic morphological changes in their cytoplasmic membranes, cell bodies, and nuclei; induce DNA
fragmentations and single strand breaks; and decrease mitotic indexes, with better pharmacological
properties in fresh fruit of M. nigra. Turan et al. [83] evaluated the anticancer activities of M. nigra fruit
extract on PC-3 cells (human prostate cancer). Dimethyl sulfoxide (DMSO) extract of M. nigra exhibited
moderate cytotoxicity against PC-3 cells with an IC50 value of 370.1 ± 5.8 μg/mL. It significantly
increased the cell number at G0/G1 phase and decreased the cell number at S phase, indicating that
M. nigra fruits inhibited the progression of the cell cycle at the G0/G1 phase. M. nigra fruit extract at a high
dose (666 μg/mL) significantly increased the number of necrotic, early apoptotic and late apoptotic cells
compared to the untreated control group. It also dose-dependently decreased mitochondrial membrane
potential and increased activities of caspase 3 and 7 (key mediators of apoptosis) in PC-3 cells [83].
11. Antioxidant Activity
Oxidative stress is characterized by an excessive increase in intracellular oxidizing species such
as reactive oxygen species (ROS) involved in the loss of antioxidant defense capacity. It plays a
critical role in various clinical conditions including aging, cancer, diabetes, atherosclerosis, chronic
inflammation, neurodegenerative diseases, rheumatoid arthritis, human immunodeficiency virus (HIV)
infection, ischemia and reperfusion injury, and obstructive sleep apnea [84,85]. Many researchers are
interested in the antioxidant activity of naturally-occurring ingredients because phenolic compounds and
flavonoids, the largest phytochemical molecules from natural resources, possess a variety of biological
properties including antioxidant activity [86–89]. It has also been widely reported that mulberries are
rich in anthocyanin constituents having remarkable antioxidant activities and other health benefits such
as anti-inflammatory, antimicrobial, anti-obesity, antidiabetic, anti-hyperlipidemic, antihypertensive,
cardioprotective (reduced risk of coronary heart disease and stroke), and anticancer effects [90–92].
Numerous researches have proven antioxidant properties of M. nigra with different in vitro methods,
including DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay [15,23–26,28,61,70,93–113],
ABTS (2,2’-azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid) radical scavenging assay [15,91,94,99–103,
107,110,112–117], reducing power assay [15,99,113,118,119], superoxide anion radical (O2−) scavenging
assay [15,118,120], hydroxyl radical (OH-) scavenging assay [15,113,120], lipid peroxidation assay [19,
52,60,62–64,70,121,122], antioxidant enzyme activity assay [21,49,52,62,63,67], β-carotene bleaching
assay [23,119,123], ferric-reducing antioxidant power (FRAP) assay [24,85,91,95,100,102,104,107,110,111],
protein carbonyl assay [49,64,96], GSH measurement [67,70,112], hydrogen peroxide (H2O2)-induced
injury assay [113,121], NO radical scavenging assay [111,118], SOD-like activity [96], cupric-ion
reducing antioxidant capacity (CUPRAC) assay [102,107,108,110], H2O2 scavenging assay [108,119],
phosphomolybdenum assay [108,119], and ROS measurement [112].
12. Other Pharmacological Activities
Malik et al. [124] investigated the cardiovascular activity of aqueous methanolic extract of M. nigra
fruit in frogs. Treatment of M. nigra fruit extract showed significant and dose-dependent decreases in
heart rate without direct effects on the contractility of frog’s heart. Results of phytochemical analysis
revealed the presence of cardiac glycosides in M. nigra fruit, along with other active constituents
including saponins, alkaloids, phenolic compounds, and flavonoids.
Crude extract and fractions of M. nigra fruits exhibit both in vitro and in vivo prokinetic, laxative,
and antidiarrheal effects [125]. M. nigra extract significantly promoted the transit of charcoal meal through
the small intestine, increased gastric emptying rate and the mean number of wet feces, and decreased
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castor oil-induced diarrhea in mice. In in vitro studies, chloroform and petroleum ether fractions of M.
nigra fruits dose-dependently inhibited carbachol- and potassium ion-induced contractions of rabbit
jejunum while aqueous and ethyl acetate fractions showed stimulatory effects on guinea-pig ileum.
Suppression of maximum responses of acetylcholine and calcium ion (Ca2+) by M. nigra fruits was also
observed, and most gastrointestinal effects were conversely affected by concomitant administration of
atropine, suggesting that the underlying mechanisms of these prokinetic, laxative, and antidiarrheal
activities might be associated with cholinergic control and Ca2+ channel antagonism [125].
Fahimi and Jahromy [126] described the effects of M. nigra fruit juice on levodopa-induced
dyskinesia in mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s
disease. After 14 days of levodopa treatment, administration of 10 or 15 mL/kg of M. nigra fruit juice
significantly decreased abnormal involuntary movement scale (AIMS) scores compared to levodopa
treatment only.
13. Drug-Food Interaction and Toxicity
Food ingredients can cause drug-food interactions, most of which are pharmacokinetic interactions
associated with the alteration in activities of drug-metabolizing enzymes or drug transporters [127].
A brief experimental report by Kim et al. [128] demonstrated that the fruit juice of M. nigra has a
potent inhibitory effect of human liver microsomal cytochrome P450 3A (CYP3A) activity, with IC50
values for midazolam (a probe drug for CYP3A) 1‘-hydroxylation of 2.96 ± 0.33% (v/v, with 20-min
preincubation) and 6.22 ± 0.47% (no preincubation). Because approximately 30% of clinically used
drugs including macrolide antibiotics, antiarrhythmics, benzodiazepines, immune modulators, human
immunodeficiency virus (HIV) antivirals, antihistamines, calcium channel blockers, and statins are
metabolized by CYP3A [129,130], concomitant intake of CYP3A substrates with M. nigra fruit can lead
to an increase in plasma drug exposure.
Figueredo et al. [131] assessed the acute and subacute toxicities of M. nigra leaves extract in Wistar
rats. A single or 28-day oral dose of ethanolic extract of M. nigra leaves did not cause any adverse
effects. It did not induce abnormal behaviors or mortality. M. nigra extract resulted in some significant
but non-toxic changes in biochemical profiles (decreased urea and AST in males; decreased total
cholesterol and AST in females) and leukocyte parameters (increased neutrophils in males; decreased
white blood cell in females). M. nigra leaves did not affect lipid peroxidation and changes in renal and
hepatic CAT enzymatic activities.
Table 1. Summary of major biological and pharmacological therapeutic activities of M. nigra.
Pharmacological
Activity
Study Model Used Part SampleType a Ref.
Antinociceptive
Swiss mice Root bark C [10]
Male Swiss mice Leaf E [14]
Male Kunming mice Fruit E [15]
Male Kunming mice Fruit E,C [16]
Anti-inflammatory
Kunming male mice; RAW 264.7 cell Fruit E [15]
Adult male rats Leaf E [18]
Rat polymorphonuclear leukocytes Bark C [19]
THP-1 human monocytic leukemia cell line Root C [20]
Male C57BL/6 mice Pulp; leaf E [21]
Antimicrobial
In vitro assay Fruit E [16]
In vitro assay Leaf E,F [22]
In vitro assay Leaf E,F [23]
In vitro assay Fruit J [24]
In vitro assay Fruit E [25]
In vitro assay Fruit E [26]
In vitro assay Stem bark; fruit; leaf E [27]
In vitro assay Stem bark; stem wood E,C [28]
In vitro assay; THP-1 cell line Root E,C [32]
In vitro assay Fruit E [34]
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Anti-melanogenic
(Skin-whitening)
In vitro assay; B16 melanoma cells Stem C [38]
In vitro assay Root; twig C [39]
In vitro assay Leaf E [40]
In vitro assay Fruit E [41]
Antidiabetic
Male Wistar rats Leaf E b [46]
Male albino mice Leaf E [47]
Female albino Fischer rats Pulp; leaf E [49]
PPARγ-transfected HEK293 cells Twig C [50]
In vitro assay Twig C [51]
Anti-obesity In vitro assay Fruit E [55]
Anti-hyperlipidemic
Wistar rats Leaf E [52]
Adult male albino Sprague-Dawley rats Fruit E [60]
Male Wistar rats Leaf E [61]
Male Spraque-Dawley rats Fruit E [62]
Organ-protective
Male BALB/c mice Leaf E [63]
Male Swiss mice Leaf E,C [64]
HepG2 human hepatocellular carcinoma
cell line; male albino rats Leaf E [65]
Male Wistar rats Leaf E [66]
HepG2 cells Fruit E [67]
Adult male Sprague-Dawley rats Fruit E [68]
Male Wistar rats Fruit E [69]
Female Swiss mice Fruit E [70]
Anticancer
Peripheral blood mononuclear cells
(PBMCs); peripheral blood T lymphocytes;
Jurkat T leukemia cells
Bark C [77]
HT-29 human colorectal adenocarcinoma
cell line Fruit E,C [80]
HeLa human cervical cancer cell line Leaf E [81]
MCF-7 human breast cancer cell line Fruit E [82]
PC-3 human prostate adenocarcinoma cells Fruit E [83]
a, E, extract; F, fraction; C, isolated compound; J, juice. b, Cell suspension cultures of M. nigra extract were used.
14. Conclusions
M. nigra, especially its leaf and fruit parts, exhibited various pharmacological properties including
antinociceptive, anti-inflammatory, antimicrobial, anti-melanogenic, antidiabetic, anti-obesity,
anti-hyperlipidemic, and anticancer activities. M. nigra also showed protective and therapeutic effects
on the central nervous system, liver, kidney, gastrointestinal tract, and female reproductive system.
Most of these features were attributable to its antioxidant capacity due to abundant phytochemical
constituents such as polyphenols, flavonoids and anthocyanins. These findings suggest that M. nigra
can be used as a promising nutraceutical resource to control and prevent various chronic diseases.
Given that most researches are performed in vitro and in animal models, further studies at the clinical
level are required to establish the efficacy and safety of M. nigra in the human body.
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Abstract: Acute otitis media (AOM) is one of the most common bacterial infections in children.
Empiric antibiotherapy leads to increasing antimicrobial resistance rates among otopathogens and
may impair the correct development of the microbiota in early life. In this context, probiotics seem
to be an attractive approach for preventing recurrent AOM (rAOM) through the restoration of the
middle ear and nasopharyngeal microbiota. The aim of this study was the selection of a probiotic
strain (Lactobacillus salivarius PS7), specifically tailored for its antagonism against otopathogens. Since
L. salivarius PS7 was safe and displayed a strong antimicrobial activity against otopathogens, its
efficacy in preventing rAOM was assessed in a trial involving 61 children suffering from rAOM.
Children consumed daily ~1 × 109 CFU of L. salivarius PS7, and the number of AOM episodes were
registered and compared with that observed in the previous 6 and 12 months. The microbiota of
samples collected from the external auditory canal samples was quantitatively and qualitatively
assessed. The number of AOM episodes during the intervention period decreased significantly (84%)
when compared to that reported during the 6 months period before the probiotic intervention. In
conclusion, L. salivarius PS7 is a promising strain for the prevention of rAOM in infants and children.
Keywords: Lactobacillus salivarius; otitis; probiotic; bacteriocin; prevention
1. Introduction
Acute otitis media (AOM) is one of the most common diseases in infancy and childhood, and the
leading cause for seeking medical care and for the prescription of antibiotics, both in high-income and
low-income countries [1,2]. Approximately 70% of infants experience at least one otitis episode by the
age of 2 years, and 20–30% suffer from recurrent AOM (rAOM) [3]. rAOM is a very relevant issue
in clinical practice since it causes pain and discomfort in children, causing a strong impact on their
families and a relevant economic burden on society [3].
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Middle ear and nasopharyngeal colonization with multiple bacterial otopathogens (mainly
Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis) is
considered to be the main risk for both AOM and rAOM [4,5]. Recent microbiome studies have
revealed that Alloiococcus otitidis may also play a relevant role in the pathogenesis of otitis media [6,7],
while other species frequently isolated from the middle ear fluid of children experiencing this condition
include Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa and Escherichia coli [8].
In practice, eradicating or decreasing the concentration of such species through empiric systemic
and topical antibiotherapy is usually considered as the main (and, often, unique) approach for the
treatment of rAOM and, also, for providing prophylaxis for this condition [9]. However, a routine
antibiotherapy may have negative consequences. First of all, it drives the selection of resistant
otopathogens [9,10]. Although rAOM episodes occurring within one month from the completion of an
antibiotic therapy may be the result of either a relapse or a new infection, antibiotic pressure seems
to be essential for selecting the causal agent(s) in both circumstances [11,12]; in fact, the incidence
of antibiotic-resistant S. pneumoniae and H. influenzae strains in nasopharyngeal samples is higher
among children with rAOM than among healthy controls [13,14]. In addition, otopathogens, such
as H. influenzae, S. pneumoniae, M. catarrhalis and A. otitidis, form polymicrobial biofilms within the
middle ear [15–17], and bacteria within these structures have an increased antibiotic resistance [18].
Recently, it was shown that A. otitidis promoted H. influenzae survival in mixed biofilms by decreasing
its antibiotic susceptibility and enhancing its growth under adverse conditions [17]. A Cochrane
review [2] aimed to assess the effects of antibiotics for children with AOM revealed that, although
they may be useful in children under two years of age with bilateral AOM and otorrhea, their global
effect on health outcomes associated to this condition is limited. The same review encouraged the
weighing of the benefits of antibiotics against possible harms, including adverse events (such as
vomiting, diarrhea or rashes), and suggested that clinical management should provide a limited role
for antibiotics, and that a search for new preventive and treatment strategies should be stimulated.
The collateral damage that antibiotics exert on the host’s health by eliminating prominent (but
sensitive) members of the microbiota must also be taken into account. Our relationship with our
microbiota is especially important during the first years of life, when the microbiome is still forming
and any strong disturbance can have short, medium and long-term consequences for homeostasis and
health [19–24]. The microbiome of the middle ear, ear canal and nasopharynx of healthy children with
no history of AOM seems to be characterized by the presence of potentially protective commensal
bacteria and the absence or low abundance of classic otopathogens [25].
In this context, probiotics seem to be an attractive approach for preventing rAOM through the
restoration of the middle ear and nasopharyngeal microbiota. The lack of specificity of the probiotics
used for this target may be one of the main reasons for the limited and contradictory results obtained
so far [25,26]. Therefore, the aim of this study was the characterization of a probiotic strain specifically
selected for its antagonism against otopathogens. In addition, other potentially properties related
to its probiotic potential and safety were investigated, including the assessment of its acute and
repeated-doses oral toxicity in a rat model. Finally, the efficacy of the selected strain (Lactobacillus
salivarius PS7) in preventing rAOM in infants and children was assessed in a pilot clinical trial.
2. Materials and Methods
2.1. Isolation and Identification of the Strain
Strain PS7 was isolated in a de Man, Rogosa, and Sharpe (MRS, Oxoid, Basingstoke, UK) agar
plate within the framework of a previous study to evaluate the bacterial diversity of milk from
healthy women. Initially, the identification of the strain was performed by PCR amplification and
the sequencing of the 16S rRNA gene using the primers pbl16 (5′-AGAGTTTGATCCTGGCTCAG-3′)
and mbl16 (5′-GGCTGCTGGCACGTAGTTAG-3′) [27]. The identification was confirmed by Matrix
Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry using a
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Vitek-MS™ instrument (BioMérieux, Marcy l’Etoile, France) [28]. The strain could be differentiated
from other L. salivarius strains of our own collection by genotyping using randomly amplified
polymorphic DNA (RAPD) analyses, as previously described [29].
2.2. Survival after In Vitro Exposure to Saliva and Gastrointestinal-Like Conditions
The survival of the strain to conditions resembling those found in the human digestive tract
(saliva, human stomach and small intestine) was assessed in the in vitro system described by
Marteau et al. [30], with the modifications reported by Martín et al. [31]. For this purpose, the strain
was vehiculated in UHT-treated milk (25 mL) at a concentration of 109 CFU/mL. The values of the
pH curve in the stomach-like compartment were those recommended by Conway et al. [32]. Different
fractions were taken at 20, 40, 60, and 80 min from this compartment, and exposed for 120 min to a
solution with a composition similar to that of human duodenal juice [30]. The survival rate of the
strain was determined by culturing the samples on MRS agar plates, which were incubated at 37 ◦C
for 48 h.
2.3. Adhesion to Caco-2/HT-29 Cells
The ability of the strain to adhere to HT-29 and Caco-2 cells was evaluated as described by
Coconnier et al. [33] with the modifications reported by Martín et al. [31]. HT-29 and Caco-2 were
cultured to confluence in 2 mL of DMEM medium (PAA, Linz, Austria) containing 25 mM of glucose,
1 mM of sodium pyruvate and supplemented with 10% heat-inactivated foetal calf serum, 2 mM
of L-glutamine and 1% of a non-essential amino acid preparation. At day 10 after the confluence,
1 mL of the medium was replaced with 1 mL of DMEM containing 108 CFU/mL of the PS7 strain.
The adherence was measured as the number of lactobacilli adhering to the cells in 20 random
microscopic fields. The assay was performed by triplicate.
2.4. Production of Riboflavin, Folate and Cyanocobalamin
The riboflavin, folate and cyanocobalamin production by strain PS7 was determined using the
microbiological assays described by Juarez del Valle et al. [34], Laiño et al. [35], and Horwitz [36],
respectively. Lactobacillus rhamnosus ATCC 7469, L. rhamnosus NCIMB 10463 and 7469, and Lactobacillus
delbrueckii B12 were used as the indicator organism for the biosynthesis of the respective vitamins. The
riboflavin production in the riboflavin-free medium was confirmed by an HPLC analysis following a
procedure described previously [34].
2.5. Antimicrobial Activity of Strain PS7 against AOM-Related Pathogens
Initially, an overlay method was used as previously described [37] to determine the ability of
strain PS7 to inhibit the growth of a spectrum of bacterial strains previously isolated from clinical
cases of AOM (own collection of the Complutense University of Madrid) including: A. otitidis MP02, S.
pneumoniae MP07, S. pyogenes MP03, Enterococcus faecalis MP64, S. aureus MP29, S. epidermidis MP33,
H. influenzae MP04, M. catarrhalis MP08, P. aeruginosa MP24 and E. coli MP69. Brain Heart Infusion
(BHI, Oxoid, Basingstoke, UK), Columbia Nalidixic Acid (CNA, Biomerieux, Marcy-l’Étoile, France)
or Trypticase Soy (TSA, Oxoid) agar plates (depending on the indicator strain) were overlaid with
bacterial indicators, incubated at 37 ◦C for 48 h, and they were examined for zones of inhibition around
the PS7 streaks.
2.6. Production of Specific Antimicrobials (Bacteriocins, Lactic Acid, Acetic Acid, Hydrogen Peroxide) by
Strain PS7
Bacteriocin production was assayed using an agar diffusion method as described by Dodd
et al. [38] and modified by Martín et al. [31], using the Gram-positive strains employed for
the overlay method as indicator bacteria. Since, at that stage, it was already known that
strain PS7 belongs to the Lactobacillus salivarius species, the strain was tested by PCR for the
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presence of the structural genes encoding salivaricins. More specifically, the primer couples
used in this study were: (i) SalB-for (5′-TGATAAGAAAGAATTGGCACATATAATTG-3′)
and SalB-rev (5′-TCTGTTTAACTACAAATATTTTGATTTGAATG-3′) for salivaricin B [39],
and (ii) Abp118A-for (5′-AAACGTGGTCCTAACTGTGTAGG-3′) and Abp118B-rev
(5′-AACGGCAACTTGTAAAACCACCAG-3′) for bacteriocin Abp-118 [40]. The PCR reactions were
carried out as indicated in the respective articles.
L-and D-lactic acid and acetic acid production by the strain PS7 was quantified in MRS cultures
using enzymatic kits (Roche Diagnostics, Mannheim, Germany), as previously reported [31]. The
assays were performed in triplicate and the values were expressed as the mean ± SD. The pH values
of the supernatants were also measured. Finally, hydrogen peroxide production by the strain PS7 was
assayed using the procedures described by Song et al. [41] and by Yap and Gilliland [42]. L. johnsonii
La1 was used as a positive control in both assays.
2.7. Coagregation Assays
The ability of the strain to aggregate with cells of the otitis-related strains cited above was
investigated following the procedure of Reid et al. [43], as adapted by Younes et al. [44].
2.8. Co-Culture Studies
Broth co-cultures of strain PS7 and some of the otitis-related strains cited above were performed
in a BHI broth, since it was observed that this medium allowed most of their growth. The tubes were
initially inoculated at a concentration of ~1 × 108 CFU/mL for each of the bacterial strains (PS7 and
the corresponding otitis-related strain) and incubated overnight at 37 ◦C in aerobic conditions. BHI
monocultures of each of the strains used in these assays were performed as control cultures. After
incubation, samples of all the co-cultures and monocultures were seeded onto MRS, CNA, TSA and
BHI agar plates for a selective enumeration based on the ability of the strains to growth and to display
differential colony morphologies when inoculated on such media.
2.9. Sensitivity to Antibiotics
The sensitivity of the strain PS7 to antibiotics was tested using the lactic acid bacteria susceptibility
test medium (LSM) [45] and the microtiter VetMIC plates for lactic acid bacteria (National Veterinary
Institute of Sweden, Uppsala, Sweden), as described previously [46]. Parallel, minimum inhibitory
concentrations (MICs) were also determined by the E-test (AB BIODISK, Solna, Sweden) following
the instructions of the manufacturer. The results were compared to the cut-off levels proposed by the
European Food Safety Authority [47].
2.10. Formation of Biogenic Amines and Degradation of Mucin
The capacity of the strain PS7 to synthesize biogenic amines (tyramine, histamine, putrescine
and cadaverine) from their respective precursor amino acids (tyrosine, histidine, ornithine and
lysine; Sigma-Aldrich) was evaluated using the method described by Bover-Cid and Holzapfel [48].
The potential of the strain to degrade gastric mucine (HGM; Sigma, St. Louis, MO, USA) was evaluated
in vitro as indicated by Zhou et al. [49].
2.11. Acute and Repeated Dose (4-Weeks) Oral Toxicity Studies in a Rat Model
Wistar male and female rats (Charles River Inc., Marget, Kent, UK) were used to study the acute
and repeated dose (4-weeks) oral toxicity of the strain PS7 in a rat model. The acclimatization, housing
and management (including feeding) of the rats was performed as previously described [50]. The rats
were 56-days old at the initiation of treatment. Acute (limit test) and repeated dose (4 weeks) studies
were conducted in accordance with the European Union guidelines (EC Council Regulation No. 440)
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and authorized by the Ethical Committee on Animal Research of the Complutense University of
Madrid (protocol 270111).
In the acute (limit test) study, 24 rats (12 males, 12 females) were distributed into two groups of
6 males and 6 females each. After an overnight fasting, each rat received skim milk (500 μL) orally
(control group or Group 1), or a single oral dose of 1 × 1010 CFU of L. salivarius PS7 dissolved in 500 μL
of skim milk (treated group or Group 2). The doses of the test and control products were administered
by gavage. At the end of a 14-day observation period, the rats were weighed, euthanized by CO2
inhalation, exsanguinated, and necropsied.
The repeated dose (4 weeks) (limit test) study was conducted in 48 rats (24 males, 24 females)
divided in four groups of 6 males and 6 females each (control group or Group 3; treated group or Group
4; satellite control group or Group 5; and satellite treated group or Group 6). Rats either received a
daily oral dose of skim milk (Groups 3 and 5) or of 1 × 109 CFU of L. salivarius PS7 dissolved in 500 μL
of skim milk (Groups 4 and 6) over 4 weeks. All rats of Groups 3 and 4 were deprived of food for
18 h, weighed, euthanized by CO2 inhalation, exsanguinated, and necropsied on day 29. All animals
of the satellite groups (Groups 5 and 6) were kept for a further 14-day period without treatment to
detect delayed occurrence, persistence or recovery from potential toxic effects. All rats from Groups 5
and 6 were deprived of food for 18 h, weighed, euthanized by CO2 inhalation, exsanguinated, and
necropsied on day 42.
The behavior and clinical observations, blood biochemistry and haematology analysis, organ
weight ratios and histopathological analysis were conducted as described previously [50]. The bacterial
translocation to the blood, liver or spleen, and the total liver glutathione (GSH) concentration was
evaluated following the methods described by Lara-Villoslada et al. [51].
2.12. Pilot Clinical Trial: Prevention of rAOM in Children
In this prospective pilot clinical assay, 64 children (aged 10 months to 6 years) with a previous
history of rAOM were recruited between September 2012 and April 2015. The primary outcome
variables were the occurrence and duration of the AOM episodes. The secondary end point was the
frequency of an otitis-related pathogen carriage in the external auditory canal. The inclusion criteria
were at least four episodes of AOM during the preceding 12 months or at least three episodes during
the preceding 6 months [52]. The exclusion criteria included chronic medication, chronic illnesses,
lip or palatal cleft, programmed tympanostomy or adenoidectomy during the study, and lactose
intolerance or cow’s milk protein allergy (because of the excipient used to administer the strain). Those
children who had undergone tympanostomy or adenoidectomy during the preceding 6 months were
also excluded. The data on the occurrence of AOM episodes from a similar population (age, gender)
of otitis-prone children (n = 60), who were attended by the same pediatrician but did not receive the
tested strain, were used for comparison purposes. Written informed consent was obtained from the
parents or legal tutorsin accordance with the Declaration of Helsinki. The protocol was approved
by the Ethical Committee on Clinical Research of Hospital Universitario Clínico San Carlos (Madrid,
Spain), under protocol B12/262.
During the 6-month intervention period, the recruited children consumed daily ~1 × 109 CFU
of L. salivarius PS7. The parents recorded whether the child had or had not received the daily dose.
Compliance was expressed as the percentage of days in which the child received the dose. The use of
antibiotics (except for the treatment of an AOM episode) or other probiotics was not allowed during
the study. A physical examination was performed by a pediatrician for each suspected AOM episode.
AOM was diagnosed according to defined clinical criteria [52,53], including evidence of middle ear
effusion, inflammation of the tympanic membrane and any other sign of an acute infection (fever,
ear ache, otorrhoea, etc.). The number of AOM episodes and the duration of each episode were also
recorded and compared to the same data obtained in the 6 months preceding the probiotic treatment.
Samples from the external auditory canal were collected with a sterile swab at the baseline and
at the end (6 months) of the study and submitted for a bacterial analysis following the guidelines
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recommended by the Spanish Society of Infectious Diseases and Clinical Microbiology [53]. Microbial
isolates were identified by a MALDI-TOF analysis as previously reported.
2.13. Statistical Analysis
All the quantitative assays included in this study were performed at least in triplicate.
The quantitative data were expressed as the mean and standard deviation (SD). When not normally
distributed, the data were presented as the median and interquartile range (IQR). For the murine
assays, the data were expressed as the means ± standard error of the mean (SEM) of the determinations.
The differences between the control and treated groups were evaluated with a one-way analysis of
variance (ANOVA) followed by Dunnett’s test. A Wilcoxon signed rank test was used to compare
paired microbiological data before and after the probiotic intake and the χ2 test was used to find
differences in the detection frequencies of the bacterial species in the external auditory canal samples.
For all the comparisons, differences were considered significant at p < 0.05. The statistical analyses
were conducted using R (version 3.0.2, R-project) software [54].
3. Results
3.1. Identification and In Vitro Characterization of the Strain
Strain PS7 was identified as a member of the L. salivarius species (from now, L. salivarius PS7).
A RAPD genotyping analysis showed that the profile of this strain was different to those of other L.
salivarius strains from our own collection. Subsequently, the strain was deposited at the Spanish Type
Culture Collection (CECT; Burjassot, Spain) under accession number CECT 9422.
In relation to the survival of L. salivarius PS7 after exposition to conditions resembling those found
in the human digestive tract, an exposure to a saliva-like solution had no deleterious effect on the strain
while the survival rate after a transit through the stomach- and small intestine-like compartments was
at approximately 52% of the population initially inoculated.
The strain produced neither folates nor cyanocobalamin under the assayed conditions. In contrast,
it was able to produce riboflavin at a total concentration of ~200 ng/mL (intracellular riboflavin:
165.00 ± 0.52 ng/mL; extracellular riboflavin: 34.74 ± 3.06 ng/mL).
L. salivarius PS7 showed a high ability to adhere to both Caco-2 and HT-29 cells. The mean ± SD
of the number of adhered lactobacilli in 20 random microscopic fields was 697.1 ± 297.6 and
251.7 ± 82.3, respectively.
L. salivarius PS7 showed a clear antimicrobial activity (inhibition zone >2 mm around the streak)
against most of the otitis-related indicator organisms used in this study (Table 1). Subsequently, and to
try to elucidate the compound(s) responsible for the antimicrobial activity, the strain was screened for
production of bacteriocins, organic acids (D-and L-lactic acid, acetic acid) and hydrogen peroxide. The
strain displayed bacteriocin activity against the Gram-positive strains included as indicator organisms
in this study (Table 1). A PCR analysis for structural genes of known salivaricins revealed that this
strain produced the bacteriocin Abp-118 (both structural genes were identical) (Figure 1). L. salivarius
PS7 produced a high concentration of L-lactic acid in the MRS broth while it did not produce the
D-lactic acid isomer (Table 2). A significant concentration of acetic acid could also be detected in the
culture supernatants of the strain (0.68 ± 0.17 mg/mL). This strain did not produce hydrogen peroxide.
L. salivarius PS7 showed a high potential for co-aggregating with bacterial strains involved in
AOM cases, particularly with those belonging to the genera Streptococcus, Alloiococcus, Enterococcus and
Staphylococcus. In addition, most of the otitis-related Gram-positive pathogens could not be detected,
or their concentrations decreased notably after their overnight co-culture with the strain PS7 in the
BHI broth (Table 1).
The antibiotic sensitivity assays showed that all the MIC values were below the cut-off values
recommended by EFSA for all antibiotics, with the exception of kanamycin (MIC in this study:
128 μg/mL; EFSA cut-off value: 64 μg/mL) (Table 3). However, recent reports suggest that L. salivarius
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may be intrinsically resistant to kanamycin, and this aspect will be discussed below. Finally, L. salivarius
PS7 was able neither to degrade gastric mucin in vitro nor to produce biogenic amines.
 
350 bp 
1 2 3 4 5 6 
Figure 1. PCR assay for the detection of the bacteriocin Abp118 structural gene. Lane 1: marker
(HyperladderTM 100 bp, BIOLINE, London, UK). Lane 2: positive control. Lane 3: negative control.
Lanes 4, 5 and 6: L. salivarius PS7.
Table 1. Antimicrobial activity of L. salivarius PS7 against bacterial strains isolated from clinical cases




Well Diffusion Assay (cm) Co-Cultures (CFU/mL)
Non-Adjusted pH pH 6.2 Initial Load Final Load
S. pneumoniae MP07 3.6 1.1 1.1 7.40 Nd a
S. pyogenes MP03 2.0 1.2 0.7 7.74 Nd a
S. aureus MP29 1.6 1.3 1.2 7.52 4.81 a
S. epidermidis MP33 2.3 1.1 1.0 7.53 5.90 a
A. otitidis MP02 1.0 1.2 1.2 – –
E. faecalis MP64 0.5 0.4 0.4 8.02 8.78 b
H. influenzae MP04 2.2 – – – –
M. catarrhalis MP08 2.1 – – – –
P. aeruginosa MP24 1.5 – – – –
E. coli MP69 1.4 – – 7.70 5.74 a
a p < 0.01. b p = 0.29; Nd, no growth detected; – not assayed. AOM: Acute otitis media; CFU: colony-forming unit.
Table 2. Final pH and production of organic acids (mg/mL; mean ± SD) in an MRS broth by L.
salivarius PS7.
pH L–Lactic Acid D-Lactic Acid Acetic Acid
4.01± 0.04 10.29 ± 0.70 Nd 0.68 ± 0.17
Nd, not detectable.
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Table 3. Minimum inhibitory concentrations (MICs) and cut-off values (μg/mL) of a variety of
antibiotics for L. salivarius PS7.












* EFSA (2018), except for linezolid and penicillin (Klare et al., 2007). n.r.: not required.
3.2. Acute and Repeated Dose (4-Weeks) oral Toxicity Studies in a Rat Model
All animals survived both oral toxicity trials. The development of the treated animals during the
experimental periods corresponded to their species and age. At no time point of the experimental
period were there any significant differences in body weight or body weight gain among the groups
treated with L. salivarius PS7 (including the satellite ones) in comparison to the control groups. No
abnormal clinical signs, behavioural changes, body weight changes, haematological and clinical
chemistry parameters, macroscopic or histological findings, or organ weight changes were observed.
There were no statistical differences in body weights among the groups. Similarly, no statistically
significant differences in body weight gain, or in food and water consumption were observed between
the groups.
No significant differences in the liver GSH concentration were observed between the control and
treated groups (9.67 ± 1.42 vs. 9.71 ± 1.56 mmol/g, p > 0.1), and lactobacilli could not be isolated from
the blood, liver or spleen of the treated rats.
3.3. Pilot Clinical Trial: Prevention of AOM in Children
A total of 64 children who fulfilled the inclusion criteria were enrolled and received the probiotic
treatment (Table 4). Three children (~4.6%) dropped out (one due to antibiotic intake; one due to
tympanostomy; one due to a previously unadvertized allergy to cow’s milk protein); thus, 61 children
completed the study. Compliance during the study was very high (≥ 96%). Twenty-two out of the 61
recruited children (36%) suffered at least one episode of AOM (median [25Q–75Q]), with a median
duration of 4 days (Table 4). In contrast, ~70% of the children with rAOM who were attended by
the same pediatrician in the same period but did not receive the probiotic strain suffered at least
one AOM episode with a median duration of 6 days. The number of AOM episodes during the
6-month intervention period decreased by 84% when compared to the number registered in the 6
months that preceded the intervention (Figure 2). Although any child suffering an AOM episode
received an antibiotic treatment, the number of antimicrobial treatments decreased by ~60% in the
children receiving the probiotic strain with respect to the other otitis-prone children treated by the
same pediatrician.
Globally, the microbial density in the external auditory canal decreased notably along the
intervention period, from ≥3.5 log10 CFU at the baseline (all the cultures were positive at this sampling
time) to ≤ 2 log10 CFU at the end of the intervention (with 22% of the cultures being negative). At time
0, M. catharralis, coagulase-negative staphylococci and A. otitidis were the dominant bacteria in swabs
taken from the external auditory canal of the recruited children, while coagulase-negative staphylococci
and viridans streptococci dominated after 6 months of the probiotic treatment (Table 5). A. otitidis, H.
haemolyticus, H. influenzae, M. catharralis, Neisseria spp, P. aeruginosa, S. aureus, S. pneumoniae and S.
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pyogenes, which were relatively common in the samples obtained at time 0, were not detected or their
frequency of detection decreased notably at the end of the intervention (Table 5).
Table 4. Main demographic characteristics of the infants and children recruited in the pilot trial (n = 61),
and main outcomes of the study.
Characteristic Sex n Mean ± SD or Median * p-Value
Age (Years) and Gender 3.31 ± 1.7
<3 years (n = 30) Males 16
Females 14















Preceding 6 months 4 (3–4) * <0.001 ¥
Preceding 12 months 5 (5–6) * <0.001 ¥
During the study 0 (0–1) *






Period (6 months) previous 
to probiotic treatment 
Period (6 months)  
of probiotic treatment 
Figure 2. Comparison between the number of AOM episodes reported during the 6 months of the
probiotic treatment and those reported during the previous 6 months. **, statistically significant change
(p < 0.05; χ2 test).
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Table 5. Results of the microbiological analysis of the samples from the external auditory canal taken
at day 0 before the probiotic intervention and at the end of the 6-month treatment period.
Time 0 After 6 Months p-Value
Number of positive samples (bacterial growth) 61 17 < 0.001 ¥
Median log10 CFU (per swab) 4 (3.5–5) 2 (1.5–2) 0.012 *
Number of samples with the presence of:
Actinomyces europaeus 2 0
Alloiococcus otitidis 12 2
Coagulase-negative staphylococci 14 15
Haemophilus haemolyticus 11 1
Haemophilus influenza 7 1
Moraxella catharralis 14 3
Neisseria spp. 6 0
Pseudomonas aeruginosa 4 0
Rhodococcus ruber 2 0
Staphylococcus aureus 11 3
Streptococcus pneumoniae 9 3
Streptococcus pyogenes 10 6
Group viridans streptococci 9 11
¥ Chi-squared test. * Wilcoxon rank sum test.
4. Discussion
In the present study, the probiotic potential of L. salivarius PS7 was characterized by using a wide
variety of in vitro and in vivo assays, including its ability to antagonize otopathogens, its toxicological
assessment in rats, and a pilot clinical trial for the initial evaluation of its efficacy for preventing rAOM
in infants and children. The characterization scheme of this strain followed the guidelines for the
evaluation of probiotics provided by FAO and WHO [55].
Both the survival rate (52%) of L. salivarius PS7 when exposed to conditions similar to those found
in the digestive tract and its capacity for adhesion to intestinal cells were similar or higher than those
found for commercial probiotic strains in previous studies using the same in vitro models [31,56].
These properties indicate that a high concentration of the strain can reach the pharynx and the gut
mucosal surfaces and adhere to them. The adhesion ability of this strain may allow the competitive
exclusion of pathogenic bacteria [57]. While its presence in the pharynx may facilitate its direct
interaction with otopathogens, its presence in the gut might also have positive consequences. It has
been shown that exposure (after swallowing) of the gut to upper respiratory pathogens involved
in otitis media provides a potent modulation of the immune responses in the middle ear [58]. The
potential ear-related immunomodulatory properties of L. salivarius PS7 were not addressed in this
work but deserve future research.
In order to select a strain for the prevention of otitis, its ability to exert antagonism against
otopathogens seems an essential property. The results of the in vitro assays to evaluate the antimicrobial
activity of L. salivarius PS7 against a wide variety of strains and species previously isolated from
clinical rAOM cases confirmed that it was a suitable candidate for such a target. All the otitis-related
indicator strains were inhibited when the overlay method was used and, among them, all the
Gram-positive strains were sensitive to the bacteriocin-like compound produced by L. salivarius PS7.
The PCR analyses revealed that L. salivarius PS7 produces Abp-118. This is a potent broad-spectrum
class II bacteriocin, which was originally described in L. salivarius UCC118 [59]. A previous study
demonstrated that Abp-118 is produced in vivo and that it was the primary mediator conferring
protection against infection by Listeria monocytogenes in mice [60]. The lack of inhibition of a few
otopathogens (E. faecalis MP64) in the co-culture assay may be due to the fact that Abp-118 is not
expressed when the bacteriocinogenic strain grows in a BHI medium. In addition, L. salivarius PS7
produced high amounts of L-lacic acid in the MRS cultures, and this is in agreement with the results
obtained with other L. salivarius strains in previous studies [31,56]. Smaller concentrations of acetic
acid were also present in the MRS cultures. The fact that L. salivarius PS7 cells were able to co-aggregate
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with most of the otopathogenic strains tested in this work may facilitate the exposure of otopathogens
to the antimicrobial substances produced by L. salivarius PS7 [44]. Recently, it was shown that, to exert
antimicrobial activity in mucosal surfaces, physical contact between lactobacilli and pathogens may be
required [61]. Interestingly, the presence of lactobacilli in the nasopharynx has been associated with a
reduced risk of respiratory conditions in children [62]. Unfortunately, the presence of Lactobacillus in
ear or nasopharynx samples was not tested in this study.
Although L. salivarius is a species included among those with the “qualified presumption of
safety” (QPS) status [63], L. salivarius PS7 was submitted to a thorough safety assessment. In relation
to its pattern of antibiotic sensitivity, all the MIC values were below the cut-off values recommended
by EFSA [47], with the exception of kanamycin. A resistance of lactobacilli to kanamycin is a common
finding among L. salivarius strains [64–66] due to the lack of a transport system for this antibiotic. This
type of intrinsic resistance does not represent a human health risk [47]. In a previous study, the MIC
value of L. salivarius CECT 5713 (a commercial probiotic strain) for kanamycin (128 μg/mL) [46] was
the same as the one obtained with L. salivarius PS7 in this study. The analysis of the genome of L.
salivarius CECT 5713 revealed the absence of transmissible genes involved in kanamycin resistance.
Moreover, L. salivarius PS7 did not produce biogenic amines and did not show any ability for mucin
degradation. These results are also similar to those reported for other L. salivarius strains using the same
assays [31,56]. An acute and repeated-dose oral toxicity assessment in rats showed that L. salivarius PS7
was completely safe in this animal model when administrated in doses ranging from 9 to 10 log10 CFU
daily. No significant differences in the liver GSH concentration were observed between the control
and treated groups, indicating that the treatment did not cause oxidative stress to rats. This result is
consistent with the absence of bacteremia since no lactobacilli could be isolated from the blood, liver
or spleen of the rats, indicating that the tested strains do not cause either a local or a systemic infection
in rats. These findings are in agreement with those previously reported for another L. salivarius strain
also isolated from human milk [51].
Because of the wide antimicrobial activity of L. salivarius PS7 against otopathogens and its safety,
a pilot clinical trial was carried out to assess its efficacy in preventing rAOM in infants and children.
Oral intakes of L. salivarius PS7 over 6 months led to a statistically significant reduction (84%) in
the number of episodes of AOM in comparison to those observed in the same population during
the 6 months preceding the probiotic intervention. Such a percentage is higher than that observed
in previous studies after oral or nasal administration of other probiotic strains, such as Lactobacillus
rhamnosus GG and LC705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS [67,68], and
Streptococcus salivarius 24SMB or Streptococcus oralis 89a [69,70]. When AOM occurred, the median
duration of AOM episodes was 4 days, which is lower than the value obtained in previous probiotic
trials (5.6 days) [68].
The external ear canal may act as a bacterial reservoir for the same otopathogens usually found in
the middle ear during AOM [17,25,71]. Therefore, ear canal samples were analyzed before and after
the probiotic intake period. The probiotic treatment led to a statistically significant decrease in the
number of ear canal samples that were positive for bacterial growth and in the bacterial density of the
positive samples (Table 5). The frequency of detection of potential otopathogens (A.otitidis, Haemophilus
haemolyticus, H. influenzae, M. catharralis, Neisseria spp., P. aeruginosa, S. aureus, S. pneumoniae and S.
pyogenes) in the samples also decreased notably after the trial (Table 5). The only bacterial groups whose
detection frequency remained similar before and after the probiotic treatment were coagulase-negative
staphylococci and viridans streptococci. This change in the composition of the ear canal microbiota
seems to be closely associated with the decrease in the number of AOM episodes. In previous studies,
otopathogens were more frequently detected in children with otitis than in healthy controls [10,72,73].
In fact, a failure to erradicate otopathogens from the ear and/or nasoparhyngeal surfaces has been
viewed as an explanation for rAOM episodes after treatments with antibiotics [4] or with generic
non-otitis-targeted probiotics [68,74]. A lack of specificity may explain the conflicting evidence on the
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effectiveness of probiotics in preventing AOM [75,76]. In contrast, the presence of coagulase-negative
staphylococci and viridans streptococci seems to be a feature of a healthy ear and nasopharynx [13,77].
We acknowledge that the clinical trial performed in this study must be considered as a preliminary
“proof of concept” trial since it faces some design limitations (e.g., lack of a placebo group and
randomization). However, the results have shown that, while antibiotics may still play a relevant
role in treatment of AOM, a target-specific probiotic strain may have a preventive role, significantly
reducing the number of episodes in children with rAOM and the number of antibiotic doses required
to treat them. This is a relevant finding within the context both of the present “antibiotic resistance
crisis” and of the steady rise in autoimmune diseases associated with host microbiota disturbances.
Additional work is in progress in order to initiate a well-designed multicenter clinical trial to further
confirm the results obtained in this work.
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